Document:

exv10w13

Exhibit 10.13

INTELLECTUAL PROPERTY RIGHTS AGREEMENT

between

Ceres, Inc.

and

The A&M University System

     This agreement (“Agreement”) is made and entered into by and between Ceres, Inc., a
corporation with principal offices in Thousand Oaks, California, a Delaware corporation (“CERES”)
and The Texas A&M University System (“SYSTEM”), an agency of the State of Texas, collectively
referred to as “Parties” and individually as “Party.”

WITNESSETH:

WHEREAS, SYSTEM and CERES have in common the desire to encourage and facilitate the discovery,
dissemination and application of new knowledge, and CERES desires to support said research;

WHEREAS, CERES and SYSTEM, through The Texas Agricultural Experiment Station (“TAES”) with
principal offices in College Station, Texas, and a member of SYSTEM have entered into a Sponsored
Research Agreement (the “SRA”) to improve germplasm, develop lines and hybrids of sorghum and its
interbreeding species and develop DNA markers and marker platform technology to advance the
development of biomass/bioenergy crops;

WHEREAS, the Parties desire that CERES will commercialize such biomass/bioenergy crops under
exclusive license(s) from SYSTEM; and

WHEREAS, pursuant to the SRA, CERES has the right to license certain INTELLECTUAL PROPERTY RIGHTS
from SYSTEM; and

WHEREAS, the Parties have agreed on the rights and obligations of the Parties and the procedures
for such licensing.

NOW THEREFORE, in consideration of the mutual covenants and premises contained in this Agreement,
the receipt and sufficiency of which is acknowledged, the Parties agree as follows:

Article 1. Licensing of Intellectual Property Rights

A. General

(1) All grants of intellectual property rights as set forth in Article 8 of the SRA, other than
copyrights, will be made through the instrument of license agreements substantially in the form of
Appendices A and B.

(2) All such grants of intellectual property rights will be subject to SYSTEM’s reservation of an
irrevocable, worldwide, nonexclusive, royalty-free right to use or practice the intellectual
property as set forth in the SRA, subject, however, to compliance with Article 1.M of the SRA and
the Guidelines for Future Collaborative Opportunities which both Parties agree to comply with and
which are included in Appendix C.

(3) It is anticipated by the Parties that CERES may, in consideration for achievement of certain
research and commercial milestones defined in Article 5 and subject to CERES Board of

Page 1 of 41

 

Directors and shareholder approval, issue warrants as set forth in Article 5.B, giving SYSTEM the
right to purchase CERES stock for a predetermined price per share. The Parties will negotiate
diligently and in good faith about such potential grant of warrants. If no warrant has been issued
by CERES to SYSTEM within nine (9) months after the last signature date of this Agreement, CERES
shall have no further obligation whatsoever with respect to the issuance of warrants to SYSTEM.

B. Patentable Inventions

(1) Negotiation of a Commercial License. SYSTEM, through TAES, has granted CERES in the SRA a
time-limited option to obtain an exclusive world-wide commercial license in SYSTEM’s rights in
Subject Inventions under the SRA, with the right to grant sublicenses. If CERES advises SYSTEM as
per the terms of the SRA that CERES elects to obtain an exclusive commercial license to such
Subject Invention, the Parties shall initiate negotiation of a license agreement based on the
Example License Agreement for Subject Inventions in Appendix A. The start of such negotiations
shall be evidenced by written notice from one Party to the other initiating such negotiations, and
such negotiations shall not extend beyond one hundred eighty (180) days from the start thereof
without the mutual consent of both Parties (“Negotiation Period”). Such license shall be negotiated
in good faith between the Parties and shall contain reasonable business terms common to CERES’
field of commercial interest and proposed application. If the Parties fail to reach agreement
within the Negotiation Period, the terms and conditions of the license on which no agreement was
reached shall be settled in accordance with the following procedures: the disputed contract terms
shall be referred to a mutually agreed impartial expert whose decision shall be final. Each Party
shall submit to the expert within fifteen (15) days of his appointment its position in writing on
the disputed contract terms and conditions. Such expert shall be limited to choosing one of such
two (2) party positions on each of the contract terms and conditions or related group of contract
terms and conditions that the expert considers most reasonable in the circumstances and shall not
make any other determination. Neither Party shall be bound by any determination by the expert
which, in the opinion of Party’s counsel, will result or be likely to result in that Party
violating any applicable law or regulation.

(2) Joint Inventions. Joint Inventions conceived under the SRA shall be subject to the option set
forth in the SRA and the provisions of (1) hereinabove.

C. Germplasm

(1) Definitions: The terms “Hybrid,” “TAES Genetic Contribution,” “Other Contributions,” “Developed
by Breeding,” “New Parental Lines,” “Lines,” and “Allele” shall have the definitions set forth in
the SRA.

(2) Negotiation of a Commercial License. SYSTEM, through TAES, has granted CERES in the SRA a
time-limited option to obtain an exclusive world-wide commercial license in SYSTEM’s rights in
Lines under the SRA, with the right to grant sublicenses. If CERES advises SYSTEM as per the terms
of the SRA that CERES elects to obtain an exclusive world-wide license to maintain and increase
seed of Lines; develop New Parental Lines; develop Hybrids; and sell Hybrids; the Parties shall
initiate negotiation of such license agreement based on the Example License Agreement for Lines in
Appendix B. The start of such negotiations shall be evidenced by written notice from one Party to
the other initiating such negotiations, and such negotiations shall not extend beyond one hundred
eighty (180) days from the start thereof without the mutual consent of both Parties (“Negotiation
Period”). Such license shall be negotiated in good faith between the Parties and shall contain
royalty rates customary in the seed industry taking into consideration (i)

Page 2 of 41

 

TAES Genetic Contribution, (ii) Other Contributions of CERES and (iii) financial contributions of
CERES, all to the development of the Lines and Hybrids. If the Parties fail to reach agreement
within the Negotiation Period, the terms and conditions of the license on which no agreement was
reached shall be settled in accordance with the following procedures: the disputed contract terms
shall be referred to a mutually agreed impartial expert whose decision shall be final. Each Party
shall submit to the expert within fifteen (15) days of his appointment its position in writing on
the disputed contract terms and conditions. Such expert shall be limited to choosing the one of
such two (2) party positions on each of the contract terms and conditions or related group of
contract terms and conditions that the expert considers most reasonable in the circumstances and
shall not make any other determination. Neither Party shall be bound by any determination by the
expert which, in the opinion of Party’s counsel, will result or be likely to result in that Party
violating any applicable law or regulation.

Article 2. Term and Termination

A. The period of performance for this Agreement shall begin on September 3, 2007 (the “Effective
Date”), and shall continue until the rights and obligations of the Parties hereunder shall expire
according to their terms, subject to earlier termination as provided herein.

B. Termination of this Agreement shall not affect the rights and obligations of the Parties accrued
prior to termination hereof nor any license or warrant grants then in existence, subject to payment
of remuneration as set forth in any relevant license/commercialization or warrant agreements.

Article 3. Confidentiality

A. SYSTEM shall make all reasonable efforts not to disclose this Agreement or the contents thereof
to third parties without the prior written consent of CERES for a period of five (5) years from the
date of this Agreement, but SYSTEM shall not be liable for unauthorized disclosures of information
which occur in spite of such efforts. SYSTEM will only make this Agreement available to SYSTEM
employees or researchers on a need-to-know basis.

B. SYSTEM shall not be obligated to keep any portion of this Agreement confidential to the extent
such portion (a) now or hereafter becomes generally available to the public on a non-confidential
basis through no fault or action or failure to act on the part of SYSTEM; or (b) is ordered
produced or disclosed by a court or administrative body of competent jurisdiction or otherwise
required by law, or required to be disclosed by the Attorney General of The State of Texas, but
only to the extent of such required production or disclosure.

Article 4. Discount to Qualifying Entities

A. Additional Definitions.

	 	1.	 	“QUALIFYING SYSTEM ENTITY” or “QSE” shall be any entity that operates a
BIOREFINERY and (i) that is established within fifteen (15) years from the Effective
Date; (ii) that is designated as such by SYSTEM to CERES in writing; (iii) in which
SYSTEM has ownership, directly or Indirectly, of one percent (1%) or more of the
voting stock or other voting interest, and such voting stock or other voting interest
is QUALIFYING EQUITY; and (iv) whose principal biorefining activities are in the
TERRITORY. “Indirectly” shall mean that SYSTEM has ownership of voting stock or other
voting interest of a legal entity (“Intermediate Entity”) that has

Page 3 of 41

 

	 	 	 	direct ownership of voting stock or other voting interest of the entity that operates a
BIOREFINERY in such manner that the result of the multiplication of the percentage of
SYSTEM ownership in the Intermediate Entity with the percentage of the Intermediate
Entity ownership in the entity operating the BIOREFINERY shall be equivalent to one
percent (1%) direct ownership, or more. For example, if the Intermediate Entity owns
ten percent (10%) of the entity operating the BIOREFINERY, SYSTEM must own ten percent
(10%) of the Intermediate Entity, or if the Intermediate Entity owns two percent (2%)
of the entity operating the BIOREFINERY, SYSTEM must own fifty percent (50%) of the
Intermediate Entity.
	 
	 	2.	 	“QUALIFYING EQUITY” shall mean voting stock or other voting interest which is
granted to SYSTEM, directly or Indirectly, (i) during the formation of a QSE in
exchange for contributions by SYSTEM to such formation; (ii) in exchange for sponsored
research or consulting performed by SYSTEM for a QSE; (iii) in exchange for the grant
of rights in intellectual property by SYSTEM; or (iv) one or more of the foregoing.
However, the discount referred to in this Article 4 shall not qualify as a
contribution for which voting stock or another voting interest is granted if it is the
sole such contribution.
	 
	 	3.	 	“BIOREFINERY” shall be any single location facility which converts raw plant
biomass into liquid transportation fuel and/or bioproducts, and/or uses biomass to
generate power or electricity.
	 
	 	4.	 	“LIST PRICE DISCOUNT” shall be fifteen percent (15%) off LIST PRICE.
	 
	 	5.	 	“BEST PRICE DISCOUNT” shall be five percent (5%) off BEST PRICE.
	 
	 	6.	 	“QUALIFYING CONDITIONS” shall be (i) that COMMERCIAL SEED orders shall be
PRE-PRODUCTION ORDERS; (ii) that all biomass grown from the COMMERCIAL SEED purchased
by a QSE will only be used by its BIOREFINERY; (iii) that payment is made as per the
“PAYMENT PROCEDURE;” and (iv) that QSE exclusively places orders in the calendar year
of the PRE-PRODUCTION ORDER with CERES for all non-grain-type sorghum seed. If a
COMPETITOR has voting stock or other voting interest in a QSE or has a CONFLICT PERSON
as a representative on the Board of Directors or other governing body of the entity, a
further QUALIFYING CONDITION shall be that the QSE must have entered into an exclusive
feedstock supply agreement with CERES as contemplated in Article 4.B.8.
	 
	 	7.	 	“PAYMENT PROCEDURE” shall be the payment of the ESTIMATED PRICE by QSE to
CERES in three tranches: fifteen percent (15%) at time of order, thirty-five (35%) at
production, and the remaining balance on delivery, with this final payment on delivery
adjusted to achieve payment of the DISCOUNT PRICE.
	 
	 	8.	 	“ESTIMATED PRICE” shall be, at the time of ordering, the lowest of the
following prices: the then-current LIST PRICE adjusted for the LIST PRICE DISCOUNT, or
the then-current BEST PRICE adjusted for the BEST PRICE DISCOUNT, provided however
that if the lowest of said adjusted prices result in CERES’ GROSS MARGIN on the sale
being reduced by more than twenty-five percent (25%), such adjusted price shall be
revised so that CERES’ GROSS MARGIN is reduced by exactly twenty-five percent (25%).
However, if CERES has granted discounts to

Page 4 of 41

 

	 	 	 	comparable customers in terms of their business relationship with CERES for comparable
orders of COMMERCIAL SEED of the same HYBRID in the TERRITORY placed at or around the
same time, resulting in CERES’ GROSS MARGIN being reduced by a percentage higher than
twenty-five percent (25%), such higher price percentage of GROSS MARGIN reduction shall
be substituted in the previous sentence.
	 
	 	9.	 	“DISCOUNT PRICE” shall be, at the time of delivery, the lowest of the
following prices: the then-current LIST PRICE adjusted for the LIST PRICE DISCOUNT, or
the then-current BEST PRICE adjusted for the BEST PRICE DISCOUNT, provided however
that if the lowest of said adjusted prices results in CERES’ GROSS MARGIN on the sale
being reduced by more than twenty-five percent (25%), such adjusted price shall be
revised so that CERES’ GROSS MARGIN is reduced by exactly twenty-five percent (25%).
However, if CERES has granted discounts to comparable customers in terms of their
business relationship with CERES for comparable orders of COMMERCIAL SEED of the same
HYBRID in the TERRITORY placed at or around the same time, resulting in CERES’ GROSS
MARGIN being reduced by a percentage higher than twenty-five percent (25%), such
higher price percentage of GROSS MARGIN reduction shall be substituted in the previous
sentence. In the case where the DISCOUNT PRICE is more than the ESTIMATED PRICE, the
DISCOUNT PRICE shall be the ESTIMATED PRICE, provided however that any production cost
increases will be added to such ESTIMATED PRICE, except if such increases are not
passed on by CERES to comparable customers in terms of their business relationship
with CERES for comparable orders of COMMERCIAL SEED of the same HYBRID in the
TERRITORY placed at or around the same time.
	 
	 	10.	 	“HYBRID” shall mean a seed or plant that has resulted from genetic
crossbreeding between two or more lines where those lines include one or more (i)
Lines under exclusive license from SYSTEM or (ii) New Parental Lines, and which seed
or plant is royalty bearing under a license to such a Line from SYSTEM to CERES.
	 
	 	11.	 	“GROSS MARGIN” shall mean, for a particular sale of COMMERCIAL SEED, NET
SALES less (i) COGS and (ii) royalties due to SYSTEM on such NET SALES.
	 
	 	12.	 	“NET SALES” shall be as defined in the Example License Agreement for Lines in
Appendix B.
	 
	 	13.	 	“COGS” shall mean cost of goods sold as determined by CERES on a consistent
basis in accordance with GAAP.
	 
	 	14.	 	“LIST PRICE” shall mean the published germplasm list price applied by CERES
at the time of delivery of the seed to the QSE for sale of COMMERCIAL SEED of the
relevant HYBRID to growers in the TERRITORY.
	 
	 	15.	 	“BEST PRICE” shall mean the germplasm price at which CERES is fulfilling
comparable orders of COMMERCIAL SEED of the relevant HYBRID in the TERRITORY to
comparable customers in terms of their business relationship with CERES to those
placed by the QSE at or around the same time. For the purposes of this definition,
all rebates offered to such customers shall be included in the calculation of the
germplasm price offered to such customers.

Page 5 of 41

 

	 	16.	 	“COMPETITOR” shall mean (i) any party that performs any of the following
activities: plant biotechnology, plant genomics or plant breeding, or development,
production or sale of sorghum or corn; (ii) Monsanto Company, E.I. DuPont de Nemours
and Company, Dow Chemical Company, Syngenta AG, BASF AG, Bayer AG and Mendel
Biotechnology, Inc., SorBio Energy Systems, Edenspace, Agrivida, Speedling, Targeted
Growth and FuturaGene or any successor to any part of such entity’s activities
relating to seed, plant biotechnology or plant genomics ; or (iii) any affiliate of
the entities listed in (i) or (ii). For purposes of this definition, ‘affiliate’
shall mean any company owned or controlled by, under common control with or
controlling the entities listed in (i) or (ii), with ‘control’ meaning in this context
the direct or indirect ownership of fifty percent (50%) or more of the voting
stock/shares of a company, or the power to nominate at least half of the directors.
	 
	 	17.	 	“CONFLICT PERSON” shall mean any employee of a COMPETITOR, or member of the
Board of Directors or Scientific Advisory Board, of a COMPETITOR, who is involved in
crop improvement activities.
	 
	 	18.	 	“COMMERCIAL SEED” shall mean HYBRID seed offered for sale in CERES’ catalog
that is sold for purposes other than the production of propagating material.
	 
	 	19.	 	“RECONDITIONING” shall mean retesting and/or rebagging seed returned to CERES
after the planting season.
	 
	 	20.	 	“TERRITORY” shall mean the United States of America.
	 
	 	21.	 	“PRE-PRODUCTION ORDERS” shall mean firm orders placed and accepted at least
eighteen (18) months prior to the applicable seed production season, so that the
applicable seeds may be planted and grown.
	 
	 	22.	 	“TRAIT FEE” shall mean any upfront or annual fee collected by CERES or any
AFFILIATED COMPANY in conjunction with NET SALES as an additional remuneration for the
sale of COMMERCIAL SEED that has a particular valuable trait or characteristic.
	 
	 	23.	 	“SERVICE FEE” shall mean any fee for services provided by CERES to growers,
BIOREFINERIES, the QSE or other relevant entities, including, but not limited to,
agronomy services, re-plant guarantees, quality assurance, quality determination,
consulting on variety selection.

B. Discounted Seed Sales by CERES to QSEs.

	 	1.	 	Subject to compliance with applicable law, CERES agrees to sell COMMERCIAL
SEED to any QSE (subject to Article 4.B.7) at a DISCOUNT PRICE under QUALIFYING
CONDITIONS. The QSE shall also be responsible for payment of any non-germplasm
related fees such as TRAIT FEES, SERVICE FEES, seed treatment etc. associated with the
relevant HYBRID. Any rebates on such non-germplasm related fees offered by CERES to
comparable customers in terms of their business relationship with CERES for comparable
orders of COMMERCIAL SEED of the relevant HYBRID in the TERRITORY to those placed by
the QSE at or around the same time shall also be offered to the QSE. Such obligation
shall apply,

Page 6 of 41

 

	 	 	 	with respect to each such QSE, for deliveries made within ten (10) years from the date
of the first delivery of COMMERCIAL SEED to such QSE.
	 
	 	2.	 	For a particular order of COMMERCIAL SEED by a QSE, CERES and the QSE shall
determine the DISCOUNT in good faith. If CERES and the QSE fail to reach agreement
within one hundred eighty (180) days after the start of such negotiations which shall
be evidenced by written notice from one party to the other initiating such
negotiations, the DISCOUNT shall be determined in accordance with the following
procedures: the dispute shall be referred to a mutually agreed impartial expert whose
decision shall be final. Each Party shall submit to the expert within fifteen (15)
days of his appointment its position in writing on the desired discount. Such expert
shall be limited to choosing the one of such two (2) party positions on the discount
and shall not make any other determination. Neither Party shall be bound by any
determination by the expert which, in the opinion of Party’s counsel, will result or
be likely to result in that Party violating any applicable law or regulation.
	 
	 	3.	 	COMMERCIAL SEED orders will be guaranteed and non-cancelable provided that
CERES will not be liable for failure to deliver COMMERCIAL SEED as a result of crop or
production failure (without limiting any obligation to refund any purchase price
paid). It is anticipated that under purchase agreements between CERES and the QSE the
QSE will own all returned or unplanted seed and will promptly return all such unused
seed to CERES for RECONDITIONING. CERES will receive a standard market rate for
RECONDITIONING.
	 
	 	4.	 	CERES will distribute COMMERCIAL SEED directly to the QSE. It is anticipated
that under purchase agreements between CERES and the QSE such seed will be provided by
the QSE to the grower in a CERES seed bag, under the CERES brand name, trademark, and
logo, with the requirement that the resulting biomass be delivered to the QSE and the
further requirement that if the seed is not used within a specified period of time
after delivery, the seed must be tested and only used if it meets the standards
specified by CERES.
	 
	 	5.	 	If SYSTEM materially breaches this Agreement or the SRA, CERES may give
SYSTEM written notice of the breach. SYSTEM shall have a period of sixty (60) days
from receipt of the notice to cure the breach. If SYSTEM does not cure the breach
within this period, CERES may terminate this Agreement without further notice, and/or
may sever the provisions of Article 4 of this Agreement. Unless CERES terminates for
breach as provided above, this Article 4 shall survive termination of this Agreement.
	 
	 	6.	 	CERES may in its discretion choose to license to a QSE certain LINES or NEW
PARENTAL LINES for COMMERCIAL SEED production on an annual basis under reasonable
commercial terms.
	 
	 	7.	 	No more than five (5) BIOREFINERIES may qualify for a DISCOUNT. Should
SYSTEM designate to CERES, within the period of time ending fifteen (15) years from
the Effective Date, BIOREFINERIES beyond such initial five (5), CERES agrees to enter
into good faith negotiations with SYSTEM to determine an appropriate discount for each
such additional BIOREFINERY and the qualifying conditions that each such BIOREFINERY
would be required to meet and restrictions that each such BIOREFINERY would be subject
to, in order to qualify for such

Page 7 of 41

 

	 	 	 	discount, taking into account then-current and projected market conditions and the
scope and nature of the use of the COMMERCIAL SEED by such BIOREFINERIES. If no
discount has been successfully negotiated within six (6) months of the commencement of
any negotiation on behalf of a particular BIOREFINERY as contemplated in this Article
4.B.7, CERES shall have no further obligation to negotiate with SYSTEM regarding such
discount or to grant any discount.
	 
	 	8.	 	For each QSE in which a COMPETITOR has voting stock or other voting interest,
or has a CONFLICT PERSON as a representative on the Board of Directors or other
governing body of the entity, CERES agrees to enter into good-faith negotiations with
such QSE for the purpose of entering into an exclusive feedstock supply agreement,
pursuant to which such QSE will purchase all cellulosic biomass to be used as
feedstock (other than (i) agricultural residues such as corn stover, wheat straw or
sugarcane bagasse (ii) in each QSE financial year, cellulosic biomass purchased from
growers with whom the QSE has no production or advance purchase contracts, up to five
percent (5%) of the total volume of cellulosic biomass purchased by the QSE in that
financial year) from a source or sources using CERES seed to produce the biomass
purchased, so as to enable the last-mentioned QUALIFYING CONDITION of Article 4.A.6 to
be met by such QSE.
	 
	 	9.	 	At its own expense, SYSTEM may annually inspect CERES’ books and records as
needed to verify compliance with this Article 4. CERES shall maintain such books and
records for at least three (3) years following the dates of the underlying
transactions. Any such inspections shall be in confidence and conducted during
ordinary business hours, not more than once a year, and SYSTEM will provide CERES
prior notice two (2) weeks before making such inspections. SYSTEM must employ an
independent Certified Public Accountant reasonably acceptable to CERES for this
purpose, who will only report to SYSTEM such information as necessary to determine
prices charged to QSEs and CERES’ compliance with any related obligations to SYSTEM.
If SYSTEM’s audit identifies an overcharge by CERES to any QSE(s) of five percent (5%)
or more and CERES does not dispute the findings of the audit, which will be fully
communicated in writing to CERES, the following shall apply: (i) CERES shall pay the
costs of SYSTEM’s audit, and (ii) CERES shall promptly pay all overcharges due as a
consequence of such audit to the QSE(s), with interest. If CERES disputes the
findings of the audit, Article 12 of the SRA, incorporated herein pursuant to Article
6.B hereof, shall apply.

Article 5. Milestones

A. Definitions.

	 	1.	 	“Research Milestone — Marker-Trait Association” shall mean the execution by
both Parties of an exclusive license agreement for a patented or patent pending
marker-trait association discovered in the Program, for a gene defined in the Program
in Appendix A to the SRA or by the Management Committee.
	 
	 	2.	 	“Research Milestone — Lines” shall mean the execution by both Parties of an
exclusive license agreement for a distinct Line (including related lines and
populations) developed in the Program.

Page 8 of 41

 

	 	3.	 	“Commercial Milestone” shall mean market introduction in the United States of
a Hybrid having at least one Line developed in the Program as a parental line and
which Hybrid is royalty bearing under an exclusive license to such Line from SYSTEM to
CERES.

B. Warrant.

	 	1.	 	Subject to CERES’ Board of Directors and shareholder approval, Article
1.A.(3), and agreement on the terms and conditions of the warrants, CERES shall issue
to SYSTEM a warrant to purchase up to a maximum of two hundred thousand (200,000) of
            shares of CERES’ Common Stock (the “Warrant”) at a defined price. The maximum
duration of the Warrant would be ten (10) years; early termination provisions may
apply. The Warrant would become exercisable in installments as follows:

	 	a)	 	equal installments of twenty five hundred (2,500) shares each
time a Research Milestone — Marker-Trait Association is reached; there will
be up to five (5) such installments;
	 
	 	b)	 	equal installments of twenty five hundred (2,500) shares each
time a Research Milestone — Lines is reached; there will be up to five (5)
such installments;
	 
	 	c)	 	equal installments of five thousand (5,000) shares each time
a Commercial Milestone is reached; there will be up to five (5) such
installments.

	 	2.	 	Each installment of shares will be quadruple the defined number, with respect
to each particular Milestone, if at the time such Milestone is achieved, (i) SYSTEM
has not breached, and is not in breach of any provision of the SRA, this Agreement
including the Guidelines for Future Collaborative Opportunities attached as Appendix C
or any license entered into pursuant to this Agreement, (ii) SYSTEM has not proceeded
to any activities (participation in an Additional Collaboration Project and/or use of
Lines or Hybrids developed in the Program) contrary to CERES’ expressed preference, as
referred to in clause 1.2 of the aforementioned Guidelines, and (iii) SYSTEM has not
collaborated or is not collaborating with, nor has granted rights to, any party other
than an academic organization for Germplasm Improvement (as defined in the SRA) of
Biomass/Bioenergy Sorghum (as defined in the SRA) intended to be used for the
bioenergy market.

C. Additional Commercial Milestones may be substituted for either type of Research Milestones up to
a total of ten (10) Commercial Milestone equivalents.

D. Mechanics of Warrant subject to advice of securities counsel.

E. For the avoidance of doubt, in no event shall the number of shares of CERES Common Stock the
subject of the Warrant exceed two hundred thousand (200,000) shares.

F. Unless CERES terminates for breach as provided in Paragraph 4.B.5 of this Agreement, this
Article 5 shall survive termination of this Agreement.

Page 9 of 41

 

Article 6. Miscellaneous

A. As an exception to Article 1.M of the SRA, CERES agrees that Chevron, Inc. may provide funding
to SYSTEM or TAES for Germplasm Improvement (as defined in the SRA) activities to be conducted by
TAES, provided that CERES shall have the same rights including, without limitation, options to
negotiate licenses, with respect to the results of such Chevron, Inc. funded Germplasm Improvement
activities as to the results of the Program (as defined in the SRA). The Guidelines for Future
Collaborative Opportunities in Appendix C will apply for Additional Collaboration Projects (as
defined in such Appendix) with Chevron, Inc.

B. This Agreement and the SRA constitute the entire agreement between the Parties relative to the
subject matter, and may be modified or amended only by a written agreement signed by both Parties.
The Parties hereby incorporate by reference Articles 12, 13 and 16 of the SRA as if set forth fully
herein.

     IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed by
their duly authorized representatives.

	 	 	 	 	 	 	 

	CERES, INC.
	 	 	 	THE TEXAS A&M UNIVERSITY SYSTEM	 	 
	 
	 	 	 	 	 	 
	/s/ Peter Mascia
 
Peter Mascia
	 	 	 	/s/ Mark A. Hussey
 
Mark A. Hussey	 	 
	Vice President of Product Development
	 	 	 	Director, Texas Agricultural Experiment Station	 	 
	Date: August 25, 2007
	 	 	 	Date: 8-29-2007	 	 
	 
	 	 	 	 	 	 
	/s/ Richard Hamilton 
Richard Hamilton
	 	 	 	/s/ Elsa Murano 
Elsa Murano	 	 
	President & Chief Executive Officer
	 	 	 	Vice Chancellor & Dean of College of Agriculture and Life Sciences	 	 
	Date: August 29, 2007
	 	 	 	Date: 8-29-07	 	 
	 
	 	 	 	 	 	 
	 	 	 	 	/s/ Guy K. Diedrich 
Guy K. Diedrich	 	 
	 	 	 	 	Vice Chancellor for
Technology Commercialization	 	 
	 	 	 	 	Date: August 29, 2007	 	 

Page 10 of 41

 

Appendix A

to the Intellectual Property Rights Agreement

between Ceres, Inc. and The Texas A&M University System

Example License Agreement for Subject Inventions

LICENSE AGREEMENT

Between

Ceres, Inc.

and

The Texas A&M University System

     This agreement (“Agreement”) is made and entered into by and between Ceres, Inc., a
corporation with principal offices in Thousand Oaks, California, (“LICENSEE”) and The Texas A&M
University System with principal offices in College Station, Texas, (“SYSTEM”), an agency of the
State of Texas, collectively referred to as “Parties” and individually as “Party.”

W I T N E S S E T H :

     WHEREAS, SYSTEM and LICENSEE have entered into a Sponsored Research Agreement dated [xxxx]
(the “SRA”) and an associated Intellectual Property Rights Agreement (“IPRA”);

     WHEREAS, pursuant to the SRA a Subject Invention (as defined in the SRA) was created in which
SYSTEM has ownership rights; such Subject Invention relates to “ “ (the “Subject Invention”);

     WHEREAS, SYSTEM desires that such intellectual property be commercialized for the public
benefit and welfare; and

     WHEREAS, LICENSEE has represented that it has certain marketing, engineering and financial
capabilities, and that it shall commit itself to a thorough and diligent program of development and
commercialization of SYSTEM’s intellectual property for public benefit; and

     WHEREAS, SYSTEM is willing to grant to LICENSEE, and LICENSEE is willing to accept, a license
to use the Subject Invention, upon the terms and conditions set forth below.

     NOW THEREFORE, in consideration of the mutual covenants and premises contained in this
Agreement, the receipt and sufficiency of which is acknowledged, the Parties agree as follows:

ARTICLE I — DEFINITIONS

	1.01	 	“LICENSED TECHNOLOGY” shall mean the Subject Invention relating to SYSTEM Disclosure of
Invention Number ________ entitled “_________________.”

Page 11 of 41

 

	1.02	 	“PATENT RIGHTS” shall mean each United States patent application filed for protection of
LICENSED TECHNOLOGY; each patent issuing from the foregoing applications; each divisional,
continuation, or continuation-in-part application of the foregoing United States applications;
each equivalent patent application in each country other than the United States which claims
priority under such applications; each patent issuing from the foregoing applications; and
each extension or reissue of such patents.
	 
	1.03	 	“LICENSED PRODUCT” or “LICENSED PRODUCTS” shall mean any product, process, or composition of
matter that is within the scope of any Valid Claim of PATENT RIGHTS. Valid Claim shall mean
and include a claim of a patent application or an unexpired patent or a patent whose
expiration date has been extended by law, so long as such claim shall not have been held
invalid and/or unenforceable in an unappealed or unappealable decision of a court or other
authority of competent jurisdiction.

[Note: The Parties expect to expand the grant to Copyrights as required.]

	1.04	 	“EFFECTIVE DATE” shall mean the date this Agreement has been executed by the last Party.
	 
	1.05	 	“NET SALES” shall mean LICENSEE’s and AFFILIATED COMPANIES’ receipts for sales of LICENSED
PRODUCTS or for SERVICES requiring the use of LICENSED PRODUCTS less the sum of the following:

	 	(a)	 	sales taxes, tariffs, duties and/or use taxes directly
imposed with reference to particular sales;
	 
	 	(b)	 	outbound transportation prepaid or allowed, shipping,
packaging, cost of insurance in transit paid by LICENSEE or an AFFILIATED
COMPANY;
	 
	 	(c)	 	amounts allowed or credited on returns;
	 
	 	(d)	 	customary trade, quality or cash discounts; and
	 
	 	(e)	 	[other deductions which are appropriate to sales of the
LICENSED PRODUCTS may be included.]

	 	 	No deductions shall be made for commissions paid to individuals whether independent sales
agencies or regularly employed by LICENSEE, or for the cost of collections. The value of
sample size quantities of LICENSED PRODUCTS provided for free shall not be included in NET
SALES. Where there is no identifiable sale price (except for samples as referred to in the
previous sentence) or when a LICENSED PRODUCT is sold to other than bona fide, arms length
customers of LICENSEE or any AFFILIATED COMPANY, LICENSEE or the AFFILIATED COMPANY shall
be deemed to have received an amount of NET SALES calculated based on the final sale of the
LICENSED PRODUCTS (wholesale level) to an independent third party. If no such current price
is available, a hypothetical fair market value price will be determined by the Parties
jointly in good faith for the purpose of calculating NET SALES. If trait fees are charged
by LICENSEE specifically for the LICENSED TECHNOLOGY, these fees shall be added to NET
SALES.
	 
	1.06	 	“LICENSE INCOME” shall mean the amount actually received by either LICENSEE or any AFFILIATED
COMPANY in consideration for the grant of sublicenses to sublicensees that are not AFFILIATED
COMPANIES to produce and sell LICENSED

Page 12 of 41

 

	 	 	PRODUCTS, including up-front fees, lump sum payments and any other non-running
royalty-based payments made on a product-by-product and jurisdiction-by-jurisdiction basis.
	 
	1.07	 	“AFFILIATED COMPANY” shall mean any company owned or controlled by, under common control with
or controlling LICENSEE, “control” meaning in this context the direct or indirect ownership of
more than fifty percent (50%) of the voting stock/shares of a company, or the power to
nominate at least half of the directors.
	 
	1.08	 	“SERVICE” shall mean any transaction with a third party in which LICENSEE or an AFFILIATED
COMPANY performs certain activities on behalf and at the request of a third party that would
if not performed by LICENSEE or an AFFILIATED COMPANY require a license under SYSTEM’S PATENT
RIGHTS licensed hereunder, in exchange for payment, but excluding any research collaboration
or sponsored research agreement.

ARTICLE II — LICENSE GRANT

	2.01	 	Grant. SYSTEM grants to LICENSEE and its AFFILIATED COMPANIES an exclusive world-wide license
and right under PATENT RIGHTS to make, have made, use, and sell the LICENSED PRODUCTS and to
perform SERVICES, and to grant sublicenses of the same scope, to the end of the term of this
Agreement as prescribed in Article VIII.
	 
	2.02	 	Reservation. SYSTEM reserves an irrevocable, worldwide, nonexclusive, royalty-free right to
practice the grant made in Article 2.01 for research and educational purposes only, and not
for commercial purposes or for the commercial benefit of third parties. SYSTEM shall comply
with the provisions of the SRA and the IPRA when exercising this right.
	 
	2.03	 	Government Reservation. Rights under this Agreement are subject to rights required to be
granted to the Government of the United States of America pursuant to 35 USC Section 200-212,
including a nonexclusive, nontransferable, irrevocable, paid-up license to practice or have
practiced for or on behalf of the United States the Subject Inventions throughout the world.

ARTICLE III — CONSIDERATION

	3.01	 	[Optional. Depends on CERES’ contributions to Subject Invention and the value of the Subject
Invention. Can be alternative to royalties in case Subject Invention will only be used
internally by CERES.] License Fee. In consideration for the license granted in this
Agreement, LICENSEE shall make an initial payment in the amount of ___________ dollars
($________). Such payment shall be due no later than thirty (30) days following the EFFECTIVE
DATE. Failure to make this payment within the specified period shall cause this Agreement to
immediately terminate.
	 
	3.02	 	Royalty Rate. As [additional] consideration for the license granted in this Agreement,
LICENSEE shall remit to SYSTEM a royalty of ____ percent (__%) of NET SALES. [Take into
account stacking with other technologies and value of licensed technology to determine rate.]

Page 13 of 41

 

	3.03	 	[Optional] Minimum Annual Consideration. In order to maintain this exclusive license to
PATENT RIGHTS, LICENSEE shall pay to SYSTEM minimum annual consideration in accordance with
the following schedule:

	 	 	 	 	 	 	 	 	 

	 	(a	)	 	Calendar Year 200
	 	$	__________	 
	 	 	 	 	 
	 	 	 	 
	 	(b	)	 	Calendar Years 200 and 200
	 	$	__________	 
	 	 	 	 	 
	 	 	 	 
	 	(c	)	 	Calendar Year 200 and every year thereafter
through the expiration of this Agreement
	 	$	__________	 

	 	 	In the event that LICENSEE’s payment of royalties for the Calendar Year due under Article
3.02 do not meet or exceed the required minimum annual consideration, as specified in this
Article, LICENSEE’s royalty payment for the last quarter of such Calendar Year shall
include payment of the balance needed to achieve the required minimum. In the event this
Agreement expires or is terminated prior to the end of a Calendar Year, the corresponding
minimum annual consideration provided for in this Article shall be prorated for that year.
	 
	3.04	 	Patent Expenses [Reimbursement]. As additional consideration for the license granted in this
Agreement, LICENSEE shall bear the expenses incurred in the prosecution and maintenance of
PATENT RIGHTS, as further described in Article VI.
	 
	3.05	 	If an exclusive license reverts to or is non-exclusive pursuant to Articles 3.02, 5.02 or
6.05, or upon LICENSEE’s election, a lower royalty rate shall be negotiated in good faith
between the Parties. The start of such negotiations shall be evidenced by written notice from
one Party to the other initiating such negotiations, and such negotiations shall not extend
beyond ninety (90) days from the start thereof without the mutual consent of both Parties
(“Negotiation Period”). If the Parties fail to reach agreement within the Negotiation Period,
the lower royalty rate shall be settled in accordance with the following procedures: the
disputed royalty rate shall be referred to a mutually agreed impartial expert whose decision
shall be final. Each Party shall submit to the expert within fifteen (15) days of his
appointment its position in writing on the disputed royalty rate. Such expert shall be
limited to choosing the one of such two (2) party positions that the expert considers most
reasonable in the circumstances and shall not make any other determination. Neither Party
shall be bound by any determination by the expert which, in the opinion of Party’s counsel,
will result or be likely to result in that Party violating any applicable law or regulation.

ARTICLE IV — SUBLICENSES

	4.01	 	Sublicenses. LICENSEE and its AFFILIATED COMPANIES may grant sublicenses to persons, firms or
corporations under such conditions as it may arrange, as consistent with this Agreement, as
long as each such sublicense is not repugnant to the public policies of SYSTEM, the State of
Texas, or the United States.
	 
	4.02	 	Sublicensee Consideration. Sales of LICENSED PRODUCTS by each sublicensee shall be subject to
the unit royalty due to SYSTEM prescribed in Article 3.02. Further, LICENSEE shall pay to
SYSTEM a royalty of ____ percent (%) LICENSE INCOME. [Take into account stacking
with other technologies and value of licensed technology to determine rate.]

Page 14 of 41

 

	4.03	 	Reporting. LICENSEE shall notify SYSTEM of the grant of sublicense to a third party and
provide a redacted copy of the sublicense to SYSTEM. LICENSEE shall not redact any
information unless it could be reasonably considered sensitive to LICENSEE’s business. Upon
reasonable notice by SYSTEM, SYSTEM may through an attorney-at-law review an unredacted copy
of the sublicense but shall not provide any redacted information to business persons within
SYSTEM. LICENSEE shall also provide SYSTEM with the name, address and scope of each
sublicense and a copy of each sublicensee’s report as is pertinent to calculation of amounts
due SYSTEM under this Agreement.
	 
	4.04	 	Non-Cash Transactions. Where there is no identifiable LICENSE INCOME, a hypothetical fair
market value price will be determined by the Parties jointly in good faith for the purpose of
calculating LICENSE INCOME.

ARTICLE V — LICENSEE RESPONSIBILITIES

	5.01	 	Milestones. In accomplishing the commercialization under this Agreement, LICENSEE shall
demonstrate to the satisfaction of SYSTEM achievement of the following milestones:
	 
	 	 	EXAMPLE: LICENSEE shall complete development of a commercial prototype of a LICENSED
PRODUCT no later than _____ months following EFFECTIVE DATE.
	 
	 	 	EXAMPLE: LICENSEE shall record first sales of LICENSED PRODUCTS no later than ______ months
following EFFECTIVE DATE.
	 
	 	 	Other Milestones to be defined upon the basis of LICENSEE’s business plan for
LICENSED PRODUCTS.
	 
	 	 	LICENSEE shall provide written notification to SYSTEM within thirty (30) days of achieving
each milestone.
	 
	 	 	[Milestones may be substituted or postponed by payments to be agreed for each particular
license agreement.]
	 
	5.02	 	Failure to Accomplish Milestones. Should LICENSEE fail to achieve any milestone specified in
Article 5.01, or should LICENSEE fail to record NET SALES for two (2) consecutive Calendar
Years once sales begin, SYSTEM, at its sole option and as its sole remedy, may waive the
requirement to achieve the milestone, may revise the license granted herein to a non-exclusive
license, or may renegotiate the missed milestone.
	 
	5.03	 	Legal Compliance. LICENSEE must comply with all applicable federal, state and local laws and
regulations in its exercise of all rights granted to it by SYSTEM under this Agreement.
	 
	5.04	 	No Royalties for Sales to U.S. Government. In accordance with 35 USC Section 200-212,
LICENSEE has no duty to pay SYSTEM royalties under this Agreement on NET SALES made to the
United States Government, including any United States Government agency. LICENSEE shall
reduce the amount charged for a LICENSED PRODUCT sold to the United States Government by an
amount equal to the royalty otherwise due SYSTEM.

Page 15 of 41

 

	5.05	 	U.S. Manufacture. In accordance with 35 USC Section 200-212, LICENSED PRODUCTS shall be
manufactured substantially in the United States of America.

ARTICLE VI — PATENTS

	6.01	 	Filing. SYSTEM will have the right to prepare and file, in accordance with its best
judgment, any and all applications for patents covering LICENSED TECHNOLOGY in the United
States that are solely owned by SYSTEM and LICENSEE will have the right to prepare and file
such applications for LICENSED TECHNOLOGY jointly owned by LICENSEE and SYSTEM. Applications
for patents shall be filed in the name of SYSTEM if owned by SYSTEM pursuant to the SRA and in
the joint names of SYSTEM and LICENSEE if jointly owned pursuant to the SRA. At LICENSEE’s
discretion, patents applications may be filed in any other jurisdiction in the world.
	 
	6.02	 	Abandoning patent applications. The following rules shall apply with respect to applications
for patents or SYSTEM owned or jointly owned LICENSED TECHNOLOGY. If the party controlling
prosecution intends to abandon any patent application or patent that party shall first give
sufficient written notice to the other party to permit the other party the opportunity to
assume such filing, examination and/or maintenance. LICENSEE and SYSTEM will consult with
regard to protection of LICENSED TECHNOLOGY.
	 
	6.03	 	Jurisdictions. The obligations of this Article 6.03 shall not apply to any jurisdictions in
which the prosecuting party has elected not to apply for intellectual property protection.
LICENSEE and SYSTEM shall avoid carrying out any act that would prejudice the grant of patent
rights.
	 
	6.04	 	Patent Maintenance. SYSTEM shall maintain at least one U.S. patent resulting from the
prosecution described hereinabove.
	 
	6.05	 	Election not to file. LICENSEE will direct SYSTEM in writing no later than nine (9) months
following the date of filing for each U.S. patent application as to LICENSEE’s selection of
countries outside the United States in which SYSTEM shall seek corresponding patent
protection. SYSTEM shall then have the right to file corresponding patent applications at its
own expense in those countries not selected by LICENSEE; however, the license granted to
LICENSEE in this Agreement shall be non-exclusive in the countries where SYSTEM has filed and
is prosecuting patents or applications at its own expense.
	 
	6.06	 	Prosecution and Maintenance of Non-U.S. Patents. Should LICENSEE select a country other than
the United States in which to file each corresponding patent application, and subsequently
elects not to continue to reimburse SYSTEM for the diligent prosecution and maintenance of
such patent or patent application, it shall so notify SYSTEM at least three (3) months prior
to taking (or not taking) any action which would result in abandonment, withdrawal, or lapse
of such patent or application. SYSTEM shall then have the right to continue maintenance or
prosecution of each such patent or application at its own expense; however, expenses incurred
prior to the point of LICENSEE taking (or not taking) such action shall remain the
responsibility of LICENSEE. The license granted to LICENSEE in this Agreement shall revert to
non-exclusive in the countries

Page 16 of 41

 

	 	 	where SYSTEM is maintaining or prosecuting such patent or application at its own expense.
	 
	6.07	 	Financial Responsibility. Except as set forth in Articles 6.05 and 6.06, LICENSEE shall
reimburse SYSTEM for all expenses incurred by SYSTEM in filing, prosecuting, and maintaining
each patent application and patent under PATENT RIGHTS. LICENSEE shall provide payment as
reimbursement of SYSTEM’s documented expenses incurred in filing, prosecuting or maintaining
patent applications or patents as described above within thirty (30) days of receipt of
SYSTEM’s supporting invoice. SYSTEM shall use patent counsel reasonably acceptable to
LICENSEE. LICENSEE acknowledges, however, that SYSTEM’s patent counsel must be approved by
the Attorney General of the State of Texas.
	 
	6.08	 	Information. SYSTEM shall disclose to LICENSEE the complete texts of all patent applications
filed by SYSTEM under PATENT RIGHTS as well as all information received concerning office
actions, the institution or possible institution of any interference, opposition,
re-examination, reissue, revocation, nullification or any other official proceeding involving
PATENT RIGHTS, all in a timely manner so as to allow LICENSEE to provide input i.e. at least
thirty (30) days before a filing needs to be made or a decision needs to be taken. SYSTEM
shall provide to LICENSEE the opportunity to provide input to the development of each patent
application and any official proceedings thereafter, and will take such input into account.

ARTICLE VII — PAYMENTS AND REPORTS

	7.01	 	When Payments are Due. Unless otherwise specified, payments shall be made annually. Payments
shall be made to The Texas A&M University System, in College Station, Texas, not later than
sixty (60) days after the last day of the calendar year in which they accrue.
	 
	7.02	 	Royalty Reports. LICENSEE shall provide a sales report to SYSTEM each year, providing
information sufficient to allow SYSTEM to calculate amounts due SYSTEM for the reporting
period, in the form attached hereto as ANNEX I.
	 
	7.03	 	Currency. Payment due to SYSTEM shall be paid in U.S. dollars. Royalty payments requiring
conversion shall use the exchange rate as reported in The Wall Street Journal on the
last business day of the royalty reporting period.
	 
	7.04	 	Inspection of Books and Records. At its own expense, SYSTEM may annually inspect LICENSEE’s
books and records as needed to determine royalties payable. LICENSEE shall maintain such books
and records for at least three (3) years following the dates of the underlying transactions.
Any such inspections shall be in confidence and conducted during ordinary business hours, and
SYSTEM will provide LICENSEE prior notice two (2) weeks before making such inspections. SYSTEM
must employ an independent Certified Public Accountant reasonably acceptable to LICENSEE for
this purpose, who will only report to SYSTEM such information as necessary, to determine
royalties payable to SYSTEM and LICENSEE’s compliance with any related obligations to SYSTEM.
If SYSTEM’s audit identifies a shortage of five percent (5%) or more of amounts due to SYSTEM,
then LICENSEE shall pay the costs of SYSTEM’s audit. LICENSEE shall pay all amounts due as a
consequence of such audit to SYSTEM promptly, with interest.

Page 17 of 41

 

	7.05	 	Interest Charges. Overdue payments may, at the sole discretion of SYSTEM, be subject to a
daily charge commencing on the 31st day after such payment is due, compounded monthly, at the
rate of either one and one-half percent (1.5%) per month or the highest legal interest rate,
whichever is lower. The payment of such interest will not foreclose SYSTEM from exercising any
other rights it may have as a consequence of the lateness of any payment.

ARTICLE VIII — TERM AND TERMINATION

	8.01	 	Expiration. This Agreement, unless sooner terminated as provided herein, shall remain in
effect on a country-by-country basis until (a) failure of SYSTEM to obtain at least one issued
patent for protection of LICENSED TECHNOLOGY, (b) expiration of the last to expire patent
under PATENT RIGHTS, or (c) final and unappealable determination by a court of competent
jurisdiction that PATENT RIGHTS are invalid.
	 
	8.02	 	Termination by Licensee. LICENSEE may terminate this Agreement by providing written notice
to SYSTEM at least ninety (90) days before the termination is to take effect.
	 
	8.03	 	Termination by System. If LICENSEE materially breaches this Agreement, SYSTEM may give
LICENSEE written notice of the breach. LICENSEE shall have a period of sixty (60) days from
receipt of the notice to cure the breach. If LICENSEE does not cure the breach within this
period, SYSTEM may terminate this Agreement in writing without further notice.
	 
	8.04	 	Matters Surviving Termination. All accrued obligations and claims, including reimbursement
of patent expenses, license fee obligations, royalty obligations, minimum annual consideration
obligations, interest charge obligations, and all other financial obligations, and claims or
causes of action for breach of this Agreement, shall survive termination of this Agreement.
Obligations of confidentiality shall survive termination of this Agreement. This section
controls in the case of a conflict with any other section of this Agreement.

ARTICLE IX — INDEMNIFICATION AND REPRESENTATION

	9.01	 	Indemnification. LICENSEE SHALL AT ALL TIMES DURING THE TERM OF THIS AGREEMENT AND THEREAFTER
INDEMNIFY, DEFEND, AND HOLD HARMLESS SYSTEM, ITS REGENTS, OFFICERS, AND EMPLOYEES AGAINST ANY
CLAIM, PROCEEDING, DEMAND, LIABILITY OR EXPENSE (INCLUDING LEGAL EXPENSE AND REASONABLE
ATTORNEYS’ FEES) WHICH RELATES TO INJURY TO PERSONS OR TO PROPERTY, ANY ACTION BROUGHT BY A
THIRD PARTY ALLEGING INFRINGEMENT OF INTELLECTUAL PROPERTY RIGHTS, OR AGAINST ANY OTHER CLAIM,
PROCEEDING, DEMAND, EXPENSE, AND LIABILITY OF ANY KIND WHATSOEVER RESULTING FROM THE
PRODUCTION, MANUFACTURE, SALE, COMMERCIAL USE, LEASE, CONSUMPTION, OR ADVERTISEMENT OF
LICENSED PRODUCTS OR ARISING FROM ANY OBLIGATION OF LICENSEE OR SUBLICENSEE(S) UNDER THIS
AGREEMENT AND NOT CAUSED BY BREACH OF THIS AGREEMENT BY SYSTEM (HEREINAFTER JOINTLY REFERRED
TO AS “CLAIMS”), PROVIDED THAT SYSTEM SHALL

Page 18 of 41

 

	 	 	PROMPTLY PROVIDE WRITTEN NOTICE OF ANY CLAIM TO LICENSEE, AND THAT, SUBJECT TO THE APPROVAL
OF THE ATTORNEY GENERAL OF THE STATE OF TEXAS, LICENSEE SHALL HAVE THE RIGHT TO CONDUCT THE
DEFENSE OF ANY CLAIM, AND THAT SYSTEM SHALL COOPERATE WITH LICENSEE AS LICENSEE MAY REQUEST
IN ANY SUCH DEFENSE, AT LICENSEE’S REQUEST AND EXPENSE.
	 
	9.02	 	Representation. SYSTEM represents that it owns and has title to PATENT RIGHTS and has the
full right and power to grant the license set forth in Article 2.01, and that there are no
outstanding agreements, assignments, or encumbrances inconsistent with the provisions of this
Agreement. SYSTEM MAKES NO OTHER REPRESENTATIONS AND EXTENDS NO OTHER WARRANTIES OF ANY KIND,
EITHER EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO WARRANTIES OF MERCHANTABILITY OR
FITNESS FOR A PARTICULAR PURPOSE, NOR DOES SYSTEM ASSUME ANY OBLIGATIONS WITH RESPECT TO
INFRINGEMENT OF PATENT RIGHTS OR OTHER RIGHTS OF THIRD PARTIES DUE TO LICENSEE’S ACTIVITIES
UNDER THIS AGREEMENT.

ARTICLE X — NOTICES

	10.01	 	Notices. Payments, notices, or other communications required by this Agreement shall be
sufficiently made or given if mailed by certified First Class United States mail, postage
pre-paid, or by commercial carrier (e.g., FedEx, UPS, etc.) when such carrier maintains
receipt or record of delivery, addressed to the address stated below, or to the last address
specified in writing by the intended recipient.
	 
	 	 	If to SYSTEM:

Executive Director

Office of Technology Commercialization

3369 TAMU

College Station, Texas, USA 77843-3369

	 	 	 

	If to LICENSEE for Legal Matters:

	 	for Financial Matters:
	Director of Business Development

	 	Director of Business Development
	cc: Legal Department

	 	cc: Controller
	Ceres, Inc.

	 	Ceres, Inc.
	1535 Rancho Conejo Blvd.

	 	1535 Rancho Conejo Blvd.
	Thousand Oaks, CA 91320

	 	Thousand Oaks, CA 91320

ARTICLE XI — MISCELLANEOUS PROVISIONS

	11.01	 	Notice of Infringement. SYSTEM and LICENSEE shall promptly notify one another in writing of
any alleged infringement of any PATENT RIGHTS. Within thirty (30) days after receipt of such
notice, SYSTEM and LICENSEE shall formulate a strategy for resolving the alleged infringement.
LICENSEE acknowledges that SYSTEM’s involvement, participation, and representation in any
litigation requires the prior written consent of SYSTEM and the Attorney General of the State
of Texas, and subject to the granting of that consent, SYSTEM may be joined as a party in any
action brought by LICENSEE, so long as LICENSEE shall pay all of SYSTEM’s reasonable costs and
expenses. LICENSEE will have the right, at its own discretion and expense, to take any

Page 19 of 41

 

	 	 	action to enforce and to initiate and prosecute suits for infringement PATENT RIGHTS
covering jointly owned Subject Inventions. LICENSEE and SYSTEM will consult with each
other upon a course of action and enforcement strategy. LICENSEE will be responsible for
the conduct of any such enforcement action, and SYSTEM will reasonably cooperate with
LICENSEE to effect the enforcement action, and if appropriate, determine a settlement
position. LICENSEE shall be responsible for retaining counsel but will consult with SYSTEM
and retain counsel reasonably acceptable to SYSTEM. For purposes of settlement, LICENSEE
shall be the contact with the Parties’ counsel as well as the opposing Party(ies) and shall
have the right to enter into settlements. LICENSEE shall keep SYSTEM advised as to all
developments with respect to the enforcement action and settlement discussions, which
includes supplying to SYSTEM copies of all papers received and filed in sufficient time for
SYSTEM to comment thereon. SYSTEM may attend any and all meetings with the Parties’
counsel and the opposing side for settlement purposes. If necessary, and subject to the
consent of the Attorney General of the State of Texas, SYSTEM agrees to enter into a joint
defense agreement. Any damages received by LICENSEE as a result of an enforcement action
of rights to jointly owned Subject Inventions, after deduction of all enforcement related
costs incurred by LICENSEE, shall be considered as NET SALES or LICENSE INCOME, as
appropriate, for the purpose of remuneration payments to SYSTEM.
	 
	11.02	 	Export Controls. It is understood that SYSTEM is subject to United States laws and
regulations controlling the export of technical data, computer software, laboratory prototypes
and other commodities, and that its obligations hereunder are contingent on compliance with
applicable United States export laws and regulations. The transfer of certain technical data
and commodities may require a license from the cognizant agency of the United States
Government or written assurances by LICENSEE that LICENSEE shall not export data or
commodities to certain countries without prior approval of such agency. SYSTEM neither
represents that a license shall not be required nor that, if required, it shall be issued.
	 
	11.03	 	Confidential Information. Sales reports submitted by LICENSEE under Article VII and audit
reports made pursuant to Article 7.04 shall be considered as Confidential Information under
this Agreement and shall not be disclosed by SYSTEM to any third party except as may be
required in response to a valid order of a court or other government body of the United States
or any political subdivision thereof, as required under the Texas Public Information Act.
Should the Parties contemplate exchange of other information of a confidential nature, they
shall enter into a separate confidentiality agreement.
	 
	11.04	 	Non-Use of Names. LICENSEE shall not use the names of The Texas A&M University System, nor
of any of its employees or components, nor any adaptation thereof, in any advertising,
promotional or sales literature without the prior written consent obtained from SYSTEM in each
case, except that LICENSEE may state that it is licensed by SYSTEM under PATENT RIGHTS.
	 
	11.05	 	Trademarks. LICENSEE may select, own and use its own trademark on LICENSED PRODUCTS.
However, nothing herein shall be construed as granting to LICENSEE any license or other right
under any trade name, trademark, or service mark owned or licensed by SYSTEM. Conversely,
SYSTEM shall have no rights to trade names, trademarks, or service marks owned by LICENSEE.

Page 20 of 41

 

	11.06	 	Assignment of this Agreement. This Agreement binds and enures to the benefit of the
Parties, their successor or assigns, but may not be assigned by either Party without the prior
written consent of the other Party; provided however, LICENSEE shall have the right to assign
its rights and obligations under this Agreement to any AFFILIATED COMPANY without such prior
consent, but with written notice to SYSTEM. LICENSEE shall also have the right to assign its
rights and obligations under this Agreement to a third party in conjunction with the transfer
to such third party of substantially all of the assets of LICENSEE associated with performance
under this Agreement without such prior consent.
	 
	11.07	 	Force Majeure. Other than an obligation for the payment of money, SYSTEM, upon receipt of
documentation from LICENSEE which it deems appropriate, shall excuse any breach of this
Agreement, which is proximately caused by war, strike, act of God, or other similar
circumstance normally deemed outside the control of well-managed businesses.
	 
	11.08	 	Entire Agreement. Other than the SRA and the IPRA this Agreement contains the entire
understanding of the Parties with respect to PATENT RIGHTS, and supersedes all other written
and oral agreements between the Parties with respect to PATENT RIGHTS. It may be modified
only by a written amendment signed by the Parties.
	 
	11.09	 	Governing Law. The validity, interpretation, and enforcement of this Agreement shall be
governed and determined by the laws of the State of Texas, excluding the conflict of laws
rules which might require the application of the laws of another jurisdiction.
	 
	11.10	 	Disputes.
	 
		 	A. The Parties shall make every possible attempt to resolve in an amicable manner all
disputes betweem the Parties concerning the interpretation of this Agreement.
	 
		 	B. The Parties must use the dispute resolution process provided in Chapter 2260, Texas
Government Code, and the related rules adopted by the Texas Attorney General to attempt to
resolve any claim for breach of contract made by LICENSEE that cannot be resolved in the
ordinary course of business. LICENSEE must submit written notice of a claim of breach of
contract under this Chapter to B.J. Crain, Associate Vice Chancellor, who will examine
LICENSEE’s claim and any counterclaim and negotiate with LICENSEE in an effort to resolve
the claim.
	 
	11.11	 	Headings. Headings appear solely for convenience of reference. Such headings are not part
of, and shall not be used to construe, this Agreement.
	 
	11.12	 	No Waiver; Severability. No waiver of any breach of this Agreement shall constitute a
waiver of any other breach of the same or other provision of this Agreement and no waiver
shall be effective unless made in writing. This Agreement, to the greatest extent
possible, shall be construed so as to give validity to all of the provisions hereof. If any
provision of this Agreement is or becomes invalid, is ruled illegal by a court of competent
jurisdiction or is deemed unenforceable under the current applicable law from time to time in
effect during the term of this Agreement, the remainder of this Agreement will not be affected
or impaired thereby and will continue to be construed to the maximum extent permitted by law.
In lieu of each provision which is invalid, illegal or

Page 21 of 41

 

	 	 	unenforceable, there will be substituted or added as part of this Agreement by mutual
written agreement of the Parties, a provision which will be as similar as possible, in
economic and business objectives as intended by the Parties to such invalid, illegal or
unenforceable provision, but will be valid, legal and enforceable.
	 
	11.13	 	Damages. Neither Party shall be liable for indirect, special, remote, incidental or
consequential damages or loss of profit in connection with this Agreement or its
implementation.

The Parties have caused this Agreement to become effective as of the date last executed below.

	 	 	 	 	 	 	 	 	 

	CERES, INC.	 	 	 	THE TEXAS A&M UNIVERSITY SYSTEM	 	 
	 
	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	By:

	 	 	 	 	 	Guy K. Diedrich	 	 
	 

	 	 

	 	 	 	Vice Chancellor Federal Relations,	 	 
	Title:

	 	 	 	 	 	Research and Commercialization	 	 
	 

	 	 

	 	 
	 	Date:
                                        
	 	 
	Date:

	 	 	 	 	 		 	 
	 

	 	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	By:
	 	 	 	 	 	 	 	 
	 

	 	 

	 	 	 	 	 	 
	Title:
	 	 	 	 	 	 	 	 
	 

	 	 

	 	 	 	 	 	 
	Date:
	 	 	 	 	 	 	 	 
	 

	 	 

	 	 	 	 	 	 

Page 22 of 41

 

ANNEX I

to the Example License Agreement for Subject Inventions

between Ceres, Inc. and The Texas A&M University System

Royalty Report

[template to be developed during negotiations of license]

Page 23 of 41

 

Appendix B

to the Intellectual Property Rights Agreement

between Ceres, Inc. and The Texas A&M University System

Example License Agreement for Lines

LICENSE AGREEMENT

Between

Ceres, Inc.

and

The Texas A&M University System

     This agreement (“Agreement”) is made and entered into by and between Ceres, Inc., a
corporation with principal offices in Thousand Oaks, California, (“LICENSEE”) and The Texas A&M
University System with principal offices in College Station, Texas, (“SYSTEM”), an agency of the
State of Texas, collectively referred to as “Parties” and individually as “Party.”

W I T N E S S E T H :

     WHEREAS, SYSTEM and LICENSEE have entered into a Sponsored Research Agreement dated [xxxx]
(the “SRA”) as well as an associated Intellectual Property Rights Agreement (“IPRA”);

     WHEREAS, pursuant to the SRA certain Lines (as defined in the SRA and further defined in
ANNEX I hereto) were created in which SYSTEM has ownership rights;

     WHEREAS, SYSTEM desires that such Lines be commercialized for the public benefit and welfare;
and

     WHEREAS, LICENSEE has represented that it has certain marketing, engineering and financial
capabilities, and that it shall commit itself to a thorough and diligent program of development and
commercialization of such Lines for public benefit; and

     WHEREAS, SYSTEM is willing to grant to LICENSEE, and LICENSEE is willing to accept, a license
to use the Lines, upon the terms and conditions set forth below.

     NOW THEREFORE, in consideration of the mutual covenants and premises contained in this
Agreement, the receipt and sufficiency of which is acknowledged, the Parties agree as follows:

ARTICLE I — DEFINITIONS

	1.01	 	“LINES” shall mean the Lines defined in ANNEX I. [include list with indication of
TAES GENETIC CONTRIBUTION and all INTELLECTUAL PROPERTY RIGHTS the subject of the Agreement].

Page 24 of 41

 

	1.02	 	“INTELLECTUAL PROPERTY RIGHTS” shall mean all rights in any patent, plant variety, plant
breeders’ rights, registration, or any applications thereof, or any other intellectual
property protection, for LINES, HYBRIDS or NEW PARENTAL LINES, that may be filed or exist in
any jurisdiction in the world, with the exception of Trademarks.
	 
	1.03	 	“NEW PARENTAL LINES” shall mean new genetic lines or populations which are developed by
breeding by LICENSEE and which have one or more of the LINES as progenitors.
	 
	1.04	 	“HYBRID” shall mean a seed or plant that has resulted from genetic crossbreeding between two
or more lines where those lines include one or more (i) LINES or (ii) NEW PARENTAL LINES.
	 
	1.05	 	“COMMERCIAL SEED” shall mean seed of HYBRIDS that is sold for purposes other than the
production of propagating material.
	 
	1.06	 	“TRAIT FEE” shall mean any upfront or annual fee collected by LICENSEE or any AFFILIATED
COMPANY in conjunction with NET SALES as an additional remuneration for the sale of COMMERCIAL
SEED that has a particular valuable trait or characteristic.
	 
	1.07	 	“TAES GENETIC CONTRIBUTION” shall mean, for any specific LINE (a) the proportion of the
nuclear genes of the LINE arisen from LINES licensed by SYSTEM to LICENSEE, based on DNA
Marker Analysis as defined in the SRA; (b) a contribution to be determined on a case-by-case
basis in each case where a specific valuable phenotype of that LINE is attributable to
specific ALLELE(s) optioned or licensed to LICENSEE by SYSTEM; and (c) OTHER CONTRIBUTIONS
from TAES.
	 
	1.08	 	“OTHER CONTRIBUTIONS” shall mean (i) intellectual and technical contributions to the
development of LINES or if from LICENSEE, to the development of LINES, NEW PARENTAL LINES or
HYBRIDS such as, without limitation, markers, gene-trait association knowledge or composition
knowledge, that inform the breeding and selection process, or transgenic traits and (ii)
financial contributions to the development of LINES, or if from LICENSEE, to the development
of LINES, NEW PARENTAL LINES or HYBRIDS.
	 
	1.09	 	“EFFECTIVE DATE” shall mean the date this Agreement has been executed by the last Party.
	 
	1.10	 	“NET SALES” shall mean LICENSEE’s and AFFILIATED COMPANIES’ receipts for sales of COMMERCIAL
SEED or for SERVICES requiring the use of LINES less the sum of the following:

	 	(a)	 	sales taxes, tariffs, duties and/or use taxes directly
imposed with reference to particular sales;
	 
	 	(b)	 	outbound transportation prepaid or allowed, shipping,
packaging, cost of insurance in transit paid by LICENSEE or an AFFILIATED
COMPANY;
	 
	 	(c)	 	amounts allowed or credited on returns;

Page 25 of 41

 

	 	(d)	 	customary trade, quality or cash discounts;
	 
	 	(e)	 	cost of any coating materials or treatments that may have
been applied to the COMMERCIAL SEED; and
	 
	 	(f)	 	[other deductions which are appropriate to sales of the
LICENSED PRODUCTS may be included].

	 	 	No deductions shall be made for commissions paid to individuals whether independent sales
agencies or regularly employed by LICENSEE. The value of sample size quantities of seed
provided for free shall not be included in NET SALES. Where there is no identifiable sale
price (except for samples as referred to in the previous sentence) or when COMMERCIAL SEED
is sold to other than bona fide, arms length customers of LICENSEE or any AFFILIATED
COMPANY, LICENSEE or the AFFILIATED COMPANY shall be deemed to have received an amount of
NET SALES calculated based on the final sale of the COMMERCIAL SEED (wholesale level) to an
independent third party. If no such current price is available, a hypothetical fair market
value price will be determined by the Parties jointly in good faith for the purpose of
calculating NET SALES. Further, TRAIT FEES, if any, net of any applicable deductions,
shall be added to NET SALES if related to a trait contributed by SYSTEM.
	 
	1.11	 	“LICENSE INCOME” shall mean the amount actually received by either LICENSEE or any AFFILIATED
COMPANY in consideration for the grant of sublicenses to sublicensees that are not AFFILIATED
COMPANIES to produce and sell COMMERCIAL SEED, including up-front fees, lump sum payments and
any running royalties on a product-by-product and jurisdiction-by-jurisdiction basis.
	 
	1.12	 	“AFFILIATED COMPANY” shall mean any company owned or controlled by, under common control with
or controlling LICENSEE, “control” meaning in this context the direct or indirect ownership of
more than fifty percent (50%) of the voting stock/shares of a company, or the power to
nominate at least half of the directors.
	 
	1.13	 	“SERVICE” shall mean any transaction with a third party in which LICENSEE or an AFFILIATED
COMPANY performs certain activities on behalf and at the request of a third party that would
if not performed by LICENSEE or an AFFILIATED COMPANY require a license under SYSTEM’S
INTELLECTUAL PROPERTY RIGHTS licensed hereunder, in exchange for payment, but excluding any
research collaboration or sponsored research agreement.
	 
	1.14	 	“ALLELE” shall mean a particular form of a gene determinant for a valuable characteristic of
a plant (e.g. drought tolerance, specific flowering time), discovered in the Program under the
SRA by SYSTEM or by SYSTEM and LICENSEE jointly.
	 
	1.15	 	“BREEDER SEED” shall mean seed of a LINE that is of a suitable standard of physical and
genetic purity to produce FOUNDATION SEED and resulted from the final breeding of the LINE as
released by the breeder.
	 
	1.16	 	“FOUNDATION SEED” shall mean foundation seed produced from plants grown directly from BREEDER
SEED, cultivated according to certification regulations and that meets the specifications of
the official seed certifying agency of the State of Texas as well as any additional quality
standards of LICENSEE.

Page 26 of 41

 

ARTICLE II — LICENSE GRANT

	2.01	 	Grant. SYSTEM grants to LICENSEE and its AFFILIATED COMPANIES an exclusive world-wide license
and right to commercialize the LINES, including a license under SYSTEM’s rights and interest
it any INTELLECTUAL PROPERTY RIGHTS covering LINES or HYBRIDS, (i) to maintain and increase
seed of LINES; (ii) to develop NEW PARENTAL LINES; (iii) to develop HYBRIDS; and (iv) to
produce and sell COMMERCIAL SEED, and to grant sublicenses of the same scope, to the end of
the term of this Agreement as prescribed in Article VIII.
	 
	2.02	 	Reservation. SYSTEM reserves an irrevocable, worldwide, nonexclusive, royalty-free right to
practice the grant made in Article 2.01 under (i), (ii) and (iii) for research and educational
purposes only, and not for commercial purposes or for the commercial benefit of third parties.
SYSTEM shall comply with the provisions of the SRA and the IPRA when exercising this right.
	 
	2.03	 	Government Reservation. Rights under this Agreement are subject to rights required to be
granted to the Government of the United States of America pursuant to 35 USC Section 200-212,
including a nonexclusive, nontransferable, irrevocable, paid-up license to practice or have
practiced for or on behalf of the United States any patented LINES throughout the world.
	 
	2.04	 	SYSTEM will supply        lbs of BREEDER SEED to LICENSEE
within         from                the EFFECTIVE DATE.

ARTICLE III — CONSIDERATION

	3.01	 	Royalty Rate. As consideration for the license granted in this Agreement, LICENSEE shall
remit to SYSTEM on NET SALES as follows:

	 	a)	 	a royalty of ___ percent (__%) of NET SALES if the COMMERCIAL SEED is of a
HYBRID which is entirely composed of TAES GENETIC CONTRIBUTION, and no OTHER
CONTRIBUTIONS from LICENSEE;
	 
	 	b)	 	if a HYBRID is not entirely composed of TAES GENETIC CONTRIBUTION, the
royalty rate set forth in Article 3.01(a) will be reduced in function of the dilution
of the TAES GENETIC CONTRIBUTION in such HYBRID by:

	 	–	 	OTHER CONTRIBUTIONS from LICENSEE;
	 
	 	–	 	crossing of the LINES which are progenitors of such HYBRID
with other germplasm, including, but not limited to NEW PARENTAL
LINES,

	 	c)	 	no royalties shall be due with respect to HYBRIDS that contain less than five
percent (5%) TAES GENETIC CONTRIBUTION and contain no specific ALLELE(s).
	 
	 	d)	 	Whenever a particular HYBRID, or for sublicensing purposes, a particular NEW
PARENTAL LINE is ready for release, LICENSEE will notify SYSTEM

Page 27 of 41

 

	 	 	 	thereof, and provide the applicable royalty rate based on the principles set forth
in Articles 3.01(b) and 4.02(b) with information on the calculation of such rate.
If SYSTEM has any comments or questions, SYSTEM will inform LICENSEE thereof in
writing within thirty (30) days from the date of LICENSEE’s notification and the
Parties will discuss in good faith. If SYSTEM does not respond in writing to the
aforementioned notification of LICENSEE within thirty (30) days, the royalty rates
in such notification shall be final. If a dispute regarding the royalty rate arises
that can not be resolved amicably within thirty (30) days after LICENSEE’s
aforementioned notification, the following procedures shall apply: such dispute
shall be referred to a mutually agreed expert whose decision shall be final. Each
Party shall submit to the expert within fifteen (15) days of his appointment its
position in writing on the appropriate royalty rate. Such expert shall be required
to choose the one of such two (2) party positions that the expert considers most
reasonable in the circumstances and shall not make any independent determination
(“Royalty Expertise Procedure”).

	3.02	 	[Optional] Minimum Annual Consideration. In order to maintain this exclusive license to
LINES, LICENSEE shall pay to SYSTEM minimum annual consideration in accordance with the
following schedule:

	 	 	 	 	 	 	 

	 

	 	(a)
	 	Calendar Year 200
	 	$__________
	 
	 

	 	(b)
	 	Calendar Years 200 and 200
	 	$__________
	 
	 

	 	(c)
	 	Calendar Year 200 and every year thereafter
through the expiration of this Agreement
	 	$__________

	 	 	In the event that LICENSEE’s payment of royalties for the Calendar Year due under Article
3.01 do not meet or exceed the required minimum annual consideration, as specified in this
Article, LICENSEE’s royalty payment for the last quarter of such Calendar Year shall
include payment of the balance needed to achieve the required minimum. In the event this
Agreement expires or is terminated prior to the end of a Calendar Year, the corresponding
minimum annual consideration provided for in this Article shall be prorated for that year.
	 
	3.03	 	Intellectual Property Rights. As additional consideration for the license granted in this
Agreement, LICENSEE shall bear the reasonable expenses incurred in the prosecution and
maintenance of INTELLECTUAL PROPERTY RIGHTS, as further described in ARTICLE VI.
	 
	3.04	 	The royalties and other payments due under Articles III and IV of this Agreement are in
consideration of all INTELLECTUAL PROPERTY RIGHTS listed in ANNEX I.
	 
	3.05	 	If an exclusive license on a LINE, which is a parental line of the HYBRID of which COMMERCIAL
SEED is sold, reverts to or is non-exclusive pursuant to Articles 3.02, 5.02 or any other
applicable provisions or upon LICENSEE’s election, a lower royalty rate shall be negotiated in
good faith between the Parties. The start of such negotiations shall be evidenced by written
notice from one Party to the other initiating such negotiations, and such negotiations shall
not extend beyond ninety (90) days from the start thereof without the mutual consent of both
Parties (“Negotiation Period”). If the Parties fail to reach agreement within the Negotiation
Period, the lower royalty rate shall

Page 28 of 41

 

	 	 	be settled in accordance with the following procedures: the disputed royalty rate shall be
referred to a mutually agreed impartial expert whose decision shall be final. Each Party
shall submit to the expert within fifteen (15) days of his appointment its position in
writing on the disputed royalty rate. Such expert shall be limited to choosing the one of
such two (2) party positions that the expert considers most reasonable in the circumstances
and shall not make any other determination. Neither Party shall be bound by any
determination by the expert which, in the opinion of Party’s counsel, will result or be
likely to result in that Party violating any applicable law or regulation.

ARTICLE IV — SUBLICENSES

	4.01	 	Sublicenses. LICENSEE and its AFFILIATED COMPANIES may grant sublicenses to persons, firms or
corporations under such conditions as it may arrange, as consistent with this Agreement, as
long as each such sublicense is not repugnant to the public policies of SYSTEM, the State of
Texas, or the United States.
	 
	4.02	 	Sublicensee Consideration. LICENSEE shall pay to SYSTEM a royalty on LICENSE INCOME as
follows:

	 	a)	 	a royalty of ____ percent (__%) of LICENSE INCOME if the sublicense is for a
HYBRID or LINE which is entirely composed of TAES GENETIC CONTRIBUTION, and no OTHER
CONTRIBUTION from LICENSEE;
	 
	 	b)	 	if the sublicense is for a HYBRID or LINE that is not entirely composed of
TAES ONLY CONTRIBUTION, or for a NEW PARENTAL LINE, the royalty rate will be reduced
in proportion to the dilution of the TAES ONLY CONTRIBUTION in such HYBRID, LINE or
NEW PARENTAL LINE as set forth in Article 3.01(b) and (d);
	 
	 	c)	 	no royalties shall be due with respect to HYBRIDS or NEW PARENTAL LINES that
contain less than five percent (5%) TAES GENETIC CONTRIBUTION and contain no specific
ALLELE(s).

	4.03	 	Reporting. LICENSEE shall notify SYSTEM of the grant of sublicense to a third party and
provide a redacted copy of the sublicense to SYSTEM. LICENSEE shall not redact any
information unless it could be reasonably considered sensitive to LICENSEE’s business. Upon
reasonable notice by SYSTEM, SYSTEM may through an attorney-at-law review an unredacted copy
of the sublicense but shall not provide any redacted information to business persons within
SYSTEM. LICENSEE shall also provide SYSTEM with the name, address and scope of each
sublicense and a copy of each sublicensee’s report as is pertinent to calculation of amounts
due SYSTEM under this Agreement.
	 
	4.04	 	Non-Cash Transactions. Where there is no identifiable LICENSE INCOME, a hypothetical fair
market value price will be determined by the Parties jointly in good faith for the purpose of
calculating LICENSE INCOME.

Page 29 of 41

 

ARTICLE V — LICENSEE RESPONSIBILITIES

	5.01	 	Milestones. In accomplishing the commercialization under this Agreement, LICENSEE shall
demonstrate to the satisfaction of SYSTEM achievement of the following milestones:
	 
	 	 	EXAMPLE: LICENSEE shall complete development of a HYBRID no later than _____ months
following EFFECTIVE DATE.
	 
	 	 	EXAMPLE: LICENSEE shall record first sales of COMMERCIAL SEED no later than ______ months
following EFFECTIVE DATE.
	 
	 	 	Other Milestones to be defined upon the basis of LICENSEE’s business plan for
COMMERCIAL SEED.
	 
	 	 	LICENSEE shall provide written notification to SYSTEM within thirty (30) days of achieving
each milestone.
	 
	 	 	[Milestones may be substituted or postponed by payments to be agreed for each particular
license agreement.]
	 
	5.02	 	Failure to Accomplish Milestones. Should LICENSEE fail to achieve any milestone specified in
paragraph Article 5.01, or should LICENSEE fail to record NET SALES for two (2) consecutive
Calendar Years once sales begin, SYSTEM, at its sole option and as its sole remedy, may waive
the requirement to achieve the milestone, may revise the license granted herein to a
nonexclusive license, or may renegotiate the missed milestone.
	 
	5.03	 	Legal Compliance. LICENSEE must comply with all applicable federal, state and local laws and
regulations in its exercise of all rights granted to it by SYSTEM under this Agreement.
	 
	5.04	 	No Royalties for Sales to U.S. Government. In accordance with 35 USC Section 200-212,
LICENSEE has no duty to pay SYSTEM royalties under this Agreement on NET SALES made to the
United States Government, including any United States Government agency. LICENSEE shall
reduce the amount charged for COMMERCIAL SEED covered by patent applications or patents
licensed under this Agreement sold to the United States Government by an amount equal to the
royalty otherwise due SYSTEM.
	 
	5.05	 	U.S. Manufacture. In accordance with 35 USC Section 200-212, COMMERCIAL SEED covered by
patent applications or patents licensed under this Agreement shall be manufactured
substantially in the United States of America.

ARTICLE VI — INTELLECTUAL PROPERTY

	6.01	 	Filing. SYSTEM will have the right to prepare and file, in accordance with its best judgment,
any and all applications for patents, plant variety rights or other forms of intellectual
property protection or variety registration for HYBRIDS, LINES or NEW PARENTAL LINES in the
United States that are solely owned by SYSTEM and LICENSEE will have the right to prepare and
file such applications for INTELLECTUAL PROPERTY RIGHTS jointly or solely owned by LICENSEE.
Applications for patents or plant variety rights on each particular HYBRID or LINE shall be
filed in the name of SYSTEM (TAES) if owned by SYSTEM pursuant to the SRA, in the name of
LICENSEE (CERES) if owned by LICENSEE pursuant to the SRA and in

Page 30 of 41

 

	 	 	the joint names of SYSTEM (TAES) and LICENSEE (CERES) if jointly owned pursuant to the SRA.
Applications for patents or plant variety rights on NEW PARENTAL LINES shall be filed in
the name of LICENSEE. At LICENSEE’s discretion, patents, plant variety rights and/or other
forms of intellectual property protection may be filed in any other jurisdiction in the
world.
	 
	6.02	 	Abandoning IP Applications. The following rules shall apply with respect to applications for
intellectual property protection on SYSTEM owned or jointly owned LINES or HYBRIDS. If the
Party controlling prosecution intends to abandon any patent plant variety rights, pending or
granted in any jurisdiction, that Party shall first give sufficient written notice to the
other Party to permit the other party the opportunity to assume such filing, examination
and/or maintenance. LICENSEE and SYSTEM will consult with regard to INTELLECTUAL PROPERTY
RIGHTS.
	 
	6.03	 	Jurisdiction. The obligations of this Article 6.03 shall not apply to any jurisdictions in
which the prosecuting party has elected not to apply for intellectual property protection.
LICENSEE and SYSTEM shall avoid carrying out any act that would prejudice the grant of
INTELLECTUAL PROPERTY RIGHTS. Without limitation, neither Party shall make available
reproductive material of the HYBRIDS or LINES at a date or in a manner that might jeopardize
the right to seek INTELLECTUAL PROPERTY RIGHTS protection for the HYBRIDS or LINES.

[add sections 6.04-6.08 from Appendix A if patents are licensed under this license.]

ARTICLE VII — PAYMENTS AND REPORTS

	7.01	 	When Payments are Due. Unless otherwise specified, payments shall be made annually. Payments
shall be made to The Texas A&M University System, in College Station, Texas, not later than
sixty (60) days after the last day of the calendar year in which they accrue.
	 
	7.02	 	Royalty Reports. LICENSEE shall provide a sales report to SYSTEM each year, providing
information sufficient to allow SYSTEM to calculate amounts due SYSTEM for the reporting
period, in the form attached hereto as ANNEX II.
	 
	7.03	 	Currency. Payment due to SYSTEM shall be paid in U.S. dollars. Royalty payments requiring
conversion shall use the exchange rate as reported in The Wall Street Journal on the
last business day of the royalty reporting period.
	 
	7.04	 	Inspection of Books and Records. At its own expense, SYSTEM may annually inspect LICENSEE’s
books and records as needed to determine royalties payable. LICENSEE shall maintain such books
and records for at least three (3) years following the dates of the underlying transactions.
Any such inspections shall be in confidence and conducted during ordinary business hours, and
SYSTEM will provide LICENSEE prior notice two (2) weeks before making such inspections. SYSTEM
must employ an independent Certified Public Accountant reasonably acceptable to LICENSEE for
this purpose, who will only report to SYSTEM such information as necessary, to determine
royalties payable to SYSTEM and LICENSEE’s compliance with any related obligations to SYSTEM.
If SYSTEM’s audit identifies a shortage of five percent (5%) or more of amounts due to SYSTEM,
then LICENSEE shall pay the costs of SYSTEM’s audit.

Page 31 of 41

 

	 	 	LICENSEE shall pay all amounts due as a consequence of such audit to SYSTEM promptly, with
interest.
	 
	7.05	 	Interest Charges. Overdue payments may, at the sole discretion of SYSTEM, be subject to a
daily charge commencing on the 31st day after such payment is due, compounded monthly, at the
rate of either one and one-half percent (1.5%) per month or the highest legal interest rate,
whichever is lower. The payment of such interest will not foreclose SYSTEM from exercising any
other rights it may have as a consequence of the lateness of any payment.
	 
	ARTICLE VIII — TERM AND TERMINATION
	 
	8.01	 	Expiration. Subject to any other rights of termination under this Article, this Agreement
shall remain in full force and effect on a LINE by LINE, HYBRID by HYBRID and country by
country basis until the expiration of all registered or patented INTELLECTUAL PROPERTY RIGHT
covering such product in such country and solely or jointly owned by SYSTEM.
	 
	8.02	 	Termination by Licensee. LICENSEE may terminate this Agreement by providing written notice
to SYSTEM at least ninety (90) days before the termination is to take effect.
	 
	8.03	 	Termination by System. If LICENSEE materially breaches this Agreement, SYSTEM may give
LICENSEE written notice of the breach. LICENSEE shall have a period of sixty (60) days from
receipt of the notice to cure the breach. If LICENSEE does not cure the breach within this
period, SYSTEM may terminate this Agreement in writing without further notice.
	 
	8.04	 	Matters Surviving Termination. All accrued obligations and claims, including reimbursement
of patent expenses, license fee obligations, royalty obligations, minimum annual consideration
obligations, interest charge obligations, and all other financial obligations, and claims or
causes of action for breach of this Agreement, shall survive termination of this Agreement.
Obligations of confidentiality shall survive termination of this Agreement. This section
controls in the case of a conflict with any other section of this Agreement.

ARTICLE IX — INDEMNIFICATION AND REPRESENTATION

	9.01	 	Indemnification. LICENSEE SHALL AT ALL TIMES DURING THE TERM OF THIS AGREEMENT AND
THEREAFTER INDEMNIFY, DEFEND, AND HOLD HARMLESS SYSTEM, ITS REGENTS, OFFICERS, AND EMPLOYEES
AGAINST ANY CLAIM, PROCEEDING, DEMAND, LIABILITY OR EXPENSE (INCLUDING LEGAL EXPENSE AND
REASONABLE ATTORNEYS’ FEES) WHICH RELATES TO INJURY TO PERSONS OR TO PROPERTY, ANY ACTION
BROUGHT BY A THIRD PARTY ALLEGING INFRINGEMENT OF INTELLECTUAL PROPERTY RIGHTS, OR AGAINST ANY
OTHER CLAIM, PROCEEDING, DEMAND, EXPENSE, AND LIABILITY OF ANY KIND WHATSOEVER RESULTING FROM
THE PRODUCTION, MANUFACTURE, SALE, COMMERCIAL USE, LEASE, CONSUMPTION, OR ADVERTISEMENT OF
COMMERCIAL SEED OR ARISING FROM ANY OBLIGATION OF LICENSEE OR SUBLICENSEE(S) UNDER THIS
AGREEMENT AND NOT

Page 32 of 41

 

	 	 	CAUSED BY BREACH OF THIS AGREEMENT BY SYSTEM (HEREINAFTER JOINTLY REFERRED TO AS “CLAIMS”),
PROVIDED THAT SYSTEM SHALL PROMPTLY PROVIDE WRITTEN NOTICE OF ANY CLAIM TO LICENSEE, AND
THAT, SUBJECT TO THE APPROVAL OF THE ATTORNEY GENERAL FO THE STATE OF TEXAS, LICENSEE SHALL
HAVE THE RIGHT TO CONDUCT THE DEFENSE OF ANY CLAIM, AND THAT SYSTEM SHALL COOPERATE WITH
LICENSEE AS LICENSEE MAY REQUEST IN ANY SUCH DEFENSE, AT LICENSEE’S REQUEST AND EXPENSE.
	 
	9.02	 	Representation. SYSTEM represents that it has the full right and power to grant the license
set forth in Article 2.01, and that there are no outstanding agreements, assignments, or
encumbrances inconsistent with the provisions of this Agreement. SYSTEM MAKES NO OTHER
REPRESENTATIONS AND EXTENDS NO OTHER WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED,
INCLUDING BUT NOT LIMITED TO WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR
PURPOSE, NOR DOES SYSTEM ASSUME ANY OBLIGATIONS WITH RESPECT TO INFRINGEMENT OF PATENT RIGHTS
OR OTHER RIGHTS OF THIRD PARTIES DUE TO LICENSEE’S ACTIVITIES UNDER THIS AGREEMENT.

ARTICLE X — NOTICES

	10.01	 	Notices. Payments, notices, or other communications required by this Agreement shall be
sufficiently made or given if mailed by certified First Class United States mail, postage
pre-paid, or by commercial carrier (e.g., FedEx, UPS, etc.) when such carrier maintains
receipt or record of delivery, addressed to the address stated below, or to the last address
specified in writing by the intended recipient.

	 	 	 

	If to SYSTEM:

	 

	 	Executive Director
	 

	 	Office of Technology Commercialization
	 

	 	3369 TAMU
	 

	 	College Station, Texas, USA 77843-3369

	 	 	 	 	 

	If to LICENSEE for Legal Matters:
	 	for Financial Matters:
	 

	 	Director of Business Development
	 	Director of Business Development
	 

	 	cc: Legal Department
	 	cc: Controller
	 

	 	Ceres, Inc.
	 	Ceres, Inc.
	 

	 	1535 Rancho Conejo Blvd.
	 	1535 Rancho Conejo Blvd.
	 

	 	Thousand Oaks, CA 91320
	 	Thousand Oaks, CA 91320

ARTICLE XI — MISCELLANEOUS PROVISIONS

	11.01	 	Notice of Infringement. SYSTEM and LICENSEE shall promptly notify one another in writing of
any alleged infringement of any INTELLECTUAL PROPERTY RIGHTS. Within thirty (30) days after
receipt of such notice, SYSTEM and LICENSEE shall formulate a strategy for resolving the
alleged infringement. LICENSEE acknowledges that SYSTEM’s involvement, participation, and
representation in any litigation requires the prior written consent of SYSTEM and the Attorney
General of the State of Texas, and subject to the granting of that consent, SYSTEM may be
joined as a party in any action brought by LICENSEE, so long as LICENSEE shall pay all of
SYSTEM’s reasonable

Page 33 of 41

 

	 	 	costs and expenses. LICENSEE will have the right, at its own discretion and expense, to
take any action to enforce and to initiate and prosecute suits for infringement of
INTELLECTUAL PROPERTY RIGHTS covering LINES, HYBRIDS and/or NEW PARENTAL LINES. LICENSEE
and SYSTEM will consult with each other upon a course of action and enforcement strategy.
LICENSEE will be responsible for the conduct of any such enforcement action, and SYSTEM
will reasonably cooperate with LICENSEE to effect the enforcement action, and if
appropriate, determine a settlement position. LICENSEE shall be responsible for retaining
counsel but will consult with SYSTEM and retain counsel reasonably acceptable to SYSTEM.
For purposes of settlement, LICENSEE shall be the contact with the Parties’ counsel as well
as the opposing Party(ies) and shall have the right to enter into settlements. LICENSEE
shall keep SYSTEM advised as to all developments with respect to the enforcement action and
settlement discussions, which includes supplying to SYSTEM copies of all papers received
and filed in sufficient time for SYSTEM to comment thereon. SYSTEM may attend any and all
meetings with the Parties’ counsel and the opposing side for settlement purposes. If
necessary, and subject to the consent of the Attorney General of the State of Texas, SYSTEM
agrees to enter into a joint defense agreement. Any damages received by LICENSEE as a
result of an enforcement action of rights to jointly owned INTELLECTUAL PROPERTY RIGHTS,
after deduction of all enforcement related costs incurred by LICENSEE, shall be considered
as NET SALES or LICENSE INCOME, as appropriate, for the purpose of remuneration payments to
SYSTEM.

	11.02	 	Export Controls. It is understood that SYSTEM is subject to United States laws and
regulations controlling the export of technical data, computer software, laboratory prototypes
and other commodities, and that its obligations hereunder are contingent on compliance with
applicable United States export laws and regulations. The transfer of certain technical data
and commodities may require a license from the cognizant agency of the United States
Government or written assurances by LICENSEE that LICENSEE shall not export data or
commodities to certain countries without prior approval of such agency. SYSTEM neither
represents that a license shall not be required nor that, if required, it shall be issued.
	 
	11.03	 	Confidential Information. Sales reports submitted by LICENSEE under Article VII and audit
reports made pursuant to Article 7.04 shall be considered as Confidential Information under
this Agreement and shall not be disclosed by SYSTEM to any third party except as may be
required in response to a valid order of a court or other government body of the United States
or any political subdivision thereof, as required under the Texas Public Information Act.
Should the Parties contemplate exchange of other information of a confidential nature, they
shall enter into a separate confidentiality agreement.
	 
	11.04	 	Non-Use of Names. LICENSEE shall not use the names of The Texas A&M University System, nor
of any of its employees or components, nor any adaptation thereof, in any advertising,
promotional or sales literature without the prior written consent obtained from SYSTEM in each
case, except that LICENSEE may state that it is licensed by SYSTEM under INTELLCTUAL PROPERTY
RIGHTS.
	 
	11.05	 	Trademarks. LICENSEE may select, own and use its own trademark on LICENSED PRODUCTS.
However, nothing herein shall be construed as granting to LICENSEE any license or other right
under any trade name, trademark, or service mark owned or licensed

Page 34 of 41

 

	 	 	by SYSTEM. Conversely, SYSTEM shall have no rights to trade names, trademarks, or service
marks owned by LICENSEE.
	 
	11.06	 	Assignment of this Agreement. This Agreement binds and enures to the benefit of the
Parties, their successor or assigns, but may not be assigned by either Party without the prior
written consent of the other Party; provided however, LICENSEE shall have the right to assign
its rights and obligations under this Agreement to any AFFILIATED COMPANY without such prior
consent, but with written notice to SYSTEM. LICENSEE shall also have the right to assign its
rights and obligations under this Agreement to a third party in conjunction with the transfer
to such third party of substantially all of the assets of LICENSEE associated with performance
under this Agreement without such prior consent.
	 
	11.07	 	Force Majeure. Other than an obligation for the payment of money, SYSTEM, upon receipt of
documentation from LICENSEE which it deems appropriate, shall excuse any breach of this
Agreement, which is proximately caused by war, strike, act of God, or other similar
circumstance normally deemed outside the control of well-managed businesses.
	 
	11.08	 	Entire Agreement. Other than the SRA and the IPRA, this Agreement contains the entire
understanding of the Parties with respect to INTELLECTUAL PROPERTY RIGHTS, and supersedes all
other written and oral agreements between the Parties with respect to INTELLECTUAL PROPERTY
RIGHTS. It may be modified only by a written amendment signed by the Parties.
	 
	11.09	 	Governing Law. The validity, interpretation, and enforcement of this Agreement shall be
governed and determined by the laws of the State of Texas, excluding the conflict of laws
rules which might require the application of the laws of another jurisdiction.
	 
	11.10	 	Disputes.

	 	A.	 	The Parties shall make every possible attempt to resolve in an amicable manner all
disputes between the Parties concerning the interpretation of this Agreement.
	 
	 	B.	 	The Parties must use the dispute resolution process provided in Chapter 2260, Texas
Government Code, and the related rules adopted by the Texas Attorney General to attempt to
resolve any claim for breach of contract made by LICENSEE that cannot be resolved in the
ordinary course of business. LICENSEE must submit written notice of a claim of breach of
contract under this Chapter to B.J. Crain, Associate Vice Chancellor, who will examine
LICENSEE’s claim and any counterclaim and negotiate with LICENSEE in an effort to resolve
the claim.

	11.11	 	Headings. Headings appear solely for convenience of reference. Such headings are not part
of, and shall not be used to construe, this Agreement.
	 
	11.12	 	No Waiver; Severability. No waiver of any breach of this Agreement shall constitute a
waiver of any other breach of the same or other provision of this Agreement and no waiver
shall be effective unless made in writing. This Agreement, to the greatest extent
possible, shall be construed so as to give validity to all of the provisions hereof. If any
provision of this Agreement is or becomes invalid, is ruled illegal by a court of competent
jurisdiction or is deemed unenforceable under the current applicable law from time to

Page 35 of 41

 

	 	 	time in effect during the term of this Agreement, the remainder of this Agreement will not
be affected or impaired thereby and will continue to be construed to the maximum extent
permitted by law. In lieu of each provision which is invalid, illegal or unenforceable,
there will be substituted or added as part of this Agreement by mutual written agreement of
the Parties, a provision which will be as similar as possible, in economic and business
objectives as intended by the Parties to such invalid, illegal or unenforceable provision,
but will be valid, legal and enforceable.
	 
	11.13	 	Damages. Neither Party shall be liable for indirect, special, remote, incidental or
consequential damages or loss of profit in connection with this Agreement or its
implementation.

ARTICLE XII — ADDITIONAL TERMS AND CONDITIONS

	12.01	 	LICENSEE agrees to negotiate in good faith with Texas Foundation Seed Service for the
production of BREEDER SEED and FOUNDATION SEED of LINES exclusively licensed to LICENSEE
pursuant to this Agreement, based on the following principles.

	 	•	 	Annual contract, neither party has an obligation to renew;
	 
	 	•	 	LICENSEE has decided to subcontract production of BREEDER SEED and
FOUNDATION SEED of LINES exclusively licensed to LICENSEE;
	 
	 	•	 	subject to Texas Foundation Seed Service offering competitive conditions,
guaranteeing quality and certification standards and other customary provisions for
exclusive seed production contracts for BREEDER SEED and FOUNDATION SEED;
	 
	 	•	 	LICENSEE will have the right to audit seed production to assess quality
standards and practices; and
	 
	 	•	 	if Texas Foundation Seed Service offers production contracts to growers,
LICENSEE will manage the seed production and assist in the selection of growers.

	 	 	If no agreement on the production contract is reached six (6) months after the EFFECTIVE
DATE, neither LICENSEE nor Texas Foundation Seed Service will have any further obligations
with respect to contract production of BREEDER SEED and FOUNDATION SEED of LINES
exclusively licensed to LICENSEE.
	 
	 	 	The Parties have caused this Agreement to become effective as of the date last executed below.

	 	 	 	 	 	 	 	 	 	 	 

	CERES, INC.	 	 	 	THE TEXAS A&M UNIVERSITY SYSTEM	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 
	By:	 	 	 	 	 	Guy K. Diedrich	 	 
	 

	 	 

	 	 	 	 	 	 	 	 
	Title:	 	 	 	 	 	Vice Chancellor Federal Relations, Research	 	 
	 	 	 	 	 	 		 	 
	

	 	 	 	 	 	and Commercialization	 	 
	Date:

	 	

 

	 	 	 	Date:	 	
 

	 	 
	 
	 	 	 	 	 	 	 	 	 
	By:
	 	 	 	 	 	 	 	 	 	 
	 

	 	 

	 	 	 	 	 	 	 	 
	Title:
	 	 	 	 	 	 	 	 	 	 
	 

	 	 

	 	 	 	 	 	 	 	 
	Date:
	 	 	 	 	 	 	 	 	 	 
	 

	 	 

	 	 	 	 	 	 	 	 

Page 36 of 41

 

ANNEX I

to the Example License Agreement for Lines

between Ceres, Inc. and The Texas A&M University System

LINES

	–	 	TAES GENETIC CONTRIBUTION (components (a) through (c) to be provided)
	 
	–	 	INTELLECTUAL PROPERTY RIGHTS
	 
	 	 	(include all patent applications/patents (including on Subject Inventions covering Lines)
plant variety protection rights etc.)

Page 37 of 41

 

ANNEX II

to the Example License Agreement for Lines

between Ceres, Inc. and The Texas A&M University System

Royalty Report

[template to be developed during negotiations of license]

Page 38 of 41

 

Appendix C

to the Intellectual Property Rights Agreement

Between

Ceres, Inc.

And

The Texas Agricultural Experiment Station of

The Texas A&M University System

Guidelines for Future Collaborative Opportunities

(Capitalized words are as defined in the Sponsored Research Agreement)

PURPOSE:

CERES and SYSTEM may jointly pursue collaborative activities with third party collaborators.
During the term of the Program, SYSTEM will notify CERES, in writing, of any contemplated internal
projects or projects with third parties that specifically involve sorghum Lines and Hybrids (as
defined in the Sponsored Research Agreement) to be used as feedstock for the bioenergy market and
that do not involve Germplasm Improvement (hereinafter “Additional Collaboration Project”). CERES
will notify SYSTEM of certain contemplated projects as provided hereinafter. The Parties will
comply with the provisions set forth hereinafter under SYSTEM CONTACT PROCESS and CERES CONTACT
PROCESS. These guidelines do not apply to Germplasm Improvement, which is addressed in the
Sponsored Research Agreement.

GUIDING PRINCIPLES:

The principles contained within this Appendix are meant to guide discussions of potential future
Additional Collaboration Project opportunities between CERES and SYSTEM. CERES is generally
interested in pursuing Additional Collaboration Project opportunities with SYSTEM as long as the
opportunity is consistent with CERES’ business interests and has no negative impact on CERES’
commercialization activities or competitive position. CERES’ intention is to position itself as
the leading provider of proprietary improved sorghum for the bioenergy market. Both Parties agree
that product differentiation, intellectual property protection, and exclusive access are important
factors to build a leading position in this market. Both Parties recognize that participation of a
Party in an Additional Collaboration Project initiated by the other Party is subject, among other
factors, to its capacity to do so, and the Parties reaching an agreement through good faith
discussions.

SYSTEM CONTACT PROCESS:

During the term of the Program the following process will apply in the event that SYSTEM is
contacted regarding an Additional Collaboration Project with a third party, or in the event that
SYSTEM is contemplating an internal Additional Collaboration Project:

SYSTEM will notify: 1) the contacting party or internal project principal investigator of the
rights of CERES to participate and 2) CERES in writing within thirty (30) days of receiving a bona
fide contact from a third party or a research proposal from an internal project principal
investigator. CERES will respond, in writing, within thirty (30) days of receipt of notice with a
decision about whether it wishes to participate in the opportunity.

	 	1.1.	 	If CERES elects to participate in the Additional Collaboration Project CERES and
SYSTEM will discuss in good faith the development of a joint proposal.
	 
	 	1.2.	 	If CERES elects not to participate in the Additional Collaboration Project, CERES
will

Page 39 of 41

 

	 	 	 	notify SYSTEM in writing that CERES does not wish to participate in the Additional
Collaboration Project and, if applicable, will provide reasons as to why CERES would
prefer that SYSTEM not use Lines or Hybrids developed in the Program, or not to pursue the
activity at all, and SYSTEM will take CERES rationale into account in deciding how to
proceed. The Parties agree to meet within thirty (30) days of the receipt of CERES’
response to discuss CERES rationale and preference for SYSTEM not to use Lines or Hybrids,
or not to pursue the activity.

	 	 1.2.1.	 	If SYSTEM elects to pursue the Additional Collaboration Project:

	 	1.2.1.1.	 	SYSTEM will take measures to ensure that material developed in the Program
and results of the Additional Collaboration Project are properly blinded so as
not to allow differentiation from other material;
	 
	 	1.2.1.2.	 	the Additional Collaboration Project will occur at a SYSTEM research
facility;
	 
	 	1.2.1.3.	 	CERES will have access to the results of such Additional Collaboration
Project to the extent allowed by the relevant agreements between SYSTEM and
the third party and SYSTEM will use reasonable efforts to obtain such right
for CERES;
	 
	 	1.2.1.4.	 	if any result obtained in an Additional Collaboration Project using
material developed in the Program has an application for Germplasm
Improvement, TAES will grant CERES an option to negotiate an exclusive
license to use such result for Germplasm Improvement.

CERES CONTACT PROCESS:

During the term of the Program the following process will apply. If CERES is approached by a third
party with a project to be conducted by such party or by CERES, related to extension research,
logistics, agriculture economics, or agricultural engineering for sorghum to be used as feedstock
for the bioenergy market, the following process will apply. If the entity to be conducting or
commissioning the research is located in the State of Texas and the work to be conducted is in the
State of Texas, CERES will, unless it deems the matter sensitive, is restricted by confidentiality
or is requested not to disclose the matter by the third party, notify SYSTEM in writing if CERES
wishes to pursue the project jointly with SYSTEM or to give SYSTEM the opportunity to pursue the
project individually. In all other cases, CERES will use its discretion as to whether or not to
involve SYSTEM in the project. After written notification, SYSTEM will respond, in writing, within
thirty (30) days of receipt with a decision to pursue the project requested by CERES. If SYSTEM
does not respond, in writing, within thirty (30) days of receipt with a decision to pursue the
project, CERES may elect to pursue the project individually.

NOTIFICATION:

The Parties shall notify one another in writing at the following addresses:

CERES Contact for Collaborative Opportunities:

Director of Business Development

Ceres, Inc.

Page 40 of 41

 

1535 Rancho Conejo Blvd.

Thousand Oaks, CA 91320

SYSTEM Contact for Collaborative Opportunities:

Bill F. McCutchen, Ph.D.

Texas Agricultural Experiment Station

113 Jack K Williams Admin Bldg

College Station, Texas 77843-2142

Page 41 of 41exv10w16

Exhibit 10.16

Pages where confidential treatment has been requested are stamped ‘Confidential Treatment
Requested and the Redacted Material has been separately filed with the Commission,’ and the
confidential section has been marked as follows: [***].

Master Research Agreement

 

 

	 	 	 	 	 

	TABLE OF CONTENTS
	 	 	 	 
	 
	1. RESEARCH PROJECTS
	 	 	2	 
	2. INTELLECTUAL PROPERTY
	 	 	6	 
	3. USE AND COMMERCIALIZATION RIGHTS
	 	 	9	 
	4. ENFORCEMENT OF JOINT INTELLECTUAL PROPERTY RIGHTS
	 	 	11	 
	5. TERMINATION
	 	 	12	 
	6. PUBLICATIONS AND DISCUSSIONS
	 	 	14	 
	7. RECORDS AND AUDITS
	 	 	14	 
	8. INDEPENDENT CONTRACTOR
	 	 	15	 
	9. CONFIDENTIALITY
	 	 	15	 
	10. NOTICES
	 	 	16	 
	11. DISPUTE RESOLUTION AND APPLICABLE LAW
	 	 	16	 
	12. PUBLICITY
	 	 	18	 
	13. MANAGEMENT COMMITTEE
	 	 	19	 
	14. EXCLUSIVITY
	 	 	20	 
	15. EXCLUSION OF WARRANTIES
	 	 	21	 
	16. GENERAL
	 	 	22	 
	16.1 Entire Agreement/Modifications
	 	 	22	 
	16.2 Severability
	 	 	22	 
	16.3 Waiver
	 	 	22	 
	16.4 Enforcement
	 	 	22	 
	16.5 Assignablility
	 	 	23	 
	16.6 Force Majeure
	 	 	23	 
	16.7 Choice of Law
	 	 	23	 
	EXHIBIT A —  DEFINITION OF COLLABORATION CROPS
	 	 	24	 
	EXHIBIT B — PREFERRED FORM OF RECEIPT FORM
	 	 	25	 
	EXHIBIT C
— PREFERRED FORM OF VARIETY EVALUATION AGREEMENT
	 	 	26	 
	EXHIBIT D — EXISTING OR PENDING EXTRAMURAL FUNDING
	 	 	28	 
	EXHIBIT E — EXCLUDED CROPS
	 	 	29	 
	EXHIBIT F — SEED PRODUCTION AND COMMERCIALIZATION ACTIVITIES
	 	 	30	 
	EXHIBIT G — MODEL LICENSE AGREEMENT FOR NON-TRANSGENIC VARIETIES
	 	 	31	 

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 1 of 57

 

 

MASTER RESEARCH AGREEMENT

     THIS AGREEMENT is made this 19 day of May, 2006 (“Effective Date”), by and between THE SAMUEL
ROBERTS NOBLE FOUNDATION, INC. (“NOBLE”), an Oklahoma nonprofit corporation, and CERES, INC., a
Delaware corporation (“CERES”).

     WHEREAS, CERES and NOBLE entered into an EVALUATION, PRODUCTION AND LICENSE AGREEMENT, dated
19 May 2006, to evaluate and develop certain germplasm and grant the exclusive option, and if
exercised, exclusive, world-wide license, to CERES to produce, use, sell and commercially exploit
such germplasm;

     WHEREAS, the parties wish to establish a research program for undertaking specific,
collaborative projects after the Effective Date, to further the scientific research and commercial
objectives of CERES as well as the scientific research objectives of NOBLE;

     WHEREAS, the research programs contemplated by this Agreement and its schedules are consistent
with and in furtherance of NOBLE research programs;

     WHEREAS, the research programs contemplated by this Agreement will further the scientific
research objectives of NOBLE in a manner consistent with its tax-exempt status;

     WHEREAS, CERES and NOBLE recognize that rights to intellectual property conceived or reduced
to practice in the performance of the parties’ various collaborations can be a strong incentive for
CERES to risk money and other resources needed to incorporate intellectual property into a product
or procedure for wide public enjoyment;

     NOW THEREFORE, in consideration of the premises and of the mutual covenants and agreements
contained herein and of other good and valuable consideration, the parties have agreed and do
hereby agree as follows:

1. RESEARCH PROJECTS.

     1.1 CERES and NOBLE anticipate that from time to time they may undertake and conduct
certain joint and collaborative research projects (individually a “RESEARCH PROJECT” and
collectively “RESEARCH PROJECTS”). The parties acknowledge and agree that the RESEARCH PROJECTS
will involve the contributions, whether financial or otherwise, of both parties. The specific terms
and respective obligations of the parties for each RESEARCH PROJECT will be negotiated by the
parties and reflected in a schedule (“SCHEDULE”) signed by authorized representatives of both
parties. Any such fully executed SCHEDULE shall become a part of this Agreement and subject to the
terms of this Agreement. Each party shall diligently perform its activities in any given RESEARCH
PROJECT.

     1.2 All rights in property, tangible or intangible, used in the RESEARCH PROJECTS shall remain
with the party providing such property, unless otherwise agreed between the parties in this
Agreement, a SCHEDULE or a separate agreement.

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 2 of 57

 

 

     1.3 RESEARCH PROJECTS will relate to crop species defined in EXHIBIT A to this
Agreement (“COLLABORATION CROPS”).

     1.4 Each SCHEDULE will at least contain the following:

	 	1.4.1	 	 Provisions that may be modified by the MANAGEMENT COMMITTEE:

	 	•	 	research activities to be performed by each party in detail
	 
	 	•	 	timelines of such activities
	 
	 	•	 	goals, expected results and deliverables
	 
	 	•	 	milestones and “go” and “no-go” decision points
	 
	 	•	 	all reports to be delivered to the MANAGEMENT
COMMITTEE (Article 13) and the required delivery dates for the same
	 
	 	•	 	additional information on RESEARCH PROJECT
activities: breeding records and biological or other material generated
in such activities to be provided to the other party, including delivery
method and time
	 
	 	•	 	location of activities
	 
	 	•	 	identity of RESEARCH PROJECT principal
investigators for CERES and NOBLE
	 
	 	•	 	identity and location of any SUBCONTRACTORS
(Paragraph 1.13) to be used for the RESEARCH PROJECT activities

	 	1.4.2	 	Provisions that may only be modified in accordance with Paragraph 16.1:

	 	•	 	number of FTE’s made available by each party for
the RESEARCH PROJECT, including names of any CERES and NOBLE PhD-level
employees
	 
	 	•	 	other inputs and resources made available by each
party for the RESEARCH PROJECT
	 
	 	•	 	financial contributions of each party to the
RESEARCH PROJECT
	 
	 	•	 	provisions on intellectual property, including
lists of BACKGROUND INTELLECTUAL PROPERTY and any provisions which are
different from those set forth in this Agreement
	 
	 	•	 	provisions on use and commercialization rights
which are different from those set forth in this Agreement
	 
	 	•	 	provisions on expiration and early termination

     1.5 Unless a SCHEDULE provides for more frequent formal reporting, each party shall provide to
the other party a detailed, written annual report on its activities in each RESEARCH PROJECT. In
addition, upon the request of either party at any time, the parties will discuss the RESEARCH
PROJECTS, their status, the progress and results achieved, and they will make available each
RESEARCH PROJECT principal investigator (and other employees as needed, in the discretion

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 3 of 57

 

 

of the respective RESEARCH PROJECT principal investigators) at mutually agreeable times, as
needed, for such discussions; provided however, such contacts and discussions shall be reasonable
in frequency and duration so as not to be disruptive to the respective research activities of each
party or the research activities of the RESEARCH PROJECTS. Each party will also voluntarily provide
data, information and material generated in the RESEARCH PROJECT to the other party as required to
further the parties’ mutual goals defined in each RESEARCH PROJECT or in any other agreement
between the parties. Each party will have the right, upon reasonable notice to the other party, to
visit any location where RESEARCH PROJECT activities are conducted for the purposes of evaluating
RESEARCH PROJECT progress and outcomes, and particularly to make observations of any plants in
growth chambers, greenhouses or fields that are a part of a RESEARCH PROJECT. Each party will
comply with any reasonable safety and security measures which may be imposed by the other party
when visiting such other party’s location.

     1.6 Any transfer of information or material pursuant to this Agreement or any SCHEDULE will be
governed by the provisions of this Agreement on CONFIDENTIALITY (Article 9) and PUBLICATIONS
(Article 6). Any transfer of material shall be accompanied by a receipt form in the preferred
format attached as EXHIBIT B to this Agreement. Such receipt forms shall be signed by
representatives of both the sending and receiving parties.

     1.7 Unless otherwise specified in a SCHEDULE, each party shall bear its own costs and pay its
own SUBCONTRACTORS, with respect to its RESEARCH PROJECT activities, out of its own funds.

     1.8 Where a SCHEDULE provides that CERES will make a financial contribution to certain
RESEARCH PROJECT activities performed by NOBLE, unless agreed otherwise in the appropriate
SCHEDULE, NOBLE will submit invoices after the end of each calendar quarter for the work performed
during that quarter. Each such invoice shall reflect only those costs that have been incurred in
performance of the RESEARCH PROJECT and shall provide a breakdown of costs similar to the detail
set forth in the budget of the related SCHEDULE. CERES will pay all such invoices within thirty
(30) days after the invoice date. Payments shall be remitted to:

Accounts Receivable

The Samuel Roberts Noble Foundation, Inc.

2510 Sam Noble Parkway

Ardmore, Oklahoma 73401

     1.9 Each party will conduct RESEARCH PROJECT activities exclusively in laboratories,
greenhouses or fields under full control of that party or of its SUBCONTRACTORS authorized by this
Agreement. Each party will take all reasonable precautions to prevent damage to, or unintentional
destruction of or release of any germplasm created in the RESEARCH ACTIVITIES.

     1.10 Each party shall be responsible for its compliance with all applicable laws, rules and
regulations, including, without limitation, those relating to genetically modified organisms (to
the extent RESEARCH PROJECTS involve such organisms), and obtaining any and all permits or
authorizations or proceed to any notifications which may be required by such laws, rules and
regulations.

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 4 of 57

 

 

     1.11 Each party will require any and all of its employees or students who will perform
activities in RESEARCH PROJECTS to be bound by a written agreement(s) that commits their
inventions, discoveries and other intellectual property to the party-employer and requires
confidential treatment of party and third-party confidential information. Each party shall further
notify each such employee, in writing, of their obligations and responsibilities under the terms of
this Agreement, including but not limited to the provisions of this Agreement on CONFIDENTIALITY
(Article 9), PUBLICATIONS (Article 6) and INTELLECTUAL PROPERTY (Article 2).

     1.12 The RESEARCH PROJECT principal investigators named in each SCHEDULE shall be charged with
leading the RESEARCH PROJECT described therein.

     1.12.1 RESEARCH PROJECT principal investigators may not vary the schedule of delivery,
amount, method of payment or any provision of a SCHEDULE. No such change shall be effective
unless and until it is reduced to writing (a) in the form of an amendment to such SCHEDULE
in accordance with the obligations of Paragraph 16.1 or (b) with respect to items listed in
Paragraph 1.4.1, in the signed minutes of a MANAGEMENT COMMITTEE meeting.

     1.12.2 Substitution by NOBLE of a RESEARCH PROJECT (a) principal investigator or (b) a
CERES-funded, PhD-level, NOBLE employee named or filling a defined position listed in a
SCHEDULE shall be subject to CERES’ prior written approval, which will not unreasonably be
withheld or delayed. NOBLE will notify CERES, in writing, of any substitution by NOBLE of a
non-CERES-funded, PhD-level employee named or who filled a defined position listed in a
SCHEDULE. CERES will notify NOBLE, in writing, of any substitution by CERES of a RESEARCH
PROJECT principal investigator or a PhD-level CERES employee named or who filled a defined
position listed in a SCHEDULE.

     1.13 Each party may subcontract certain parts of its RESEARCH PROJECT activities to third
parties, or use third party consultants in connection with RESEARCH PROJECT activities, but only if
the subcontract or consultancy agreement is in writing and complies with the terms and conditions
set forth hereinafter. Such third parties with whom such a subcontract or consultancy agreement is
executed will be referred to as “SUBCONTRACTORS”.

     1.13.1 The following terms and conditions shall apply to NOBLE’s SUBCONTRACTORS: (a)
the SUBCONTRACTOR shall perform defined activities on behalf and for the benefit of NOBLE in
exchange for a fee or other tangible consideration; (b) the SUBCONTRACTOR shall deliver all
the results of the SUBCONTRACTOR’S activities under the subcontract to NOBLE only, and
assign ownership of or exclusively license any inventions made during the performance of the
subcontracting activities to NOBLE, without any further remuneration and (c) the
SUBCONTRACTOR shall not have the right to use any results, whether information or material,
for any purpose whatsoever other than the performance of the subcontract; provided however,
not-for-profit research institution SUBCONTRACTORS may be granted the right to use certain
information generated pursuant to the subcontract for their internal academic research and
educational purposes (i.e., not in collaboration with or for the benefit of any third
party). NOBLE will provide a true copy of any subcontract to CERES within thirty (30) days
of its execution.

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 5 of 57

 

 

     1.13.2 It is anticipated that any agreements with commercial SUBCONTRACTORS will be
entered into by CERES, and NOBLE will assist CERES in identifying SUBCONTRACTORS for any
field activities. The following conditions shall apply to CERES SUBCONTRACTORS: CERES will
inform NOBLE, in writing, of any SUBCONTRACTORS used by CERES for the performance of
RESEARCH PROJECT activities and will verify that nothing in the subcontract would prevent
CERES from implementing or carrying out the obligations of the RESEARCH PROJECT.

     1.13.3 All SUBCONTRACTORS shall be bound by confidentiality obligations consistent with
the terms and obligations of this Agreement. All SUBCONTRACTORS shall be responsible for
their respective compliance with all laws, rules and regulations that govern their
activities.

     1.13.4 For variety evaluation and performance testing using not-for-profit research
institution SUBCONTRACTORS, the parties agree that each transfer of seed (or other plant
material) shall be governed by a written agreement consistent with the preferred form set
forth in EXHIBIT C to this Agreement.

     1.13.5 Any intended agreement with a SUBCONTRACTOR shall be identified in a SCHEDULE if
known at the time the SCHEDULE is executed by the parties. NOBLE will obtain CERES’ prior
written consent before entering into any agreement with a SUBCONTRACTOR which is not listed
in a SCHEDULE.

     1.14 The parties mutually agree that any applications for extramural funding for a RESEARCH
PROJECT, from governmental authorities or other public sources, will be subject to the prior,
written agreement, neither unreasonably withheld or delayed, by both parties; provided however, the
parties acknowledge that CERES and/or NOBLE has or has applied for certain government, extramural
funding prior to the Effective Date (EXHIBIT D to this Agreement), and such funding (or
possible funding, if awarded) shall not be construed as a breach of the obligations of this
paragraph.

     1.15 The parties agree not to accept targeted research funding from for-profit entities to
perform any RESEARCH PROJECT, whether in whole or in part, initiated under this Agreement without
the prior, written consent of the other party.

2. INTELLECTUAL PROPERTY.

     2.1 “JOINT INTELLECTUAL PROPERTY” shall mean (a) all patentable inventions conceived,
discovered, developed and/or reduced to practice (i) jointly by one or more employees, agents, or
students of CERES and by one or more employees, agents, or students of NOBLE in the performance of
any RESEARCH PROJECT(S) or (ii) by one or more employees, agents or students of NOBLE in the
performance of any RESEARCH PROJECT(S) to the extent CERES provides a financial contribution for
NOBLE’s activities in such RESEARCH PROJECT; (b) U.S. and/or foreign patents, patent applications,
plant variety rights, plant variety right applications, reissues, continuations,
continuations-in-part and divisionals claiming such patentable inventions; (c) all copyrighted
works created jointly by one or more employees, agents, or students of CERES and by one or more
employees, agents, or students of NOBLE in the performance of any RESEARCH

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 6 of 57

 

 

PROJECT(S); and (d) all germplasm and plant varieties created in the performance of plant
breeding activities in the performance of any RESEARCH PROJECT(S).

     2.2 “CERES INTELLECTUAL PROPERTY” shall mean (a) all patentable inventions conceived,
discovered, developed, and/or reduced to practice by one or more employees, agents, or students of
CERES in the performance of any RESEARCH PROJECT(S), except as set forth in Article 2.1; (b) U.S.
and/or foreign patents, patent applications, plant variety rights, plant variety right
applications, reissues, continuations, continuations-in-part, and divisionals claiming such
patentable inventions; and (c) all copyrighted works created by one or more employees, agents, or
students of CERES in the performance of any RESEARCH PROJECT(S) .

     2.3 “NOBLE INTELLECTUAL PROPERTY” shall mean (a) all patentable inventions conceived,
discovered, developed, and/or reduced to practice by one or more employees, agents, or students of
NOBLE in the performance of RESEARCH PROJECT(S), except as set forth in Article 2.1; (b) U.S.
and/or foreign patents, patent applications, plant variety rights, plant variety right
applications, reissues, continuations, continuations-in-part, and divisionals claiming such
patentable inventions; and (c) all copyrighted works created by one or more employees, agents, or
students of NOBLE in the performance of RESEARCH PROJECT(S).

     2.4 “OTHER RESEARCH RESULTS” shall mean all data, information, procedures and techniques
generated in the performance of RESEARCH PROJECT(S), but expressly excludes JOINT INTELLECTUAL
PROPERTY, CERES INTELLECTUAL PROPERTY, and NOBLE INTELLECTUAL PROPERTY.

     2.5 “BACKGROUND INTELLECTUAL PROPERTY” shall mean (i) inventions, discoveries, materials, data
and information, whether patentable or not; including related know-how; (ii) U.S. and/or foreign
patents, patent applications, plant variety rights, plant variety right applications, reissues,
continuations, continuations-in-part and divisionals; and (iii) copyrighted works, which are
individually or collectively created, developed, made, acquired or licensed in by CERES or NOBLE
independent of this Agreement.

     2.5.1 Any party asserting that certain intellectual property is BACKGROUND INTELLECTUAL
PROPERTY shall have the burden of substantiating such claim, if necessary, with tangible
evidence, including but not limited to paper or electronic records.

     2.5.2 The parties acknowledge and agree that all relevant BACKGROUND INTELLECTUAL
PROPERTY for a RESEARCH PROJECT should be set forth within the corresponding SCHEDULE. With
respect to each element of BACKGROUND INTELLECTUAL PROPERTY listed in a SCHEDULE, the
listing party shall include the following: ownership or licensed rights (exclusive or
non-exclusive) held by the listing party (if no ownership) with respect to the COLLABORATION
CROPS. Notwithstanding, subject to Paragraph 2.5.1, failure to specifically set forth such
BACKGROUND INTELLECTUAL PROPERTY in a SCHEDULE will not foreclose a later claim that certain
intellectual property is BACKGROUND INTELLECTUAL PROPERTY.

     2.6 CERES and NOBLE shall have an undivided interest in JOINT INTELLECTUAL PROPERTY.
Consequently, any and all patent applications or plant variety rights applications that

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 7 of 57

 

 

cover JOINT INTELLECTUAL PROPERTY shall be assigned jointly to CERES and NOBLE as soon as
practicable.

     2.6.1 All rights and title to CERES INTELLECTUAL PROPERTY and CERES BACKGROUND
INTELLECTUAL PROPERTY shall belong to CERES, and NOBLE shall not acquire any interest in the
same by its performance under this Agreement.

     2.6.2 All rights and title to NOBLE INTELLECTUAL PROPERTY and NOBLE BACKGROUND
INTELLECTUAL PROPERTY shall belong to NOBLE, and CERES shall not acquire any interest in the
same by its performance under this Agreement.

     2.7 Each party will notify the other party, in writing (“INVENTION NOTICE”), within thirty
(30) days of reduction to practice or knowledge of conception or discovery of JOINT INTELLECTUAL
PROPERTY, and each INVENTION NOTICE will describe the JOINT INTELLECTUAL PROPERTY with sufficient
specificity to allow assessment by the other party.

     2.8 Unless circumstances (e.g., publication submission, presentation, etc.) prohibit such
duration, the parties shall consult within twenty (20) days of receiving an INVENTION NOTICE, such
consultation shall concern whether to proceed to obtain intellectual property protection on the
disclosed JOINT INTELLECTUAL PROPERTY or whether to protect the same through other methods. CERES
shall have the first option to pursue such protection in its best judgment in the joint names of
both parties. If CERES so elects by written notice within sixty (60) days of such initial
consultation, CERES shall be the “ADMINISTERING PARTY” for the purposes of this Agreement.

     2.8.1 The ADMINISTERING PARTY shall be responsible for retaining counsel, overseeing
the process of securing intellectual property protection (i.e., the preparation, filing and
prosecution of patent or plant variety rights application(s)) and maintaining intellectual
property protection for the mutual benefit of the parties, in its best judgment, for that
which it had prosecution responsibility. In addition to other reporting responsibilities
provided below, the ADMINISTERING PARTY shall promptly notify the other party following
retention of counsel. The parties will provide, and cause their respective employees, agents
and students to provide, all reasonable assistance which may be required in connection with
the filing and prosecution of such intellectual property rights, including without
limitation the signing of documents.

     2.8.2 The ADMINISTERING PARTY shall keep the non-administering party advised as to all
developments with respect to all patent and plant variety rights application(s) and issued
patents and plant variety rights covering jointly owned JOINT INTELLECTUAL PROPERTY, which
includes supplying copies of all papers received and filed in connection with such
applications and patents in sufficient time for the non-administering party to comment
thereon.

     2.9 CERES agrees to bear all legal expenses incurred by CERES as an ADMINISTERING PARTY in
obtaining and maintaining patents and plant variety rights, U.S. and foreign, covering JOINT
INTELLECTUAL PROPERTY.

     2.10 If CERES does not elect to file an application for a patent or plant variety rights or
continue maintenance of a patent or plant variety rights in a particular country, consistent with
the

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 8 of 57

 

 

consultation of Paragraph 2.8, NOBLE may file such application, continue such prosecution, or
maintain such patent or plant variety rights at its own expense; provided however, that prior to
filing any such application NOBLE will grant CERES the opportunity to discuss the possible
disclosure of confidential information which may occur through such filing. NOBLE will take into
account any issues raised by CERES during such discussion, but NOBLE will have the right to proceed
with such filing in accordance with its best judgment. For any such application, patent or plant
variety rights, NOBLE shall serve as the ADMINISTERING PARTY. CERES shall have non-exclusive rights
under the specific patent application(s), plant variety right application(s), patent(s) and/or
plant variety right(s) in the country(ies) in which CERES declined to initiate or continue its
participation, subject to paying NOBLE reasonable remuneration (whether as a royalty or in some
other form as the parties may agree) to be negotiated in good faith, and in any case CERES shall
remain free to use and practice the JOINT INTELLECTUAL PROPERTY covered by such specific patent
application(s)/patent(s) or plant variety rights application(s)/plant variety right(s) for research
and evaluation purposes.

     2.11 At each quarterly meeting of the MANAGEMENT COMMITTEE, CERES will report CERES
INTELLECTUAL PROPERTY on which patent applications were filed in the preceding quarter and the
general subject matter of patent applications reasonably anticipated to be filed in the near term,
and NOBLE will report NOBLE INTELLECTUAL PROPERTY on which patent applications were filed in the
preceding quarter and the general subject matter of patent applications reasonably anticipated to
be filed in the near term. In addition, the parties may exchange information regarding their
respective INTELLECTUAL PROPERTY at other times as they deem fit.

3. USE AND COMMERCIALIZATION RIGHTS.

     3.1 Through the express grant of such rights in any SCHEDULE, CERES may grant NOBLE the
right to use CERES BACKGROUND INTELLECTUAL PROPERTY to the extent required for, and for the sole
purpose of, the performance by NOBLE (or its SUBCONTRACTORS) of RESEARCH PROJECTS. SCHEDULES may
specify that similar rights are granted with respect to defined elements of CERES BACKGROUND
INTELLECTUAL PROPERTY.

     3.2 NOBLE shall have the right to use JOINT INTELLECTUAL PROPERTY and OTHER RESEARCH RESULTS
(a) for the purpose of the implementation of RESEARCH PROJECTS; (b) for internal research purposes
(i.e., not in collaboration with or for the benefit of third parties), which do not concern the
breeding or germplasm improvement of COLLABORATION CROPS; and (c) for research purposes in all
crops except (i) the COLLABORATION CROPS and (ii) the specific crops set forth in EXHIBIT
E. The provisions of this Agreement on CONFIDENTIALITY (Article 9) and PUBLICATIONS (Article 6)
will apply with respect to all the foregoing activities.

     3.2.1 CERES shall have an exclusive first option to commercialize any results of
NOBLE’s research activities under Paragraphs 3.2(a) and 3.2(b). NOBLE shall notify CERES, in
writing, of any such results.

     3.2.2 If CERES exercises its option by written notice within ninety (90) days of
NOBLE’S written notice under Paragraph 3.2.1, CERES and NOBLE shall negotiate the terms of a
commercialization agreement that covers the reported results. If, despite the parties’ good
faith efforts, CERES and NOBLE are unable to agree upon the terms and conditions of such
agreement within one hundred and eighty (180) days after commencing good faith negotiations,

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 9 of 57

 

 

or at any earlier time agreed to by the parties, then NOBLE shall be free to
commercially exploit the results or grant licenses, with the right to grant sublicenses, to
third parties, to use and commercially exploit such results for all crops except (a) the
COLLABORATION CROPS and (b) the specific crops set forth in EXHIBIT E.

     3.2.3 If CERES declines to exercise this option or fails to respond within ninety (90)
days of NOBLE’S written notice under Paragraph 3.2.1, NOBLE shall then be free to
commercially exploit the results or grant licenses, with the right to grant sublicenses, to
third parties to use and commercially exploit such results for all crops except (a) the
COLLABORATION CROPS and (b) the specific crops set forth in EXHIBIT E.

     3.2.4 Pursuant to Paragraphs 3.2.2 or 3.2.3, if NOBLE proceeds to commercial
exploitation of such results whether through the grant of a license to a third party or
otherwise (subject to Paragraph 14.2 on exclusivity), such exploitation shall result in
NOBLE paying CERES reasonable remuneration (whether as a royalty or in some other form as
the parties may agree) to be negotiated in good faith. This remuneration shall take into
account the financial contribution of each party in research, development, marketing and
commercialization with respect to the relevant products.

     3.3 Subject to the reservations and rights granted to NOBLE in Paragraph 3.2, the parties
acknowledge and agree that CERES shall have the exclusive right, with the right to grant
sublicenses to this right, to use and commercially exploit JOINT INTELLECTUAL PROPERTY and OTHER
RESEARCH RESULTS for any and all uses and fields, including, but not limited to, use in the
COLLABORATION CROPS and crops other than the COLLABORATION CROPS. Any commercialization (including,
but not limited to, the grant of commercialization licenses) of JOINT INTELLECTUAL PROPERTY and/or
OTHER RESEARCH RESULTS shall result in CERES paying NOBLE a reasonable remuneration (whether as a
royalty or in some other form as the parties may agree) to be negotiated in good faith. This
remuneration shall take into account the financial contribution of each party in research
development, marketing and commercialization with respect to the relevant products. The terms for
remuneration will be specified, with respect to specific RESEARCH PROJECTS, JOINT INTELLECTUAL
PROPERTY and/or OTHER RESEARCH RESULTS, either in the respective SCHEDULES or in other agreements
to be executed by the parties.

     3.4 Subject to the reservations of Paragraph 3.2, NOBLE agrees to grant CERES an exclusive,
world-wide license, with the right to grant sublicenses, to use and exploit commercially (a)
NOBLE’s interest in any JOINT INTELLECTUAL PROPERTY and OTHER RESEARCH RESULTS; (b) NOBLE
INTELLECTUAL PROPERTY and (c) when necessary for the commercialization or use of JOINT INTELLECTUAL
PROPERTY and/or OTHER RESEARCH RESULTS and/or NOBLE INTELLECTUAL PROPERTY for the COLLABORATION
CROPS, NOBLE BACKGROUND INTELLECTUAL PROPERTY, subject to paying NOBLE reasonable remuneration
(whether as a royalty or in some other form as the parties may agree) to be negotiated in good
faith. This remuneration shall take into account the financial contribution of each party in
research, development, marketing and commercialization with respect to the relevant products. Such
license grants will be further specified in other agreements to be executed by the parties.
SCHEDULES to this Agreement may refer to the Model License Agreement for Non-transgenic Varieties
in EXHIBIT G.

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 10 of 57

 

 

4. ENFORCEMENT OF JOINT INTELLECTUAL PROPERTY RIGHTS.

     4.1 CERES will have the right, at its own discretion and expense, to take any action to
enforce and to initiate and prosecute suits for infringement of jointly owned intellectual property
rights covering JOINT INTELLECTUAL PROPERTY. CERES and NOBLE will consult with each other upon a
course of action and enforcement strategy. CERES will be responsible for the conduct of any such
enforcement action, and NOBLE will reasonably cooperate with CERES to effect the enforcement
action, and if appropriate, determine a settlement position. CERES shall be responsible for
retaining counsel and shall promptly notify NOBLE following retention of counsel, and NOBLE agrees
to be represented by such counsel as may be required for any enforcement action or settlement. For
purposes of settlement, CERES shall be the contact with the parties’ counsel as well as the
opposing party(ies) and shall have the right to enter into settlements. CERES shall keep NOBLE
advised as to all developments with respect to the enforcement action and settlement discussions,
which includes supplying to NOBLE copies of all papers received and filed in sufficient time for
NOBLE to comment thereon. NOBLE may attend any and all meetings with the parties’ counsel and the
opposing side for settlement purposes. NOBLE agrees to voluntarily join in any action brought by
CERES as a party plaintiff/defendant, if necessary, at the expense of CERES. If necessary, NOBLE
agrees to enter into a joint defense agreement.

     4.2 In situations where a substantial commercial interest of NOBLE’s is harmed by
infringement, and CERES elects not to pursue any action to enforce and to initiate and prosecute
suits for infringement, NOBLE shall have the right to pursue any such action in all crops except
(a) the COLLABORATION CROPS and (b) the specific crops set forth in EXHIBIT E, and CERES
will reasonably cooperate with NOBLE, if necessary, to permit NOBLE to properly enforce its rights.
NOBLE will be responsible for the conduct of any such enforcement action. NOBLE shall be
responsible for retaining counsel and shall promptly notify CERES following retention of counsel,
and CERES agrees to be represented by such counsel as may be required for any enforcement action or
settlement. For purposes of settlement, NOBLE shall be the contact with the parties’ counsel as
well as the opposing party(ies) and shall have the right to enter into settlements. NOBLE shall
keep CERES advised as to all developments with respect to the enforcement action and settlement
discussions, which includes supplying to CERES copies of all papers received and filed in
sufficient time for CERES to comment thereon. CERES may attend any and all meetings with the
parties’ counsel and the opposing side for settlement purposes. CERES agrees to voluntarily join in
any action brought by NOBLE as a party plaintiff/defendant, if necessary, at the expense of NOBLE.
If necessary, CERES agrees to enter into a joint defense agreement.

     4.3 Any damages received by CERES as a result of an enforcement action of rights to JOINT
INTELLECTUAL PROPERTY, after deduction of all enforcement related costs incurred by CERES, shall be
considered as revenues for the purpose of remuneration payments to NOBLE, as set forth in any
applicable license/commercialization agreement between the parties. In the absence of any such
license/commercialization agreement, the parties will share such damages after deduction of all
enforcement related costs incurred by CERES, in proportion to their relative financial
contributions to the creation (i.e., research and development) of such JOINT INTELLECTUAL PROPERTY.

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 11 of 57

 

 

5. TERMINATION.

     5.1. The term of this Agreement shall be twenty (20) years from the Effective Date,
unless sooner terminated in accordance with the following provisions of this Paragraph:

     (a) mutual, written agreement of the parties;

     (b) failure of one party to satisfy its material obligations under this Agreement, and
such party subsequently fails to cure such failure(s) within (i) thirty (30) days for
failures to remit payment for amounts due under this Agreement and (ii) ninety (90) days for
all other obligations in each case after receipt of written notice from the non-breaching
party specifying such failure(s);

     (c) one (1) year’s written notice of termination by either CERES or NOBLE to the other
party in case either the terminating party or the other party ceases substantially all
activities in the COLLABORATION CROPS;

     (d) NOBLE will have the right to terminate this Agreement unilaterally with thirty (30)
days’ written notice to CERES, (i) if CERES seeks protection under any bankruptcy,
insolvency, receivership, trust, deed, creditors arrangement or comparable proceeding or if
any such proceeding is instituted against CERES (and not dismissed within one hundred twenty
(120) days); (ii) in case of dissolution or winding up of CERES (excluding any situation
where all or substantially all of CERES’ assets, stock or business to which this Agreement
relates are acquired by a third party (whether by sale, acquisition, merger, operation of
law or otherwise)); (iii) with written notice to CERES, to be given no later than March 31,
2010 if Ceres has failed in a substantial manner, by December 31, 2009, to implement the
activities set forth in EXHIBIT F, and does not remedy such failure or offer a
remediation plan which is reasonably acceptable to NOBLE within ninety (90) days after
receipt of a written notice from NOBLE specifying such failure; or (iv) with one hundred
twenty (120) days’ written notice to CERES, if the institutional mission, purpose or
structure of NOBLE would change substantially and adversely affect NOBLE’S ability to
satisfy its obligations hereunder;

     (e) CERES will have the right to terminate this Agreement unilaterally: (i) with thirty
(30) days’ written notice to NOBLE if Dr. Joe Bouton ceases to be associated with NOBLE and
the RESEARCH PROJECTS contemplated by this Agreement, and NOBLE has not replaced him within
one hundred twenty (120) days by a person reasonably acceptable to CERES; (ii) with ninety
(90) days’ written notice to NOBLE, if the institutional mission, purpose or structure of
NOBLE would change substantially and adversely affect NOBLE’S ability to satisfy its
obligations hereunder; or (iii) with one (1) years’ written notice to NOBLE, if CERES has a
documented, compelling business reasons to cease the collaboration; or

     (f) either party will have the right to terminate this Agreement if no active RESEARCH
PROJECTS exist for more than two (2) years, provided that on or after the second anniversary
of the expiration or termination of the last SCHEDULE to expire or terminate, the parties
have not agreed on any new SCHEDULE despite (i) negotiations in good faith by both parties
or (ii) diligent, documented attempts by the terminating party to conduct negotiations in
good faith with respect to one or more new SCHEDULES, to which attempts the other party has
not been responsive.

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 12 of 57

 

 

     5.2 Promptly upon the delivery of a notice of termination of this Agreement, the parties will
meet to discuss the ongoing RESEARCH PROJECTS, and each party will provide to the other party any
data, information and germplasm that constitutes or is covered by JOINT INTELLECTUAL PROPERTY and
which has not been provided prior to the notice of termination, without prejudice to additional
on-going delivery obligations set forth in any SCHEDULES.

     5.3 Termination of this Agreement shall not affect the rights and obligations of the parties
accrued prior to termination hereof nor any license grants then in existence, subject to payment of
remuneration as set forth in any relevant license/commercialization agreements. Further, the
provisions set forth hereinafter shall apply.

     5.3.1 In case of termination on the basis of (w) Paragraph 5.1(b) if CERES is the
breaching party; (x) Paragraph 5.1(c) if CERES ceases substantially all activities in the
COLLABORATION CROPS; (y) Paragraphs 5.1(d)(i), 5.1(d)(ii) or 5.1(d)(iii); or (z) Paragraph
5.1(e)(iii), at or about the effective date of termination, the parties will negotiate in
good faith to reach agreement as to the rights to use and commercially exploit JOINT
INTELLECTUAL PROPERTY, which will be addressed in one or more written agreements. If the
parties fail to reach agreement within ninety (90) days after the start of such
negotiations, which shall be evidenced by written notice from one party to the other
initiating such negotiations, each party shall have the non-exclusive right to use and
commercially exploit JOINT INTELLECTUAL PROPERTY for any and all purposes, with the right to
grant sublicenses, subject to the obligations of the first sentence of Paragraph 5.3 and the
provisions set forth hereinafter. With respect to commercialization by either party of
varieties of COLLABORATION CROPS which constitute or incorporate JOINT INTELLECTUAL PROPERTY
not yet exclusively licensed to CERES as of the termination date (a) during a period of
three (3) years after the termination date of this Agreement, CERES will pay remuneration to
NOBLE for CERES’ commercialization activities as if such varieties were licensed exclusively
to CERES, and the remuneration shall be settled in accordance with the dispute resolution
procedure in Article 11, and NOBLE will pay one-half of the remuneration so determined to
CERES for NOBLE’S commercialization activities and (b) after the expiration of a three (3)
year period from the termination date of this Agreement, each party shall pay the other
party remuneration at one-half of the rate so determined for their respective
commercialization activities. No remuneration shall be due by either party with respect to
any other use or commercialization of JOINT INTELLECTUAL PROPERTY.

     5.3.2 In case of termination on the basis of (v) Paragraph 5.1(b) if NOBLE is the
breaching party; (w) Paragraph 5.1(c) if NOBLE ceases substantially all activities in the
COLLABORATION CROPS; (x) Paragraph 5.1(d)(iv); (y) Paragraphs 5.1(e)(i) or 5.1(e)(ii) or (z)
Paragraph 5.1(f), subject to the obligations of the first sentence of Paragraph 5.3, CERES
shall have the exclusive right to commercialize any JOINT INTELLECTUAL PROPERTY to the
extent such JOINT INTELLECTUAL PROPERTY is not covered by any relevant
license/commercialization agreement between the parties. At or about the effective date of
termination, the parties will negotiate in good faith to reach agreement as to reasonable
remuneration (whether as a royalty or in some other form as the parties may agree), which
will be addressed in one or more written agreements. If the parties fail to reach agreement
within ninety (90) days after the start of such negotiations, which shall be evidenced by
written notice from one party to the other initiating such negotiations, the remuneration
shall be settled in

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 13 of 57

 

 

accordance with the dispute resolution procedure in Article 11. Further, for
termination under Paragraphs 5.1(b), 5.1(c), 5.1(d)(iv) and 5.1(e)(ii), NOBLE’S internal
research rights under Paragraph 3.2 shall terminate simultaneously.

     5.4 Termination of this Agreement for any reason will not relieve either party of any
obligation or liability accrued under this Agreement before termination or rescind any payments
made or due before termination. Articles 2, 3 (subject to Paragraph 5.3), 4, 5, 6, 7, 9, 11, 15 and
16 will survive any termination of this Agreement.

     5.5 Termination of this Agreement shall not automatically terminate any existing RESEARCH
PROJECT, which can only be terminated according to the specific terms of the related SCHEDULE. The
terms and provisions of this Agreement shall continue to apply to the activities and outcomes of
any such RESEARCH PROJECTS, notwithstanding the termination of this Agreement, unless provided
otherwise in the relevant SCHEDULE or by written agreement of the parties upon termination.

6. PUBLICATIONS AND DISCUSSIONS.

     6.1 The parties agree that the researchers involved in the RESEARCH PROJECTS are
permitted to present methods and/or results of the RESEARCH PROJECTS at symposia and professional
meetings and to publish the same in journals or the like; provided however, the disclosing party
must furnish copies of any proposed publication, presentation or disclosure (collectively
“Disclosure”) to the other party at least thirty (30) days in advance of the specific submission,
presentation or other disclosure.

     6.2 The non-disclosing party shall have the thirty (30) day notice period to object, in
writing, to such proposed Disclosure because it contains (a) potentially patentable subject matter
that needs protection or (b) BACKGROUND INTELLECTUAL PROPERTY or JOINT INTELLECTUAL PROPERTY or
INTELLECTUAL PROPERTY of the non-disclosing party or OTHER RESEARCH RESULTS which need to be kept
confidential for compelling business reasons in the non-disclosing party’s reasonable judgment. In
the event that the non-disclosing party makes such objection, the disclosing party will (x) if
applicable, elect to cooperate with the non-disclosing party to obtain proper protection in
accordance with the provisions of Article 2 herein or (y) remove the objectionable subject matter
from the Disclosure. No delay caused by the non-disclosing party under this paragraph shall extend
beyond three (3) months, wherein upon such delay, the disclosing party shall be permitted to
proceed without being in breach of this Article.

     6.3 CERES and NOBLE shall use reasonable effort to avoid any action that might jeopardize the
ability of the parties, individually or jointly as the case may be, to obtain or retain
valid/enforceable intellectual rights in JOINT INTELLECTUAL PROPERTY, NOBLE INTELLECTUAL PROPERTY
or CERES INTELLECTUAL PROPERTY.

7. RECORDS AND AUDITS.

The parties shall keep accurate and detailed records in accordance with good accounting practices
of all expenses and extramural income, if any, relating to the RESEARCH PROJECTS. All such records
shall be subject to inspection by an independent auditor designated by the other party and
reasonably

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 14 of 57

 

 

acceptable to the audited party within normal business hours with at least fourteen (14) days
notice. Such inspection rights shall terminate, with respect to each RESEARCH PROJECT, on the third
anniversary of the expiration or termination of such RESEARCH PROJECT.

8. INDEPENDENT CONTRACTOR.

The relationship of the parties is that of independent contractors. Nothing herein is intended or
will be construed to establish any agency, partnerships or joint ventures. Neither party is
authorized or empowered to act as an agent for the other party for any purpose, nor shall either
party be bound by the acts or conduct of the other party.

9. CONFIDENTIALITY.

     9.1 As used in this Agreement, the term “Confidential Information” shall mean (a) all
non-public information and material received by one party from the other in furtherance of the
collaboration contemplated by this Agreement and (b) any and all information, results including
material and observations generated in the performance of any RESEARCH PROJECT including, without
limitation, CERES INTELLECTUAL PROPERTY, NOBLE INTELLECTUAL PROPERTY, JOINT INTELLECTUAL
PROPERTY and OTHER RESEARCH RESULTS. Confidential Information can include, but is not limited
to, information concerning the disclosing party’s operations, research, processes, techniques, data
and non-public materials.

     9.2 Subject to Paragraph 9.3, for a period of five (5) years after the termination of the
related RESEARCH PROJECT, the receiving party shall not use, except (a) for the benefit of the
parties’ collaboration or (b) such use as is expressly allowed by this Agreement and/or disclose
any Confidential Information to any third party without the prior written consent of the disclosing
party if the Confidential Information was received from the other party, or the prior written
consent of both parties if the Confidential Information was generated during a RESEARCH PROJECT.
Confidential Information shall only be made accessible to each party’s employees or students on a
need-to-know basis. Manuscripts and papers published in scientific journals and presentations made
at public meetings that include Confidential Information are exempt from the conditions of this
Paragraph, provided the parties followed the procedure set forth in Article 6.

     9.3 The receiving party shall have no obligations of confidentiality for information that:
can be established through written evidence to be in the possession of the receiving party prior to
the disclosure by the disclosing party; is or becomes public knowledge through no fault of the
disclosing party; and/or is acquired from others not under an obligation of confidentiality to the
disclosing party. In addition, the parties, pursuant to the express terms of this Agreement or any
SCHEDULE or other agreement between the parties, shall have the right to proceed to disclosures of
Confidential Information (a) as required to file for intellectual property protection or
registration or deregulation or approval of genetically modified organisms; (b) as required to
exercise commercialization rights granted in or on the basis of this Agreement and for related
marketing activities; (c) as required by laws, rules or regulation or court ordering such as,
without limitation, SEC regulations and IRS regulations; or (d) in CERES’ reasonable judgment for
the limited purpose of (potential) investors and business partners.

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 15 of 57

 

 

10. NOTICES.

Any notices required to be given or which shall be given under this Agreement shall be in writing
and delivered by first class mail or overnight (trackable) courier addressed to the parties as
follows:

Vice President of Product Development

Ceres, Inc.

1535 Ranch Conejo Blvd.

Thousand Oaks, California 91320

Vice President, General Counsel

The Samuel Roberts Noble Foundation, Inc.

2510 Sam Noble Parkway

Ardmore, Oklahoma 73401

In the event that notices under this Agreement are sent by certified or registered mail (or
alternatively, by overnight courier) by one party to the other party at its above address, they
shall be deemed to have been given or made as of the date so mailed.

11. DISPUTE RESOLUTION AND APPLICABLE LAW.

All disputes, differences or questions arising out of or in connection with this Agreement or its
SCHEDULES, or related to the alleged breach, termination, validity, interpretation or violation
thereof, shall be submitted to the MANAGEMENT COMMITTEE for resolution, which shall convene,
whether in person or otherwise, to resolve such dispute in a timely manner. Either party may
initiate a resolution procedure by providing written notice (“Dispute Notice”) to the other party,
and any such Dispute Notice must set forth the subject matter of the dispute, difference or
question. If after sixty (60) days the dispute remains unresolved, the presidents of CERES and
NOBLE shall seek to resolve the dispute through negotiation or mediation. If negotiation is
elected, the parties agree that at least eight (8) cumulative hours of negotiations between the
presidents will be undertaken. If mediation is elected, the presidents will meet at a neutral site
for mediation. Unless agreed to otherwise, the neutral site shall be Denver, Colorado. The
mediation shall be conducted in accordance with the then existing Commercial Mediation Rules of the
American Arbitration Association (AAA). The mediator shall be selected by mutual agreement of the
parties. If the parties cannot agree on a mediator, AAA shall designate a mediator at the request
of either party. Any mediator so designated must be acceptable to both parties. Fees for the
mediation will be shared equally, and the parties will responsible for their respective expenses.
Settlement reached in mediation or negotiation will not be binding until the parties have signed a
written settlement agreement.

Any dispute, controversy, or claim arising out of or in connection with this Agreement or its
SCHEDULES, or related to the alleged breach, termination, validity, interpretation or violation
thereof, not settled by negotiation or mediation in accordance with the terms hereof, shall be
finally settled and determined by arbitration administered by the AAA under its then current
Commercial Arbitration Rules and Mediation Procedures (including Procedures for Large, Complex
Commercial Disputes) (the “Rules”). The written reasoned award of the arbitrators shall be final
and binding upon the parties, and judgment on or enforcement of the award so rendered may be
sought, had or entered in any court having jurisdiction.

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 16 of 57

 

 

     (a) Initiation of Arbitration. Any party may initiate arbitration by filing a written
request for arbitration with the AAA. A copy of the request shall be furnished to all other parties
in accordance with the provisions of the Rules and the provisions in the agreement between the
parties concerning notices. For all purposes the “commencement of the arbitration” shall be deemed
to be the date on which any party issues a written demand for arbitration in accordance with the
requirements of Article 10.

     (b) Appointment of Arbitrators. Each party shall appoint an arbitrator, and the two
arbitrators so appointed shall appoint the third arbitrator. The party initiating the arbitration
shall appoint its arbitrator at the commencement of the arbitration. The other party shall appoint
its arbitrator within thirty (30) days of the commencement of the arbitration. If the arbitrators
appointed by the parties fail to appoint the third arbitrator within sixty (60) days of the
commencement of the arbitration, the AAA shall appoint the third arbitrator following consultation
with the parties.

     (c) Qualifications of Arbitrators. Each arbitrator so appointed shall have a
reputation as being experienced in the legal and technical matters related to the dispute, shall be
required to disclose, among other disclosures, any prior involvement with the legal and technical
matters related to the dispute and any involvement with a competitor of any party, and shall not be
presently nor in the past have been affiliated with any party or a competitor of any party.
Notwithstanding the method of their appointment, each arbitrator shall be required to meet the
standards contained in the Rules with respect to impartiality, independence and neutrality.

     (d) Location of the Arbitration. The seat of arbitration shall be Denver, Colorado.
The arbitrators may hold hearings at such other locations as the arbitrators shall determine, after
consultation with the parties.

     (e) Language of Arbitration. The arbitral proceedings and all pleadings and written
evidence shall be in the English language. Any written evidence originally in a language other than
English shall be submitted in English translation accompanied by the original or true copy thereof.

     (f) Procedural Requirements. The arbitrators shall, after consultation with the
parties, make appropriate provision in the arbitration process for rules specific to this
arbitration which:

          (i) require the disclosure of all exhibits expected to be used by the parties at
the arbitration, and the exchange of complete copies of all such exhibits in advance
of the arbitration;

          (ii) determine the dates for the exchange of said written disclosures and copies
of said exhibits;

          (iii) require the written disclosure of the identity of all witnesses whom the
parties expect to call at the arbitration;

          (iv) determine the dates for the exchange of the written disclosures of the
identity of witnesses which the parties expect to call at the arbitration;

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 17 of 57

 

 

          (v) determine the dates for the exchange of sworn narrative statements
containing the testimony of all witnesses whom the parties expect to call at the
arbitration;

          (vi) require that the sworn narrative testimony of witnesses be submitted in
substitution for the direct examination of the witness, and that all witnesses whose
sworn testimony is submitted for consideration by the arbitrators must present him or
herself for cross examination at the time and place of the arbitration hearing,
unless some other procedure providing the parties with a full and complete
opportunity for cross-examination has been established and provided by the
arbitrators, the parties and the witness;

          (vii) prohibit, except upon a showing of good cause, or for purposes of
rebuttal, the receipt into evidence of any exhibit not disclosed by the parties, nor
shall the arbitrators permit a party to present the testimony of any witness whose
identity and testimony was not exchanged prior to the arbitration;

          (viii) permit discovery as reasonable and necessary for the orderly preparation
of the dispute for hearing and determination of the dispute (said discovery may
include requests for production of documents and depositions of witnesses who cannot
be summoned to the arbitration or are otherwise unavailable to attend the
arbitration); and

          (ix) require all parties and experts to maintain all information and documents
they have received , reviewed, exchanged or given testimony about in confidence
pursuant to an appropriate confidentiality undertaking and order.

     (g) Limitation on Remedies. The arbitrators are precluded from awarding punitive or
exemplary damages. In no event shall the arbitrators have the powers of an amiable compositeur.

     (h) Resort to the Courts. Nothing in this Agreement prohibits any party from seeking
interim or conservatory relief in any court of competent jurisdiction; provided
however, that neither the filing of an application for a temporary restraining order,
preliminary injunction or other interim or conservatory relief, as necessary, nor the granting of
such relief, shall be deemed to be a waiver of the obligation of the party to have the dispute
heard and determined solely and exclusively by arbitration.

     (i) Survival. The rights and obligations of the parties as described herein shall
survive the termination, expiration, non-renewal or rescission of the Agreement between the
parties.

12. PUBLICITY.

     12.1 NOBLE will not identify CERES in any products, publicity, promotion, promotional
advertising or other promotional materials to be disseminated to the public, or use any trademark,
service mark, trade name, logo or symbol that is representative of CERES or its entities, whether
registered or not, or use the name, title, likeness or statement of any CERES employee or student,
without CERES’ prior written consent. Any use of CERES’ name shall be limited to statements of fact
and shall not imply endorsement by CERES of NOBLE’S research, products or services.

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 18 of 57

 

 

     12.2 CERES will not identify NOBLE in any products, publicity, promotion, promotional
advertising or other promotional materials to be disseminated to the public, or use any trademark,
service mark, trade name, logo or symbol that is representative of NOBLE or its entities, whether
registered or not, or use the name, title, likeness or statement of any NOBLE faculty member,
employee or student, without NOBLE’S prior written consent. Any use of NOBLE’S name shall be
limited to statements of fact and shall not imply endorsement by NOBLE of CERES’ research, products
or services.

     12.3 Notwithstanding any provision of this Article, either of the parties can disclose or
otherwise acknowledge, without restriction, the existence of this Agreement as well as the
collaborative relationship between the parties without the prior consent of the other party.
Notwithstanding the unilateral disclosure rights provided for in this paragraph, if the disclosure
or acknowledgement takes the form of a written release, the disclosing party shall provide the
other party a copy of any such unilateral disclosure prior to its release so as to allow the other
party to comment and shall take such comments reasonably into account. However, no advance copy
needs to be provided of any releases referred to in Paragraph 12.4(a) or 12.4(b) or of any releases
which are identical to previous releases.

     12.4 The parties intend to issue joint press releases regarding their collaboration. Any such
press release and any press release by either party will be subject to the prior written approval
of both parties; provided however, that (a) CERES shall have the right to otherwise disclose
information as may be required in CERES’ judgment to comply with SEC regulations or other laws,
rules or regulations governing disclosure of information and (b) NOBLE shall have the right to
otherwise disclose information as may be required in NOBLE’S judgment to comply with IRS or state
regulations or other laws, rules or regulations governing disclosure of information.
Notwithstanding the unilateral disclosure rights provided for in this paragraph, the disclosing
party shall provide the other party a copy of any such unilateral disclosure preferably prior to
its release.

13. MANAGEMENT COMMITTEE.

     13.1 The parties will establish a MANAGEMENT COMMITTEE to supervise the implementation,
execution and progress of this Agreement and its RESEARCH PROJECTS. The MANAGEMENT COMMITTEE will
consist of four (4) members, two (2) to be appointed by each party and will meet at least once
every calendar quarter, in person or by telephone, on dates and at locations to be mutually agreed.
The representatives of each party may invite other employees of that party to meeting on an
as-needed basis, subject to prior notification of the other party.

     13.2 The MANAGEMENT COMMITTEE shall approve project teams and RESEARCH PROJECT principal
investigators. The MANAGEMENT COMMITTEE shall determine the resources necessary to achieve the
goals of each RESEARCH PROJECT, within the limits of the total RESEARCH PROJECT budget provided in
the relevant SCHEDULE. The RESEARCH PROJECT principal investigators shall report to the MANAGEMENT
COMMITTEE at such intervals as may be determined by the MANAGEMENT COMMITTEE. The MANAGEMENT
COMMITTEE shall review progress and may, as appropriate, revise stated or set additional goals. The
MANAGEMENT COMMITTEE shall have the authority to modify those provisions of each SCHEDULE listed in
Paragraph 1.4.1.

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 19 of 57

 

 

     13.3 Decisions of the MANAGEMENT COMMITTEE shall be made by unanimous agreement and recorded
in a manner prescribed by the MANAGEMENT COMMITTEE as a true record of the decisions. If the
MANAGEMENT COMMITTEE cannot come to a unanimous agreement on any matter then the status quo shall
apply. If either party believes that the matter is materially adverse to the objectives of this
Agreement and/or the matter significantly hinders the party’s ability to satisfy its obligations
under this Agreement, then the matter shall be settled in accordance with the disputes procedure in
Article 11.

14. EXCLUSIVITY.

     14.1 In consideration of CERES’ development of a new market for the COLLABORATION CROPS
and the significant activities associated with the development of this market, NOBLE agrees to
grant CERES exclusive access to NOBLE’S plant improvement activities specifically involving the
COLLABORATION CROPS, whether through plant breeding or transformation.

     14.2 During the term of this Agreement, subject to the provisions of this Agreement on
subcontracting (Paragraph 1.13 and its related subparagraphs), NOBLE (a) will not collaborate with
or perform any activities for the benefit of or grant any rights to any for-profit third party in
the field of the COLLABORATION CROPS without the prior written consent of CERES or (b) will not
collaborate with or perform any activities for the benefit of or grant any rights to any
not-for-profit third party with respect to breeding or germplasm improvement of COLLABORATION CROPS
without the prior written consent of CERES.

     14.2.1 The parties contemplate entering a separate agreement, in partial consideration
for the exclusivity granted to CERES in this Article, that would provide NOBLE the right,
pursuant to the terms of such agreement and the continuation of such exclusivity, to obtain
a minor equity position in CERES. If the parties have not agreed to the terms of such
agreement prior to the conclusion of two hundred and seventy (270) days from the Effective
Date of this Agreement, despite negotiations in good faith by both parties, unless this
period is extended by the mutual agreement of the parties, NOBLE shall have the right to
terminate its obligations set forth in this Article 14.2 by written notice to CERES, to be
delivered no later than one (1) year from the Effective Date of this Agreement.

     14.3 During the term of this Agreement, NOBLE will promptly notify CERES, in writing, of any
contemplated internal research activities (i.e., non-RESEARCH PROJECTS) that specifically involve
the COLLABORATION CROPS and will submit a detailed, written research proposal to CERES. If CERES
so requests, the parties will negotiate in good faith to agree on a new RESEARCH PROJECT and
accompanying SCHEDULE or an amendment to an existing SCHEDULE on the basis of such research
proposal. If CERES does not request such negotiations, or if the parties fail to reach agreement
on a new SCHEDULE (or amendment to an existing SCHEDULE) based on such research proposal within
ninety (90) days from delivery of the research proposal, NOBLE will have the right, subject to
Paragraphs 3.2 and 14.2, to proceed to such internal research, and CERES is hereby granted an
exclusive first option to commercialize any results of such activities. NOBLE shall notify CERES,
in writing, of any such results.

     14.3.1 If CERES exercises its option by written notice within ninety (90) days of
NOBLE’S written notice under Paragraph 14.3, CERES and NOBLE shall negotiate the terms

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 20 of 57

 

 

of a commercialization agreement that covers the reported result. If, despite the
parties’ good faith efforts, CERES and NOBLE are unable to agree upon the terms and
conditions of such agreement within one hundred and eighty (180) days after commencing good
faith negotiations, or at any earlier time agreed to by the parties, then NOBLE shall be
free to commercially exploit the results or offer rights in such results to third parties in
any and all crops.

     14.3.2 If CERES declines to exercise this option or fails to respond within ninety (90)
days of NOBLE’S notice under Paragraph 14.3, then NOBLE shall then be free to commercially
exploit the results or offer rights in such results to third parties in any and all crops.

     14.4 Prior to entering into any agreement pursuant to which a third party would perform
breeding activities for any COLLABORATION CROP intended for commercialization in Alabama, Arkansas,
Florida, Georgia, Kansas, Kentucky, Louisiana, Mississippi, Missouri, North Carolina, Oklahoma,
South Carolina, Tennessee, Texas, Virginia and West Virginia of the United States, CERES will first
provide NOBLE the opportunity to conduct such breeding activities. CERES shall notify NOBLE in
writing of its intent to enter into any such agreement, and NOBLE shall, within thirty (30) days
after receiving such notice, notify CERES in writing whether or not it desires to conduct such
work. If NOBLE notifies CERES that it desires to conduct such work, CERES and NOBLE will negotiate
in good faith the terms and conditions pursuant to which NOBLE shall conduct such breeding
activities. If, despite the parties’ good faith efforts, CERES and NOBLE are unable to agree upon
the terms and conditions for such work within sixty (60) days after commencing good faith
negotiations, or at any earlier time agreed to by the parties, then CERES shall be free to enter
into an agreement with a third party for such breeding activities.

15. EXCLUSION OF WARRANTIES.

     15.1 THE PARTIES ACKNOWLEDGE AND AGREE THAT NEITHER PARTY HAS MADE ANY REPRESENTATIONS OR
WARRANTIES, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO, WARRANTIES OF MERCHANTABILITY OR
FITNESS FOR A PARTICULAR PURPOSE. IN NO EVENT SHALL EITHER PARTY BE HELD RESPONSIBLE FOR ANY
SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES OR LOSS OF PROFIT ARISING OUT OF THE USE OF
ANY JOINT INTELLECTUAL PROPERTY, CERES INTELLECTUAL PROPERTY, NOBLE INTELLECTUAL PROPERTY, OTHER
RESEARCH RESULTS OR BACKGROUND INTELLECTUAL PROPERTY COVERED BY THIS AGREEMENT OR ANY SCHEDULE OR
ARISING OUT OF THE IMPLEMENTATION OF THIS AGREEMENT, EVEN IF SUCH PARTY IS ADVISED IN ADVANCE OF
THE POSSIBILITY OF SUCH DAMAGES.

     15.2 Nothing in this Agreement is or shall be construed as:

(a) a warranty or representation by either party as to the validity or scope of any
patent rights or plant variety rights;

(b) a warranty or representation by either party that anything made, used, sold
or otherwise disposed of pursuant to any license granted under this Agreement is or
will be free from infringement of patents, copyrights or other rights of third
parties;

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 21 of 57

 

 

(c) any obligations by either party to bring or prosecute actions or suits against
third parties for patent infringement; or

(d) a grant by implication, estoppel or otherwise of any licenses under patent
applications, patents, plant variety rights applications and/or plant variety rights
of CERES and/or NOBLE or other person other than as provided in the express
provisions of this Agreement or a SCHEDULE on this Agreement.

16. GENERAL.

     16.1 Entire Agreement/Modifications.

     This Agreement constitutes the entire agreement between the parties hereto with respect to the
subject matter hereof, and there are no representations, warranties, covenants or obligations
except as set forth herein. This Agreement supersedes all prior and contemporaneous agreements,
understandings, negotiations and discussions, written or oral, of the parties hereto relating to
the subject matter hereof. This Agreement may only be amended, modified or superseded by a writing
executed by the authorized representative of the parties hereto. It is anticipated that SCHEDULES
will be attached to and become part of this Agreement as new RESEARCH PROJECTS are undertaken, as
described in Paragraph 1.1.

     16.2 Severability.

     This Agreement, to the greatest extent possible, shall be construed so as to give validity to
all of the provisions hereof. If any provision of this Agreement is or becomes invalid, is ruled
illegal by a court of competent jurisdiction or is deemed unenforceable under the current
applicable law from time to time in effect during the term of this Agreement, the remainder of this
Agreement will not be affected or impaired thereby and will continue to be construed to the maximum
extent permitted by law. In lieu of each provision which is invalid, illegal or unenforceable,
there will be substituted or added as part of this Agreement by mutual written agreement of the
parties, a provision which will be as similar as possible, in economic and business objectives as
intended by the parties to such invalid, illegal or unenforceable provision, but will be valid,
legal and enforceable.

     16.3 Waiver.

     No failure or delay by either party in exercising any right or remedy under this Agreement
will waive any provision of this Agreement. Nor will any single or partial exercise by either party
of any right or remedy under this Agreement preclude it from otherwise or further exercising any
rights or remedies which it may have, or any other rights or remedies granted by any law or any
related document.

     16.4 Enforcement.

     In the event an action is commenced by either party against the other to enforce any of the
provisions of this Agreement, the prevailing party shall be entitled to recover from the other
party reasonable attorneys’ fees, court costs and necessary disbursements incurred in connection
with such action.

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 22 of 57

 

 

     16.5 Assignablility.

     This Agreement binds and enures to the benefit of the parties, their successor or assigns, but
may not be assigned by either party without the prior written consent of the other party; provided
however, CERES shall have the right to assign its rights and obligations under this Agreement to
any Affiliated Company without such prior consent. Each party shall have the right to assign its
rights and obligations under this Agreement to a third party in conjunction with the transfer to
such third party of substantially all of the assets of such party associated with performance under
this Agreement without such prior consent. “Affiliated Company” defined as any company owned or
controlled by, under common control with or controlling CERES, “control” meaning in this context
the direct or indirect ownership of fifty percent (50%) or more of the voting stock/shares of a
company, or the power to nominate at least half of the directors.

     16.6 Force Majeure.

     No party shall be responsible to the other party for delay or failure in performance of any
the obligations imposed by this Agreement, provided such failure shall be occasioned by fire,
flood, explosion, lightning, wind storm, hailstorm, earthquake, subsidence of soil, failure of
machinery or equipment or supply of materials, discontinuity in the supply of power, court order or
governmental interference, terrorist attacks, civil commotion, riot, war, strikes, labor
disturbances, transportation difficulties, labor shortage, natural genetic variation of any living
matter or by any other cause of like or unlike nature beyond the reasonable control and without
fault or negligence of such party.

     16.7 Choice of Law.

     This Agreement shall be governed by, and construed and interpreted in accordance with, the
laws of the State of Delaware without regard to the principles of conflicts of law thereof.

     IN WITNESS WHEREOF, NOBLE and CERES have caused this Agreement to be duly executed as
indicated below.

	 	 	 	 	 	 	 	 	 

	THE SAMUEL ROBERTS NOBLE
FOUNDATION, INC.	CERES, INC.	 	 
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ Michael A. Cawley	 	By:	 	/s/ Richard Flavell	 	 
	Name:

	 	 

Michael A. Cawley
	 	Name:
	 	 

Richard Flavell, CBE, FRS
	 	 
	Title:

	 	President
	 	Title:
	 	Chief Scientific Officer	 	 
	Date:

	 	19 May 2006	 	Date:	 	May 19, 2006	 	 
	 

	 	 

	 	 	 	 

	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	 	 	By:	 	/s/ Richard Hamilton	 	 
	 

	 	 	 	Name:
	 	 

Richard Hamilton
	 	 
	 

	 	 	 	Title:
	 	President and Chief Executive
Officer	 	 
	 

	 	 	 	Date:	 	May 19, 2006	 	 
	 

	 	 	 	 	 	 

	 	 

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 23 of 57

 

 

EXHIBIT A —  DEFINITION OF COLLABORATION CROPS

“COLLABORATION CROPS” is defined as and expressly limited to the following species:

     Panicum virgatum species.

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 24 of 57

 

 

EXHIBIT B — PREFERRED FORM OF RECEIPT FORM

Packing Slip and Receipt Form

for material transferred pursuant to the Master Research Agreement dated 19 May 2006 between

THE SAMUEL ROBERTS NOBLE FOUNDATION, INC. and CERES, INC. and SCHEDULES to such Agreement.

Material transferred pursuant to SCHEDULE [x] dated [...]

The undersigned [NOBLE/CERES] signatory certifies that the material and related information set
forth hereinafter are included in the shipment with which this form is enclosed.

The undersigned [NOBLE/CERES] signatory acknowledges having received in good order the material and
related information set forth hereinafter. The signature does not constitute an acceptance of the
receiving party’s qualification of the intellectual property (IP) status of the material
transferred, such IP status being defined in the parties’ Master Research Agreement.

[Include description of material and related information with indication of IP status (e.g.
Background, Joint IP) and any restrictions on transfer to subcontractors.]

THIS MATERIAL AND RELATED INFORMATION ARE TRANSFERRED ONLY FOR USE IN COMPLIANCE WITH THE ABOVE
MENTIONED MASTER RESEARCH AGREEMENT AND SCHEDULE. CONFIDENTIALITY OBLIGATIONS APPLY.

	 	 	 	 	 	 	 	 	 

	For sending/receipt,	 	 	 	For receipt/sending,
	 
	 	 	 	 	 	 	 	 
	Signature:

	 	 	 	 	 	Signature:	 	 
	 

	 	 

	 	 	 	 	 	 
 
	Date:

	 	 	 	 	 	Date:	 	 
	 

	 	 

	 	 	 	 	 	 
 
	Name: Walter E. Nelson	 	 	 	Name:
	 
	 	 	 	 	 	 	 	 
	Title: Product Development Manager	 	 	 	Title:
	CERES, INC.	 	 	 	THE SAMUEL ROBERTS NOBLE FOUNDATION, INC.

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 25 of 57

 

 

EXHIBIT
C — PREFERRED FORM OF VARIETY EVALUATION AGREEMENT

A. Recipient:

B. Address:

C. Plant Material:

	 	 	 	 	 
	SPECIES	 	CODE/DESCRIPTION	 	WEIGHT
	 
	 	 
	 	 

D. Research Purpose: Variety production evaluation and performance testing with .

E. Location for Conduct of Research:

The <<INSTITUTION>> (“Provider”) will provide the Recipient the Plant Material subject
to the following terms and conditions:

     1. The Recipient shall use the Plant Material solely for the Research Purpose.

     2. Provider is (i) owner of all or a portion of the intellectual property rights in the Plant
Material and/or (ii) licensee of all or a portion of the intellectual property rights in the Plant
Material.

     3. Without the prior written consent of Provider, the Recipient shall not use the Plant
Material, seed, or any product derived therefrom in any form of reselection, breeding, sexual
crossing, seed production, back crossing, tissue culturing, mutagenesis, genetic transformation or
any biotechnological process, except as specifically approved in this Agreement.

     4. The Recipient shall not supply or otherwise transfer the Plant Material or any products or
progeny derived therefrom, be it seed or vegetative material, to any other person or entity without
the prior written permission from an authorized representative of Provider.

     5. The Recipient shall take all precautions to prevent theft or pilferage of any material
related to and including the Plant Material.

     6. The Recipient shall voluntarily provide Provider the results of any evaluation using this
Plant Material, including any proposed publication concerning the Plant Material.

     7. The Recipient will be free to publish the research results from the evaluation contemplated
by this Agreement; provided however, the Recipient must provide Provider any proposed publication
at least thirty (30) days prior to submission. Provider will review such proposed publication for
the need of intellectual property protection and/or to identify any inadvertent disclosure of
proprietary information. If necessary, the Recipient agrees to (i) delay publication by no more
than sixty (60) days to enable the filing of an application for intellectual property protection
and/or (ii) remove any proprietary information identified by Provider.

     8. Provider represents that it has the right to transfer the Plant Material under this
Agreement.

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 26 of 57

 

 

     9. At the end of the evaluation trial, the Recipient shall, at the option of Provider, (i)
return to Provider all unused Plant Material supplied by Provider and all materials, regardless of
type, produced from the Plant Material or (ii) destroy all unused Plant Material supplied by
Provider and all materials, regardless of type, produced from the Plant Material. The Recipient
agrees that all such unused Plant Material and all materials, regardless of type, produced from the
Plant Material are the property of Provider.

     10. The Recipient acknowledges and agrees that Provider shall not be liable for any damages or
loss that may arise from testing of the Plant Material.

     11. The Recipient acknowledges and accepts that the Plant Material is being supplied with no
warranties, expressed or implied. In particular, as the use of the Plant Material is limited to the
furtherance of the Research Purpose, there is no basis for and no warranty given for fitness for a
particular purpose or merchantability.

Organization:

Recipient:

	 	 	 	 	 

	 

Date
	 	 

	 	 

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 27 of 57

 

 

EXHIBIT D — EXISTING OR PENDING EXTRAMURAL FUNDING

	 	 	 	 	 	 	 	 	 
	 	 	 	 	Other	 	Agency –	 	Filing Date /
	Entity	 	Application
Title	 	Institutions	 	Program	 	Award Date
	CERES

	 	Genes for Enhancing Carbon Sequestration in Poplar (R. Flavell)
	 	Oregon State University
	 	DOE/Office of Science
	 	Sept. 9, 2005 (A)
	 
	 	 	 	 	 	 	 	 
	NOBLE

	 	Development of low-lignin switchgrass for improved ethanol production (Z. Wang)
	 	Oak Ridge National Laboratory
	 	USDA
	 	April 3, 2006 (A)
	 
	 	 	 	 	 	 	 	 
	NOBLE

	 	Systemic modification of monolignol pathway gene expression for improved lignocellulose utilization (F. Chen, R. Dixon)
	 	None
	 	USDA/DOE Plant Feedstock
	 	Feb 17, 2006 (F)
	 
	 	 	 	 	 	 	 	 
	NOBLE

	 	Genetic dissection of the lignocellulosic pathway of gene (F. Chen, R. Dixon)
	 	Kansas State University (lead)
	 	USDA/DOE Plant Feedstock
	 	Feb 23, 2006 (F)
	 
	 	 	 	 	 	 	 	 
	NOBLE

	 	Molecular-functional map and genome analysis of switchgrass (Panicum virgatum L.) (M. Saha, J. Bouton)
	 	USDA-ARS,

Albany, California
	 	USDA/DOE Plant Feedstock
	 	Feb 27, 2006 (F)

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 28 of 57

 

 

EXHIBIT E — EXCLUDED CROPS 

Corn

Cotton

Wheat

Rice

Sugarcane

Miscanthus

Sweet sorghum

Soybean

Sunflower

Safflower

Jatropha

Castor

Canola

Oil Palm

Hevea

Guayule

St. Augustine (turf applications only)

Trees in all fields, excluding variety evaluation and testing

Fruits, Nuts & Vegetables in all fields, excluding variety evaluation and testing and research to
use these platforms to deliver natural products/compounds to benefit human and/or animal health.

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 29 of 57

 

 

EXHIBIT F — SEED PRODUCTION AND COMMERCIALIZATION ACTIVITIES

CERES will:

	 	1.	 	Identify growers and establish grower contracts
	 
	 	2.	 	Lease, build or buy production facility
	 
	 	3.	 	Establish quality testing capability
	 
	 	4.	 	Establish a sales force and distribution network and/or distribution
through existing distribution systems such as retail outlets and regional seed
companies and/or establish any other commercialization system.

CERES shall provide to NOBLE a detailed, written annual report on its activities in furtherance of
the obligations of this EXHIBIT, such report shall be due at or about March 31 of each year. In
addition, upon the request of NOBLE at any time, CERES will discuss the their progress and results
achieved in regard to such activities; provided however, such contacts and discussions shall be
reasonable in frequency and duration so as not to be disruptive to the respective operations of
either party.

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 30 of 57

 

 

EXHIBIT
G — MODEL LICENSE AGREEMENT FOR NON-TRANSGENIC
VARIETIES

LICENSE AGREEMENT FOR [VARIETY X]

     THIS AGREEMENT is made this ___ day of _________, 2006 (“Effective Date”), by and between THE
SAMUEL ROBERTS NOBLE FOUNDATION, INC. (“NOBLE”), an Oklahoma nonprofit corporation, and CERES,
INC., a Delaware corporation (“CERES”).

     WHEREAS, CERES and NOBLE entered into a MASTER RESEARCH AGREEMENT, (“MRA”), that contemplates
a long-term research relationship by and between the parties for the enhancement and improvement of
COLLABORATION CROPS (as defined in the MRA) for biomass crops;

     WHEREAS, CERES and NOBLE have jointly developed and jointly own a new SWITCHGRASS variety [X]
pursuant to SCHEDULE(S) [2] [and...] to the MRA;

     WHEREAS, CERES wishes to commercialize SWITCHGRASS variety [X];

WHEREAS, CERES has the ability to assume production of and to commercialize SWITCHGRASS variety [X]
and wishes to receive an exclusive, world-wide license to produce, use, sell and commercially
exploit SWITCHGRASS variety [X];

     WHEREAS, in accordance with the provisions of the MRA concerning the commercialization of
SWITCHGRASS varieties jointly developed and jointly owned by the parties under the MRA, the parties
have developed this Agreement and its terms in accordance with the terms and obligations set forth
in the MRA;

     WHEREAS, CERES and NOBLE recognize that the rights intended to be granted hereunder can be a
strong incentive for CERES to risk money and other resources needed to produce, use, sell and
commercially exploit SWITCHGRASS for wide public enjoyment;

     NOW THEREFORE, in consideration of the premises and of the mutual covenants and agreements
contained herein and of other good and valuable consideration, the parties have agreed and do
hereby agree as follows:

1. DEFINITIONS.

     1.1 “SWITCHGRASS” shall mean the species Panicum virgatum.

     1.2 “LICENSED VARIETY” means the [NAME] SWITCHGRASS variety jointly developed by the parties
pursuant to SCHEDULE(S) [2] to the MRA and released, jointly by NOBLE and CERES, pursuant to the
terms of SCHEDULE(S) [2].

     1.3 “RELEASE DATE” means the date the LICENSED VARIETY was released pursuant to the terms of
SCHEDULE(S) [2].

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 31 of 57

 

 

     1.4 “LICENSED TERRITORY” means the United States of America and all other countries of the
world.

     1.5 “LICENSED PRODUCTION TERRITORY” means the United States of America and all other countries
of the world.

     1.6 “BREEDER SEED” means seed of the LICENSED VARIETY that (a) is identified by NOBLE and
CERES jointly as being of a suitable standard of physical and genetic purity to produce FOUNDATION
SEED and (b) resulted from the final breeding of the LICENSED VARIETY.

     1.7 “FOUNDATION SEED” means seed produced from plants grown directly from BREEDER SEED,
cultivated according to certification regulations and that meets the specifications of the official
seed certifying agency of the jurisdiction in which said seed is/was produced.

     1.8 “REGISTERED SEED” means seed produced from plants grown directly from FOUNDATION SEED,
cultivated according to certification regulations and that meets the specifications of the official
seed certifying agency of the jurisdiction in which the seed is/was produced.

     1.9 “CERTIFIED SEED” means seed produced from plants grown directly from FOUNDATION SEED or
REGISTERED SEED, cultivated according to certification regulations and that meets the
specifications of the official seed certifying agency of the jurisdiction in which the seed is/was
produced.

     1.10 “NON-CERTIFIED SEED” means seed produced from plants cultivated according to
certification regulations of the official seed certifying agency of the jurisdiction in which the
seed is/was produced; however, such seed does not meet the specifications of CERTIFIED SEED but may
be sold as LICENSED VARIETY.

     1.11 “COMMERCIAL SEED” means REGISTERED SEED, CERTIFIED SEED, or NON-CERTIFIED SEED, that is
sold for purposes other than seed production.

     1.12 “INTELLECTUAL PROPERTY RIGHTS” means all rights in any plant variety, patent, plant
breeders rights, registration or equivalent intellectual property protection, or any applications
thereof, for the LICENSED VARIETY, which may be filed in United States of America, or other
jurisdictions, with the exception of TRADEMARKS. INTELLECTUAL PROPERTY RIGHTS, when applied for or
granted, will be set forth in ANNEX A.

     1.13 “JOINT INTELLECTUAL PROPERTY” is expressly defined in the MRA, and such definition is
incorporated by reference herein. Any and all JOINT INTELLECTUAL PROPERTY licensed under this
Agreement shall be set forth in ANNEX A.

     1.14 “NOBLE INTELLECTUAL PROPERTY” is expressly defined in the MRA, and such definition is
incorporated by reference herein. Any and all NOBLE INTELLECTUAL PROPERTY licensed under this
Agreement shall be set forth in ANNEX A.

     1.15 “OTHER RESEARCH RESULTS” is expressly defined in the MRA, and such definition is
incorporated by reference herein.

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 32 of 57

 

 

     1.16 “BACKGROUND INTELLECTUAL PROPERTY” is expressly defined in the MRA, and such definition
is incorporated by reference herein. Any and all NOBLE BACKGROUND INTELLECTUAL PROPERTY licensed
under this Agreement shall be set forth in ANNEX A.

     1.17 “TRADEMARK” means any trademark, trade name or logo owned by CERES and intended for use
with a LICENSED VARIETY; provided however, it is recognized that U.S. regulations prohibit the
registration of any plant variety name as a trademark or trade name.

     1.18 “COMMERCIAL NAME” means the complete, preferred name of a LICENSED VARIETY under which a
specific LICENSED VARIETY will be marketed and sold.

     1.19 “NET SELLING PRICE” means the actual wholesale price for seeds of the LICENSED VARIETY
received by CERES or any AFFILIATED COMPANY for the sale of such seed, excluding seed for further
seed production, less any (a) customary trade, quantity, or cash discounts; (b) amounts repaid or
credited by reason of rejection or return; (c) any sales, use, tariff, customs duties, V.A.T.
and/or other taxes, duties and similar governmental assessments (except taxes based on income); and
(d) outbound transportation, shipping, packing, costs of insurance in transit paid by CERES or an
AFFILIATED COMPANY; subject in all cases to (a) to (d) being separately charged on customer
invoices or credit notes. Where there is no identifiable sale price or when a LICENSED VARIETY is
sold to other than bona fide, arms length customers of CERES or any AFFILIATED COMPANY, CERES or
the AFFILIATED COMPANY shall be deemed to have received the NET SELLING PRICE calculated based only
on the final sale of the seed (wholesale level) to an independent third party, otherwise referred
to as net wholesale price payable by dealers. If no such current price is available, a hypothetical
fair market value price will be determined by the parties jointly in good faith for the purpose of
calculating NET SELLING PRICE.

     1.20 “LICENSE INCOME” means the gross amount actually received by either CERES or any
AFFILIATED COMPANY in consideration for the grant of SUBLICENSES to SUBLICENSEES that are not
AFFILIATED COMPANIES to produce and sell seed of the LICENSED VARIETIES, including up-front fees,
lump sum payments and any running royalties on a product-by-product and
jurisdiction-by-jurisdiction basis, without deduction of any kind.

     1.21 “AFFILIATED COMPANY” means any company owned or controlled by, under common control with
or controlling CERES, “control” meaning in this context the direct or indirect ownership of fifty
percent (50%) or more of the voting stock/shares of a company, or the power to nominate at least
half of the directors.

     1.22 “SUBLICENSE” means any sublicense granted (a) by CERES to an AFFILIATED COMPANY or (b) by
CERES or an AFFILIATED COMPANY to any third party (“SUBLICENSEE”), as authorized by this Agreement,
to produce and sell a LICENSED VARIETY (or LICENSED VARIETIES).

     1.23 “NOBLE CONTRIBUTION” means NOBLE’S percentage of contribution to the total research and
development costs of the LICENSED VARIETY in accordance with the agreement of the parties set forth
in ANNEX B.

     1.24 “MARKETING PLAN” means a detailed written plan for production, distribution, selling and
promotion of each LICENSED VARIETY prepared by or on behalf of CERES and

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 33 of 57

 

 

submitted to NOBLE. A MARKETING PLAN may be (a) binding, i.e., the performance of CERES
(through CERES and/or any SUBLICENSEE) shall be reasonably compared to forecasts and/or projections
therein, or (b) non-binding, i.e., the performance of CERES (through CERES and/or any SUBLICENSEE)
shall not be compared by forecasts and/or projections therein and such forecasts and/or projections
are merely advisory. Each MARKETING PLAN, binding or non-binding, shall include at least the
information outlined in ANNEX C. Actual, adopted MARKETING PLANS shall be attached as
further annexes to this Agreement as adopted and identified as “binding” or “non-binding” as agreed
to by the parties.

2. GRANT OF LICENSE.

     2.1 Subject to the reservations of Paragraph 2.2, NOBLE hereby grants CERES under NOBLE’S
interest in any JOINT INTELLECTUAL PROPERTY and OTHER RESEARCH RESULTS; the NOBLE INTELLECTUAL
PROPERTY set forth in ANNEX A; and the NOBLE BACKGROUND INTELLECTUAL PROPERTY set forth in
ANNEX A:

	 	(a)	 	the exclusive right of access to BREEDERS SEED, whether produced
by NOBLE or CERES;
	 
	 	(b)	 	the exclusive right to produce all seed of the LICENSED VARIETY
in the LICENSED PRODUCTION TERRITORY, including BREEDER SEED for which such
production right shall be non-exclusive between CERES and NOBLE; and
	 
	 	(c)	 	the exclusive right to use, sell and commercially exploit the
seed of the LICENSED VARIETY in the LICENSED TERRITORY.

     2.2 Notwithstanding Paragraph 2.1, NOBLE shall have an irrevocable, nonexclusive,
nontransferable, royalty-free right to produce, use and evaluate the LICENSED VARIETY for any
research, development, breeding, evaluation, demonstration and/or educational purpose or program
conducted by NOBLE in accordance with the terms of the MRA.

     2.3 Sublicenses. CERES shall have the right to grant SUBLICENSES within the LICENSED
TERRITORY provided that:

	 	(a)	 	Any such SUBLICENSE shall be personal to the SUBLICENSEE and
shall not be assignable unless to an affiliated company of that SUBLICENSEE,
defined similarly as in Paragraph 1.21.
	 
	 	(b)	 	The terms and obligations of any such SUBLICENSE shall be
consistent with the terms and obligations of this Agreement. Notwithstanding,
CERES shall remain responsible for the operations of its SUBLICENSEES relevant
to this Agreement as if such operations were conducted and carried out by CERES,
including, but not limited to, the payment of all fees and royalties due under
this Agreement.
	 
	 	(c)	 	CERES further shall deliver to NOBLE (under an obligation of
confidentiality) a written summary of each SUBLICENSE agreement, which shall
include the

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 34 of 57

 

 

	 	 	 	name and address of the SUBLICENSEE, scope of the SUBLICENSE,
exclusive/non-exclusive status, territory, remuneration, reporting and
diligence obligations, if any. This summary shall be provided within thirty
(30) days after execution, modification or termination of the summarized
agreement.
	 
	 	(d)	 	CERES will use commercially reasonable efforts to collect any and
all amounts due to CERES under any sublicense for the sale of seed of the
LICENSED VARIETY.

     2.4 CERES shall not sell or supply to any SUBLICENSEE, seed growing contractor or to any other
third party any BREEDER SEED or FOUNDATION SEED for the purpose of seed production without an
agreement obligating the recipient to sell or deliver the resultant seed to CERES, any AFFILIATED
COMPANY, a SUBLICENSEE or authorized distributor or retailers as directed by CERES.

     2.5 Nothing in this Agreement shall be construed as conferring by implication, estoppel, or
otherwise any license or rights under any INTELLECTUAL PROPERTY RIGHTS, whether owned by NOBLE or
licensed to NOBLE, other than the one(s) expressly set forth in this Agreement.

     2.6 Notwithstanding Paragraph 2.4, CERES may supply unlabelled (i.e. without certification
tag) COMMERCIAL SEED to a third party for the limited purposes of evaluating the agronomic
performance of the LICENSED VARIETY. The third party shall enter into a written agreement with
CERES that the seed supplied will not be used for further multiplication.

3. INTELLECTUAL PROPERTY RIGHTS.

     3.1 CERES agrees to prepare and file, or have prepared and filed, any and all applications for
plant variety rights or other forms of intellectual property protection for the LICENSED VARIETY in
the United States. Applications for plant variety rights shall be filed in the name of CERES and
NOBLE and patent applications in the name of CERES and NOBLE, CERES or NOBLE, depending on who owns
the invention. At CERES’ discretion, plant variety rights and/or other forms of intellectual
property protection may be filed in any other jurisdiction.

     3.1.1 If CERES intends to abandon any plant variety rights, pending or granted in any
jurisdiction, CERES shall first give sufficient written notice to NOBLE to permit NOBLE the
opportunity to assume such filing, examination and/or maintenance without prejudice and
Paragraph 2.10 of the MRA will apply.

     3.1.2 Any application for plant variety rights shall reflect the COMMERCIAL NAME of the
LICENSED VARIETY (Paragraph 5).

     3.2 CERES and NOBLE will consult with regard to INTELLECTUAL PROPERTY RIGHTS.

     3.3 The obligations of this paragraph shall not apply to any jurisdictions in which CERES has
elected not to apply for intellectual property protection. CERES and NOBLE shall avoid carrying out
any act that would prejudice the grant of INTELLECTUAL PROPERTY RIGHTS. Without limitation, neither
party shall make available reproductive material of the LICENSED VARIETY at a

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 35 of 57

 

 

date or in a manner that might jeopardize the right to seek INTELLECTUAL PROPERTY RIGHTS protection
for the LICENSED VARIETY. CERES, whether directly or through any SUBLICENSEE, shall not sell any
seeds of the LICENSED VARIETY until such time as the requirements for INTELLECTUAL PROPERTY RIGHTS
have been established. The provisions of this Paragraph 3.3 shall not restrict or otherwise
penalize any Disclosure authorized pursuant to Paragraph 11.4 of this Agreement.

     3.4 CERES shall use all reasonable endeavors to ensure in any sales jurisdiction of the
LICENSED TERRITORY in which INTELLECTUAL PROPERTY RIGHTS exist that all bags or containers supplied
by CERES and any SUBLICENSEE containing only seed of such LICENSED VARIETY are clearly labeled to
show that the LICENSED VARIETY is protected by INTELLECTUAL PROPERTY RIGHTS.

4. LICENSED VARIETY CONSIDERATION.

     4.1 In partial consideration for the rights granted in Paragraph 2.1 of this Agreement, CERES
shall be responsible for any and all fees and expenses incurred in filing, examining, certifying
and maintaining any INTELLECTUAL PROPERTY RIGHTS for the LICENSED VARIETY, subject to the
provisions of Paragraph 3.

     4.2 In partial consideration for the rights granted hereunder, CERES agrees to pay to NOBLE,
on behalf of CERES and any AFFILIATED COMPANY, for the LICENSED VARIETY, a royalty of:

	 	(a)	 	the percentage determined in accordance with Section 1.1 of
ANNEX B multiplied by the NOBLE CONTRIBUTION, of the NET SELLING PRICE for
the naked seed weight (exclusive of any coating materials that may be applied)
of all COMMERCIAL SEED of the LICENSED VARIETY, except that seed subject to
Paragraphs 4.2(c), sold in the United States by CERES or any AFFILIATED COMPANY;
	 
	 	(b)	 	the percentage set forth in Section 1.2 of ANNEX B
multiplied by the NOBLE CONTRIBUTION, of any LICENSE INCOME received by CERES or
any AFFILIATED COMPANY from a SUBLICENSEE who is not an AFFILIATED COMPANY; and
	 
	 	(c)	 	[***] of the NET SELLING PRICE for the naked seed weight
(exclusive of any coating materials that may be applied) of all seed sold as
“variety not stated,” wherein such “variety not stated” seed (i.e., limited
quantities of COMMERCIAL SEED sold for inventory control and seed that does not
satisfy the standards of COMMERCIAL SEED) cannot be associated with, directly or
indirectly, any COMMERCIAL NAME or include any other designations that identify
such material as the LICENSED VARIETY.

     4.3 [OPTIONAL] Notwithstanding any other provision contained in this Agreement and
irrespective of the level of sales of seeds of the LICENSED VARIETY under this Agreement, CERES
shall pay to NOBLE for each calendar year of the term hereof a minimum royalty with respect to the

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 36 of 57

Confidential
Treatment Requested and the Redacted Material has been separately filed with the Commission

 

 

designated LICENSED VARIETY only, according to the following schedule. Payment of this minimum
royalty shall be due on or before March 31 of the succeeding year for which the payment is due.

Minimum Royalties for LICENSED VARIETY ONLY:

	 	 	 

	Calendar Year
	 	Minimum Royalty (USD)

     4.4 [OPTIONAL] The minimum royalty of Paragraph 4.3 shall not carry forward to subsequent
calendar years as royalty credit against future sales. For clarification, the following rules shall
guide the relationship between royalties and minimum royalties:

	 	(a)	 	if the royalty payments due under Paragraph 4.2 are less than the
minimum royalty of Paragraph 4.3 in a given year, then only the minimum royalty
of Paragraph 4.3 shall be payable;
	 
	 	(b)	 	if the royalty payments due under Paragraph 4.2 exceed the
minimum royalty of Paragraph 4.3 in a given year, then the minimum annual
royalty shall not be payable; and
	 
	 	(c)	 	should there be a failure in production of seed of the LICENSED
VARIETY where CERES can evidence that sufficient acreage was established to
produce adequate seed for payment of the minimum royalty of Paragraph 4.3 and
production of seed failed due to circumstances beyond the control of CERES or
CERES’ contract grower(s), then the minimum royalty will be paid pro-rata to the
extent of the failure of seed production.

     4.5 CERES shall be responsible for the collection and payment of royalties due to NOBLE for
all seed sold in the LICENSED TERRITORY.

     4.6 CERES shall, in addition to any payments due under Paragraphs 4.1 or 4.2, pay all goods
and service taxes (or other taxes) due on its commercial activity. Where any royalty payments are
subject to a withholding tax then:

	 	(a)	 	where the tax is reclaimable by CERES or any AFFILIATED COMPANY,
then CERES shall make the royalty payment without deduction; and
	 
	 	(b)	 	where the tax is non reclaimable by CERES or any AFFILIATED
COMPANY, then CERES shall pay the net royalty and shall provide to NOBLE proper
certificates for such withholding tax.

     4.7 All sums payable by CERES to NOBLE under this Agreement shall be payable in United States
dollars. Royalties shall be payable by March 31 of each year with respect to the NET

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 37 of 57

 

 

SELLING PRICE and LICENSE INCOME received by CERES and any AFFILIATED COMPANIES in the
preceding calendar year. Payments shall be made by check to the following address:

Vice President, General Counsel

The Samuel Roberts Noble Foundation, Inc.

2510 Sam Noble Parkway

Ardmore, Oklahoma 73401

     Such payments shall be accompanied by a written report setting forth the production, sales by
CERES, and each SUBLICENSEE, of seed during the calendar year, permitted exclusions, NET SELLING
PRICE, LICENSE INCOME, the royalties due, and all uncollected amounts due CERES (and any AFFILIATED
COMPANY) from SUBLICENSEES. If no royalties are due, CERES also shall so report.

     4.8 If the LICENSED VARIETY is sold in jurisdictions other than the United States, the parties
will jointly determine in good faith the applicable royalty rates and minimum annual royalties (if
any).

     4.9 Payments required under this Agreement shall, if overdue, bear interest at a per annum
rate of one percent (1%) above the prime interest rate in effect on the due date, as reported in
the Wall Street Journal, from the date the payment is due until it is received.

5. DENOMINATIONS, VARIETY NAMES, TRADE MARKS AND BRAND INTEGRITY.

     5.1 The parties acknowledge that the denomination for the subject variety is established as:
[X].

     5.2 CERES shall use the denomination of the LICENSED VARIETY to identify that variety and
shall not associate any TRADEMARK or any tradename or similar indication with the denomination.

     5.3 CERES will determine a COMMERCIAL NAME for the LICENSED VARIETY under which the seed of
the LICENSED VARIETY will be marketed and sold.

     5.4 CERES shall use all reasonable endeavors to ensure that all references made by CERES, any
AFFILIATED COMPANY, or any SUBLICENSEE to the LICENSED VARIETY shall use the COMMERCIAL NAME for
the LICENSED VARIETY, as specified in applicable INTELLECTUAL PROPERTY RIGHTS, and shall use its
best endeavors to ensure that all references by other parties shall use the same COMMERCIAL NAME
and shall use this name in a manner which distinguishes it from any TRADEMARK. CERES, any
AFFILIATED COMPANY or any SUBLICENSEE shall not falsely represent that any seeds of another variety
being sold or offered for sale are seeds of the LICENSED VARIETY.

     5.5 CERES may determine TRADEMARK(s) associated or intended for use with a LICENSED VARIETY.
CERES shall be the owner of all rights in any such TRADE MARK, chosen, applied to, used or
registered in association with the LICENSED VARIETY.

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 38 of 57

 

 

6. SEED QUALITY AND PERFORMANCE REGULATIONS.

     6.1 CERES shall be responsible for multiplying seed of the LICENSED VARIETY within the
LICENSED PRODUCTION TERRITORY and using commercially reasonable efforts to produce, market and sell
the resultant seed so as to ensure that COMMERCIAL SEED of the LICENSED VARIETY is commercially
available in the United States in reasonable quantities and at a reasonable price no later than
three (3) years from the Effective Date. Availability in foreign markets, if any, of the LICENSED
VARIETY shall be determined by CERES no later than two (2) years after U.S. commercialization of
such LICENSED VARIETY.

     6.2 CERES shall meet its own cost of promotion, overseas trials and listing of the LICENSED
VARIETY in the LICENSED TERRITORY.

     6.3 CERES shall use reasonable endeavors to ensure that all seed of the LICENSED VARIETY
offered for sale by CERES, any AFFILIATED COMPANY or SUBLICENSEE shall meet the normally accepted
standards of the seed trade or certifying authorities relating to seed quality within the relevant
jurisdiction of the LICENSED TERRITORY.

     6.4 Where CERES wishes to dispose of seeds of the LICENSED VARIETY without identity, CERES
shall obtain prior written approval by NOBLE before disposing of any seed of the LICENSED VARIETY,
such approval not to be unreasonably withheld. In the event that no response is received within
five (5) working days of the request for approval being made then it shall be deemed that consent
has been granted.

     6.5 CERES shall advise NOBLE of any downgrading of FOUNDATION SEED of the LICENSED VARIETY.

     6.6 When performing activities pursuant to this Agreement, each party shall be responsible for
complying with all applicable laws, rules and regulations and obtaining any and all permits or
authorizations or proceed to any notifications which may be required by such laws, rules and
regulations.

     6.6.1 CERES shall at all times comply with and abide by any governing act, rules,
regulations, by-laws, plant variety rights legislation or the like and/or requirements
relating to the quality and sale of seeds of the LICENSED VARIETY in the relevant
jurisdictions of the LICENSED TERRITORY and shall use all reasonable commercial endeavors to
obtain any necessary regulatory approvals for the LICENSED VARIETY.

7. DILIGENCE.

     7.1 CERES will use commercially reasonable efforts to actively market the LICENSED VARIETY in
the LICENSED TERRITORY, wherein such efforts shall be appropriately reflected in the MARKETING
PLAN.

     7.2 CERES shall submit to NOBLE with its annual report under Paragraph 4.7 a report of
progress made by CERES (and any AFFILIATED COMPANY), directly or through its SUBLICENSEES, in
achieving marketing goals of previous years and meeting the objectives of the MARKETING PLAN
submitted and agreed upon for the LICENSED TERRITORY. From time to

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 39 of 57

 

 

time, but at least annually, CERES shall submit an amended and updated MARKETING PLAN for
NOBLE’S review and acceptance, which will not be unreasonably withheld or delayed.

     7.3 [IF A BINDING MARKETING PLAN] If CERES fails to meet the MARKETING PLAN performance
requirements with respect to the LICENSED VARIETY in two (2) subsequent years and such failure
amounts to more than 20% percent in each such year, NOBLE shall have the right to convert the
license granted to CERES with respect to such LICENSED VARIETY to non-exclusive, by written notice
to CERES, provided that the parties shall first, upon the initiative of either party, discuss the
circumstances and make good faith efforts to provide an alternative solution. If this Agreement is
converted to a non-exclusive grant, no further diligence obligations shall apply.

     7.4 [OPTIONAL] Minimum diligence requirements for each LICENSED VARIETY, if any, shall be
satisfied by the payment of the annual minimum royalty amounts for the prescribed years for only
the specific LICENSED VARIETY set forth in Paragraph 4.4.

     7.4.1 If CERES fails to pay to NOBLE the prescribed annual minimum royalty, NOBLE shall
have the right to convert the license granted to CERES with respect to such LICENSED VARIETY
to non-exclusive, by written notice to CERES.

     7.4.2 Upon CERES’ written request, this Agreement shall be amended to terminate the
annual minimum royalty and to convert the exclusive license grant of Paragraph 2.1 to a
non-exclusive license grant.

8. BOOKS, RECORDS AND RIGHT OF AUDIT.

     8.1 CERES shall keep and shall cause any SUBLICENSEE to keep accurate records of all
production and sales of seeds of the LICENSED VARIETY in each country of the LICENSED TERRITORY
where such sales are made. These records should include, at least, the number of acres of LICENSED
VARIETY seed under production, the physical location of each LICENSED VARIETY production field
owned or controlled by CERES, any AFFILIATED COMPANY or any SUBLICENSEE, the total amount of
LICENSED VARIETY seed produced, the total amount of LICENSED VARIETY seed sold, including
specifically the amount of COMMERCIAL SEED sold and the amount of seed sold and/or disposed of
without identity (under Paragraph 6.4 and subject to royalties under Paragraph 7.2(e)) and all
invoices or shipping documents relating to such sales.

     8.2 CERES shall allow an independent auditor, reasonably acceptable to CERES, appointed by and
paid for by NOBLE to inspect the records of CERES and any AFFILIATED COMPANY pertaining to the
LICENSED VARIETY for the exclusive purpose of verifying the accuracy of the reports provided. Any
such audit shall occur no more frequently than annually. Any such inspection shall occur during
normal business hours and after NOBLE has provided written notice at least ten business days prior
to the date of the intended inspection. NOBLE agrees that it and its representatives will hold the
information obtained from the inspection in confidence, and not use it for any purpose other than
verification of the royalties required to be paid hereunder.

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 40 of 57

 

 

9. ABATEMENT OF INFRINGEMENT.

     9.1 Each party shall notify the other of any suspected infringement of any INTELLECTUAL
PROPERTY RIGHTS covering the LICENSED VARIETY. During the term of this Agreement, CERES shall have
right, but shall not be otherwise required, to bring suit to abate such infringement.

     9.1.1 Subject to Paragraph 9.1.2, CERES will have the exclusive right, at its own
discretion and expense, to take any action to enforce and to initiate and prosecute suits
for infringement of the INTELLECTUAL PROPERTY RIGHTS. CERES and NOBLE will consult with each
other upon a course of action and enforcement strategy. CERES will be responsible for the
conduct of any such enforcement action, and NOBLE will reasonably cooperate with CERES to
effect the enforcement action, and if appropriate, determine a settlement position. CERES
shall be responsible for retaining counsel and shall promptly notify NOBLE following
retention of counsel, and NOBLE agrees to be represented by such counsel as may be required
for any enforcement action or settlement. For purposes of settlement, CERES shall be the
contact with the parties’ counsel as well as the opposing party(ies) and shall have the
right to enter into settlements. CERES shall keep NOBLE advised as to all developments with
respect to the enforcement action and settlement discussions, which includes supplying to
NOBLE copies of all papers received and filed in sufficient time for NOBLE to comment
thereon. NOBLE may attend any and all meetings with the parties’ counsel and the opposing
side for settlement purposes. NOBLE agrees to voluntarily join in any action brought by
CERES as a party plaintiff/defendant, if necessary, at the expense of CERES. If necessary,
NOBLE agrees to enter into a joint defense agreement.

     9.1.2 If the license grant of Paragraph 2.1 converts from exclusive to non-exclusive
pursuant to Paragraph 7.3, or Paragraph 7.4.1 or Paragraph 7.4.2, either party will have the
right, after the date such conversion occurs (“CONVERSION DATE”), to initiate any new action
to enforce and to initiate and prosecute new suits for infringement of the INTELLECTUAL
PROPERTY RIGHTS, provided however, that (a) nothing in this Paragraph 9.1.2 shall affect any
actions, suits or proceedings pending before the CONVERSION DATE and (b) NOBLE shall not
have the right to take any action relating to any infringement matters for which CERES had
initiated any action, suit or proceeding prior to the CONVERSION DATE nor grant any license
or sublicense on the INTELLECTUAL PROPERTY RIGHTS to any party against whom CERES had
initiated such action, suit or proceeding or with whom CERES is involved in any proceedings
(e.g. interference, opposition in any patent office).

     9.2 Any damages received by the CERES as a result of an enforcement action of the INTELLECTUAL
PROPERTY RIGHTS, after deduction of all enforcement related costs incurred by such party, shall be
considered as either NET SELLING PRICE or LICENSE INCOME for the purpose of remuneration payments
to NOBLE, to whichever the damages are reasonably deemed equivalent; provided however, that any
award that exceeds compensation for loss of revenue, costs and expenses incurred by CERES (e.g.
punitive damages), after deduction of all enforcement related costs incurred by CERES, will be
shared as follows: NOBLE will be entitled to a percentage of the award equal to the NOBLE
CONTRIBUTION (See ANNEX B Article 2) and CERES will be entitled to the remainder.

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 41 of 57

 

 

10. TERM AND TERMINATION.

     10.1 Subject to any other rights of termination under this paragraph, this Agreement shall
have a term equal to:

(a) on a jurisdiction-by-jurisdiction basis, the term of the
INTELLECTUAL PROPERTY RIGHTS in the respective jurisdiction covering the
LICENSED VARIETY; or

 

(b) in those jurisdictions in which the LICENSED VARIETY is sold but
no INTELLECTUAL PROPERTY RIGHTS are obtained, fifteen (15) years from the date
of the first sale of a LICENSED VARIETY in such jurisdiction.

 

     10.2 Each party shall have the right to terminate this Agreement unilaterally by giving
written notice of termination to the other party if such other party fails to satisfy its material
obligations, which shall include but are not limited to, making required reports and making
required payments, under this Agreement, and such party subsequently fails to cure such failure(s)
within (a) thirty (30) days for failures to remit payment for amounts due under this Agreement and
(b) ninety (90) days for all other obligations after receipt of written notice from the
non-breaching party specifying such failure.

     10.3 NOBLE will have the right to terminate this Agreement unilaterally with thirty (30) days’
written notice to CERES, (a) if CERES seeks protection under any bankruptcy, insolvency,
receivership, trust, deed, creditors arrangement or comparable proceeding or if any such proceeding
is instituted against CERES (and not dismissed within one hundred twenty (120) days) or (b) in case
of dissolution or winding up of CERES (excluding any situation where all or substantially all of
CERES’ assets, stock or business to which this Agreement relates are acquired by a third party
(whether by sale, acquisition, merger, operation of law or otherwise)).

     10.4 CERES may after consultation with NOBLE terminate this Agreement by written notice if in
the commercially reasonable opinion of CERES the markets for the LICENSED VARIETY change or do not
develop as anticipated, so as to render the production, promotion and sale of the LICENSED VARIETY
uneconomical or impractical or if CERES decides to cease substantially all activities in
SWITCHGRASS; provided however, CERES shall terminate its promotion, marketing and sales of the
LICENSED VARIETY, whether directly or through any SUBLICENSEES.

     10.5 The parties may terminate this Agreement at any time by mutual, written agreement.

     10.6 Termination of this Agreement for any reason will not relieve either party of any
obligation or liability accrued under this Agreement before termination or rescind any payments
made or due before termination. Paragraphs 8, 10, 11, 13, 14, 15, 16, and 17 will survive any
termination of this Agreement.

     10.7 Upon termination by CERES pursuant to Paragraph 10.2, NOBLE will promptly deliver to
CERES any and all BREEDER SEED in its possession and promptly upon harvesting, any of the
aforementioned seed from plants which are in the field on the termination date, and NOBLE will
grant CERES access to facilities and fields under its control for the purpose of collecting
germplasm of the LICENSED VARIETIES other than seed.

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 42 of 57

 

 

     10.8 Termination of this Agreement shall not affect the rights and obligations of the parties
accrued prior to termination hereof.

     10.9 Upon termination of this Agreement, no existing SUBLICENSES granted by CERES or
AFFILIATED COMPANIES to third parties shall be affected by such termination, and all such
sublicenses shall remain in effect according to their terms, pursuant to the election of each
SUBLICENSEE. NOBLE shall continue to be entitled to payments relating to such SUBLICENSES pursuant
to this Agreement and such SUBLICENSES.

     10.10 Termination of this Agreement shall not prevent:

     (a) NOBLE from recovering any royalties due as of termination; and

     (b) either party from obtaining a remedy for any breach of the
provisions of this Agreement.

11. CONFIDENTIALITY AND PUBLICATIONS.

     11.1 As used in this Agreement, the term “Confidential Information” shall mean (a) all
non-public-information received by one party from the other in the framework of this Agreement and
(b) any and all information, results (including materials) and observations generated by NOBLE in
the performance of any this Agreement. Confidential Information can include, but is not limited to,
information concerning the disclosing party’s operations, research, processes, techniques, data,
and non-public materials.

     11.2 From receipt to five (5) years after the disclosure of the relevant CONFIDENTIAL
INFORMATION, the receiving party shall not use, except (a) for the benefit of the parties’
collaboration, or (b) such use as is expressly allowed by this Agreement, and/or disclose any
Confidential Information to any third party without the prior written consent of the disclosing
party if the Confidential Information was received from the other party, or the prior written
consent of both parties if the Confidential Information was generated during the performance of
this Agreement, excepting that information described in Paragraph 11.3. Confidential Information
shall only be made accessible to each party’s employees or students on a need-to-know basis.
Manuscripts and papers published in scientific journals and presentations made at public meetings
that include Confidential Information are exempt from the conditions of this paragraph, provided
the parties followed the procedure set forth in Paragraph 11.4.

     11.3 The receiving party shall have no obligations of confidentiality for information that:
can be established through written evidence to be in the possession of the receiving party prior to
the disclosure by the disclosing party; is or becomes public knowledge through no fault of the
disclosing party; is acquired from others not under an obligation of confidentiality to the
disclosing party. In addition, CERES shall have the right to proceed to disclosures of Confidential
Information (a) as required to file for INTELLECTUAL PROPERTY RIGHTS or registration, (b) as
required to exercise its commercialization rights granted in or on the basis of this Agreement and
for related marketing activities, (c) as required by laws, rules or regulation or court ordering
such as, without limitation, SEC regulations, or (d) in CERES’ reasonable judgment, to (potential)
investors and business partners.

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 43 of 57

 

 

     11.4 The parties agree that the researchers involved in the development of the LICENSED
VARIETY are permitted to present methods and/or results of the development activities at symposia
and professional meetings and to publish the same in journals or the like, subject to the
obligations of this paragraph. If either party wishes to present results of the evaluation
activities set forth in this Agreement at symposia and professional meetings or publish the same in
journals or the like, the disclosing party must furnish copies of any proposed publication,
presentation, or disclosure (collectively “Disclosure”) to the other party at least thirty (30)
days in advance of the specific submission, presentation, or other disclosure. If the
non-disclosing party raises an objection within such thirty (30) day period with respect to any
part of the proposed Disclosure, the parties will diligently cooperate to modify the objected
matter. The non-disclosing party’s consent will be required for such Disclosure, but such consent
will not unreasonably be withheld. If no objection is raised within the aforementioned thirty (30)
day period, the disclosing party may proceed with the Disclosure.

     11.5 Each party shall be responsible for requiring any and all of its employees or students
who will perform activities under this Agreement to be bound by a written agreement(s) that commits
their inventions, discoveries, and other intellectual property to the party-employer and requires
confidential treatment of party and third-party confidential information. Each party shall further
notify each such employee, in writing, of their obligations and responsibilities under the terms of
this Agreement, including but not limited to the provisions of this Paragraph 11.

12. NOTICES.

     Any notices required to be given or which shall be given under this Agreement shall be in
writing and delivered by first class mail or overnight (trackable) courier addressed to the Parties
as follows:

Vice President of Product Development

Ceres, Inc.

1535 Ranch Conejo Blvd.

Thousand Oaks, California 91320

Vice President, General Counsel

The Samuel Roberts Noble Foundation, Inc.

2510 Sam Noble Parkway

Ardmore, Oklahoma 73401

     In the event that notices under this Agreement are sent by certified or registered mail (or
alternatively, by overnight courier) by one party to the other party at its above address, they
shall be deemed to have been given or made as of the date so mailed.

13. DISCLAIMERS.

     13.1 EXCEPT AS SET FORTH IN PARAGRAPH 17, THE PARTIES ACKNOWLEDGE AND AGREE THAT NEITHER PARTY
HAS MADE ANY REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO,
WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 44 of 57

 

 

     13.2 IN NO EVENT SHALL EITHER PARTY BE HELD RESPONSIBLE FOR ANY SPECIAL, INDIRECT, INCIDENTAL
OR CONSEQUENTIAL DAMAGES OR LOSS OF PROFIT ARISING OUT OF THE USE OF ANY INTELLECTUAL PROPERTY
RIGHTS COVERED BY THIS AGREEMENT, OR THE IMPLEMENTATION OF THIS AGREEMENT, EVEN IF SUCH PARTY IS
ADVISED IN ADVANCE OF THE POSSIBILITY OF SUCH DAMAGES.

     13.3 NOBLE shall not be liable under any circumstances, whether in contract, in tort, under
any warranty, in negligence or otherwise, for any incidental, indirect, special or consequential
damages resulting from the exercise of CERES’ rights under the option and/or license granted
pursuant to this Agreement or from the production, sale, storage, use or attempted use of the
LICENSED VARIETY, including, but not limited to, damage to real or personal property, including
land, livestock, crops, plants, seed or feed crop.

     13.4 Nothing in this Agreement shall be construed as:

	 	(a)	 	a warranty or representation by either party as to the validity
or scope of any INTELLECTUAL PROPERTY RIGHTS, patent rights or plant variety
rights;
	 
	 	(b)	 	a warranty or representation by either party that anything made,
used, sold or otherwise disposed of pursuant to any license granted under this
Agreement is or will be free from infringement of patents of third parties;
	 
	 	(c)	 	any obligations by either party to bring or prosecute actions or
suits against third parties for patent infringement; and
	 
	 	(d)	 	a grant by implication, estoppel, or otherwise of any licenses
under any intellectual property rights of NOBLE or other persons other than as
provided in Paragraph 2.1 hereof.

14. INDEMNIFICATION.

     Excluding those acts directly attributable to the negligence or willful misconduct of NOBLE,
CERES agrees to indemnify, hold harmless and defend NOBLE, its trustees, officers, employees and
agents and the breeders (as named in the INTELLECTUAL PROPERTY RIGHTS, if any) against any and all
liability and/or damages with respect to any claims, suits, demands, judgments or causes arising
out of (a) the production, development, storage, sale or any other use of the LICENSED VARIETY seed
and/or exercise of rights granted hereunder by CERES, its SUBLICENSEES, distributors, agents,
representatives or AFFILIATED COMPANIES; (b) the use by end-users and other third parties of
LICENSED VARIETY seed; and/or (c) any representation, warranty or statement by CERES, its
SUBLICENSEES, distributors, agents, representatives or AFFILIATED COMPANIES, concerning NOBLE,
LICENSED VARIETY seed or any INTELLECTUAL PROPERTY RIGHTS. In the event any such claims, demands or
actions are made, CERES shall defend NOBLE at CERES’ sole expense by counsel selected by CERES and
reasonably acceptable to NOBLE. NOBLE shall promptly notify CERES, in writing, of any such claims,
suits or demands upon discovery and shall cooperate with CERES in the defense, provided that CERES
shall have the right to lead the defense including entering into any settlement. CERES will keep
NOBLE informed about the conduct of the defense and consult NOBLE regarding any settlement
proposals.

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 45 of 57

 

 

15. PUBLICITY AND USE OF NAMES.

     15.1 Neither party shall publicize or disclose the terms of this Agreement without the prior
written approval of the other party, subject to the same exceptions as set forth in Paragraph
11.3(a) through (d).

     15.2 The parties intend to issue joint press releases regarding this collaboration. Any such
press release and any press release by either party will be subject to the prior written approval
of both parties; provided however, that (i) CERES shall have the right to otherwise disclose
information as may be required in CERES’ judgment to comply with SEC regulations or other laws,
rules or regulations governing disclosure of information and (ii) NOBLE shall have the right to
otherwise disclose information as may be required in NOBLE’S judgment to comply with IRS or state
regulations or other laws, rules or regulations governing disclosure of information.
Notwithstanding the unilateral disclosure rights provided for in this paragraph, the disclosing
party shall provide the other party a copy of any such unilateral disclosure preferably prior to
its release.

     15.3 CERES, any AFFILIATED COMPANY and any SUBLICENSEE may make known in promotional materials
and technical literature that the LICENSED VARIETY was evaluated and developed for
commercialization at NOBLE and seed is produced, marketed, and sold under a license from NOBLE;
provided, however, that such use shall not state or otherwise imply that NOBLE has any relationship
with CERES outside its publicized relationships (e.g., licensor-licensee, etc.). NOBLE shall have
the right to review and must pre-approve, in writing, any and all such provided materials and
technical literature that references NOBLE or its employees prior to its public release.

     15.4 CERES, any AFFILIATED COMPANY and any SUBLICENSEE shall include on (or affix to) the seed
packaging (e.g., bag or other container) and promotional materials the NOBLE mark set forth in
ANNEX D to this Agreement in accordance with the terms and conditions set forth therein.
NOBLE shall have the right to review and must pre-approve, in writing, any and all materials,
including seed packaging, that includes or is intended to include the mark of ANNEX D.

16. DISPUTE RESOLUTION.

     All disputes, differences or questions arising out of or in connection with this Agreement or
its ANNEXES, or related to the alleged breach, termination, validity, interpretation or violation
thereof, shall be submitted to the MANAGEMENT COMMITTEE for resolution, which shall convene,
whether in person or otherwise, to resolve such dispute in a timely manner. Either party may
initiate a resolution procedure by providing written notice (“Dispute Notice”) to the other party,
and any such Dispute Notice must set forth the subject matter of the dispute, difference or
question. If after sixty (60) days the dispute remains unresolved, the presidents of CERES and
NOBLE shall seek to resolve the dispute through negotiation or mediation. If negotiation is
elected, the parties agree that at least eight (8) cumulative hours of negotiations between the
presidents will be undertaken. If mediation is elected, the presidents will meet at a neutral site
for mediation. Unless agreed to otherwise, the neutral site shall be Denver, Colorado. The
mediation shall be conducted in accordance with the then existing Commercial Mediation Rules of the
American Arbitration Association (AAA). The mediator shall be selected by mutual agreement of the
parties. If the parties cannot agree on a mediator, AAA shall designate a mediator at the request
of either party. Any mediator so designated must be acceptable to both parties. Fees for the
mediation will be shared equally, and the parties will responsible for their

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 46 of 57

 

 

respective expenses. Settlement reached in mediation or negotiation will not be binding until
the parties have signed a written settlement agreement.

     Any dispute, controversy, or claim arising out of or in connection with this Agreement or its
ANNEXES, or related to the alleged breach, termination, validity, interpretation or violation
thereof, not settled by negotiation or mediation in accordance with the terms hereof, shall be
finally settled and determined by arbitration administered by the AAA under its then current
Commercial Arbitration Rules and Mediation Procedures (including Procedures for Large, Complex
Commercial Disputes) (the “Rules”). The written reasoned award of the arbitrators shall be final
and binding upon the parties, and judgment on or enforcement of the award so rendered may be
sought, had or entered in any court having jurisdiction.

	 	(a)	 	Initiation of Arbitration. Any party may initiate arbitration by filing
a written request for arbitration with the AAA. A copy of the request shall be
furnished to all other parties in accordance with the provisions of the Rules and the
provisions in the agreement between the parties concerning notices. For all purposes
the “commencement of the arbitration” shall be deemed to be the date on which any party
issues a written demand for arbitration in accordance with the requirements of Article
18.
	 
	 	(b)	 	Appointment of Arbitrators. Each party shall appoint an arbitrator,
and the two arbitrators so appointed shall appoint the third arbitrator. The party
initiating the arbitration shall appoint its arbitrator at the commencement of the
arbitration. The other party shall appoint its arbitrator within thirty (30) days of
the commencement of the arbitration. If the arbitrators appointed by the parties fail
to appoint the third arbitrator within sixty (60) days of the commencement of the
arbitration, the AAA shall appoint the third arbitrator following consultation with the
parties.
	 
	 	(c)	 	Qualifications of Arbitrators. Each arbitrator so appointed shall have
a reputation as being experienced in the legal and technical matters related to the
dispute, shall be required to disclose, among other disclosures, any prior involvement
with the legal and technical matters related to the dispute and any involvement with a
competitor of any party, and shall not be presently nor in the past have been
affiliated with any party or a competitor of any party. Notwithstanding the method of
their appointment, each arbitrator shall be required to meet the standards contained in
the Rules with respect to impartiality, independence and neutrality.
	 
	 	(d)	 	Location of the Arbitration. The seat of arbitration shall be Denver,
Colorado. The arbitrators may hold hearings at such other locations as the arbitrators
shall determine, after consultation with the parties.
	 
	 	(e)	 	Language of Arbitration. The arbitral proceedings and all pleadings and
written evidence shall be in the English language. Any written evidence originally in a
language other than English shall be submitted in English translation accompanied by
the original or true copy thereof.

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 47 of 57

 

 

	 	(f)	 	Procedural Requirements. The arbitrators shall, after consultation with
the parties, make appropriate provision in the arbitration process for rules specific
to this arbitration which:

	 	(i)	 	require the disclosure of all exhibits expected to be used by the
parties at the arbitration, and the exchange of complete copies of all such
exhibits in advance of the arbitration;
	 
	 	(ii)	 	determine the dates for the exchange of said written disclosures
and copies of said exhibits;
	 
	 	(iii)	 	require the written disclosure of the identity of all witnesses
whom the parties expect to call at the arbitration;
	 
	 	(iv)	 	determine the dates for the exchange of the written disclosures
of the identity of witnesses which the parties expect to call at the
arbitration;
	 
	 	(v)	 	determine the dates for the exchange of sworn narrative
statements containing the testimony of all witnesses whom the parties expect to
call at the arbitration;
	 
	 	(vi)	 	require that the sworn narrative testimony of witnesses be
submitted in substitution for the direct examination of the witness, and that
all witnesses whose sworn testimony is submitted for consideration by the
arbitrators must present him or herself for cross examination at the time and
place of the arbitration hearing, unless some other procedure providing the
parties with a full and complete opportunity for cross-examination has been
established and provided by the arbitrators, the parties and the witness:
	 
	 	(vii)	 	prohibit, except upon a showing of good cause, or for purposes
of rebuttal, the receipt into evidence of any exhibit not disclosed by the
parties, nor shall the arbitrators permit a party to present the testimony of
any witness whose identity and testimony was not exchanged prior to the
arbitration;
	 
	 	(viii)	 	permit discovery as reasonable and necessary for the orderly preparation of
the dispute for hearing and determination of the dispute (said discovery may
include requests for production of documents and depositions of witnesses who
cannot be summoned to the arbitration or are otherwise unavailable to attend the
arbitration); and
	 
	 	(ix)	 	require all parties and experts to maintain all information and
documents they have received , reviewed, exchanged or given testimony about in
confidence pursuant to an appropriate confidentiality undertaking and order.

	 	(g)	 	Limitation on Remedies. The arbitrators are precluded from awarding
punitive or exemplary damages. In no event shall the arbitrators have the powers of an
amiable compositeur.

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 48 of 57

 

 

	 	(h)	 	Resort to the Courts. Nothing in this Agreement prohibits any party
from seeking interim or conservatory relief in any court of competent jurisdiction;
provided however, that neither the filing of an application for a
temporary restraining order, preliminary injunction or other interim or conservatory
relief, as necessary, nor the granting of such relief, shall be deemed to be a waiver
of the obligation of the party to have the dispute heard and determined solely and
exclusively by arbitration.
	 
	 	(i)	 	Survival. The rights and obligations of the parties as described
herein shall survive the termination, expiration, non-renewal or rescission of the
Agreement between the parties.

17. GENERAL.

     17.1 Entire Agreement/Modifications. This Agreement together with its ANNEXES
constitutes the entire agreement between the parties hereto with respect to the subject matter
hereof, and there are no representations, warranties, covenants or obligations except as set forth
herein. This Agreement supersedes all prior and contemporaneous agreements, understandings,
negotiations and discussions, written or oral, of the parties hereto relating to the subject matter
hereof. This Agreement may only be amended, modified or superseded by a writing executed by the
authorized representative of the parties hereto. Pursuant to the obligations of this Agreement, the
parties anticipate that ANNEXES will be attached to and become part of this Agreement during its
term.

     17.2 Severability. This Agreement, to the greatest extent possible, shall be construed
so as to give validity to all of the provisions hereof. If any provision of this Agreement is or
becomes invalid, is ruled illegal by a court of competent jurisdiction or is deemed unenforceable
under the current applicable law from time to time in effect during the term of this Agreement, the
remainder of this Agreement will not be affected or impaired thereby and will continue to be
construed to the maximum extent permitted by law. In lieu of each provisions which is invalid,
illegal or unenforceable, there will be substituted or added as part of this Agreement by mutual
written agreement of the parties, a provision which will be as similar as possible, in economic and
business objectives as intended by the parties to such invalid, illegal or unenforceable provision,
but will be valid, legal and enforceable.

     17.3 Waiver. No failure or delay by either party in exercising any right or remedy
under this Agreement will waive any provision of this Agreement. Nor will any single or partial
exercise by either party of any right or remedy under this Agreement preclude it from otherwise or
further exercising any rights or remedies which it may have, or any other rights or remedies
granted by any law or any related document.

     17.4 Enforcement. In the event an action is commenced by either party against the
other to enforce any of the provisions of this Agreement, the prevailing party shall be entitled to
recover from the other party reasonable attorneys’ fees, court costs and necessary disbursements
incurred in connection with such action.

     17.5 Licensor-Licensee Relationship. The relationship of the parties is that of
independent contractors and licensor-licensee. Nothing herein is intended or will be construed to
establish any agency, partnerships, or joint ventures. Neither party has any authority to act for
and/or to bind the other party in any way or to represent that either is in any way responsible for
the acts of the other,

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 49 of 57

 

 

except as may be explicitly provided for herein or authorized by the non-acting party in
writing. Neither party is authorized or empowered to act as an agent for the other party for any
purpose, nor shall either party be bound by the acts or conduct of the other party.

     17.6 Assignablility. This Agreement binds and enures to the benefit of the parties,
their successor or assigns, but may not be assigned by either party without the prior written
consent of the other party; provided however, that CERES shall have the right to assign its rights
and obligations under this Agreement to any AFFILIATED COMPANY and either party shall have the
right to assign its rights and obligations under this Agreement to a third party in conjunction
with the transfer to the third party of substantially all of the assets of that party associated
with performance under this Agreement without prior consent.

     17.7 Force Majeure. No party shall be responsible to the other party for delay or
failure in performance of any the obligations imposed by this Agreement, provided such failure
shall be occasioned by fire, flood, explosion, lightning, wind storm, hailstorm, earthquake,
subsidence of soil, failure of machinery or equipment or supply of materials, discontinuity in the
supply of power, court order or governmental interference, terrorist attacks, civil commotion,
riot, war, strikes, labor disturbances, transportation difficulties, labor shortage, natural
genetic variation of any living matter or by any other cause of like or unlike nature beyond the
reasonable control and without fault or negligence of such party.

     17.8 Choice of Law. This Agreement shall be governed by, and construed and
interpreted in accordance with, the laws of the State of Delaware without regard to the principles
of conflicts of law thereof.

     IN WITNESS WHEREOF, CERES and NOBLE have caused this Agreement to be duly executed as
indicated below.

	 	 	 	 	 	 	 	 	 	 	 

	THE SAMUEL ROBERTS NOBLE FOUNDATION, INC.	 	CERES, INC.	 	 
	 
	By:

	 	 	 	 	 	By:	 	 	 	 
	 

	 	 

	 	 	 	 	 	 

	 	 
	Name:

	 	 	 	 	 	Name:	 	 	 	 
	 

	 	 

	 	 	 	 	 	 

	 	 
	Title:

	 	 	 	 	 	Title:	 	 	 	 
	 

	 	 

	 	 	 	 	 	 

	 	 
	Date:

	 	 	 	 	 	Date:	 	 	 	 
	 

	 	 

	 	 	 	 	 	 

	 	 
	 
	By:

	 	 	 	 	 	By:	 	 	 	 
	 

	 	 

	 	 	 	 	 	 

	 	 
	Name:

	 	 	 	 	 	Name:	 	 	 	 
	 

	 	 

	 	 	 	 	 	 

	 	 
	Title:

	 	 	 	 	 	Title:	 	 	 	 
	 

	 	 

	 	 	 	 	 	 

	 	 
	Date:

	 	 	 	 	 	Date:	 	 	 	 
	 

	 	 

	 	 	 	 	 	 

	 	 

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 50 of 57

 

 

ANNEX A — INTELLECTUAL PROPERTY

INTELLECTUAL PROPERTY RIGHTS for the LICENSED VARIETY

(Paragraph 1.12)

JOINT INTELLECTUAL PROPERTY

(Paragraph 1.13)

NOBLE INTELLECTUAL PROPERTY

(Paragraph 1.14)

NOBLE BACKGROUND INTELLECTUAL PROPERTY

(Paragraph 1.16)

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 51 of 57

 

 

ANNEX B — ROYALTY RATE

1. TOTAL ROYALTY RATE TABLE AND CALCULATION:

     1.1 The following table illustrates the total royalty rates on NET SELLING PRICE:

	 	 	 	 	 
	Percent Increase in	 	 
	Biomass	 	Royalty
	0%
	 	 	[***]	 
	7%
	 	 	[***]	 
	20%
	 	 	[***]	 
	33%
	 	 	[***]	 
	47%
	 	 	[***]	 
	60%
	 	 	[***]	 
	73%
	 	 	[***]	 
	87%
	 	 	[***]	 
	100%
	 	 	[***]	 
	113%
	 	 	[***]	 
	127%
	 	 	[***]	 
	140%
	 	 	[***]	 
	153%
	 	 	[***]	 
	167%
	 	 	[***]	 

The total royalty shall equal [***] times the percent increase in biomass plus
[***], wherein the total royalty rate shall be shall be no greater than [***] and no
lower than [***].

This can be expressed using the following formula:

Royalty = [***] X percent increase in biomass + [***]

Such percent increase in biomass has been determined in accordance with Paragraph 15.1 of
SCHEDULE 2, PERFORMANCE EVALUATION PLAN at [complete].

[OPTIONAL] The MANAGEMENT COMMITTEE has determined, pursuant to Paragraph 15.1.7 of SCHEDULE
2, that the total applicable royalty rate is [complete].

     1.2 Royalty rate on LICENSE INCOME: [***]

2. NOBLE CONTRIBUTION:

NOBLE’s contribution to the research and development of the LICENSED VARIETY has been
determined in accordance with Article 14 of SCHEDULE 2 at [complete percentage].

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 52 of 57

Confidential
Treatment Requested and the Redacted Material has been separately filed with the Commission

 

 

ANNEX C — MARKETING PLAN

(Paragraph 1.24)

	1.	 	TIMING
	 
	 	 	The MARKETING PLAN is to cover a five year period and shall be reviewed annually with
adjustments made for further five year periods in line with market conditions (or
projections of the same) and the agronomic performance of the LICENSED VARIETY.
	 
	2.	 	POSITIONING
	 
	 	 	An assessment of the potential of the LICENSED VARIETY in an identified market.
	 
	3.	 	PROMOTION
	 
	 	 	Details of all project promotional activities, plus anticipated, related expenditures, that
are intended to the LICENSED VARIETY achieves its maximum market potential.
	 
	4.	 	DISTRIBUTION
	 
	 	 	Details of the proposed distribution network and activities for supporting the distributor
or retailer plus anticipated promotion activities of the distributor/retailer. NOTE: If the
anticipated distribution network includes the creation of a new seed company, details
regarding this important component should be included here.
	 
	5.	 	EVALUATION
	 
	 	 	Details of planned evaluation and demonstration, if any.
	 
	6.	 	PROTECTION
	 
	 	 	Anticipated intellectual property protection requirements.
	 
	7.	 	SEED SALES
	 
	 	 	Estimated sales including grade of seed, volume and price and country of destination.
	 
	8.	 	ROYALTY INCOME

	 	a.	 	Estimated royalty payments; and
	 
	 	b.	 	Commencement date of payment.

	9.	 	SEED PRODUCTION
	 
	 	 	Estimated production, including grade of seed, land area to be sown, estimated production
and harvest date.

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 53 of 57

 

 

ANNEX D - NON-EXCLUSIVE LICENSE TO AND TERMS OF USE FOR “NOBLE RESEARCH” MARK

(Paragraph 15.4)

Terms and Conditions for Non-exclusive License Agreement

for

     1. Recitals.

     1.1 NOBLE owns and uses the trademark NOBLE Research (the “Mark”) in connection with
plants, plant seed, plant material and research tools developed by or improved directly
through NOBLE research efforts (“Qualifying Products”).

     1.2 NOBLE acknowledges and intends that the LICENSED VARIETY be promoted, marketed and
sold under one or more primary marks specific to CERES and/or the LICENSED VARIETY.

     2. Grant of License. NOBLE hereby grants to CERES a non-exclusive, world-wide,
royalty-free license to use the Mark in connection with the LICENSED VARIETY to promote, market,
sell and deliver LICENSED VARIETY to SUBLICENSEES, distributors and consumers.

     3. Reservation of Rights. NOBLE hereby reserves any and all rights not expressly and
explicitly granted in these terms and conditions, including NOBLE’S right to authorize or license
use of the Mark or any other trademarks or names containing NOBLE, to any third party for use in
connection with any goods and services. Without limiting the rights reserved in this paragraph,
NOBLE hereby reserves any and all rights to use, authorize use or license use of the Mark or any
other trademarks or names containing the Marks in any geographic territory and in any language.

     4. Ownership of Mark. CERES hereby acknowledges that NOBLE is the owner of the Mark,
and any trademark applications and/or registrations thereto, agrees that it will not challenge the
validity of or NOBLE’S ownership of the Mark, and agrees that all use of the Mark by CERES shall
inure to the benefit of NOBLE. CERES agrees that nothing in these terms and conditions shall give
CERES any right, title or interest in the Mark other than the right to use the Mark in accordance
with

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 54 of 57

 

 

this Agreement and as permitted by law. CERES agrees not to register or attempt to register or
use the Mark, or the term NOBLE, as a trademark, service mark, Internet domain name, trade name
excepted as permitted herein.

     5. Use of the Mark; Protection of the Mark.

5.1 Proper Use.

     5.1.1 CERES may use the Mark in connection with the promotion, marketing and
selling of the LICENSED VARIETY, and CERES agrees that all use of the Mark shall only
occur in connection with the LICENSED VARIETY and shall be in compliance with the
terms of this EXHIBIT.

     5.1.1 CERES may only use the Mark as a collective whole (as shown above) and
shall not separately use any element or elements of the Mark. Notwithstanding the
foregoing, CERES may make fair uses of specific terms (e.g., “research”) comprising
the Mark.

     5.1.2 The Mark is not to be altered and must be reproduced from the supplied
artwork as provided by NOBLE from time to time. The Mark is not to be used in
conjunction with any other mark or design, i.e., the Mark must stand alone in terms
of its commercial impression generated by the particular usage; provided however, the
parties acknowledge and agree that the Mark will appear on packaging and other
related promotional material with other trademarks, service marks, and/or trade names
(e.g., the CERES mark).

     5.1.3 CERES has no right to sublicense the use of the Mark other than as
described herein.

     5.1.4 CERES may not use the Mark in connection with or for the benefit of
non-Qualifying Products, whether CERES’ or another third party’s.

     5.1.5 CERES must not use as its own trademark any word(s) or design(s)
confusingly similar to the Mark.

     5.1.6 NOBLE shall have the right to review and must pre-approve, in writing, any
and all materials, including seed packaging, that includes or is intended to include
the Mark.

     5.2 Monitoring. CERES acknowledges that NOBLE has the right to monitor CERES’
use of the Mark in conjunction with the LICENSED VARIETY. Upon reasonable request by NOBLE,
CERES shall provide NOBLE with representative samples of each CERES use of the Mark. If
NOBLE determines in good faith that CERES is using the Mark improperly, NOBLE shall notify
CERES, and CERES shall use reasonable efforts to remedy the improper use within thirty (30)
days following receipt of such notice.

5.3 Legend. CERES must identify the Mark as a trademark of NOBLE with each
usage in the following format:

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 55 of 57

 

 

“NOBLE Research is a trademark of The Samuel Roberts Noble Foundation, Inc.”

CERES must exercise care in the use of the Mark so as not to indicate to the public: that
CERES is more than a licensee of NOBLE (i.e., not a part or affiliate of NOBLE or otherwise
related to NOBLE) or that the LICENSED VARIETY is produced or has been tested or approved by
NOBLE.

     6. Protection of Interests. In the event CERES becomes aware of any unauthorized use
of the Mark by a third party, CERES agrees to promptly notify NOBLE and to cooperate fully, at
NOBLE’S expense, in the enforcement of NOBLE’S rights against such a third party. Nothing
contained in this paragraph of this EXHIBIT shall be construed as to require NOBLE to enforce any
rights against a third party or to restrict NOBLE’S rights to license or consent to such a third
party’s use of the Mark.

     7. Indemnification. NOBLE agrees to indemnify and hold CERES, and its officers,
agents, directors employees, attorneys, shareholders, subsidiaries, affiliates, distributors, and
licensees, harmless from any and all liability, loss, damages, claims or causes of action,
including reasonable legal fees and expenses, that may be incurred by CERES or one of the foregoing
parties arising out of assertions or claims by a third party that CERES’ use of the Mark in
accordance with the license granted in this EXHIBIT infringes such third party’s rights in the
Mark. CERES shall provide NOBLE with prompt written notice of any claim for which indemnification
is sought, and shall cooperate fully with and allow NOBLE to control the defense and settlement of
such claim at NOBLE’S sole expense. NOBLE shall have the exclusive right to settle any such claim.

     8. Termination; Suspension.

     8.1 Term of Agreement. Unless sooner terminated under the provisions of this
Paragraph of this EXHIBIT, the license granted in this EXHIBIT shall remain in effect until
such time as (a) the termination of the Agreement or (b) NOBLE provides written notice of
its intent to terminate no less than ninety (90) days prior to the intended termination
date. Termination pursuant to this Paragraph may be for any reason or no reason.

     8.2 Termination for Default or Action. Either party shall have the right to
terminate the license grant in this EXHIBIT if (a) the other party materially defaults on
any of its obligations under the terms of this EXHIBIT, including without limitation a
material breach by CERES of its obligations under Paragraphs 5.2 unless (i) such breach is
cured within the thirty (30) days following receipt of written notice of such breach from
NOBLE or (ii) CERES provides NOBLE, within such thirty (30) day period, a written plan to
remedy such breach that is acceptable to NOBLE, in its sole discretion; (b) CERES decides
not to develop and launch the LICENSED VARIETY pursuant to the terms of the MRA and/or this
Agreement; or (c) the LICENSED VARIETY is discontinued and removed from the marketplace.

     8.3 Effect of Termination. Upon termination of the license granted in this
EXHIBIT, CERES shall immediately cease use of the Mark. In the event of termination in
accordance with Paragraph 8.1 or Paragraph 8.2(a) of this EXHIBIT, CERES may continue to use
the Mark to deplete any stock of packaging and promotional materials it has on hand at the
time of such termination, so long as such use is in compliance with the terms of this
EXHIBIT.

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 56 of 57

 

 

     8.4 Suspension. Notwithstanding Paragraph 8.2 of this EXHIBIT, if in its
reasonable discretion, NOBLE determines that as a result of a breach of the terms set forth
in this EXHIBIT that NOBLE will be materially and adversely affected in a substantial manner
by failing to immediately suspend the license granted in this EXHIBIT, NOBLE may suspend the
licenses hereunder until such breach is appropriately cured, in the sole determination of
NOBLE.

	 	 	 

	CERES-NOBLE Master Research Agreement
	 	Page 57 of 57

 

 

Pages
where confidential treatment has been requested are stamped
‘Confidential Treatment Requested and the Redacted Material has
been separately filed with the Commission,’ and the confidential
section has been marked as follows: [***].

REVISED

SCHEDULE 1

THIS REVISED SCHEDULE is made this 18th day of September, 2006.

	 	 	 
	BETWEEN

	 	CERES, INC., a Delaware corporation,
having its principal place of business at
1535 Rancho Conejo Blvd., Thousand Oaks,
CA 91320 (“CERES”) and
	 
	 	 
	 

	 	THE SAMUEL ROBERTS NOBLE FOUNDATION
INCORPORATED, an Oklahoma non-profit
corporation, having its principal place
of business at 2510 Sam Noble Parkway,
Ardmore, Oklahoma 73401 (“NOBLE”);

WHEREAS, CERES and NOBLE have entered into a Master Research Agreement (“MRA”), dated 19 May 2006,
which allows for the undertaking of RESEARCH PROJECTS pursuant to SCHEDULES, these terms being
defined in the MRA; and

WHEREAS, CERES and NOBLE entered into an original Schedule 1 to the MRA, dated 19 May 2006, and the
parties hereby seek to replace the terms and conditions of such schedule, in its entirety, with
this revised SCHEDULE effective as of the date shown above; and

THEREFORE, the parties have agreed to undertake the following RESEARCH PROJECT as defined herein on
the following terms and conditions:

GENERAL

	A.	 	Unless otherwise specified herein, the terms of the MRA shall apply to this SCHEDULE.
	 
	B.	 	In the event of any difference between the terms of this SCHEDULE and the MRA, then the terms
of this SCHEDULE shall prevail.

RESEARCH PROJECT TITLE: Best Management Practices for Switchgrass in a Biomass Cropping System

	1.	 	BACKGROUND:

	 	 	 	Switchgrass (Panicum virgatum L.) is a target species for use as crop biomass for bioenergy
production in the southern USA. Establishing switchgrass directly
into [non-***] soil is a problem. Even when plants emerge and establish, their productivity during the initial year can
be very poor. Preliminary experiments continue to show a need for using a pre-plant and
post-plant herbicide program, especially when using no-till methods, to give more productive
stands. Management research to better establish switchgrass will need to continue in the
future. Good seedling establishment was also part of the protocol for selecting parents for
our experimental cultivars. It is hoped that these new experimentals will have better establishment traits
that will be apparent in future trials.

	2.	 	PROPOSAL OBJECTIVES:

     2.1     To conduct agronomic trials to assess best management practices for establishment
and management of switchgrass as a crop for both seed and biomass production.

	 	 	 
	CERES-NOBLE Schedule 1
	 	Page 1 of 8

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

 

     2.2     To
evaluate switchgrass system with winter annual grasses and legumes along with
[***] to reduce the need for nitrogen fertilizer and increase off-season production.

	 	2.3	 	To evaluate alternative biomass energy crops

	3.	 	WORK TO BE UNDERTAKEN:

	 	 	 	See RESEARCH AND DEVELOPMENT PLAN (Attachment A to this SCHEDULE).
	 
	 	 	 	Subject to the RESEARCH AND DEVELOPMENT PLAN, an overview of NOBLE work includes:

Objective 1 (Establishment). In the initial trials to be established in the spring of 2006, we
will evaluate planting date and herbicides to control crabgrass and other warm season weeds in order to
assess the best methods for establishing the crop. One of the most
advanced of the [***] experimentals (GA993)
will be used as the cultivar for conducting this trial.

Treatments will be as follows in a split-split plot design under irrigated soil in 2006:

Planting Date: Feb ,April, June

[***] treatment

Herbicide treatment

PRE:
Atrazine, [***], [***], [***],
[***] amine, [***], and [***]

POE ([***]): Atrazine, [***], [***],
[***], amine, [***], [***], [***], and [***].

Objective 2a (Establishment). In the fall of 2006 and spring of 2007, we will evaluate planting
date and herbicides to control crabgrass and other warm season weeds in order to assess the best methods for
establishing the crop. Two of the most advanced of the
[***] experimentals (GA993 lowland) and ([***] upland)
will be used as the cultivars for conducting this trial.

Treatments will be as follows in a split-split plot design under irrigated soil in 2006 and 2007:

Planting Date: Sept and May

Species: upland and lowland switchgrass

Seed treatment: None, [***] ([***]), [***] (herbicide [***]), Banded [***] (herbicide [***]).

Herbicide treatment

PRE: atrazine, [***], [***], [***], and [***]

The following measurements will be then be made: seedling counts 30 and 60 DAE and DM yield at end
of growing season.

Objective
2b ([***]). In the fall of 2006, we will evaluate
[***] herbicides on upland and lowland
switchgrass. Surviving plants will be used to develop new breeding
population

PRE
Herbicides: [***], [***], [***], [***], [***], [***], [***], [***]

POE ([***]): Atrazine, [***],
[***], [***], [***], [***], [***], [***], [***], [***], [***].

Objective 3 (crop rotation). In the fall of 2006 and spring of 2007, we will evaluate switchgrass
establishment where grassy weeds were controlled the previous year
and where various Summer legume were
grown and weeds were controlled

	 	 	 
	CERES-NOBLE Schedule 1
	 	Page 2 of 8

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

 

Treatments will be in a strip-split design:

Species: Upland and Lowland Switchgrass

Planting Dates: Sept and May

Summer annual reseeding legumes: [***] ([***], [***]).

Winter legume: hairy vetch

Spray
Selective grass herbicides to control annual grasses

Objective 4. In the fall of 2006 and spring of 2007, we will evaluate planting dates, seeding
rates, and row spacings under dryland and irrigated soils

Planting dates: Sept and May

Species: upland and lowland switchgrass

Seeding Rates: [***] lb PLS/A

Row Spacings: [***] inches

Objective 5. In the fall of 2007 and the spring of 2008, we will evaluate species
compatibility with established switchgrass. Study will be replicated in the fall of 2008 and spring
of 2009.

Species to be evaluated: upland and lowland switchgrass

Cool-season annual grasses: [***] and [***] with N Fertilizer

Cool-season annual legumes: medic, vtech, and clover

Warm-season legumes: [***] (fall planted), [***], and [***]

Measure switchgrass yield response to species mixtures and compare switchgrass

yields with N rate response to legume treatments

Objective 6. In the fall of 2007 and 2008, we will evaluate seed production strategies.

Treatments: [***], [***], [***], others as needed?

Objective 7. In the 2007, we will evaluate various bioenergy crops.

Conditions: dryland and irrigated

N fertilizer levels: high ([***] N), [***]
([***] N), low ([***] N), none ([***] N)

Species: Miscanthus sp., [***], Panicum virgatum (lowland),
Panicum virgatum (upland), Sorghum sp., others?

	4.	 	DETAILED WORKPLAN:

	 	 	 	The RESEARCH AND DEVELOPMENT PLAN (Attachment A to this SCHEDULE) contains:

	 	•	 	Research and evaluation activities to be performed by each party in
detail, including locations for such activities
	 	•	 	Timelines of such activities
	 	•	 	Goals, expected results and deliverables
	 	•	 	Milestones and go/no-go decision points, if applicable
	 	•	 	FTEs

	5.	 	LOCATION OF WORK:

	 	 	 	NOBLE Work:

	 	 	 	NOBLE laboratory and greenhouse facilities and properties at its Ardmore location and
potential subcontractor locations.

	 	 	 
	CERES-NOBLE Schedule 1
	 	Page 3 of 8

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

 

	 	 	 	CERES Work:

	 	 	 	Thousand Oaks, CA

	6.	 	PHD LEVEL SCIENTIFIC STAFF:

	 	 	 	Dr. Twain Butler (NOBLE)

Dr. Joe Bouton (NOBLE)

Post Doc TBD (CNF, wherein “CNF” indicates a CERES-funded, NOBLE employee)
	 
	 	 	 	Dr. Peter Mascia (CERES)

Dr. Steve Thomas (CERES)

Dr. Richard Flavell (CERES)

	7.	 	MAJOR CONSUMABLES/LIVESTOCK TO BE PURCHASED:

	 	 	 	None.

	8.	 	REPORTS:

	 	 	 	All reports shall be delivered to the MANAGEMENT COMMITTEE on or before the required
delivery dates for the same.

	 	 	 	NOBLE will deliver at each quarterly MANAGEMENT COMMITTEE meeting (or annual meeting, as the
case may be):

	 	•	 	Annual Report (compilation of slide presentations and quarterly
minutes) (annual meeting).
	 	•	 	Quarterly status update and FTE breakout based on attached planning
document.
	 	•	 	Actual spending relative to budget.
	 	•	 	INTELLECTUAL PROPERTY generated during the period.
	 	•	 	Copies of slide presentations summarizing research progress (template
attached as Attachment B to this SCHEDULE).
	 	•	 	Content for the development of a grower’s manual, which the parties intend to be
a deliverable of this SCHEDULE.

	 	 	 	Additional information, if not specifically included in the delivered information (above),
shall be delivered (or later provided, wherein the delivering party shall indicate the
delivery method and time) as supporting information at the related quarterly meeting, if
available:

	 	•	 	Copies of raw field trial data

	 	 	 
	CERES-NOBLE Schedule 1
	 	Page 4 of 8

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

 

	9.	 	COMMENCEMENT/TERMINATION:

	 	 	 	Commencement: 19 May 2006

	 	 	 	Termination: 30 September 2009

	10.	 	REPORT PREPARATION:

	 	 	 	Dr Twain Butler (NOBLE)

Dr Peter Mascia (CERES)

	11.	 	REPORT DATES:

	 	 	 	Annual report: Due at annual meeting in March.

	 	 	 	Quarterly reports and information: Due at quarterly meetings of the MANAGEMENT
COMMITTEE per the MRA (e.g., March, June, September, December).

	12.	 	ASSETS:

	 	 	 	Not applicable

	13.	 	INSURANCE:

	 	 	 	Not applicable

	14.	 	CONTRIBUTION TO JOINT INTELLECTUAL PROPERTY:

	 	 	 	Controlled by MRA.

	15.	 	SPECIAL CONDITIONS:

	 	 	 	Not applicable.

	16.	 	INTELLECTUAL PROPERTY RIGHTS:

	 	16.1	 	NOBLE Background Intellectual Property:

	 	 	 	[***] (NOBLE), [***] (NOBLE),
[***] (NOBLE), NF/GA001
(in-licensed from UGARF), NF/GA002 (in-licensed from UGARF), NF/GA991
(in-licensed from UGARF), NF/GA992
(in-licensed from UGARF), and NF/GA993 (in-licensed from UGARF).
	 
	 	 	 	Management practices and protocols for forage cropping systems.

	 	16.2	 	CERES Background Intellectual Property:

	 	 	 	None.

	17.	 	SUBCONTRACTORS AND LOCATIONS:

	 	 	 	Actual locations and work at the locations will be decided by the MANAGEMENT COMMITTEE at
the quarterly meetings. Currently projected locations may include:

	 	 	 
	CERES-NOBLE Schedule 1
	 	Page 5 of 8

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

 

	 	•	 	[***]

	18.	 	PROVISIONS FOR EARLY TERMINATION:

	 	 	 	This SCHEDULE does not terminate automatically upon termination of the MRA.
	 
	 	 	 	This SCHEDULE shall expire pursuant to the terms set forth in this SCHEDULE, unless extended
by the mutual agreement of the parties, or unless sooner terminated in accordance with the
following provisions of this Paragraph:

     (a)     mutual, written agreement of the parties;

     (b)     failure of one party to satisfy its material obligations under this
Agreement, and such party subsequently fails to cure such failure(s) within (i)
thirty (30) days for failures to remit payment for amounts due under this Agreement
and (ii) ninety (90) days for all other obligations in each case after receipt of
written notice from the non-breaching party specifying such failure;

     (c)     one (1) year’s written notice of termination by either CERES or NOBLE to
the other party in case either the terminating party or the other party ceases
substantially all activities in the COLLABORATION CROPS;

     (d)     NOBLE will have the right to terminate this Agreement unilaterally with
thirty (30) days’ written notice to CERES, (i) if CERES seeks protection under any
bankruptcy, insolvency, receivership, trust, deed, creditors arrangement or
comparable proceeding or if any such proceeding is instituted against CERES (and not
dismissed within one hundred twenty (120) days); (ii) in case of dissolution or
winding up of CERES (excluding any situation where all or substantially all of
CERES’ assets, stock or business to which this Agreement relates are acquired by a
third party (whether by sale, acquisition, merger, operation of law or otherwise));
(iii) with written notice to CERES, to be given no later than March 31, 2010 if
Ceres has failed in a substantial manner, by December 31, 2009, to implement the
activities set forth in EXHIBIT F, and does not remedy such failure or offer a
remediation plan which is reasonably acceptable to NOBLE within ninety (90) days
after receipt of a written notice from NOBLE specifying such failure; or (iv) with
one hundred twenty (120) days’ written notice to CERES, if the institutional
mission, purpose or structure of NOBLE would change substantially and adversely
affect NOBLE’S ability to satisfy its obligations hereunder; or

     (e)     CERES will have the right to terminate this Agreement unilaterally: (i)
with thirty (30) days’ written notice to NOBLE if Dr. Joe
Bouton ceases to be associated with
NOBLE and the research activities associated with this SCHEDULE, and NOBLE has not
replaced him within one hundred twenty (120) days by a person reasonably acceptable
to CERES; (ii) with ninety (90) days’ written notice to NOBLE, if the institutional
mission, purpose or structure of NOBLE would change substantially; or (iii) with one
(1) years’ written notice to NOBLE, if CERES has compelling business reasons to
cease the collaboration.

	 	 	 
	CERES-NOBLE Schedule 1
	 	Page 6 of 8

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

 

	19.	 	USE AND COMMERCIALIZATION RIGHTS:

	 	 	 	Controlled by MRA.

	20.	 	CONFIDENTIALITY/PUBLICATION:

	 	 	 	Controlled by MRA.

	21.	 	Proposed FUNDING:

Projected Budget (per year from CERES):

	 	 	 	 	 	 	 	 	 
	 	 	Year 1	 	Year 2	 	Year 3	 	 
	 	 	Salaries	 	Salaries	 	Salaries	 	 
	 	 	incl.	 	incl.	 	incl.	 	 
	Personnel	 	fringe	 	fringe	 	fringe	 	Subtotals
	 
	Postdoc + Fringe Benefits

	 	$[***]
	 	$[***]
	 	$[***]
	 	$[***]
	Res. Assistant + Fringe Benefits

	 	$[***]
	 	$[***]
	 	$[***]
	 	$[***]
	Part-time hourly ($8/hr)

	 	$[***]
	 	$[***]
	 	$[***]
	 	$[***]
	Location testing site [***]

	 	$[***]
	 	$[***]
	 	$[***]
	 	$[***]
	Travel

	 	$[***]
	 	$[***]
	 	$[***]
	 	$[***]
	Supplies

	 	$[***]
	 	$[***]
	 	$[***]
	 	$[***]
	[***]

	 	$[***]
	 	$[***]
	 	$[***]
	 	$[***]
	Seed

	 	$[***]
	 	$[***]
	 	$[***]
	 	$[***]
	Total Direct Costs

	 	$[***]
	 	$[***]
	 	$[***]
	 	$[***]
	Indirect (50% of Direct)

	 	$[***]
	 	$[***]
	 	$[***]
	 	$[***]
	 

	 	 	 	 	 	 	 	TOTAL
	 
	Total

	 	$[***]
	 	$[***]
	 	$[***]
	 	$[***]

Billing Schedule: Invoices will be sent by NOBLE to CERES for actual expenses from the previous
period on the 15th of the first month of each calendar quarter, not to exceed the total
amount specified above.

(SIGNATURES ON FOLLOWING PAGE)

	 	 	 
	CERES-NOBLE Schedule 1
	 	Page 7 of 8

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

 

IN WITNESS THEREOF this SCHEDULE has been executed on the date hereinbefore entered.

CERES, INC.

	 	 	 	 	 
	 	/s/ Peter Mascia 	10/6/06
	By:
	 	 	Date

	 	 	 	 	 
	 	/s/ Patrick McCroskey	10/10/06
	By:
	 	 	Date

THE SAMUEL ROBERTS NOBLE FOUNDATION, INC.

	 	 	 	 	 
	 	/s/ Michael Cawley	9/25/06
	By:

	 	Michael A. Cawley

President
	Date	 

	 	 	 
	CERES-NOBLE Schedule 1
	 	Page 8 of 8

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

 

     

CERES-NOBLE
- Schedule 1 - Attachment A - RESEARCH AND DEVELOPMENT PLAN

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Ceres FTE sum	 	[***]	 	[***]	 	[***]	[***]	[***]	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	CNF FTE Sum	 	[***]	 	[***]	 	[***]	[***]	[***]	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	NF FTE sum	 	[***]	 	[***]	 	[***]	[***]	[***]	 
	Project Planning	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	#	 	Yearly	 	 	 	 	 	 	 	 
	Template	 	 	 	Ex Start	 	Ex Finish	 	Loc	 	 	 	# people	 	%	 	Months	 	FTE	 	2006	 	2007	 	2008	 	2009
	Objective
	 	Develop best management practices for establishing
and managing switchgrass
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Product Concept
	 	Increasing speed of establishment will allow
faster utilization of switchgrass. Adding legumes
to the system will allow for greater switchgrass
yields with less N fertilizer
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Business Plan
	 	Conduct field trials to determine optimal
management to increase establishment and yield
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Management
	 	 

	 	4/1/06
	 	12/31/09
	 	CERES
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 

	 	4/1/06
	 	12/31/09
	 	NF
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Goal 1
	 	Evaluate switchgrass establishment under irrigated 

field conditions in 2006 where no previous grass 

weed control was implemented
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Impact
	 	Improve establishment to utilize switchgrass sooner
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Action Item
	 	Test efficacy of planting dates (Feb and Apr and
June).

	 	2/15/06
	 	9/30/06
	 	CNF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 

	 	2/15/06
	 	9/30/06
	 	NF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Action Item
	 	Test
efficacy of [***] as seed treatment

	 	2/16/06
	 	10/1/06
	 	CNF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 

	 	2/16/06
	 	10/1/06
	 	NF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Action Item
	 	Test
herbicides for weed control applied PRE: Atrazine [***] amine and
[***] (others at needed)

	 	3/15/06
	 	10/2/06
	 	CNF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 

	 	3/15/06
	 	10/2/06
	 	NF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 

	 	 	 	 	 	 	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Test
herbicides for weed control applied POE:
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Action Item
	 	([***])
Atrazine [***] amine [***].

	 	4/15/06
	 	10/3/06
	 	CNF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 

	 	4/15/06
	 	10/3/06
	 	NF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	New Action Item
	 	Screen
upland and lowland switchgrass to [***] herbicide [***];
select plants with [***] for new breeding
population

	 	9/15/06
	 	6/3/07
	 	CNF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 

	 	9/15/06
	 	6/3/07
	 	NF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

					
	 	 	 	 	 
	Ceres, Inc. Confidential
	 	9/25/2006
	 	Page 1

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

 

CERES-NOBLE
- Schedule 1 - Attachment A - RESEARCH AND DEVELOPMENT PLAN

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	2006	 	2007	 	2008	 	2009
	J	 	F	 	M	 	A	 	M	 	J	 	J	 	A	 	S	 	O	 	N	 	D	 	J	 	F	 	M	 	A	 	M	 	J	 	J	 	A	 	S	 	O	 	N	 	D	 	J	 	F	 	M	 	A	 	M	 	J	 	J	 	A	 	S	 	O	 	N	 	D	 	J	 	F	 	M	 	A	 	M	 	J	 	J	 	A	 	S	 	O	 	N	 	D
	 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

					
	 	 	 	 	 
	Ceres, Inc. Confidential
	 	9/25/2006
	 	Page 2

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

 

     

CERES-NOBLE
- Schedule 1 - Attachment A - RESEARCH AND DEVELOPMENT PLAN

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

	Deliverable
	 	Document best management strategies for 

establishing switchgrass under irrigated field 

conditions

	 	10/1/06
	 	9/30/07	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	New Goal 4
	 	Evaluate seeding rates, row spacings, and planting
dates to improve establishment and management
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Impact
	 	Improve establishment and management of switchgrass
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Action Item
	 	Test efficacy of planting dates (May and Sept).

	 	9/15/06
	 	9/30/08
	 	CNF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 

	 	9/15/06
	 	9/30/08
	 	NF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Action Item
	 	Test efficacy of seeding rates ([***] lb PLS/A)

	 	9/15/06
	 	9/30/08
	 	CNF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 

	 	9/15/06
	 	9/30/08
	 	NF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Action Item
	 	Test efficacy of row spacing for improved harvest
efficiency ([***] inches)

	 	9/15/06
	 	9/30/08
	 	CNF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 

	 	9/15/06
	 	9/30/08
	 	NF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Deliverable
	 	Document best management strategies for
establishing and managing switchgrass under
irrigated field conditions

	 	10/1/06
	 	9/30/08	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

					
	 	 	 	 	 
	Ceres, Inc. Confidential
	 	9/25/2006
	 	Page 3

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

 

     

CERES-NOBLE
- Schedule 1 - Attachment A - RESEARCH AND DEVELOPMENT PLAN

[***]

					
	 	 	 	 	 
	Ceres, Inc. Confidential
	 	9/25/2006
	 	Page 4

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

 

CERES-NOBLE
- Schedule 1 - Attachment A - RESEARCH AND DEVELOPMENT PLAN

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

	Goal 2
	 	Evaluate switchgrass (lowland and upland)
establishment under dryland field conditions in
2006 and 2007 where no previous grass weed contrl
was implemented
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Impact
	 	Improve establishment to utilize switchgrass sooner
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Action Item
	 	Test efficacy of planting dates (Sept and May)

	 	2/15/07
	 	10/31/08
	 	CNF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 

	 	2/15/07
	 	10/31/08
	 	NF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Action Item
	 	Test efficacy of seed treatments ([***])

	 	2/15/07
	 	10/31/08
	 	CNF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 

	 	2/15/07
	 	10/31/08
	 	NF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Action Item
	 	Test
herbicides for weed control applied PRE

	 	2/15/07
	 	10/31/08
	 	CNF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 

	 	2/15/07
	 	10/31/08
	 	NF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	New Action Item
	 	Screen
[***] herbicides on switchgrass, select surviving 

plants for new breeding population

	 	2/15/07
	 	10/31/08
	 	CNF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 

	 	2/15/07
	 	10/31/08
	 	NF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Action Item
	 	Test
herbicides for weed control applied POE

	 	2/15/07
	 	10/31/08
	 	CNF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 

	 	2/15/07
	 	10/31/08
	 	NF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Deliverable	 	Document best management strategies for 

establishing switchgrass under dryland field 

conditions
	 	10/31/07	 	9/30/08	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Goal 3
	 	Evaluate switchgrass establishment where grass
weed contrl was implemented on [***] the year
prior to planting
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Impact
	 	Improve establishment of switchgrass
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Action Item
	 	Establish [***] and control weeds during summer

	 	4/10/06
	 	10/31/08
	 	CNF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 

	 	4/10/06
	 	10/31/08
	 	NF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Action Item
	 	Plant
switchgrass (upland and lowland) into legume fields where annual grasses were controlled the
previous year: Planting dates, Sept and May

	 	4/11/06
	 	11/1/08
	 	CNF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 

	 	4/11/06
	 	11/1/08
	 	NF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Action Item
	 	Test
efficacy winter cover crop (vetch)

	 	9/12/06
	 	11/2/08
	 	CNF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 

	 	9/12/06
	 	11/2/08
	 	NF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Deliverable	 	Document best agronomic management strategies for 

establishing switchgrass under dryland field 

conditions
	 	11/1/08	 	3/3/09	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	New Goal 6
	 	Evaluate switchgrass seed production on 

established stands
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Impact
	 	Increase seed yield and efficiency
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Action Item
	 	Test efficacy of [***]

	 	10/1/07
	 	11/1/09
	 	CNF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 

	 	10/1/07
	 	11/1/09
	 	NF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Action Item
	 	Test efficacy of [***]

	 	10/2/07
	 	11/2/09
	 	CNF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]

					
	 	 	 	 	 
	Ceres, Inc. Confidential
	 	9/25/2006
	 	Page 5

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

 

     

CERES-NOBLE
- Schedule 1 - Attachment A - RESEARCH AND DEVELOPMENT PLAN

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
		 		 		 	
		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 	
	 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

					
	 	 	 	 	 
	Ceres, Inc. Confidential
	 	9/25/2006
	 	Page 6

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

 

     

CERES-NOBLE
- Schedule 1 - Attachment A - RESEARCH AND DEVELOPMENT PLAN

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

	 
	 	 

	 	10/1/07
	 	11/1/09
	 	NF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Action Item
	 	Test efficacy of [***]

	 	10/2/07
	 	11/2/09
	 	CNF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	 	 

	 	10/2/07
	 	11/2/09
	 	NF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Action Item
	 	Test
[***] ([***] vs [***])

	 	4/1/08
	 	11/3/9
	 	CNF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 

	 	4/1/08
	 	11/3/09
	 	NF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Deliverable
	 	Document best agronomic management strategies for
producing seed
	 	
	 	
	 	
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]

					
	 	 	 	 	 
	Ceres, Inc. Confidential
	 	9/25/2006
	 	Page 7

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

 

     

CERES-NOBLE
- Schedule 1 - Attachment A - RESEARCH AND DEVELOPMENT PLAN

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
		 		 		 	
		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 	
	[***]

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

					
	 	 	 	 	 
	Ceres, Inc. Confidential
	 	9/25/2006
	 	Page 8

	 	 	 
	Confidential Treatment Requested and the Redacted Material has been separately filed with
the Commission.

 

     

CERES-NOBLE
- Schedule 1 - Attachment A - RESEARCH AND DEVELOPMENT PLAN

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

	Goal 5
	 	Evaluate species compatibility with established
switchgrass (in 2008 and 2009)
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Impact
	 	Maximize DM yield with minimum N fertilizer
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Action Item
	 	Evaluate
winter legumes interseeded into established 

switchgrass

	 	10/1/07
	 	11/1/09
	 	CNF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 

	 	10/1/07
	 	11/1/09
	 	NF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Action Item
	 	Evaluate
[***] grasses interseeded into established 

switchgrass

	 	10/2/07
	 	11/2/09
	 	CNF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 

	 	10/2/07
	 	11/2/09
	 	NF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Action Item
	 	Evaluate
summer legumes interseeded into established 

switchgrass

	 	4/1/08
	 	11/3/09
	 	CNF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 

	 	4/1/08
	 	11/3/09
	 	NF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Action Item
	 	Evaluate
both winter species and summer legumes into established
switchgrass

	 	10/1/07
	 	11/4/09
	 	CNF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 

	 	10/1/07
	 	11/4/09
	 	NF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Action Item
	 	Evaluate yield response to N fertilizer to
estimate N contribution from the legume systems

	 	4/1/08
	 	11/5/09
	 	CNF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 

	 	4/1/08
	 	11/5/09
	 	NF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Deliverable
	 	Document
which legumes are compatible with
switchgrass and will maximize yield with little N
Fertilizer
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	New Goal 7
	 	Evaluate alternative biomass energy crops
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Impact
	 	Determine
appropriate biomass crops under various
conditions
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Action Item
	 	Evaluate
bioenergy crops for DM yield ([***] upland and lowland
switchgrass, [***])

	 	5/15/07
	 	9/30/09
	 	CNF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 

	 	5/15/07
	 	9/30/09
	 	NF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Action Item
	 	Evaluate DM yield under irrigated and dryland
conditions

	 	5/15/07
	 	9/30/09
	 	CNF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 

	 	5/15/07
	 	9/30/09
	 	NF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Action Item
	 	Evaluate DM yield with varying N rates

	 	5/15/07
	 	9/30/09
	 	CNF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 

	 	5/15/07
	 	9/30/09
	 	NF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Deliverable
	 	Document DM yield potential under dryland and
irrigated field conditions and with high and low
levels of Nitrogen

	 	5/1/07
	 	9/30/09	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Goal 8	 	Develop comprehensive switchgrass production and
growers guidelines and manuals
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Impact	 	Maximize yield with existing varieties. Identify
conditions for optimal yield. Provide feedback to breeders to optimize breeding strategies
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

					
	 	 	 	 	 
	Ceres, Inc. Confidential
	 	9/25/2006
	 	Page 9

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

 

     

    CERES — NOBLE — Schedule 1 — Attachment A —
    RESEARCH AND DEVELOPMENT PLAN

 

    [***]

 

			
	    Ceres, Inc.
    Confidential
    	     9/25/2006
    	     Page 10
    

	 	 	 
	Confidential Treatment Requested and the Redacted Material has been separately filed with
the Commission.

 

     

CERES-NOBLE
- Schedule 1 - Attachment A - RESEARCH AND DEVELOPMENT PLAN

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

	Impact
	 	Maximize yield with existing varieties. Identify
conditions for optimal yield. Provide feedback to
breeders to optimize breeding strategies
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Action Item
	 	Compile and summarize current best practices for
switchgrass production

	 	5/1/06
	 	12/1/06
	 	NF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 

	 	5/1/06
	 	12/1/06
	 	CNF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 

	 	5/1/06
	 	12/1/06
	 	Ceres
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 

	 	 	 	 	 	 	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 

	 	10/2/07
	 	11/2/09
	 	NF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Action Item
	 	Test [***] ([***] vs [***])

	 	4/1/08
	 	11/3/09
	 	CNF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 

	 	4/1/08
	 	11/3/09
	 	NF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Deliverable
	 	Document best agronomic management strategies for 

producing seed

	 	 	 	 	 	 	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Action Item
	 	Incorporate
herbicide and [***] data

	 	9/1/07
	 	12/1/08
	 	NF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 

	 	9/1/07
	 	12/1/08
	 	CNF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 

	 	9/1/07
	 	12/1/08
	 	Ceres
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 

	 	 	 	 	 	 	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Deliverable
	 	Draft manuals

	 	 	 	12/1/07
	 	NF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 

	 	 	 	 	 	CNF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Deliverable
	 	Final manuals

	 	 	 	12/1/08
	 	NF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 

	 	 	 	 	 	CNF
	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]

					
	 	 	 	 	 
	Ceres, Inc. Confidential
	 	9/25/2006
	 	Page 11

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

 

     

CERES-NOBLE
- Schedule 1 - Attachment A - RESEARCH AND DEVELOPMENT PLAN

 

 

[***]

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
		 		 		 	
		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 	
	 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

					
	 	 	 	 	 
	Ceres, Inc. Confidential
	 	9/25/2006
	 	Page 12

	 	 	 
	Confidential Treatment Requested and the Redacted Material has been separately filed with
the Commission.

 

Quarterly Report Format

Prepared by

Date

			
	 	 	 
	Confidential     Schedule # and name
	 	

1

 

Concept and Goals

	•	 	Concept

	•	 	Goals

			
	 	 	 
	Confidential     Schedule # and name
	 	

2

 

FTEs and Budget Projected vs. Actual

	•	 	People and activities

Dollars

FTEs

			
	 	 	 
	Confidential     Schedule # and name
	 	

3

 

Action Items and Deliverables for the Period

	 	 	 	 	 	 	 	 	 
	 	 	Expected	 	 	Actual	 
	Action Item or Deliverable	 	Finish	 	 	Finish	 
	 
	 	 	 	 	 	 	 	 

			
	 	 	 
	Confidential     Schedule # and name
	 	

4

 

Key Milestones or Deliverables for the Period

	•	 	Progress on Key Milestones and Deliverables
	 
	•	 	Are we on, ahead or behind schedule

			
	 	 	 
	Confidential     Schedule # and name
	 	

5

 

Technical Highlights

	•	 	1 or 2 slides covering technical highlights

			
	 	 	 
	Confidential     Schedule # and name
	 	

6

 

Results

	•	 	Several slides summarizing results (if applicable)

			
	 	 	 
	Confidential     Schedule # and name
	 	

7

 

Key Milestones and Deliverables Next 4 Quarters

	•	 	Quarter 1
	 
	•	 	Quarter 2
	 
	•	 	Quarter 3
	 
	•	 	Quarter 4

			
	 	 	 
	Confidential     Schedule # and name
	 	

8

 

Research Plan

	•	 	Goal

	 	—	 	Impact
	 
	 	—	 	Tasks
	 
	 	—	 	Milestones
	 
	 	—	 	Deliverables

	•	 	Duplicate this slide as needed to cover each goal for the next period

			
	 	 	 
	Confidential     Schedule # and name
	 	

9

 

Timeline Summary

	Time to achieve Milestone 1 2 3 4 5 6 7 8 9 10 11 12
Milestone 1
Milestone 2
Milestone 3
Etc.

	•	 	Assumptions and risk factors
	 
	•	 	Use additional slide if necessary
	 
	•	 	Use red if behind schedule until completed or otherwise resolved
	 
	•	 	Should be indicated in red as soon as the delay is identified
	 
	•	 	See issue resolution if behind schedule

			
	 	 	 
	Confidential     Schedule # and name
	 	

10

 

IP

	•	 	Filings during the period

	•	 	Applications in progress

			
	 	 	 
	Confidential     Schedule # and name
	 	

11

 

SOPs

	•	 	List SOPS for all Key processes

			
	 	 	 
	Confidential     Schedule # and name
	 	

12

 

Issue Resolution and Decision Making Slides

These can be used to address new issues or

implement corrective action or assist in decision

making such as variety release, etc.

			
	 	 	 
	Confidential     Schedule # and name
	 	

13

 

Issue Resolution and Decision Making

	•	 	Issue (e.g. milestone 3 behind schedule)

	 	 	Actual
	 
	•	 	What is happening

 

	 	 	Expected
	 
	•	 	What should be happening

			
	 	 	 
	Confidential     Schedule # and name
	 	

14

 

Issue Resolution and Decision Making

	•	 	Issue (e.g. milestone 3 behind schedule)
	 
	•	 	Possible alternative slide to address new issues

Needs

Wants

			
	 	 	 
	Confidential     Schedule # and name
	 	

15

 

Decision

	•	 	Summary of decision to be made

			
	 	 	 
	Confidential     Schedule # and name
	 	

16

 

Options

	•	 	Summary of options

			
	 	 	 
	Confidential     Schedule # and name
	 	

17

 

Recommendations

	•	 	What do we need to do to get back on track or address new issue

			
	 	 	 
	Confidential     Schedule # and name
	 	

18

 

Resources Required

			
	 	 	 
	Confidential     Schedule # and name
	 	

19

 

Plan and Schedule

	 	 	 	 	 	 	 	 	 
	Action Items	 	Who	 	 	When	 
	 
	 	 	 	 	 	 	 	 

			
	 	 	 
	Confidential     Schedule # and name
	 	

20

 

SCHEDULE 2

     THIS SCHEDULE is made this 19th day of May, 2006;

			
	BETWEEN 	 	CERES, INC., a Delaware corporation, having its
principal place of business at 1535 Rancho
Conejo Blvd., Thousand Oaks, CA 91320 (“CERES”)
and
	 	 	
	 	 	THE SAMUEL ROBERTS NOBLE FOUNDATION
INCORPORATED, an Oklahoma non-profit
corporation, having its principal place of
business at 2510 Sam Noble Parkway, Ardmore,
Oklahoma 73401 (“NOBLE”);

WHEREAS, CERES and NOBLE have entered into a Master Research Agreement (“MRA”), dated 19 May 2006,
which allows for the undertaking of RESEARCH PROJECTS pursuant to a SCHEDULES, these terms being
defined in the MRA; and

THEREFORE, the parties have agreed to undertake the following RESEARCH PROJECT as defined herein on
the following terms and conditions:

GENERAL

	A.	 	Unless otherwise specified herein, the terms of the MRA shall apply to this SCHEDULE.
	 
	B.	 	In the event of any difference between the terms of this SCHEDULE and the MRA, then the terms
of this SCHEDULE shall prevail.

RESEARCH PROJECT TITLE: Developing Switchgrass Cultivars for Use in Bioenergy and Forage Crop

	1.	 	BACKGROUND:
	 
	 	 	Switchgrass (Panicum virgatum L.) is a target species for use as crop biomass for bioenergy
production in the southern USA. In the mid 1990s, a breeding program
was begun at the University of Georgia (UGA) to
develop adaptive, high-yielding switchgrass cultivars for use in bioenergy crop production
systems in the region. Four experimental cultivars were produced in
this project, GA991, GA992,
GA993, and GA001, which are currently owned by the University of
Georgia Research Foundation (UGARF). Initial performance results of these experimentals demonstrated
up to a [***] yield enhancement over [***] when tested over years
and locations in Georgia. This type of
performance warrants release and commercialization of at least one of these cultivars for
use in the region including the southern Great Plains of Oklahoma and Texas.
	 
	 	 	The original UGA breeding effort was initiated by randomly selecting 1,000 [***] from
[***] and [***] and space planting these into a [***] design. This design was used because
of its ability to remove micro-environmental variation during assessment of individual,
un-replicated [***]. Initial data showed genetic variances
for yield were high, especially
for [***] selections, indicating good potential to increase yield within these populations.
Based on phenotypic selection using the [***] planting design, heritability estimates were
found to be adequate to incur good gains from selection and [***] were then identified from
each cultivar which had excellent performance. Cuttings of each of these superior [***] were
[***] multiplied in the greenhouse and used in a [***] program

Page 1 of 10

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

	 	 	to produce [***] progeny of each and to assess their seed
yield. The highest seed  yielding [***] were then
progeny tested in sward plots over locations and years and the highest yielding [***] selected for
inclusion into another  [***] to generate new experimental [***] cultivars.
	 
	 	 	We plan to continue this population improvement approach of developing new experimental [***] cultivars.
However, for this project, we will use more genetically diverse lowland and upland material
from outside the UGA program including released cultivars, [***], and [***] from our own
regional collections. This should greatly enhance our genetic base. The main trait of
interest will be biomass yield, although we plan also to begin examining specific value
added traits such as better seedling establishment and forage chemical aspects that affect
biomass feedstock quality during long term storage.
	 
	 	 	Switchgrass is highly self-incompatible  allowing [***] from simple mutual or
[***]. High [***] is found when [***] were
made from specific, [***]. [***] using tissue
culture is also
possible for large scale production of the individual [***] which should allow their use in
a commercially viable seed production program. These three characteristics demonstrate the
potential is high for developing high yielding [***] of switchgrass.
	 
	2.	 	PROPOSAL OBJECTIVES:
	 
	 	 	     2.1 To use previous population improvement procedures to develop new [***] cultivars
based strictly on germplasm other than the UGA parental base and containing value added
traits such as better yield, establishment characteristics, and chemical composition than
the best UGA experimental and the commercial cultivar, [***].
	 
	 	 	     2.2 To develop and assess [***] between the best parental  using a system of [***] of the parental [***]
to produce and maintain the commercial [***] cultivars.
	 
	3.	 	WORK TO BE UNDERTAKEN:
	 
	 	 	See RESEARCH AND DEVELOPMENT PLAN (Attachment A to this SCHEDULE).
	 
	4.	 	DETAILED WORKPLAN:
	 
	 	 	The RESEARCH AND DEVELOPMENT PLAN (Attachment A to this SCHEDULE) contains:

	 	•	 	Research and evaluation activities to be performed by each party in
detail, including locations for such activities
	 
	 	•	 	Timelines of such activities
	 
	 	•	 	Goals, expected results and deliverables
	 
	 	•	 	Milestones and go/no-go decision points, if applicable
	 
	 	•	 	FTEs

	5.	 	LOCATION OF WORK:
	 
	 	 	NOBLE Work:
	 
	 	 	NOBLE laboratory and greenhouse facilities and properties at its Ardmore location and
potential subcontractor locations.

Page 2 of 10

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

	 	 	CERES Work:
	 
	 	 	Thousand Oaks, CA.
	 
	6.	 	PHD LEVEL SCIENTIFIC STAFF:
	 
	 	 	Dr. Joe Bouton (NOBLE)

Post Doc TBD (CNF, wherein “CNF” indicates a CERES-funded, NOBLE employee)
	 
	 	 	Dr. Peter Mascia (CERES)

Dr. Steve Thomas (CERES)

Dr. Richard Flavell (CERES)
	 
	7.	 	MAJOR CONSUMABLES/LIVESTOCK TO BE PURCHASED:
	 
	 	 	None.
	 
	8.	 	REPORTS:
	 
	 	 	All reports shall be delivered to the MANAGEMENT COMMITTEE on or before the required
delivery dates for the same.
	 
	 	 	NOBLE will deliver at each quarterly MANAGEMENT COMMITTEE meeting (or annual meeting, as the
case may be):

	 	•	 	Annual Report (compilation of slide presentations and quarterly
minutes) (annual meeting).
	 
	 	•	 	Quarterly status update and FTE breakout based on attached planning
document.
	 
	 	•	 	Actual spending relative to budget.
	 
	 	•	 	INTELLECTUAL PROPERTY generated during the period.
	 
	 	•	 	Copies of slide presentations summarizing research progress (template
attached as Attachment C to this SCHEDULE).

	 	 	Additional information, if not specifically included in the delivered information (above),
shall be delivered (or later provided, wherein the delivering party shall indicate the
delivery method and time) as supporting information at the related quarterly meeting, if
available:

	 	•	 	Breeding records.
	 
	 	•	 	Copies of field or greenhouse books and records.
	 
	 	•	 	Copies of raw field trial data.
	 
	 	•	 	Biological material, including parental lines from [***] and/or [***].

	9.	 	COMMENCEMENT/TERMINATION:
	 
	 	 	Commencement: 19 May 2006.
	 
	 	 	Termination: 30 April 2009; provided however, each year, before the anniversary of
this SCHEDULE, the parties shall decide whether to extend it for one (1) year, with

Page 3 of 10

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

	 	 	appropriate updates to the RESEARCH AND DEVELOPMENT PLAN, PERFORMANCE EVALUATION PLANS
and/or FUNDING (Section 21 of this SCHEDULE).
	 
	10.	 	REPORT PREPARATION:
	 
	 	 	Dr Joe Bouton (NOBLE)

Dr Peter Mascia (CERES)
	 
	11.	 	REPORT DATES:
	 
	 	 	Annual report: Due at annual meeting in March.
	 
	 	 	Quarterly reports and information: Due at quarterly meetings of the MANAGEMENT
COMMITTEE per the MRA (e.g., March, June, September, December).
	 
	12.	 	ASSETS:
	 
	 	 	Not applicable.
	 
	13.	 	INSURANCE:
	 
	 	 	Not applicable.
	 
	14.	 	CONTRIBUTION TO JOINT INTELLECTUAL PROPERTY:
	 
	 	 	Based on the development and design of this RESEARCH PROJECT, the parties acknowledge and
agree that each party anticipates equal contribution (i.e., 50% for each party) to the
research and development of the switchgrass varieties contemplated by this SCHEDULE.
	 
	 	 	For any given variety, however, the parties agree that the respective contributions of the
parties for research and development may be disparate, and in such instances the parties
will define the appropriate contribution for each party, as negotiated in good faith, prior
to such variety’s release pursuant to the terms of this SCHEDULE.
	 
	 	 	NOBLE’s specific contribution shall be noted and made a part of any and all variety license
agreements for any released variety developed, tested and evaluated pursuant to the terms of
this SCHEDULE.
	 
	15.	 	SPECIAL CONDITIONS:

	 	15.1	 	PERFORMANCE EVALUATION PLAN
	 
	 	 	 	     15.1.1 The parties will jointly develop a PERFORMANCE EVALUATION PLAN to assess
the performance of selected varieties developed pursuant to this SCHEDULE relative
to a jointly agreed upon reference variety (the “STANDARD”), with the goal to
determine the percent increase in biomass

Page 4 of 10

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

	 	 	 	relative to the STANDARD. A template of the PERFORMANCE EVALUATION PLAN is
attached hereto as Attachment B.

	 	 	 	     (a) Either party may propose modifications to the PERFORMANCE
EVALUATION PLAN to achieve the mutual goals of assessing the performance
and/or range of selected varieties developed pursuant to this SCHEDULE.
	 
	 	 	 	     (b) The MANAGEMENT COMMITTEE shall review the PERFORMANCE EVALUATION
PLAN at least annually and modify it as appropriate.

	 	 	 	     15.1.2. The PERFORMANCE EVALUATION PLAN shall define specific testing and
evaluation activities, including timelines and the specific party responsible for
such activities. Each party shall use reasonable efforts to execute the activities
for which it is responsible in the PERFORMANCE EVALUATION PLAN.
	 
	 	 	 	     15.1.3 Upon CERES’ request, NOBLE shall deliver to CERES seed, other biological
material or biomass material the varieties used or grown for development, testing
and evaluation pursuant to the terms of this SCHEDULE, and CERES shall reimburse all
reasonable costs for harvesting, treatment and shipping incurred in connection with
such delivery by NOBLE.
	 
	 	 	 	     15.1.4. Each party will voluntarily provide to the other party reports and
information generated from execution of the PERFORMANCE EVALUATION PLAN. NOBLE will
regularly provide pictures to CERES of the subject plants under evaluation, wherein
the parties will discuss and agree to the desired imagery, e.g., set-up, content and
the like.
	 
	 	 	 	     15.1.5 Before the release of a variety developed pursuant to the terms of this
SCHEDULE, the MANAGEMENT COMMITTEE will designate a “percent increase in biomass”
for each such variety based on the variety’s performance as to the STANDARD. This
percentage shall be used by the parties to determine the total royalty rate on NET
SELLING PRICE associated with the variety in accordance with the table and formula
provided hereinbelow. This determined royalty shall be made a part of a separate,
written variety license agreement by and between the parties pursuant to which CERES
will be granted an exclusive license:

	 	 	 
	Percent Increase in	 	 
	Biomass	 	Royalty
	0%

	 	[***]%
	7%

	 	[***]%
	20%

	 	[***]%
	33%

	 	[***]%
	47%

	 	[***]%
	60%

	 	[***]%
	73%

	 	[***]%
	87%

	 	[***]%
	100%

	 	[***]%
	113%

	 	[***]%
	127%

	 	[***]%
	140%

	 	[***]%
	153%

	 	[***]%
	167%

	 	[***]%

Page 5 of 10

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

	 	 	 	The royalty shall equal [***] times the percent increase in biomass plus [***],
wherein the royalty rate shall be shall be no greater than [***] percent ([***]%)
and no lower than [***] percent ([***]%).
	 
	 	 	 	This can be expressed using the following formula:
	 
	 	 	 	Royalty = [***] X percent increase in biomass + [***]
	 
	 	 	 	     15.1.6 Notwithstanding the foregoing, if the relative value of the LICENSED
VARIETY as compared to the STANDARD is reasonably deemed by the MANAGEMENT COMMITTEE
to reside in factors other than percent increase in biomass, the MANAGEMENT
COMMITTEE shall determine in good faith the total applicable royalty rate.
	 
	 	 	 	     15.1.7 If NOBLE does not wish to participate in a PERFORMANCE EVALUATION PLAN
for a particular variety developed pursuant to this SCHEDULE, CERES may proceed
without NOBLE, following the template in Attachment B, and CERES will determine the
“percent increase in biomass.” CERES will give NOBLE full information on the results
achieved.
	 
	 	15.2.	 	DENOMINATIONS AND TRADEMARKS
	 
	 	 	 	     15.2.1 “TRADEMARK” means any trademark, trade name or logo owned by CERES and
intended for use with a variety developed pursuant to the terms of this SCHEDULE;
provided however, it is recognized that U.S. regulations prohibit the registration
of any plant variety name as a trademark or trade name.
	 
	 	 	 	     15.2.2 The MANAGEMENT COMMITTEE shall determine and adopt a denomination for
any variety developed pursuant to the terms of this SCHEDULE for use in at least
testing and evaluation.
	 
	 	 	 	     15.2.3 The parties shall use the respective denomination of each variety
developed pursuant to the terms of this SCHEDULE to identify such variety and shall
not associate any TRADEMARK or any trade name or similar indication with the
denomination.
	 
	 	15.3.	 	VARIETY RELEASE

Page 6 of 10

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

	 	 	 	     15.3.1 “RELEASE DATE” means the date that CERES determines that a variety
developed, tested and evaluated pursuant to the terms of this SCHEDULE is ready for
release, wherein upon such decision, such variety will be formally released by the
institutions of the variety’s breeder(s), whether NOBLE, CERES or CERES and NOBLE
jointly.
	 
	 	 	 	     15.3.2 For the purposes of this SCHEDULE, CERES, on advice of the breeder(s) of
each variety via the MANAGEMENT COMMITTEE, shall establish, in its sole discretion,
an appropriate RELEASE DATE for such varieties.
	 
	 	 	 	     15.3.3 At or about the RELEASE DATE for a variety, CERES will determine a
COMMERCIAL NAME for such variety under which the seed of the same will be marketed
and sold. “COMMERCIAL NAME” means the complete, preferred name of a released variety
under which it will be marketed and sold.
	 
	 	 	 	     15.3.4 All parties agree that the development of new varieties will not always
result in varieties that are commercially acceptable or releasable. Provided all
parties execute their respective obligations under this SCHEDULE in an appropriate
and reasonable manner, no one party shall be liable to the other for any refund or
other recompense because no commercially acceptable new variety is produced.

	16.	 	INTELLECTUAL PROPERTY RIGHTS:

	 	16.1	 	NOBLE Background Intellectual Property:
	 
	 	 	 	[***] (NOBLE), [***] (NOBLE),
[***] (NOBLE), NF/GA001
(in-licensed from UGARF), NF/GA002 (in-licensed from UGARF), NF/GA991
(in-licensed from UGARF), NF/GA992
(in-licensed from UGARF), and NF/GA993 (in-licensed from UGARF).
	 
	 	16.2.	 	CERES Background Intellectual Property:
	 
	 	 	 	None.

	17.	 	SUBCONTRACTORS AND LOCATIONS:
	 
	 	 	Actual locations and work at the locations will be decided by the MANAGEMENT COMMITTEE at
the quarterly meetings.
	 
	 	 	The parties agree that the evaluation locations shall include (each site includes each of
the varieties identified in Paragraph 16.1 of this SCHEDULE unless otherwise stated):

	 	•	 	[***]

	 	–	 	[***] NF/GA991; NF/GA992; NF/GA993; and NF/GA001

Page 7 of 10

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

	 	–	 	[***] NF/GA993 and NF/GA001

	 	•	 	[***]

	 	–	 	[***] NF/GA991; NF/GA992; NF/GA993; and NF/GA001
	 
	 	–	 	[***] NF/GA991; NF/GA992; NF/GA993; and NF/GA001

	 	•	 	[***]

	 	–	 	NF/GA992 and NF/GA993

	 	•	 	[***]

	 	–	 	[***] NF/GA991; NF/GA992; NF/GA993; and NF/GA001

	 	•	 	[***]

	 	–	 	[***] NF/GA991; NF/GA992; NF/GA993; and NF/GA001

	 	•	 	[***])

	 	–	 	[***] NF/GA991; NF/GA992; NF/GA993; and NF/GA001

	18.	 	PROVISIONS FOR EARLY TERMINATION:
	 
	 	 	This SCHEDULE does not terminate automatically upon termination of the MRA.
	 
	 	 	This SCHEDULE shall expire pursuant to the terms set forth in this SCHEDULE, unless extended
by the mutual agreement of the parties, or unless sooner terminated in accordance with the
following provisions of this Paragraph:

	 	 	 	     (a) mutual, written agreement of the parties;
	 
	 	 	 	     (b) failure of one party to satisfy its material obligations under this
Agreement, and such party subsequently fails to cure such failure(s) within (i)
thirty (30) days for failures to remit payment for amounts due under this Agreement
and (ii) ninety (90) days for all other obligations in each case after receipt of
written notice from the non-breaching party specifying such failure;
	 
	 	 	 	     (c) one (1) year’s written notice of termination by either CERES or NOBLE to
the other party in case either the terminating party or the other party ceases
substantially all activities in the COLLABORATION CROPS;
	 
	 	 	 	     (d) NOBLE will have the right to terminate this Agreement unilaterally with
thirty (30) days’ written notice to CERES, (i) if CERES seeks protection under any
bankruptcy, insolvency, receivership, trust, deed, creditors arrangement or
comparable proceeding or if any such proceeding is instituted against CERES (and not
dismissed within one hundred twenty (120) days); (ii) in case of dissolution or
winding up of CERES (excluding any situation where all or substantially all of
CERES’ assets, stock or business to which this Agreement relates are acquired by a
third party (whether by sale, acquisition, merger, operation of law or otherwise));
(iii) with written notice to CERES, to be given no later than March 31, 2010 if
Ceres has failed in a substantial manner, by December 31, 2009, to implement the
activities set forth in EXHIBIT F, and does not remedy such failure or offer a
remediation plan which is reasonably acceptable to NOBLE within ninety (90) days
after receipt of a written notice from NOBLE specifying such failure; or (iv) with
one hundred twenty (120) days’ written notice to CERES, if the institutional
mission, purpose or structure of

Page 8 of 10

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

	 	 	 	NOBLE would change substantially and adversely affect NOBLE’S ability to
satisfy its obligations hereunder; or
	 
	 	 	 	     (e) CERES will have the right to terminate this Agreement unilaterally: (i)
with thirty (30) days’ written notice to NOBLE if Dr. Joe Bouton ceases to be associated with
NOBLE and the research activities associated with this SCHEDULE, and NOBLE has not
replaced him within one hundred twenty (120) days by a person reasonably acceptable
to CERES; (ii) with ninety (90) days’ written notice to NOBLE, if the institutional
mission, purpose or structure of NOBLE would change substantially; or (iii) with one
(1) years’ written notice to NOBLE, if CERES has compelling business reasons to
cease the collaboration.

	19.	 	USE AND COMMERCIALIZATION RIGHTS:
	 
	 	 	Controlled by MRA. License agreements for non-transgenic varieties developed pursuant to
this SCHEDULE 2 will be based on the Model License Agreement for Non-transgenic Varieties in
EXHIBIT G to the MRA.
	 
	20.	 	CONFIDENTIALITY/PUBLICATION:
	 
	 	 	Controlled by MRA.
	 
	21.	 	FUNDING APPROVED:

Projected Budget (per year from Ceres):

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Year 1	 	 	Year 2	 	 	Year 3	 	 	 	 
	 	 	Salaries incl.	 	 	Salaries incl.	 	 	Salaries incl.	 	 	 	 
	Personnel	 	fringe	 	 	fringe	 	 	fringe	 	 	Subtotals	 
	 
	Postdoctoral + Fringe Benefits
	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 
	Travel
	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 
	Supplies
	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 
	Total Direct Costs
	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 
	Indirect (50% of Direct)
	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 
	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	TOTAL
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Total
	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

Billing Schedule: Invoices will be sent by NOBLE to CERES for actual expenses from the
previous period on the 15th of the first month of each calendar quarter, not to exceed
the amounts specified above.

Page 9 of 10

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

IN WITNESS THEREOF this SCHEDULE has been executed on the date hereinbefore entered.

	 	 	 	 	 

	CERES, INC.
	 
	 	 	 	 
	 	/s/ Richard Flavell	May 19th 2006
	By:

	 	Richard Flavell, CBE, FRS
	 	Date
	 

	 	Chief Scientific Officer	 	 
	 
	 	 	 	 
	 
	 	 	 	 
	 	/s/ Richard Hamilton	May 19, 2006
	By:

	 	Richard Hamilton
	 	Date
	 

	 	President and Chief Executive Officer	 	 
	 
	 	 	 	 
	 
	 	 	 	 
	THE SAMUEL ROBERTS NOBLE FOUNDATION, INC.
	 
	 	 	 	 
	 	/s/ Michael Cawley	19 May 2006
	By:

	 	Michael A. Cawley
	 	Date
	 

	 	President	 	 

Page 10 of 10

 

CERES-NOBLE
- Schedule 2 - Attachment A - RESEARCH AND DEVELOPMENT PLAN

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Ceres FTE sum	 	 	[***]	 	 	[***]	 	 	[***]	 	 	[***]	 	 	[***]	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	CNF FTE Sum	 	 	[***]	 	 	[***]	 	 	[***]	 	 	[***]	 	 	[***]	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	NF FTE sum	 	 	[***]	 	 	[***]	 	 	[***]	 	 	[***]	 	 	[***]	 
	Project Planning	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	#	 	 	Yearly	 	 	 	 	 	 	 	 	 	 	 	 	 
	Template	 	 	 	Ex Start	 	 	Ex Finish	 	 	Loc	 	 	Personnel	 	 	# people	 	 	%	 	 	Months	 	 	FTE	 	 	2006	 	 	2007	 	 	2008	 	 	2009	 
	Objective	 	Develop Commercial Switchgrass Cultivars for Use in Bioenergy and
Forage Cropping Systems
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Product Concept	 	High
yielding cultivars that have good seed quality and high seedling
vigor are lacking currently in the commercial seed trade. New
cultivars produced by this collaboration should be in good position
to [***] this market.
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Business Plan	 	To initiate project in anticipation of Ceres commercialization of
new Switchgrass varieties and [***]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Management FTE
	 	 	4/1/06	 	 	 	12/31/09	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	 	 	 
	 	 	4/1/06	 	 	 	12/31/09	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	Goal	 	To use
population improvement procedures to develop parental [***] for new
[***] cultivars
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Impact	 	To identify
and assess the best parental [***] from NF and Ceres germplasm and
produce initial [***]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Action Item	 	Initiate and manage sources nurseries ([***])
	 	 	3/15/06	 	 	 	9/30/06	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	 	 	 
	 	 	3/15/06	 	 	 	9/30/06	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	Action Item	 	Select best initial [***] and remove and process [***] seed from them;
perform initial phenotypic selection
	 	 	9/30/06	 	 	 	3/1/07	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	 	 	 
	 	 	9/30/06	 	 	 	3/1/07	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	Action Item	 	Establish and harvest trials with [***] ([***])
	 	 	3/15/07	 	 	 	10/2/08	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	 	 	 
	 	 	3/15/07	 	 	 	10/2/08	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	Action Item	 	Identify best performing [***] and place into [***] nursery to produce
[***] seed ([***])
	 	 	4/15/08	 	 	 	10/31/08	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	 	 	 
	 	 	4/15/08	 	 	 	10/31/08	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	Deliverable	 	[***]
parental [***] and [***] seed of new experimental [***] for use in advanced testing
	 	 	10/31/08	 	 	 	3/14/09	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

	 	 	 	 	 
	Ceres, Inc.
Confidential	 	5/18/2006	 	Page 1

 

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

CERES-NOBLE
- Schedule 2 - Attachment A - RESEARCH AND DEVELOPMENT PLAN

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	2006	 	2007	 	2008	 	2009
	J	 	F	 	M	 	A	 	M	 	J	 	J	 	A	 	S	 	O	 	N	 	D	 	J	 	F	 	M	 	A	 	M	 	J	 	J	 	A	 	S	 	O	 	N	 	D	 	J	 	F	 	M	 	A	 	M	 	J	 	J	 	A	 	S	 	O	 	N	 	D	 	J	 	F	 	M	 	A	 	M	 	J	 	J	 	A	 	S	 	O	 	N	 	D
	 	 	 	 	[***]	 	 

	 	 	 	 	 
	Ceres, Inc.
Confidential	 	5/18/2006	 	Page 2

 

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

CERES-NOBLE
- Schedule 2 - Attachment A - RESEARCH AND DEVELOPMENT PLAN

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Project Planning	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	#	 	 	Yearly	 	 	 	 	 	 	 	 	 	 	 	 	 
	Template	 	 	 	Ex Start	 	 	Ex Finish	 	 	Loc	 	 	Personnel	 	 	# people	 	 	%	 	 	Months	 	 	FTE	 	 	2006	 	 	2007	 	 	2008	 	 	2009	 
	Goal	 	To
develop high yielding, [***]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Impact	 	Identify
parental [***] for use in [***] based production system to produce [***]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Action Item	 	Initiate and
manage sources nurseries (Summer, [***])
	 	 	3/15/06	 	 	 	9/30/06	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	 	 	 
	 	 	3/15/06	 	 	 	9/30/06	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	Action Item	 	Produce [***] among selected [***] (in greenhouse; limited capacity)
	 	 	10/1/06	 	 	 	3/1/07	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	 	 	 
	 	 	10/1/06	 	 	 	3/1/07	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	Action Item	 	Establish and harvest trials with [***] ([***])
	 	 	3/15/07	 	 	 	10/31/08	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	 	 	 
	 	 	3/15/07	 	 	 	10/31/08	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	Action Item	 	Identify
best parental [***] based on [***] performance and [***] ability (based
on biomass production).
	 	 	10/31/08	 	 	 	3/14/09	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	 	 	 
	 	 	10/31/08	 	 	 	3/14/09	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	Deliverable	 	[***]
parental [***] for use in producing [***] and estimates of their [***] abilities
	 	 	10/31/08	 	 	 	3/14/09	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Goal	 	To develop [***] system to [***]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Impact	 	Establish an tissue culture system to produce [***]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Action Item	 	Evaluate for
tissue culture [***] ability [***] identified as
parents for [***]
	 	 	10/31/06	 	 	 	10/31/08	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	 	 	 
	 	 	10/31/06	 	 	 	10/31/08	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	Action Item	 	Establish
and maintain small [***] seed increase based on best [***]
(establish nursery as proof-of-concept with [***] capacity)
	 	 	4/30/08	 	 	 	10/31/08	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	 	 	 
	 	 	4/30/08	 	 	 	10/31/08	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	Action Item	 	Evaluate seed production
	 	 	4/12/07	 	 	 	11/2/08	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	 	 	 
	 	 	4/12/07	 	 	 	11/2/08	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	Deliverable	 	[***]
parental [***] for use in producing [***] and establishment of a seed increase
plan based on tissue culture
	 	 	11/1/08	 	 	 	3/14/09	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 

	 	 	 	 	 
	Ceres, Inc.
Confidential	 	5/18/2006	 	Page 3

 

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

CERES-NOBLE
- Schedule 2 - Attachment A - RESEARCH AND DEVELOPMENT PLAN

[***]

	 	 	 	 	 
	Ceres, Inc.
Confidential	 	5/18/2006	 	Page 4

	 	 	 
	Confidential Treatment Requested and the Redacted Material has been separately filed with
the Commission.

 

 

Attachment B

PERFORMANCE EVALUATION PLAN

All of the following will apply unless otherwise decided by the MANAGEMENT COMMITTEE.

	 	•	 	The Performance Trial is a multi-location trial coordinated by the parties jointly or
by Ceres.
	 	•	 	Goal: to determine the biomass yield of [***]  experimental varieties compared to the standard
checks ‘NF/GA993’, [***], [***], and [***] (or other check varieties to be agreed) at multiple
locations throughout the southern USA and the Southern great plains region (or other
locations to be agreed).
	 	•	 	Prior to changing check variety NF/GA993 the MANAGEMENT COMMITTEE will agree on the
relative performance of the new standard check varieties to NF/GA993.
	 	•	 	The trial will be carried out over a three (3) year period.
	 	•	 	Individual locations or entries may be dropped during the evaluation period if such
locations have been severely damaged due to environmental conditions as agreed by the
MANAGEMENT COMMITTEE.
	 	•	 	No fewer than [***] representative locations shall be selected.
	 	•	 	Ceres or the parties shall be responsible for contracting with each site pursuant to
the terms and obligations of this Agreement.
	                                                       
	 	•	 	At each location, multiple entries will be planted as [***] plots. Plot size is [***] X [***]
with [***] (randomized complete block design).
	                                                        
	                                                       
	 	•	 	The core entries that will be evaluated at all test locations
are NF/GA993, [***] (commercially available),
[***] (commercially available) and [***] (commercially
available), and [***].
	                                                        
	 	•	 	In addition to the baseline evaluations reference above the MANAGEMENT COMMITTEE may
elect to include other entries in the Performance Trial for competitive or other purposes.
Planting of other entries may be at any or all locations depending on availability of
sees, or other factors.
	 	•	 	A seeding rate of [***] per acre pure live seed (PLS) or another planting rate or rates
to be agreed.
	 	•	 	Below is the NOBLE protocol, developed internally, that will apply to all test
locations for the establishment and management of these trials.

	 	1.	 	[***] as soon as possible (April).
	 	2.	 	Roller pack after [***].
	 	3.	 	Wait for rain or irrigate to germinate annual weeds (4-5 weeks).
	 	4.	 	After weeds, seed switchgrass [***] at [***] of [***].
	 	5.	 	Roller pack again if planter does not have heavy press wheels.
	 	6.	 	Immediately after planting, spray glyphosate within three (3) days to
kill existing weeds.
	 	7.	 	Take notes on seedling emergence (e.g., each week score plots from 1
to 5 with 1=no emergence and 5=excellent emergence). Promptly send such raw data
available to NOBLE for statistical analysis.

CERES-NOBLE Schedule 2

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

	 	8.	 	After the majority of the switchgrass plots reaches [***], then spray
[***] for broadleaf weed control and [***]
Atrazine for PRE weed control, do not apply crop
oil with Atrazine.
	 	9.	 	Fertilize with [***] lbs N per acre as complete fertilizer (P and K
amounts applied to soil test).
	 	10.	 	After switchgrass plants show good [***], apply [***] as needed.
	 	11.	 	Harvest (dry matter yield) in first year during September — October
period. Promptly send such raw data available to NOBLE for statistical analysis.
	 	12.	 	In the two subsequent years (2007 and 2008), the plan will be the
same from #8 onward with the following exceptions: mow off plants in April and
then apply [***] for broadleaf weed control and [***] Atrazine; apply [***] lbs of N
fertilizer per acre (April); harvest again in September-October period.

	 	•	 	Statistical analysis:

	 	1.	 	A statistical analysis of the biomass results will be carried out
using standard statistical analysis of variance procedures.
	 	2.	 	If the yield of [***] is not significantly different at the [***]
from NF/GA993 and the MANAGEMENT COMMITTEE elects to commercialize [***] the royalty
rate will be the same as for NF/GA993.
	 	3.	 	If the yield of [***] is significantly higher at the [***] than the
yield of NF/GA993 the percentage increase of [***] over NF/GA993 will be calculated and
the royalty rate will be determined using the formula in EXHIBIT C, ROYALTY RATE.

Examples:

	 	1.	 	The average biomass yield of NF/GA993 in the Performance Trial is [***] tons per acre.
[***] yields [***] tons per acre. The increase is statistically significant at the [***]. The
percentage increase in [***]%.
	 	2.	 	The average biomass yield of NF/GA993 in the Performance Trial is [***] tons per acre.
[***] yields [***] tons per acre. The increase is not statistically significant at the [***]. The
percentage increase in [***]%.
	 	3.	 	The average biomass yield of NF/GA993 in the Performance Trial is [***]  tons per acre.
[***] yields [***] tons per acre. The increase is statistically
significant at the [***]. The
percentage increase in [***]%.
	 	4.	 	NF/GA993 has been replaced with a new standard check variety. The MANAGEMENT COMMITTEE
has agreed the new standard check variety has a yield [***]% higher than NF/GA993. In this
Performance Trial the new standard check variety has an actual yield of [***] tons per
acre. [***] has a yield of [***] tons per acre. The increase is statistically significant
at the [***]. The percentage increase is [***]%.

	 	 	 	 	 
	 	 	Biomass	 	% increase
	Calculated NF/GA993 yield

	 	[***]	 	 
	

	Observed new check yield

	 	[***]
	 	[***]%
	

	Observed [***] yield

	 	[***]
	 	[***]%

CERES-NOBLE Schedule 2

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

	 	5.	 	NF/GA993 has been replaced with a new standard check variety. The MANAGEMENT COMMITTEE
has agreed the new standard check variety has a yield [***]% higher than NF/GA993. In this
Performance Trial the new standard check variety has an actual yield of [***] tons per
acre. [***] has a yield of [***] tons per acre. The increase is statistically significant
at the [***]. The percentage increase is [***]%.

	 	 	 	 	 
	 	 	Biomass	 	% increase
	Calculated NF/GA993 yield

	 	[***]	 	 
	

	Observed new check yield

	 	[***]
	 	[***]%
	

	Observed [***]yield

	 	[***]
	 	[***]%

	 	•	 	Reporting:

	 	1.	 	Reports and data will be generated for review by the MANAGEMENT
COMMITTEE:

	 	•	 	Annual reports summarizing the results of the Performance Trial
	 	•	 	Raw data generated during the performance of the trial annually
	 	•	 	On a quarterly basis the MANAGEMENT COMMITTEE will be updated on the status
of the trial.
	 	•	 	Samples of breeders seed will be provided to Ceres after the first year of
the trial.

COSTS AND EXPENSES

To be determined

CERES-NOBLE Schedule 2

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

Quarterly Report Format

Prepared by

Date

			
	 	 	 
	Confidential     Schedule # and name
	 	

1

 

Concept and Goals

	•	 	Concept

	•	 	Goals

			
	 	 	 
	Confidential     Schedule # and name
	 	

2

 

FTEs and Budget Projected vs. Actual

	•	 	People and activities

Dollars

FTEs

			
	 	 	 
	Confidential     Schedule # and name
	 	

3

 

Action Items and Deliverables for the Period

	 	 	 	 	 
	 	 	Expected	 	Actual
	Action Item or Deliverable	 	Finish	 	Finish
	 

	 	 	 	 

			
	 	 	 
	Confidential     Schedule # and name
	 	

4

 

Key Milestones or Deliverables for the Period

	•	 	Progress on Key Milestones and Deliverables
	 
	•	 	Are we on, ahead or behind schedule

			
	 	 	 
	Confidential     Schedule # and name
	 	

5

 

Technical Highlights

	•	 	1 or 2 slides covering technical highlights

			
	 	 	 
	Confidential     Schedule # and name
	 	

6

 

Results

	•	 	Several slides summarizing results (if applicable)

			
	 	 	 
	Confidential     Schedule # and name
	 	

7

 

Key Milestones and Deliverables Next 4 Quarters

	•	 	Quarter 1
	 
	•	 	Quarter 2
	 
	•	 	Quarter 3
	 
	•	 	Quarter 4

			
	 	 	 
	Confidential     Schedule # and name
	 	

8

 

Research Plan

	•	 	Goal

	 	—	 	Impact
	 
	 	—	 	Tasks
	 
	 	—	 	Milestones
	 
	 	—	 	Deliverables

	•	 	Duplicate this slide as needed to cover each goal for the next period

			
	 	 	 
	Confidential     Schedule # and name
	 	

9

 

Timeline Summary

	•	 	Assumptions and risk factors
	 
	•	 	Use additional slide if necessary
	 
	•	 	Use red if behind schedule until completed or otherwise resolved
	 
	•	 	Should be indicated in red as soon as the delay is identified
	 
	•	 	See issue resolution if behind schedule

			
	 	 	 
	Confidential     Schedule # and name
	 	

10

 

IP

	•	 	Filings during the period

	•	 	Applications in progress

			
	 	 	 
	Confidential     Schedule # and name
	 	

11

 

SOPs

	•	 	List SOPS for all Key processes

			
	 	 	 
	Confidential     Schedule # and name
	 	

12

 

Issue Resolution and Decision Making Slides

These can be used to address new issues or

implement corrective action or assist in decision

making such as variety release, etc.

			
	 	 	 
	Confidential     Schedule # and name
	 	

13

 

Issue Resolution and Decision Making

	•	 	Issue (e.g. milestone 3 behind schedule)

	 	 	Actual
	 
	•	 	What is happening

 

	 	 	Expected
	 
	•	 	What should be happening

			
	 	 	 
	Confidential     Schedule # and name
	 	

14

 

Issue Resolution and Decision Making

	•	 	Issue (e.g. milestone 3 behind schedule)
	 
	•	 	Possible alternative slide to address new issues

Needs

Wants

			
	 	 	 
	Confidential     Schedule # and name
	 	

15

 

Decision

	•	 	Summary of decision to be made

			
	 	 	 
	Confidential     Schedule # and name
	 	

16

 

Options

	•	 	Summary of options

			
	 	 	 
	Confidential     Schedule # and name
	 	

17

 

Recommendations

	•	 	What do we need to do to get back on track or address new issue

			
	 	 	 
	Confidential     Schedule # and name
	 	

18

 

Resources Required

			
	 	 	 
	Confidential     Schedule # and name
	 	

19

 

Plan and Schedule

	 	 	 	 	 	 	 	 	 
	Action Items	 	 	Who	 	 	When	 

			
	 	 	 
	Confidential     Schedule # and name
	 	

20

 

May 4, 2009

Via Electronic Mail

Cory Christenson, Ph.D.

Ceres, Inc.

1535 Rancho Conejo Blvd.

Thousand Oaks, California 91320

			
	     RE:	 	Developing Switchgrass Cultivars for Use in Bioenergy and Forage

Crop (Schedule 2) and Genomic Technologies to Enhance 
Switchgrass Breeding
(Schedule 3) to the Ceres-Noble Master Research 
Agreement (the “Agreement”)

Dear Cory:

     Per our collective discussions, Ceres and Noble hereby agree to extend the terms of Schedules
2 and 3 of the Agreement. Upon execution of this letter agreement, Schedules 2 and 3 shall each
have a termination date of November 15, 2009, or any earlier date which may be mutually agreed upon
by the Parties in writing. All other terms of the schedules, including respective project
objectives, will remain unchanged and binding. This is a no-cost extension.

     This amendment of Schedules 2 and 3 shall be deemed retroactive to May 1, 2009, and no lapse
of either schedule is intended by the parties.

     This amendment is consistent with the requirements of Paragraph 16.1 of the Agreement.

     Please acknowledge Ceres’ acceptance of this extension of Schedules 2 and 3 through the
signature of an authorized representative of Ceres and returning a copy of the signed document to
my attention by mail, email or by facsimile.

     If you have any questions, please contact me. Thank you for your assistance in this matter.

Sincerely,

/s/ Steven Rhines

Steven P. Rhines

Vice President, General Counsel

     Acknowledged and agreed:

	 	 	 	 	 

	 

	 	/s/ Anna Rath	 	 
	 

	 	 	 	 
	 

	 	Name: Anna Rath
	 	Date: 5/12/09
	 

	 	Title: Vice President of Commercial Development	 	 

The Samuel Roberts Noble Foundation, Inc.

2510 Sam Noble Parkway • Ardmore, Oklahoma 73401

www.noble.org • 580.223.5810

 

Pages where confidential treatment has been requested are stamped ‘Confidential Treatment
Requested and the Redacted Material has been separately filed with
the Commission,’ and the confidential section has been marked as follows: [***].

SCHEDULE 3

THIS SCHEDULE is made this 19th day of May, 2006;

	 	 	 

	BETWEEN

	 	CERES, INC., a Delaware corporation, having its
principal place of business at 1535 Rancho
Conejo Blvd., Thousand Oaks, CA 91320 (“CERES”)
and
	 
	 	 
	 

	 	THE SAMUEL ROBERTS NOBLE FOUNDATION
INCORPORATED, an Oklahoma non-profit
corporation, having its principal place of
business at 2510 Sam Noble Parkway, Ardmore,
Oklahoma 73401 (“NOBLE”);

WHEREAS, CERES and NOBLE have entered into a Master Research Agreement (“MRA”), dated 19 May 2006,
which allows for the undertaking of RESEARCH PROJECTS pursuant to SCHEDULES, these terms being
defined in the MRA; and

THEREFORE, the parties have agreed to undertake the following RESEARCH PROJECT as defined herein on
the following terms and conditions:

GENERAL

	A.	 	Unless otherwise specified herein, the terms of the MRA shall apply to this SCHEDULE.
	 
	B.	 	In the event of any difference between the terms of this SCHEDULE and the MRA, then the terms
of this SCHEDULE shall prevail.

RESEARCH PROJECT TITLE: Genomic Technologies to Enhance Switchgrass Breeding

	1.	 	BACKGROUND:

	 	 	Switchgrass (Panicum virgatum L.) is a perennial grass with a high potential for biomass
production with estimated ethanol yields between [***] and [***] ha-1. It is a
heteromorphic cross-pollinated species with a high degree of
self-incompatibility. Switchgrass has not
received much attention in genetic research, despite its agricultural, bioenergetic, and
environmental attributes. Development and application of molecular tools will help to improve
yields, facilitate conversion of biomass into biofuel, enable synthesis of valuable
co-products or alter feedstock quality. Besides, analysis of [***] and associated [***] will
facilitate [***] approaches to efficiently exploit
beneficial gene [***] in breeding programs.
	 
	 	 	Molecular [***] are powerful tools for genetic
mapping, [***], population structure and genetic diversity studies. [***] have become the [***] class of
choice because they are mostly co-dominant, abundant in genomes, highly reproducible, and some
have high rates of transferability across species (Thiel et al. 2003; Saha et al. 2004).
Regular use of molecular [***] for breeding and other applied research in a plant species depends on
development of a large number of [***] for the species of
interest. A very limited number of molecular [***] is currently available for switchgrass.
	 
	 	 	In addition to the 11,990 switchgrass EST sequences reported by Tobias et al. (2005), to
date, Ceres has completed over [***] sequences. In total Ceres will
sequence [***]. [***] from selected
clusters will be further sequenced and [***] that are
particularly important will be fully sequenced.

			
	 	 	 
	CERES-NOBLE Schedule 3
	 	Page 1 of 7

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

 

	 	 	Ceres will develop a [***] using public and
proprietary sequences from switchgrass, maize, wheat, rice, barley
and other grasses. [***]
developed will include [***].

	 	 	Consensus sequences of [***] were derived
from an assembly of [***] wheat, rice, maize, sorghum, and
barley genes (Yu et al, 2004). A set of [***] developed
from these sequences was found highly transferable across grass
species.
These have a high potential for [***]. We will seek to identify additional highly conserved
[***] sequences. In total we plan to develop
[***] for several [***] genes that are involved in [***],
[***], N and [***] and
utilization, [***], [***], and other
important traits. A Candidate gene-based map
will facilitate the study of close association between
genes and [***] controlling traits of
interest.
	 
	 	 	Genetic linkage maps denote the linear order of [***] on
a particular chromosome. [***] based genetic linkage maps have
been developed for most of the agriculturally important crops. These
maps are exploited to
identify, tag and locate genes and [***] for
important traits to facilitate the breeding
process. In spite of its tremendous importance as an alternative
fuel, no genetic linkage map has been developed for switchgrass
to date.
	 
	 	 	Because of self incompatibility, polyploidy,
heterozygosity and heterogeneity, [***] will be important for
determining the genetic behavior of switchgrass genes and chromosomes. In addition, the [***] will be used to evaluate the
genetic diversity of switchgrass and aid in the identification of [***].
	 
	 	 	In addition to proprietary [***] mapping populations the publicly
available UGA mapping population will be used to create a
framework map using public [***].

	2.	 	PROPOSAL OBJECTIVES:

	 	2.1	 	To generate a comprehensive molecular [***] system for switchgrass.
	 
	 	2.2	 	To conduct genetic diversity analysis and select [***].
	 
	 	2.3	 	To construct genetic linkage maps with high [***].
	 
	 	2.4	 	To conduct [***] with other important
[***] species.
	 
	 	2.5	 	To tag important traits and [***].
	 
	 	2.6	 	Identify molecular [***] closely associated with
different traits.

	3.	 	WORK TO BE UNDERTAKEN:
	 
	 	 	See RESEARCH AND DEVELOPMENT PLAN (Attachment A to this SCHEDULE).

	4.	 	DETAILED WORKPLAN:
	 
	 	 	The RESEARCH AND DEVELOPMENT PLAN (Attachment A to this SCHEDULE) contains:

	 	•	 	Research and evaluation activities to be performed by each party in
detail, including locations for such activities
	 
	 	•	 	Timelines of such activities
	 
	 	•	 	Goals, expected results and deliverables

			
	 	 	 
	CERES-NOBLE Schedule 3
	 	Page 2 of 7

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

 

	 	•	 	Milestones and go/no-go decision points, if applicable
	 
	 	•	 	FTEs

	5.	 	LOCATION OF WORK:
	 
	 	 	NOBLE Work:
	 
	 	 	All NOBLE laboratory and greenhouse facilities and properties at its Ardmore location are
available for this project.
	 
	 	 	CERES Work:
	 
	 	 	Thousand Oaks, CA.

	6.	 	PHD LEVEL SCIENTIFIC STAFF:

	 	 	Dr. Malay Saha (NOBLE)
	 
	 	 	Dr. Joe Bouton (NOBLE)
	 
	 	 	Post Doc TBD (CNF, wherein “CNF” indicates a CERES-funded, NOBLE employee)
	 
	 	 	Dr. Peter Mascia (CERES)
	 
	 	 	Dr. Steve Thomas (CERES)
	 
	 	 	Dr. Richard Flavell (CERES)

	7.	 	MAJOR CONSUMABLES/LIVESTOCK TO BE PURCHASED:

	 	 	None.

	8.	 	REPORTS:

	 	 	All reports shall be delivered to the MANAGEMENT COMMITTEE on or before the required
delivery dates for the same.
	 
	 	 	NOBLE will deliver at each quarterly MANAGEMENT COMMITTEE meeting (or annual meeting, as the
case may be):

	 	•	 	Annual Report (compilation of slide presentations and quarterly
minutes) (annual meeting).
	 
	 	•	 	Quarterly status update and FTE breakout based on attached planning
document.
	 
	 	•	 	Actual spending relative to budget.
	 
	 	•	 	INTELLECTUAL PROPERTY generated during the period.
	 
	 	•	 	Copies of slide presentations summarizing research progress (template
attached as Attachment B to this SCHEDULE).
	 
	 	•	 	Information on the phenotype of parental lines and each line involved
in mapping and [***] populations. Phenotype information to be collected including:

	 	-	 	Pest problems
	 
	 	-	 	General plant appearance (e.g., tall or short, spreading or upright, etc.)

	 
	 	-	 	Data related to the target traits
	 
	 	-	 	[***]
	 
	 	-	 	[***] and [***]
	 
	 	-	 	Seed yield
	 
	 	-	 	Emergence and seedling [***]
	 
	 	-	 	Biomass dry matter yield (if specified in plan), including
components of yield such as
[***] and [***]

			
	 	 	 
	CERES-NOBLE Schedule 3
	 	Page 3 of 7

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

 

	 	 	Additional information, if not specifically included in the delivered information (above),
shall be delivered (or later provided, wherein the delivering party shall indicate the
delivery method and time) as supporting information at the related quarterly meeting, if
available:
	 
	 	 	NOBLE will deliver:

	 	•	 	Copies of field or greenhouse books and records
	 
	 	•	 	Copies of raw field trial data
	 
	 	•	 	Raw [***] and plant data
	 
	 	•	 	[***], dry tissue, [***] from mapping populations
	 
	 	•	 	[***], dry tissue, [***] from [***] populations

	 	 	CERES will deliver:

	 	•	 	[***] related sequence information
	 
	 	•	 	[***] information

	9.	 	COMMENCEMENT/TERMINATION:
	 
	 	 	Commencement: 19 May 2006
	 
	 	 	Termination: 30 April 2009

	10.	 	REPORT PREPARATION:
	 
	 	 	Dr Malay Saha (Noble)
	 
	                                                       
	 	 	Dr Peter Mascia (Ceres)
	                                                        

	11.	 	REPORT DATES:
	 
	 	 	Annual report: Due at annual meeting in March.
	 
	 	 	Quarterly reports and information: Due at quarterly meetings of the MANAGEMENT
COMMITTEE per the MRA (e.g., March, June, September, December).

	12.	 	ASSETS:
	 
	 	 	Not applicable.
	 
	13.	 	INSURANCE:
	 
	 	 	Not applicable.
	 
	14.	 	CONTRIBUTION TO JOINT INTELLECTUAL PROPERTY:
	 
	 	 	Controlled by MRA.
	 
	15.	 	SPECIAL CONDITIONS:

			
	 	 	 
	CERES-NOBLE Schedule 3
	 	Page 4 of 7

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

 

	 	 	Not applicable.
	 
	16.	 	INTELLECTUAL PROPERTY RIGHTS:

	 	16.1	 	NOBLE Background Intellectual Property:

	 	•	 	mapping populations (parents and approximately
[***])
	                                                        

	                                                       
	 	16.2	 	CERES Background Intellectual Property:
	                                                        

	 	•	 	Sequences from switchgrass and other species
	 
	 	•	 	Gene trait association information
	 
	 	•	 	Patent applications covering any of the foregoing

	17.	 	SUBCONTRACTORS AND LOCATIONS:
	 
	 	 	Not applicable.
	 
	18.	 	PROVISIONS FOR EARLY TERMINATION:
	 
	 	 	This SCHEDULE does not terminate automatically upon termination of the MRA.
	 
	 	 	This SCHEDULE shall expire pursuant to the terms set forth in this SCHEDULE, unless extended
by the mutual agreement of the parties, or unless sooner terminated in accordance with the
following provisions of this Paragraph:

     (a) mutual, written agreement of the parties;

     (b) failure of one party to satisfy its material obligations under this
Agreement, and such party subsequently fails to cure such failure(s) within (i)
thirty (30) days for failures to remit payment for amounts due under this Agreement
and (ii) ninety (90) days for all other obligations in each case after receipt of
written notice from the non-breaching party specifying such failure(s);

     (c) one (1) year’s written notice of termination by either CERES or NOBLE to
the other party in case either the terminating party or the other party ceases
substantially all activities in the COLLABORATION CROPS;

     (d) NOBLE will have the right to terminate this Agreement unilaterally with
thirty (30) days’ written notice to CERES, (i) if CERES seeks protection under any
bankruptcy, insolvency, receivership, trust, deed, creditors arrangement or
comparable proceeding or if any such proceeding is instituted against CERES (and not
dismissed within one hundred twenty (120) days); (ii) in case of dissolution or
winding up of CERES (excluding any situation where all or substantially all of
CERES’ assets, stock or business to which this Agreement relates are acquired by a
third party (whether by sale, acquisition, merger, operation of law or otherwise));
(iii) with written notice to CERES, to be given no
later than March 31, 2010 if CERES has failed in a substantial manner, by

			
	 	 	 
	CERES-NOBLE Schedule 3
	 	Page 5 of 7

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

 

December 31, 2009, to implement the activities set forth in EXHIBIT F, and does not
remedy such failure or offer a remediation plan which is reasonably acceptable to
NOBLE within ninety (90) days after receipt of a written notice from NOBLE
specifying such failure; or (iv) with one hundred twenty (120) days’ written notice
to CERES, if the institutional mission, purpose or structure of NOBLE would change
substantially and adversely affect NOBLE’S ability to satisfy its obligations
hereunder; or

     (e) CERES will have the right to terminate this Agreement unilaterally: (i)
with thirty (30) days’ written notice to NOBLE if Dr. Joe
Bouton ceases to be
associated with NOBLE and the research activities associated with this SCHEDULE, and
NOBLE has not replaced him within one hundred twenty (120) days by a person
reasonably acceptable to CERES; (ii) with ninety (90) days’ written notice to NOBLE,
if the institutional mission, purpose or structure of NOBLE would change
substantially; or (iii) with one (1) years’ written notice to NOBLE, if CERES has
compelling business reasons to cease the collaboration.

	19.	 	USE AND COMMERCIALIZATION RIGHTS:
	 
	 	 	Controlled by MRA.
	 
	20.	 	CONFIDENTIALITY/PUBLICATION:
	 
	 	 	Controlled by MRA.
	 
	21.	 	FUNDING APPROVED:

Projected Budget (per year from CERES):

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Year 2	 	Year 3	 	 
	 	 	Year 1	 	Salaries	 	Salaries	 	 
	 	 	Salaries	 	incl.	 	incl.	 	 
	Personnel	 	incl. fringe	 	fringe	 	fringe	 	Subtotals
	Postdoctoral + Fringe Benefits
	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 
	Travel
	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 
	Supplies
	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Total Direct Costs
	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Indirect ( 50% of Direct)
	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 
	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	TOTAL
	Total
	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 

Billing Schedule: Invoices will be sent by NOBLE to CERES for actual expenses from the
previous period on the 15th of the first month of each calendar quarter, not to exceed
the amounts specified above.

			
	 	 	 
	CERES-NOBLE Schedule 3
	 	Page 6 of 7

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

 

IN WITNESS THEREOF this SCHEDULE has been executed on the date hereinbefore entered.

CERES, INC.

	 	 	 

	/s/ Richard Flavell
 
 By:
Richard Flavell, CBE, FRS

	 	May 19th 2006
 
 Date
	        Chief Scientific Officer
	 	 
	 
	 	 
	/s/ Richard Hamilton
 
 By:
Richard Hamilton

	 	May 19, 2006
 
 Date
	        President and Chief Executive Officer
	 	 
	 
	 	 
	THE SAMUEL ROBERTS NOBLE FOUNDATION, INC.
	 	 
	 
	 	 
	/s/ Michael A. Cawley
 
 By:
Michael A. Cawley

	 	19 MAY 2006
 
 Date
	        President
	 	 

			
	 	 	 
	CERES-NOBLE Schedule 3
	 	Page 7 of 7

 

 

CERES-NOBLE Schedule 3 — Attachment A — RESEARCH AND DEVELOPMENT PLAN

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

	Ceres FTE sum
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	CNF FTE Sum
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	NF FTE sum
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Project	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Planning	 	 	 	Expected	 	Expected	 	 	 	 	 	#	 	%	 	#	 	Yearly	 	 	 	 	 	 	 	 
	Template	 	 	 	Start	 	Finish	 	Location	 	Personnel	 	People	 	Effort	 	Months	 	FTE	 	2006	 	2007	 	2008	 	2009
	 
	Objective
	 	Discover the nature and locations of [***] in
selected switchgrass genes, develop the means of
[***] the [***] efficiently and thereby increase
the efficiency of a breeding program for
improvements in yield and [***]

	 	10/15/05
	 	10/15/07	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Product Concept
	 	Identification of switchgrass [***] and breeding
[***] for use in development of enhanced
switchgrass
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Business Plan
	 	Initiate project in anticipation of collaboration
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Management FTE

	 	4/1/06
	 	12/31/09
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 

	 	4/1/06
	 	12/31/09
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 
	Goal 1
	 	Develop switchgrass [***] using [***] of tissues
and conditions
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Impact
	 	Development of switchgrass [***] with a large
representation of [***]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Action Item
	 	Isolate tissue for [***] from tissues of [***]

	 	8/15/05
	 	6/1/06
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Action Item
	 	[***], [***] prep, [***] plating and
management

	 	9/1/05
	 	7/1/06
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Deliverable
	 	Initial
switchgrass [***] available for sequencing

	 	 	 	12/1/05	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Deliverable
	 	Switchgrass [***] construction complete (all
[***] including [***])

	 	 	 	7/1/06	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	Goal 2
	 	Phase
1 [***] Sequencing to identify novel and [***]
switchgrass [***]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Impact
	 	Identification representation and isolation of
[***] in [***]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Action Item
	 	Picking of switchgrass [***]

	 	11/1/05
	 	12/1/06
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Action Item
	 	Sequencing of [***] to [***]

	 	11/1/05
	 	7/1/07
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Action Item
	 	BLAST and clustering of switchgrass [***]

	 	12/1/05
	 	8/1/07
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Deliverable
	 	[***] reads analyzed

	 	 	 	8/10/07	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	Goal 3
	 	Phase
2 Sequencing of [***] switchgrass [***]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Impact
	 	Confirmation of [***] identified and additional
[***] read for determination of [***] quality
and novelty
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Action Item
	 	Rearray of [***] phase 2 [***]

	 	2/14/06
	 	11/1/06
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Action Item
	 	Phase
2 Sequencing of [***]

	 	2/21/06
	 	12/20/06
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Action Item
	 	Assembly and clustering of [***]

	 	6/1/06
	 	1/20/07
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Deliverable
	 	[***] phase 2 reads analyzed

	 	 	 	2/14/07
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]

					
	 	 	 	 	 
	Ceres, Inc. Confidential
	 	5/18/2006
	 	Page 1

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

 

CERES-NOBLE — Schedule 3 — Attachment A — RESEARCH AND DEVELOPMENT PLAN

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	2006

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	2007	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	2008	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	2009	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	
J
 

	 	 	F
	 	 	M
	 	 	A
	 	 	M
	 	 	J
	 	 	J
	 	 	A
	 	 	S
	 	 	O
	 	 	N
	 	 	D
	 	 	 	J	 	 	 	F
	 	 	M
	 	 	A
	 	 	M
	 	 	J
	 	 	J
	 	 	A
	 	 	S
	 	 	O
	 	 	N
	 	 	D
	 	 	 	J	 	 	 	F
	 	 	M
	 	 	A
	 	 	M
	 	 	J
	 	 	J
	 	 	A
	 	 	S
	 	 	O
	 	 	N
	 	 	D
	 	 	 	J	 	 	 	F
	 	 	M
	 	 	A
	 	 	M
	 	 	J
	 	 	J
	 	 	A
	 	 	S
	 	 	O
	 	 	N
	 	 	D	 
	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 

[***]

	 				
	Ceres, Inc. Confidential
	 	5/18/2006
	 	Page 2

	 	 	 
	Confidential Treatment Requested and the Redacted Material has been separately filed with
the Commission.

 

CERES-NOBLE Schedule 3 — Attachment A — RESEARCH AND DEVELOPMENT PLAN

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Project	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Planning	 	 	 	Expected	 	Expected	 	 	 	 	 	#	 	%	 	#	 	Yearly	 	 	 	 	 	 	 	 
	Template	 	 	 	Start	 	Finish	 	Location	 	Personnel	 	People	 	Effort	 	Months	 	FTE	 	2006	 	2007	 	2008	 	2009
	 
	Goal 4
	 	Generate [***] and compare to other [***]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Impact
	 	Identification
of [***] in selected genes

	 	 	 	4/1/06
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Action Item
	 	Rearray of [***] selected switchgrass [***] (possibly
include selection list here)

	 	7/1/06
	 	7/14/06
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Action Item
	 	[***]
determination and [***] for [***] sequencing
	 	7/1/06
	 	8/1/06
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Action Item
	 	Genomic
[***] isolation from multiple ([***]) populations isolates
(Discussion about what [***] to be done)

	 	5/1/06
	 	8/1/06
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Action Item
	 	[***]
from [***] and sequencing of positive [***]

	 	8/1/06
	 	12/1/06
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Action Item
	 	Evaluation
of [***] sequence and identification of [***]

	 	9/1/06
	 	12/10/06
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Deliverable
	 	[***]
for [***] high priority switchgrass genes identified

	 	 	 	12/20/06	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	Goal 5
	 	Develop [***] assays
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Impact
	 	Low cost [***] system for routine [***] work
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Action Item
	 	consider relevant options for low cost [***] system and
make decision

	 	1/1/06
	 	6/1/06
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Action Item
	 	develop [***] assays

	 	6/1/06
	 	3/31/07
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Action Item
	 	implement [***] system

	 	9/1/06
	 	5/31/07
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Deliverable
	 	[***] assays

	 	 	 	6/30/07	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	Goal 6
	 	Develop
switchgrass map
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Impact
	 	Having
a proprietary high [***] map will allow rapid breeding
progress
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Action Item
	 	Identify
parents, develop a useful mapping population of at least
[***] progeny

	 	1/1/07
	 	3/31/07
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 

	 	1/1/07
	 	3/31/07
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Action Item
	 	Screening
of parents and a [***] of mapping population with developed
[***]

	 	4/1/07
	 	5/31/07
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 

	 	 	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Action Item
	 	 

	 	4/1/07
	 	12/31/09
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 

	 	 	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Action Item
	 	Isolate [***] from each [***] that will be used in the
mapping program

	 	5/1/07
	 	5/31/07
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 

	 	 	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Action Item
	 	[***]
mapping population with selected [***], resolve conflicts, store data

	 	5/1/07
	 	9/30/07
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 

	 	 	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Action Item
	 	Make
map

	 	8/1/07
	 	9/30/07
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 

	 	 	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Deliverable
	 	High
density, unambiguous [***] map with [***] to [***]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	Goal 7
	 	[***] identification
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Impact
	 	trait/[***] associations will be used to accelerate breeding
for the selected traits, identify [***] associated with
traits
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Action Item
	 	select
populations with relevant phenotypic and [***]. These may
incluse those used to develop the map and others being
used in the breeding program.

	 	6/1/07
	 	7/31/07
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Action Item
	 	Develop sufficient [***] material to run [***] trials on
the relevant traits.

	 	7/1/07
	 	9/1/07
	 	[***]

[***]
	 	[***]

[***]
	 	[***]

[***]
	 	[***]

[***]
	 	[***]

[***]
	 	[***]

[***]
	 	[***]

[***]
	 	[***]

[***]
	 	[***]

[***]
	 	[***]

[***]
	 	 	 

	 	7/1/07
	 	9/1/07
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Action Item
	 	Set up [***] trials

	 	10/1/07
	 	11/30/07
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 

	 	10/1/07
	 	11/30/07
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Action Item
	 	evaluate [***] in greenhouse and field trials

	 	10/1/07
	 	10/31/08
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 

	 	10/1/07
	 	10/31/08
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]

					
	 	 	 	 	 
	Ceres, Inc. Confidential
	 	5/18/2006
	 	Page 3

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

 

CERES-NOBLE — Schedule 3 — Attachment A — RESEARCH AND DEVELOPMENT PLAN

[***]

					
	 	 	 	 	 
	Ceres, Inc. Confidential
	 	5/18/2006
	 	Page 4

	 	 	 
	Confidential Treatment Requested and the Redacted Material has been separately filed with
the Commission.

 

 

CERES-NOBLE Schedule 3 — Attachment A — RESEARCH AND DEVELOPMENT PLAN

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Project	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Planning	 	 	 	Expected	 	Expected	 	 	 	 	 	#	 	%	 	#	 	Yearly	 	 	 	 	 	 	 	 
	Template	 	 	 	Start	 	Finish	 	Location	 	Personnel	 	People	 	Effort	 	Months	 	FTE	 	2006	 	2007	 	2008	 	2009
	 
	Action Item
	 	determine
linkage between traits and [***]

	 	7/1/07
	 	12/31/08
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 

	 	7/1/07
	 	12/31/08
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Deliverable
	 	Association
of [***] with traits of interest
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	Goal 8
	 	Genetic
diversity analysis
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Impact
	 	Understanding of the relationships among [***] and [***]
of switchgrass will allow better selection of parents for
breeding [***] and developing [***]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Action Item
	 	Search literature and database, find switchgrass [***],
develop [***] and [***]

	 	6/1/06
	 	7/31/06
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 

	 	6/1/06
	 	7/31/06
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Action Item
	 	obtain [***] and [***] collection. Collect new
appropriate [***] as needed

	 	6/1/06
	 	7/31/06
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 

	 	 	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Action Item
	 	run [***] panel against each isolate

	 	8/1/06
	 	10/31/06
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 

	 	 	 	 	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Action Item
	 	cluster analysis and development of [***]

	 	11/1/06
	 	12/31/06
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	 	 

	 	11/1/06
	 	12/31/06
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Deliverable
	 	Detailed [***] of switchgrass [***]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	Goal 9
	 	Evaluate up to [***] in [***]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Impact
	 	Identify
[***] traits as well as identify [***] function of [***]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Action Item
	 	Rearray up to [***]

	 	6/1/06
	 	10/1/06
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Action Item
	 	[***] up to [***] from switchgrass and other species into
[***] using [***]

	 	7/1/06
	 	4/1/07
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Action Item
	 	Generate [***] for up to [***]

	 	7/1/06
	 	4/1/07
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Action Item
	 	Sequence verification of up to [***] in [***]

	 	7/1/06
	 	4/1/07
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Action Item
	 	Transformation of up to [***] into [***]

	 	7/1/06
	 	4/1/07
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Action Item
	 	Transform
selected number of [***] into rice and
switchgrass

	 	7/1/06
	 	4/1/07
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Action Item
	 	Planting, maintenance and seed collection of [***]

	 	8/1/06
	 	5/1/07
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Action Item
	 	Phenotyping and screening of plant [***]

	 	1/1/07
	 	6/1/07
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Deliverable
	 	[***] screened [***] containing [***]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	Goal 10
	 	Switchgrass microarrays
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Impact
	 	Identify [***] and the relationship of results achieved
in [***], maize and rice to switchgrass to accelerate
breeding and [***] enhancement
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Action Item
	 	Design arrays

	 	7/1/06
	 	10/1/06
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Action Item
	 	Design [***] experiments

	 	9/1/06
	 	6/1/07
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Action Item
	 	Evaluate [***] results

	 	11/1/06
	 	9/1/07
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Action Item
	 	Ongoing [***] experiments and analysis

	 	6/1/07
	 	12/31/08
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Action Item
	 	Computational
analysis of [***] and developmental [***]

	 	6/1/06
	 	12/31/08
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	Deliverable
	 	Detailed transcript analysis under multiple conditions
linked to results from other species allowing discovery
of novel developmental and [***]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

					
	 	 	 	 	 
	Ceres, Inc. Confidential
	 	5/18/2006
	 	Page 5

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

 

CERES-NOBLE — Schedule 3 — Attachment A — RESEARCH AND DEVELOPMENT PLAN

[***]

					
	 	 	 	 	 
	Ceres, Inc. Confidential
	 	5/18/2006
	 	Page 6

	 	 	 
	Confidential Treatment Requested and the Redacted Material has been separately filed with
the Commission.

 

 

Quarterly Report Format

Prepared by

Date

			
	 	 	 
	Confidential     Schedule # and name
	 	

1

 

Concept and Goals

	•	 	Concept

	•	 	Goals

			
	 	 	 
	Confidential     Schedule # and name
	 	

2

 

FTEs and Budget Projected vs. Actual

	•	 	People and activities

Dollars

FTEs

			
	 	 	 
	Confidential     Schedule # and name
	 	

3

 

Action Items and Deliverables for the Period

	 	 	 	 	 	 	 	 	 
	 	 	 	 	Expected	 	 	Actual	 
	Action Item or Deliverable	 	 	Finish	 	 	Finish	 

			
	 	 	 
	Confidential     Schedule # and name
	 	

4

 

Key Milestones or Deliverables for the Period

	 	•	 	Progress on Key Milestones and Deliverables
	 
	 	•	 	Are we on, ahead or behind schedule

			
	 	 	 
	Confidential     Schedule # and name
	 	

5

 

Technical Highlights

	•	 	1 or 2 slides covering technical highlights

			
	 	 	 
	Confidential     Schedule # and name
	 	

6

 

Results

	•	 	Several slides summarizing results (if applicable)

			
	 	 	 
	Confidential     Schedule # and name
	 	

7

 

Key Milestones and Deliverables Next 4 Quarters

	•	 	Quarter 1
	 
	•	 	Quarter 2
	 
	•	 	Quarter 3
	 
	•	 	Quarter 4

			
	 	 	 
	Confidential     Schedule # and name
	 	

8

 

Research Plan

	•	 	Goal

	 	—	 	Impact
	 
	 	—	 	Tasks
	 
	 	—	 	Milestones
	 
	 	—	 	Deliverables

	•	 	Duplicate this slide as needed to cover each goal for the next period

			
	 	 	 
	Confidential     Schedule # and name
	 	

9

 

Timeline Summary

	•	 	Assumptions and risk factors
	 
	•	 	Use additional slide if necessary
	 
	•	 	Use red if behind schedule until completed or otherwise resolved
	 
	•	 	Should be indicated in red as soon as the delay is identified
	 
	•	 	See issue resolution if behind schedule

			
	 	 	 
	Confidential     Schedule # and name
	 	

10

 

IP

	•	 	Filings during the period

	•	 	Applications in progress

			
	 	 	 
	Confidential     Schedule # and name
	 	

11

 

SOPs

	•	 	List SOPS for all Key processes

			
	 	 	 
	Confidential     Schedule # and name
	 	

12

 

Issue Resolution and Decision Making Slides

These can be used to address new issues or

implement corrective action or assist in decision

making such as variety release, etc.

			
	 	 	 
	Confidential     Schedule # and name
	 	

13

 

Issue Resolution and Decision Making

	•	 	Issue (e.g. milestone 3 behind schedule)

	 	 	Actual
	 
	•	 	What is happening

 

	 	 	Expected
	 
	•	 	What should be happening

			
	 	 	 
	Confidential     Schedule # and name
	 	

14

 

Issue Resolution and Decision Making

	•	 	Issue (e.g. milestone 3 behind schedule)
	 
	•	 	Possible alternative slide to address new issues

Needs

Wants

			
	 	 	 
	Confidential     Schedule # and name
	 	

15

 

Decision

	•	 	Summary of decision to be made

			
	 	 	 
	Confidential     Schedule # and name
	 	

16

 

Options

	•	 	Summary of options

			
	 	 	 
	Confidential     Schedule # and name
	 	

17

 

Recommendations

	•	 	What do we need to do to get back on track or address new issue

			
	 	 	 
	Confidential     Schedule # and name
	 	

18

 

Resources Required

			
	 	 	 
	Confidential     Schedule # and name
	 	

19

 

Plan and Schedule

	 	 	 	 	 	 	 	 	 
	Action Items	 	 	Who	 	 	When	 

			
	 	 	 
	Confidential     Schedule # and name
	 	

20

 

May 11, 2009

Via Electronic Mail

Cory Christenson, Ph.D.

Ceres, Inc.

1535 Rancho Conejo Blvd.

Thousand Oaks, California 91320

			
	     RE:	 	Developing Switchgrass Cultivars for Use in Bioenergy and Forage

Crop (Schedule 2) and Genomic Technologies to Enhance 
Switchgrass Breeding
(Schedule 3) to the Ceres-Noble Master Research 
Agreement (the “Agreement”)

Dear Cory:

     Per our collective discussions, Ceres and Noble hereby agree to extend the terms of Schedules
2 and 3 of the Agreement. Upon execution of this letter agreement, Schedules 2 and 3 shall each
have a termination date of November 15, 2009, or any earlier date which may be mutually agreed upon
by the Parties in writing. All other terms of the schedules, including respective project
objectives, will remain unchanged and binding. This is a no-cost extension.

     This amendment of Schedules 2 and 3 shall be deemed retroactive to May 1, 2009, and no lapse
of either schedule is intended by the parties.

     This amendment is consistent with the requirements of Paragraph 16.1 of the Agreement.

     Please acknowledge Ceres’ acceptance of this extension of Schedules 2 and 3 through the
signature of an authorized representative of Ceres and returning a copy of the signed document to
my attention by mail, email or by facsimile.

     If you have any questions, please contact me. Thank you for your assistance in this matter.

Sincerely,

/s/ Steven Rhines

Steven P. Rhines

Vice President, General Counsel

     Acknowledged and agreed:

	 	 	 	 	 

	 

	 	/s/ Anna Rath	 	 
	 

	 	 	 	 
	 

	 	Name: Anna Rath
	 	Date: 5/12/09
	 

	 	Title: Vice President of Commercial Development	 	 

The Samuel Roberts Noble Foundation, Inc.

2510 Sam Noble Parkway • Ardmore, Oklahoma 73401

www.noble.org • 580.223.5810

 

Pages where confidential treatment has been requested are stamped ‘Confidential Treatment
Requested and the Redacted Material has been separately filed with
the Commission,’ and the confidential section has been marked as follows: [***].

SCHEDULE 4

THIS REVISED SCHEDULE is made this 10th day of March, 2007.

	 	 	 

	BETWEEN

	 	CERES, INC., a Delaware corporation, having
its principal place of business at 1535
Rancho Conejo Blvd., Thousand Oaks, CA
91320 (“CERES”) and
	 
	 	 
	 

	 	THE SAMUEL ROBERTS NOBLE FOUNDATION
INCORPORATED, an Oklahoma non-profit
corporation, having its principal place of
business at 2510 Sam Noble Parkway,
Ardmore, Oklahoma 73401 (“NOBLE”);

WHEREAS, CERES and NOBLE have entered into a Master Research Agreement (“MRA”), dated 19 May 2006,
which allows for the undertaking of RESEARCH PROJECTS pursuant to SCHEDULES, these terms being
defined in the MRA; and

WHEREAS, CERES and NOBLE entered into an original Schedule 1 to the MRA, dated 19 May 2006, and the
parties hereby seek to replace the terms and conditions of such schedule, in its entirety, with
this revised SCHEDULE effective as of the date shown above; and

THEREFORE, the parties have agreed to undertake the following RESEARCH PROJECT as defined herein on
the following terms and conditions:

GENERAL

	A.	 	Unless otherwise specified herein, the terms of the MRA shall apply to this SCHEDULE.
	 
	B.	 	In the event of any difference between the terms of this SCHEDULE and the MRA, then the terms
of this SCHEDULE shall prevail.

RESEARCH PROJECT TITLE: Production-scale agronomics and economics of switchgrass for bioenergy in
the southern Great Plains

	1.	 	BACKGROUND:
	 
	 	 	Limited information is available on agronomic management and production economics of
switchgrass for bioenergy purposes in the southern Great Plains. NOBLE has initiated
research to improve the genetics of switchgrass to produce greater biomass yields and
research to identify management practices that allow for better stand establishment.
Research on nitrogen, phosphorous, and potassium fertilization rates and harvest management
practices to optimum biomass yields have not been addressed. Research and demonstration
projects that identify the best fertilization and harvest management practices may
facilitate quicker producer adoption of switchgrass and stimulate a budding bioenergy
industry. Research on switchgrass production in the southern Great Plains will also improve
understanding about the westward adaptability of switchgrass, biomass yield relationships
with site precipitation, and the dual purpose value of switchgrass as a forage and bioenergy
crop, vital information considering that much of the agricultural sector in the southern
Great Plains is tied to beef cattle production.
	 
	2.	 	PROPOSAL OBJECTIVES:

	 	 	 

	 
	 	Page 1 of 8

 

 

	 	2.1	 	To determine biomass yields and production economics of switchgrass as a
bioenergy crop under one and two harvest per year systems across southern Oklahoma.
	 
	 	2.2	 	To quantify effects of nitrogen fertilization rate and harvest frequency/time
interactions on switchgrass biomass yields, stand persistence, and forage quality.
	 
	 	2.3	 	To determine interactions of nitrogen, phosphorous, and potassium fertilization
on switchgrass biomass production, nutrient uptake, and soil nutrient removal rates.

	3.	 	WORK TO BE UNDERTAKEN:
	 
	 	 	See RESEARCH AND DEVELOPMENT PLAN (Attachment A to this SCHEDULE).
	 
	 	 	Subject to the RESEARCH AND DEVELOPMENT PLAN, an overview of NOBLE work includes:
	 
	 	 	Objective 1. In the spring of 2007, research will be initiated on four NOBLE
cooperators’ farms and one NOBLE farm to determine biomass yields and production economics
of switchgrass as a bioenergy crop under one and two harvest per year systems across
southern Oklahoma. The five locations will span a 15 to 50 inch rainfall gradient:
1) far-west; 2) west; 3) central (NOBLE farm); 4) east; and 5) far-east. Two
harvest frequencies will be evaluated: 1) cut once at the end of the growing season for
biofuel purposes; 2) cut twice — ‘boot’ stage for forage and at the end of the growing
season for biofuel purposes. Contracts will be established with cooperators to allow NOBLE
to establish and produce switchgrass through 2011. Plot size will be [***] acres and will be
replicated [***] times per treatment for a total of [***] acres of production at each
location.
	 
	 	 	In March-April 2007, soils will be tested for phosphorous, potassium, and pH and
deficiencies will be corrected so as not to limit yield responses. Fields will be planted
with [***] switchgrass between April and June 2007. In the 2nd and subsequent
production years, N will be applied at [***] pounds/acre so as not to limit yield. If stands
fail to establish in 2007 and 2008, the effected sites will be replanted in 2008 and 2009,
respectively, and subsequently, the treatment applications and data collection schedule will
be delayed for the appropriate period of time.
	 
	 	 	Stand establishment success will be assessed in the fall of the 1st growing
season before biomass harvest. Biomass will be harvested at the same time for all treatments
in the fall of 2007 and by treatment schedule from 2008-11. Subsamples of the harvested
biomass will be collected for forage quality analysis from 2008-09. Stand persistence will
be assessed in the spring of 2009-11 with counts of tiller densities.
	 
	 	 	The experiment will be analyzed as randomized complete block with repeated measures. Year
(5), location (5), and replication ([***]) will be considered random factors and harvest
frequency (2) a fixed factor.
	 
	 	 	Full Information Enterprise Budgets detailing both variable and fixed production expenses
will be developed for each treatment (system) for each farm location and year. Variable
expenses include all cash expenses for seed, chemicals, fertilizer, custom

Page 2 of 8

Confidential Treatment Requested and the Redacted Material has been separately filed with the
Commission

 

	 	 	services, hired labor, and interest on investment. Fixed expenses include depreciation,
interest, taxes, and insurance on farm machinery, fences, and other capital items used in
the production process. Breakeven price of harvested switchgrass will be computed to
determine the price a producer would have to be paid in order to break-even. Sensitivity
analysis will be conducted to determine how robust results are to changes in prices of
inputs and yields.
	 
	 	 	Objective 2. In the spring of 2007, field plots of [***] switchgrass will be
established on three NOBLE farm sites (highly productive, moderately productive, and lowly
productive) to evaluate biomass production responses to N fertilizer rates ([***], [***],
[***], [***], [***], and [***] lbs/acre) and harvest frequency/time periods (a. once — at
the end of the growing season; b. twice — at ‘boot’ stage and at the end of the growing
season; and c. twice — during vegetative growth and at the end of the growing season) . The
field plot trials will cover ~ [***] each and will be conducted through 2011.
	 
	 	 	In March-April 2007, soils will be tested for for phosphorous, potassium, and pH and
deficiencies will be corrected so as not to limit yield responses. Fields will be planted
with [***] switchgrass between April and June 2007. If stands fail to establish in 2007 and
2008, the affected sites will be replanted in 2008 and 2009, respectively, and subsequently,
the treatment applications and data collection schedule will be delayed for the appropriate
period of time.
	 
	 	 	Stand establishment success will be assessed in the fall of the 1st growing
season before biomass harvest. Biomass will be harvested at the same time for all treatments
in the fall of 2007 and by treatment schedule from 2008-11. Subsamples of the harvested
biomass will be collected for forage quality analysis from 2008-09. Stand persistence will
be assessed in the spring of 2009-11 with counts of tiller densities.
	 
	 	 	The field plot trials will be arranged in split plots with repeated measures over years.
Nitrogen rates will be whole plots and harvest frequency/time periods the subplots. Each
trial will have [***] replications.
	 
	 	 	Objective 3. In the spring of 2007, field plots of [***] switchgrass will be
established on three NOBLE farm sites (highly productive, moderately productive, and lowly
productive) to determine if biomass production responds to N, P, and K fertilization and to
quantify rates of soil nutrient removal under annual biomass harvests . Treatments will
include applications of N ([***] and [***] lbs/acre), P ([***] and [***] lbs/acre) and K
([***] and [***] lbs/acre). The field plot trials will cover ~ [***] each and will be
conducted through 2011.
	 
	 	 	Fields will be planted between April and June 2007. In the 2nd and subsequent
production years, the N, P, and K treatments will be applied according to the treatment
schedule. If stands fail to establish in 2007 and 2008, the effected sites will be replanted
in 2008 and 2009, respectively, and subsequently, the treatment applications and data
collection schedule will be delayed for the appropriate period of time.
	 
	 	 	Stand establishment success will be assessed in the fall of the 1st growing
season before biomass harvest. Biomass will be harvested at the same time for all treatments
in the fall of 2007 and by treatment schedule from 2008-11. Subsamples of the harvested
biomass

Page 3 of 8

Confidential Treatment Requested and the Redacted Material has been separately filed with the
Commission

 

	 	 	will be collected for nutrient concentration analysis (N, P, K, Ca, and Mg) from 2008-09.
Stand persistence will be assessed in the spring of 2009-11 with counts of tiller densities.
	 
	 	 	The field plot trials will be arranged in split plots with repeated measures across years.
Nitrogen fertilization rate will be the whole plot treatment factor in each trial.
Phosphorous and K will be subplot treatments arranged in [***] x [***] factorial manner.
Each trial will have [***] replications.
	 
	4.	 	DETAILED WORKPLAN:
	 
	 	 	The RESEARCH AND DEVELOPMENT PLAN (Attachment A to this SCHEDULE) contains:

	 	•	 	Research and evaluation activities to be performed by each party in
detail, including locations for such activities
	 
	 	•	 	Timelines of such activities
	 
	 	•	 	Goals, expected results and deliverables
	 
	 	•	 	Milestones and go/no-go decision points, if applicable
	 
	 	•	 	FTEs

	5.	 	LOCATION OF WORK:

NOBLE Work:

NOBLE properties and subcontractor locations.

CERES Work:

Thousand Oaks, CA

	6.	 	PHD LEVEL SCIENTIFIC STAFF:

Dr.
John Guretzky (NOBLE)

Dr. John Biermacher(NOBLE)

Dr.  Billy Cook (NOBLE)

Post Doc TBD (CNF, wherein “CNF” indicates a CERES-funded, NOBLE employee)

Dr. Peter Mascia (CERES)

Dr. Emily Heaton (CERES)

Dr. Steve Thomas (CERES)

	7.	 	MAJOR CONSUMABLES/LIVESTOCK TO BE PURCHASED:
	 
	 	 	None.
	 
	8.	 	REPORTS:
	 
	 	 	All reports shall be delivered to the MANAGEMENT COMMITTEE on or before the required
delivery dates for the same.
	 
	 	 	NOBLE will deliver at each quarterly MANAGEMENT COMMITTEE meeting (or annual meeting, as the
case may be):

	 	•	 	Annual Report (compilation of slide presentations and quarterly
minutes) (annual meeting).

Page 4 of 8

Confidential Treatment Requested and the Redacted Material has been separately filed with the
Commission

 

	 	•	 	Quarterly status update and FTE breakout based on attached planning
document.
	 
	 	•	 	Actual spending relative to budget.
	 
	 	•	 	INTELLECTUAL PROPERTY generated during the period.
	 
	 	•	 	Copies of slide presentations summarizing research progress (template
attached as Attachment B to this SCHEDULE).
	 
	 	•	 	Content for the development of a grower’s manual, which the parties
intend to be a deliverable of this SCHEDULE.

	 	 	Additional information, if not specifically included in the delivered information (above),
shall be delivered (or later provided, wherein the delivering party shall indicate the
delivery method and time) as supporting information at the related quarterly meeting, if
available:

	 	•	 	Copies of raw field trial data

	9.	 	COMMENCEMENT/TERMINATION:

Commencement: 15 Mar 2007

Termination: 31 December 2011

	10.	 	REPORT PREPARATION:

Dr.
John Guretzky (NOBLE)

Dr Peter Mascia (CERES)

	11.	 	REPORT DATES:
	 
	 	 	Annual report: Due at annual meeting in March.
	 
	 	 	Quarterly reports and information: Due at quarterly meetings of the MANAGEMENT
COMMITTEE per the MRA (e.g., March, June, September, December).
	 
	12.	 	ASSETS:
	 
	 	 	Not applicable
	 
	13.	 	INSURANCE:
	 
	 	 	Not applicable
	 
	14.	 	CONTRIBUTION TO JOINT INTELLECTUAL PROPERTY:
	 
	 	 	Controlled by MRA.
	 
	15.	 	SPECIAL CONDITIONS:
	 
	 	 	Not applicable.
	 
	16.	 	INTELLECTUAL PROPERTY RIGHTS:

	 	16.1	 	NOBLE Background Intellectual Property:

	 	 	Management practices and protocols for forage cropping systems.

Page 5 of 8

 

	 	16.2	 	CERES Background Intellectual Property:
	 
	 	 	 	None.

	17.	 	SUBCONTRACTORS AND LOCATIONS:
	 
	 	 	NOBLE cooperators (growers) to be determined by the NOBLE Agricultural Division. Final NOBLE
cooperators and locations will be reported to the MANAGEMENT COMMITTEE at the quarterly
meetings.
	 
	18.	 	PROVISIONS FOR EARLY TERMINATION:
	 
	 	 	This SCHEDULE does not terminate automatically upon termination of the MRA.
	 
	 	 	This SCHEDULE shall expire pursuant to the terms set forth in this SCHEDULE, unless extended
by the mutual agreement of the parties, or unless sooner terminated in accordance with the
following provisions of this Paragraph:

     (a) mutual, written agreement of the parties;

     (b) failure of one party to satisfy its material obligations under this
Agreement, and such party subsequently fails to cure such failure(s) within (i)
thirty (30) days for failures to remit payment for amounts due under this Agreement
and (ii) ninety (90) days for all other obligations in each case after receipt of
written notice from the non-breaching party specifying such failure;

     (c) one (1) year’s written notice of termination by either CERES or NOBLE to
the other party in case either the terminating party or the other party ceases
substantially all activities in the COLLABORATION CROPS;

     (d) NOBLE will have the right to terminate this Agreement unilaterally with
thirty (30) days’ written notice to CERES, (i) if CERES seeks protection under any
bankruptcy, insolvency, receivership, trust, deed, creditors arrangement or
comparable proceeding or if any such proceeding is instituted against CERES (and not
dismissed within one hundred twenty (120) days); (ii) in case of dissolution or
winding up of CERES (excluding any situation where all or substantially all of
CERES’ assets, stock or business to which this Agreement relates are acquired by a
third party (whether by sale, acquisition, merger, operation of law or otherwise));
(iii) with written notice to CERES, to be given no later than March 31, 2010 if
Ceres has failed in a substantial manner, by December 31, 2009, to implement the
activities set forth in EXHIBIT F, and does not remedy such failure or offer a
remediation plan which is reasonably acceptable to NOBLE within ninety (90) days
after receipt of a written notice from NOBLE specifying such failure; or (iv) with
one hundred twenty (120) days’ written notice to CERES, if the institutional
mission, purpose or structure of NOBLE would change substantially and adversely
affect NOBLE’S ability to satisfy its obligations hereunder; or

     (e) CERES will have the right to terminate this Agreement unilaterally: (i)
with thirty (30) days’ written notice to NOBLE if Dr.  Joe
Bouton ceases to be associated
with NOBLE and the research activities associated with this

Page 6 of 8

Confidential Treatment Requested and the Redacted Material has been separately filed with the
Commission

 

SCHEDULE, and NOBLE has not replaced him within one hundred twenty (120) days
by a person reasonably acceptable to CERES; (ii) with ninety (90) days’ written
notice to NOBLE, if the institutional mission, purpose or structure of NOBLE would
change substantially; or (iii) with one (1) years’ written notice to NOBLE, if CERES
has compelling business reasons to cease the collaboration.

	19.	 	USE AND COMMERCIALIZATION RIGHTS:
	 
	 	 	Controlled by MRA.
	 
	20.	 	CONFIDENTIALITY/PUBLICATION:
	 
	 	 	Controlled by MRA.
	 
	21.	 	Proposed FUNDING:

Projected Budget (per year from CERES):

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Year 1	 	 	Year 2	 	 	Year 3	 	 	Year 4	 	 	Year 5	 	 	5 yr total	 
	Postdoc
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	$	[***]	 
	Research assistant #1 50%
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	$	[***]	 
	Research assistant #2 50%
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	$	[***]	 
	Research assistant #3 25%
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	$	[***]	 
	Research assistant #4 25%
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	$	[***]	 
	Research assistant #5 25%
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	$	[***]	 
	Research assistant #6 25%
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	$	[***]	 
	Location testing (land rent)
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	$	[***]	 
	Fencing
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	$	[***]	 
	Travel
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	$	[***]	 
	Seed
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	$	[***]	 
	Herbicides and other chemicals
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	$	[***]	 
	Fertilizer & lime
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	$	[***]	 
	Farm operations (fuel)
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	$	[***]	 
	Research supplies
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	$	[***]	 
	Soil sampling
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	$	[***]	 
	Forage quality analysis
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	$	[***]	 
	 
	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 
	Indirect
Cost (of 50%):
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	[***]	 
	Total:
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	[***]	 

Billing Schedule: Invoices will be sent by NOBLE to CERES for actual expenses from the
previous period on the 15th of the first month of each calendar quarter, not to exceed
the total amount specified above.

Page 7 of 8

Confidential Treatment Requested and the Redacted Material has been separately filed with the
Commission

 

IN WITNESS THEREOF this SCHEDULE has been executed on the date hereinbefore entered.

CERES, INC.

	 	 	 	 	 	 	 

	By:

	 	/s/ Steven R. Thomas
 

	 	 
	 	Date 4/10/09
	 

	 	Steven  Thomas	 	 	 	 
	 

	 	Director of BioProducts	 	 	 	 
	 
	 	 	 	 	 	 
	By:

	 	/s/ Peter Mascia
 

	 	 
	 	Date 4/10/07
	 

	 	Peter Mascia	 	 	 	 
	 

	 	Vice President of Product Development	 	 	 	 

THE SAMUEL ROBERTS NOBLE FOUNDATION, INC.

	 	 	 	 	 	 	 

	By:

	 	/s/ Michael A. Cawley
 

	 	 
	 	Date 10 APR 07
	 

	 	Michael A. Cawley	 	 	 	 
	 

	 	President	 	 	 	 

Page 8 of 8

 

Ceres/Noble
- Schedule 4 - Attachment A - RESEARCH AND DEVELOPMENT PLAN

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Ceres FTE sum	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	CNF FTE Sum	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	NF FTE sum	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	2007	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	2008	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	2009	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Project Planning	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	#	 	 	Yearly	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Template	 	 	 	Ex Start	 	Ex Finish	 	 	Loc	 	 	 	 	 	 	# people	 	 	%	 	 	Months	 	 	FTE	 	 	2007	 	 	2008	 	 	2009	 	 	2010	 	 	2011	 	 	J	 	 	F	 	 	M	 	 	A	 	 	M	 	 	J	 	 	J	 	 	A	 	 	S	 	 	O	 	 	N	 	 	D	 	 	J	 	 	F	 	 	M	 	 	A	 	 	M	 	 	J	 	 	J	 	 	A	 	 	S	 	 	O	 	 	N	 	 	D	 	 	J	 	 	F	 	 	M	 	 	A	 	 	M	 	 	J	 	 	J	 	 	A	 	 	S	 	 	O	 	 	N	 	 	D	 
	Objectives
	 	Determine agronomics and economics of switchgrass grown for bioenergy in the southern Great Plains	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Product Concept
	 	Research that demonstrates best agronomic and economic production practices may faciltitate earlier producer adoption of switchgrass and stimulate a budding bioenergy industry	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Business Plan
	 	Conduct field plot and on cooperator farm trials to determine optimal soil fertility and harvest management practices for biomass yields	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Management
	 	 	 	2/15/07	 	 	4/1/12	 	 	CERES	 	Director	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	 
	 	 	 	2/15/07	 	 	4/1/12	 	 	NF	 	Director	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 

Page 1

Confidential Treatment Requested and the Redacted Material has been separately filed with the
Commission

 

Ceres/Noble
- Schedule 4 - Attachment A - RESEARCH AND DEVELOPMENT PLAN

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Project Planning	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	#	 	 	Yearly	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Template	 	 	 	Ex Start	 	Ex Finish	 	 	Loc	 	 	 	 	 	 	# people	 	 	%	 	 	Months	 	 	FTE	 	 	2007	 	 	2008	 	 	2009	 	 	2010	 	 	2011	 	 	J	 	 	F	 	 	M	 	 	A	 	 	M	 	 	J	 	 	J	 	 	A	 	 	S	 	 	O	 	 	N	 	 	D	 	 	J	 	 	F	 	 	M	 	 	A	 	 	M	 	 	J	 	 	J	 	 	A	 	 	S	 	 	O	 	 	N	 	 	D	 	 	J	 	 	F	 	 	M	 	 	A	 	 	M	 	 	J	 	 	J	 	 	A	 	 	S	 	 	O	 	 	N	 	 	D	 
	Goal
	 	Assess potential on-farm biomass yields and production economics of switchgrass across southern Oklahoma	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Impact
	 	Provides expected yields under two harvest management systems and breakeven price growers need for switchgrass	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Action Item
	 	Identify and visit potential sites and establish land rental agreements with producers	 	1/1/07	 	 	12/31/07	 	 	CNF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	1/1/07	 	 	12/31/07	 	 	NF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Action Item
	 	Build fences to control on-site activities	 	1/1/07	 	 	12/31/07	 	 	CNF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	1/1/07	 	 	12/31/07	 	 	NF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Action Item
	 	Sample soils	 	1/1/07	 	 	12/31/11	 	 	CNF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	 
	 	 	 	1/1/07	 	 	12/31/11	 	 	NF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	Action Item
	 	Prepare sites for planting and establish switchgrass stands	 	1/1/07	 	 	12/31/07	 	 	CNF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	1/1/07	 	 	12/31/07	 	 	NF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Action Item
	 	Control weeds	 	1/1/07	 	 	12/31/11	 	 	CNF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	 
	 	 	 	1/1/07	 	 	12/31/11	 	 	NF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	Action Item
	 	Assess establishment and harvest 1st year stands	 	1/1/07	 	 	12/31/07	 	 	CNF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	1/1/07	 	 	12/31/07	 	 	NF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Action Item
	 	Assess stand persistence	 	1/1/08	 	 	12/31/11	 	 	CNF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	 
	 	 	 	1/1/08	 	 	12/31/11	 	 	NF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	Action Item
	 	Harvest biomass production yrs 2-5	 	1/1/08	 	 	12/31/11	 	 	CNF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	 
	 	 	 	1/1/08	 	 	12/31/11	 	 	NF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	Action Item
	 	Replant if necessary	 	1/1/08	 	 	12/31/09	 	 	CNF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	 
	 	 	 	1/1/08	 	 	12/31/09	 	 	NF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	Action Item
	 	Lay out field plots and assign treatments	 	1/1/08	 	 	12/31/09	 	 	CNF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	 
	 	 	 	1/1/08	 	 	12/31/09	 	 	NF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	Action Item
	 	Fertilize plots annually with N ([***] lbs/acre) and P, K, and lime if soils are limited	 	1/1/08	 	 	12/31/11	 	 	CNF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	 
	 	 	 	1/1/08	 	 	12/31/11	 	 	NF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	Action Item
	 	Prepare biomass subsamples for forage quality analysis years 2-3	 	1/1/08	 	 	12/31/09	 	 	CNF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	 
	 	 	 	1/1/08	 	 	12/31/09	 	 	NF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	Action Item
	 	Data input, analysis, report preparation, presentation development, meetings	 	1/1/07	 	 	12/31/11	 	 	CNF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	 
	 	 	 	1/1/07	 	 	12/31/11	 	 	NF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	Action Item
	 	Follow-up cooperator relations	 	1/1/07	 	 	12/31/11	 	 	CNF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	 
	 	 	 	1/1/07	 	 	12/31/11	 	 	NF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	Deliverable
	 	Report on stand establishment and 1st year biomass yields	 	1/1/08	 	 	4/1/08	 	 	NF	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Deliverable
	 	Report economics (cost of production) regarding 1st year of production	 	2/1/08	 	 	4/1/08	 	 	NF	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	X	 	 	 	X	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Deliverable
	 	Report on 2nd year biomass yields and forage quality	 	1/1/09	 	 	4/1/09	 	 	NF	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Deliverable
	 	Report economics (cost of production) regarding 1st and 2nd year of production	 	2/1/08	 	 	4/1/09	 	 	NF	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Deliverable
	 	Report on 3rd year stand persistence, biomass yields, and forage quality	 	1/1/10	 	 	4/1/10	 	 	NF	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Deliverable
	 	Report economics (cost of production) regarding 1st-3rd year of production	 	2/1/08	 	 	4/1/10	 	 	NF	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Deliverable
	 	Report on 4th year stand persistence and biomass yields	 	1/1/11	 	 	4/1/11	 	 	NF	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Deliverable
	 	Report economics (cost of production) regarding 1st-4th year of production	 	2/1/08	 	 	4/1/11	 	 	NF	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Deliverable
	 	Report on 5th year stand persistence and biomass yields	 	1/1/12	 	 	4/1/12	 	 	NF	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Deliverable
	 	Provide comprehensive agronomic and economic report, including cost of production, breakeven prices and costs, and sensitivty analysis.	 	1/1/12	 	 	6/1/12	 	 	NF	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

Page 2

Confidential Treatment Requested and the Redacted Material has been separately filed with the
Commission

 

Ceres/Noble
- Schedule 4 - Attachment A - RESEARCH AND DEVELOPMENT PLAN

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Project Planning	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	#	 	 	Yearly	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Template	 	 	 	Ex Start	 	Ex Finish	 	 	Loc	 	 	 	 	 	 	# people	 	 	%	 	 	Months	 	 	FTE	 	 	2007	 	 	2008	 	 	2009	 	 	2010	 	 	2011	 	 	J	 	 	F	 	 	M	 	 	A	 	 	M	 	 	J	 	 	J	 	 	A	 	 	S	 	 	O	 	 	N	 	 	D	 	 	J	 	 	F	 	 	M	 	 	A	 	 	M	 	 	J	 	 	J	 	 	A	 	 	S	 	 	O	 	 	N	 	 	D	 	 	J	 	 	F	 	 	M	 	 	A	 	 	M	 	 	J	 	 	J	 	 	A	 	 	S	 	 	O	 	 	N	 	 	D	 
	Goal
	 	Evaluate switchgrass biomass production responses to N fertilization rates and harvest frequency/time periods	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Impact
	 	Provides best management practices to maximize biomass yields and sustain productive stands	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Action Item
	 	Identify three NOBLE sites (highly productive, moderately productive, and lowly productive) to establish field plot trials	 	1/1/07	 	 	12/31/07	 	 	CNF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	1/1/07	 	 	12/31/07	 	 	NF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Action Item
	 	Sample soils	 	1/1/07	 	 	12/31/11	 	 	CNF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	 
	 	 	 	1/1/07	 	 	12/31/11	 	 	NF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	Action Item
	 	Prepare sites for planting and establish switchgrass stands	 	1/1/07	 	 	12/31/07	 	 	CNF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	1/1/07	 	 	12/31/07	 	 	NF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Action Item
	 	Control weeds	 	1/1/07	 	 	12/31/11	 	 	CNF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	 
	 	 	 	1/1/07	 	 	12/31/11	 	 	NF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	Action Item
	 	Assess establishment and harvest 1st year stands	 	1/1/07	 	 	12/31/07	 	 	CNF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	1/1/07	 	 	12/31/07	 	 	NF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Action Item
	 	Assess stand persistence	 	1/1/08	 	 	12/31/11	 	 	CNF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	 
	 	 	 	1/1/08	 	 	12/31/11	 	 	NF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	Action Item
	 	Harvest biomass production yrs 2-5	 	1/1/08	 	 	12/31/11	 	 	CNF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	 
	 	 	 	1/1/08	 	 	12/31/11	 	 	NF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	Action Item
	 	Replant if necessary	 	1/1/08	 	 	12/31/09	 	 	CNF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	 
	 	 	 	1/1/08	 	 	12/31/09	 	 	NF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	Action Item
	 	Lay out field plots and assign treatments	 	1/1/08	 	 	12/31/09	 	 	CNF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	 
	 	 	 	1/1/08	 	 	12/31/09	 	 	NF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	Action Item
	 	Fertilize plots according to
treatment schedule with N ([***], [***], [***], [***], [***] and [***] lbs/a) for production years 2-5	 	1/1/08	 	 	12/31/11	 	 	CNF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	 
	 	 	 	1/1/08	 	 	12/31/11	 	 	NF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	Action Item
	 	Prepare biomass subsamples for forage quality analysis years 2-3	 	1/1/08	 	 	12/31/09	 	 	CNF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	 
	 	 	 	1/1/08	 	 	12/31/09	 	 	NF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	Action Item
	 	Data input, analysis, report preparation, presentation development, meetings	 	1/1/07	 	 	12/31/11	 	 	CNF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	 
	 	 	 	1/1/07	 	 	12/31/11	 	 	NF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	Deliverable
	 	Report on stand establishment and 1st year biomass yields	 	1/1/08	 	 	4/1/08	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Deliverable
	 	Report on 2nd year biomass yields and forage quality	 	1/1/09	 	 	4/1/09	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Deliverable
	 	Report on 3rd year stand persistence, biomass yields, and forage quality	 	1/1/10	 	 	4/1/10	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Deliverable
	 	Report on 4th year stand persistence and biomass yields	 	1/1/11	 	 	4/1/11	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Deliverable
	 	Report on 5th year stand persistence and biomass yields	 	1/1/12	 	 	4/1/12	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

Page 3

Confidential Treatment Requested and the Redacted Material has been separately filed with the
Commission

 

Ceres/Noble
- Schedule 4 - Attachment A - RESEARCH AND DEVELOPMENT PLAN

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Project Planning	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	#	 	 	Yearly	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Template	 	 	 	Ex Start	 	Ex Finish	 	 	Loc	 	 	 	 	 	 	# people	 	 	%	 	 	Months	 	 	FTE	 	 	2007	 	 	2008	 	 	2009	 	 	2010	 	 	2011	 	 	J	 	 	F	 	 	M	 	 	A	 	 	M	 	 	J	 	 	J	 	 	A	 	 	S	 	 	O	 	 	N	 	 	D	 	 	J	 	 	F	 	 	M	 	 	A	 	 	M	 	 	J	 	 	J	 	 	A	 	 	S	 	 	O	 	 	N	 	 	D	 	 	J	 	 	F	 	 	M	 	 	A	 	 	M	 	 	J	 	 	J	 	 	A	 	 	S	 	 	O	 	 	N	 	 	D	 
	Goal
	 	Evaluate switchgrass biomass production responses to P and K on three sites with and without N fertilization	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Impact
	 	Addresses whether biomass production responds to P and K and quantifies annual biomass harvest effects on soil nutrient removal rates	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Action Item
	 	Identify three NOBLE sites (highly productive, moderately productive, and lowly productive) to establish field plot trials	 	1/1/07	 	 	12/31/07	 	 	CNF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	1/1/07	 	 	12/31/07	 	 	NF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Action Item
	 	Sample soils	 	1/1/07	 	 	12/31/11	 	 	CNF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	 
	 	 	 	1/1/07	 	 	12/31/11	 	 	NF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	Action Item
	 	Prepare sites for planting and establish switchgrass stands	 	1/1/07	 	 	12/31/07	 	 	CNF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	1/1/07	 	 	12/31/07	 	 	NF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Action Item
	 	Control weeds	 	1/1/07	 	 	12/31/11	 	 	CNF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	 
	 	 	 	1/1/07	 	 	12/31/11	 	 	NF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	Action Item
	 	Assess establishment and harvest 1st year stands	 	1/1/07	 	 	12/31/07	 	 	CNF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	1/1/07	 	 	12/31/07	 	 	NF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Action Item
	 	Assess stand persistence	 	1/1/08	 	 	12/31/11	 	 	CNF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	 
	 	 	 	1/1/08	 	 	12/31/11	 	 	NF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	Action Item
	 	Harvest biomass production yrs 2-5	 	1/1/08	 	 	12/31/11	 	 	CNF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	 
	 	 	 	1/1/08	 	 	12/31/11	 	 	NF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	Action Item
	 	Replant if necessary	 	1/1/08	 	 	12/31/09	 	 	CNF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	 
	 	 	 	1/1/08	 	 	12/31/09	 	 	NF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	Action Item
	 	Lay out field plots and assign treatments	 	1/1/08	 	 	12/31/09	 	 	CNF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	 
	 	 	 	1/1/08	 	 	12/31/09	 	 	NF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	Action Item
	 	Fertilize plots according to
treatment schedule with N ([***] and
[***] lbs/acre),  P([***] and
[***] lbs/acre) and K ([***] and
[***] lbs/acre) in production years 2-5	 	1/1/08	 	 	12/31/11	 	 	CNF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	 
	 	 	 	1/1/08	 	 	12/31/11	 	 	NF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	Action Item
	 	Prepare biomass subsamples for nutrient concentration analysis (N, P, K, Ca, Mg) years 2-3	 	1/1/08	 	 	12/31/09	 	 	CNF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	 
	 	 	 	1/1/08	 	 	12/31/09	 	 	NF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	Action Item
	 	Data input, analysis, report preparation, presentation development, meetings	 	1/1/07	 	 	12/31/11	 	 	CNF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	 
	 	 	 	1/1/07	 	 	12/31/11	 	 	NF	 	 	 	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	X	 
	Deliverable
	 	Report on stand establishment and 1st year biomass yields	 	1/1/08	 	 	4/1/08	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Deliverable
	 	Report on 2nd year biomass yields and nutrient concentration analysis	 	1/1/09	 	 	4/1/09	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	X	 	 	 	X	 	 	 	X	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Deliverable
	 	Report on 3rd year stand persistence, biomass yields, and nutrient concentration analysis	 	1/1/10	 	 	4/1/10	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Deliverable
	 	Report on 4th year stand persistence and biomass yields	 	1/1/11	 	 	4/1/11	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Deliverable
	 	Report on 5th year stand persistence and biomass yields	 	1/1/12	 	 	4/1/12	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

Page 4

Confidential Treatment Requested and the Redacted Material has been separately filed with the
Commission

 

Quarterly Report Format

Prepared by

Date

			
	 	 	 
	Confidential     Schedule # and name
	 	

1

 

Concept and Goals

	•	 	Concept

	•	 	Goals

			
	 	 	 
	Confidential     Schedule # and name
	 	

2

 

FTEs and Budget Projected vs. Actual

	•	 	People and activities

Dollars

FTEs

			
	 	 	 
	Confidential     Schedule # and name
	 	

3

 

Action Items and Deliverables for the Period

	 	 	 	 	 	 	 	 	 
	 	 	 	 	Expected	 	Actual
	Action Item or Deliverable	 	Finish	 	Finish

			
	 	 	 
	Confidential     Project # and name
	 	

4

 

Key Milestones or Deliverables for the Period

	 	•	 	Progress on Key Milestones and Deliverables
	 
	 	•	 	Are we on, ahead or behind schedule

			
	 	 	 
	Confidential     Project # and name
	 	

5

 

Technical Highlights

	•	 	1 or 2 slides covering technical highlights

			
	 	 	 
	Confidential     Project # and name
	 	

6

 

Results

	•	 	Several slides summarizing results (if applicable)

			
	 	 	 
	Confidential     Project # and name
	 	

7

 

What’s
Ahead: Key Milestones and Deliverables Next 4 Quarters

	•	 	Quarter 1
	 
	•	 	Quarter 2
	 
	•	 	Quarter 3
	 
	•	 	Quarter 4

			
	 	 	 
	Confidential     Project # and name
	 	

8

 

Research Plan

	•	 	Goal

	 	–	 	Impact
	 
	 	–	 	Tasks
	 
	 	–	 	Milestones
	 
	 	–	 	Deliverables

	•	 	Duplicate this slide as needed to cover each goal for the next period

			
	 	 	 
	Confidential     Schedule # and name
	 	

9

 

Timeline Summary

	•	 	Assumptions and risk factors
	 
	•	 	Use additional slide if necessary
	 
	•	 	Use red if behind schedule until completed or otherwise resolved
	 
	•	 	Should be indicated in red as soon as the delay is identified
	 
	•	 	See issue resolution if behind schedule

			
	 	 	 
	Confidential     Schedule # and name
	 	

10

 

IP

	•	 	Filings during the period

	•	 	Applications in progress

			
	 	 	 
	Confidential     Schedule # and name
	 	

11

 

SOPs

	•	 	List SOPS for all Key processes

			
	 	 	 
	Confidential     Schedule # and name
	 	

12

 

Issue Resolution and Decision Making Slides

These can be used to address new issues or

implement corrective action or assist in decision

making such as variety release, etc.

			
	 	 	 
	Confidential     Project # and name
	 	

13

 

Issue Resolution and Decision Making

	•	 	Issue (e.g. milestone 3 behind schedule)

	 	 	Actual
	 
	•	 	What is happening

 

	 	 	Expected
	 
	•	 	What should be happening

			
	 	 	 
	Confidential     Schedule # and name
	 	

14

 

Issue Resolution and Decision Making

	•	 	Issue (e.g. milestone 3 behind schedule)
	 
	•	 	Possible alternative slide to address new issues

Needs

Wants

			
	 	 	 
	Confidential     Schedule # and name
	 	

15

 

Decision

	•	 	Summary of decision to be made

			
	 	 	 
	Confidential     Schedule # and name
	 	

16

 

Options

	•	 	Summary of options

			
	 	 	 
	Confidential     Schedule # and name
	 	

17

 

Recommendations

	•	 	What do we need to do to get back on track or address new issue

			
	 	 	 
	Confidential     Schedule # and name
	 	

18

 

Resources Required

			
	 	 	 
	Confidential     Schedule # and name
	 	

19

 

Plan and Schedule

	 	 	 	 	 	 	 	 	 
	Action Items	 	 	Who	 	 	When	 

			
	 	 	 
	Confidential     Schedule # and name
	 	

20

 

Pages where confidential treatment has been requested are stamped ‘Confidential Treatment
Requested and the Redacted Material has been separately filed with the Commission,’ and the
confidential section has been marked as follows: [***].

SCHEDULE 5

THIS SCHEDULE is made this 15th day of July 2009;

			
	BETWEEN	 	CERES, INC., a Delaware corporation, having its
principal place of business at 1535 Rancho
Conejo Blvd., Thousand Oaks, CA 91320 (“CERES”)
and

THE SAMUEL ROBERTS NOBLE FOUNDATION
INCORPORATED, an Oklahoma non-profit
corporation, having its principal place of
business at 2510 Sam Noble Parkway, Ardmore,
Oklahoma 73401 (“NOBLE”);

WHEREAS, CERES and NOBLE have entered into a Master Research Agreement (“MRA”), dated 19 May 2006,
which allows for the undertaking of RESEARCH PROJECTS pursuant to SCHEDULES, these terms being
defined in the MRA; and

THEREFORE, the parties have agreed to undertake the following RESEARCH PROJECT as defined herein on
the following terms and conditions:

GENERAL

	A.	 	Unless otherwise specified herein, the terms of the MRA shall apply to this SCHEDULE.
	 
	B.	 	In the event of any difference between the terms of this SCHEDULE and the MRA, then the terms
of this SCHEDULE shall prevail.

RESEARCH
PROJECT TITLE: Breeding and Genomic Approaches to Enhance
Switchgrass Cultivar Development

	1.	 	BACKGROUND:
	 
	 	 	Switchgrass (Panicum virgatum L.) is a perennial grass with a high potential for biomass
production with estimated  [***] yields between [***] and [***]. It is a heteromorphic
cross-pollinated species with a high degree of self-incompatibility. Switchgrass is a
dedicated feedstock crop for bioenergy production in the USA. Development of improved
switchgrass [***] cultivars can substantially increase the
acceptability of these cultivars to the growers.
[***] cultivars are of [***] in this regard.
	 
	 	 	We have successfully concluded the first three years of CERES — NOBLE collaboration
projects on breeding and [***] development. During this time substantial improvements have
been made on germplasm characterization, population development and
evaluation, parental selection, molecular [***]
development, genetic linkage mapping, and [***]. The plant
germplasm and genomic tools developed through this
collaboration make an excellent foundation for further improvement of this dedicated
cellulosic feedstock species. Thus, an extension of the current collaboration should be of
great value to all parties.
	 
	 	 	In last three year project period, significant progress has been toward lowland switchgrass
cultivar development. A number of [***] and [***] were produced and

			
	 	 	 
	CERES-NOBLE
Schedule Breeding-Genomics
	 	Page 1 of 13

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

 

	 	 	evaluated in multiple environments. Based on [***]
performance, a few parental [***] of superior
[***] and several superior [***] within selected [***] have been identified to produce new [***] for
evaluation as new varieties. These new [***] varieties will be evaluated in multilocation
yield trials. Several [***] ([***]),
that are currently being tested, have shown potential for
development of [***] cultivars. To increase the selection
efficiency for producing [***] cultivars, [***] breeding is being implemented. This is
expected to expedite the genetic gain through selection. In addition, further improvement in
pipeline varieties; [***], [***], [***], [***] and [***] is in place following the
conventional [***] evaluation procedure, and expected to
further improve biomass yield potential.
	 
	 	 	Because of self incompatibility, polyploidy, heterozygosity
and heterogeneity, molecular [***]
will be important for determining the genetic behavior of switchgrass
genes and chromosomes.
Thousands of molecular [***] have been developed.
Comprehensive genetic linkage maps were constructed with both [***]
and [***]. The Ceres proprietary mapping population was planted in field trials and is being evaluating
for different morphological, biomass and quality traits. At the end of 2009 we will be able
to identify [***] associated with traits of interest.
Molecular [***] associated with these [***] and traits will facilitate
[***] approaches to efficiently exploit beneficial gene combinations in breeding programs.
Besides, molecular [***] selected from the genetic linkage maps will expedite the
parental and progeny selection in the breeding
populations.
	 
	2.	 	PROPOSAL OBJECTIVES:

	 	2.1	 	[***] Cultivar Development
	 
	 	2.2	 	[***] Cultivar Development
	 
	 	2.3	 	[***]

	3.	 	WORK TO BE UNDERTAKEN:
	 
	 	 	See RESEARCH AND DEVELOPMENT PLAN (Attachment A to this SCHEDULE).
	 
	4.	 	DETAILED WORKPLAN:
	 
	 	 	The PROJECT PLAN BREEDING-GENOMICS (Attachment A to this SCHEDULE) contains:

	 	•	 	Research and evaluation activities to be performed by each party in
detail, including locations for such activities
	 
	 	•	 	Timelines of such activities
	 
	 	•	 	Goals, expected results and deliverables
	 
	 	•	 	Milestones and go/no-go decision points, if applicable
	 
	 	•	 	FTEs

	5.	 	LOCATION OF WORK:
	 
	 	 	NOBLE Work:
	 
	 	 	All NOBLE laboratory and greenhouse facilities and properties at its Ardmore and Burneyville
locations are available for this project.
	 
	 	 	CERES Work:

			
	CERES-NOBLE Schedule Breeding-Genomics
	 	Page 2 of 13

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

 

	 	 	Thousand Oaks, CA

College Station, TX

Ceres Net Plots (location TBD)
	 
	6.	 	PHD LEVEL SCIENTIFIC STAFF:
	 
	 	 	Dr. Joe Bouton (NOBLE)

Dr. Malay Saha (NOBLE)

Dr. Hem Bhandari (50% NOBLE and 50% CNF)
	 
	 	 	Dr. Jeff Gwyn (CERES)

Dr. Charlie Rodgers CERES)

Dr. Xue Feng Ma (CERES)
	 
	7.	 	MAJOR CONSUMABLES/LIVESTOCK TO BE PURCHASED:
	 
	 	 	None
	 
	8.	 	REPORTS:
	 
	 	 	All reports shall be delivered to the MANAGEMENT COMMITTEE on or before the required
delivery dates for the same.
	 
	 	 	Each quarter regardless of whether there is a meeting of the MANAGEMENT COMMITTEE in that
quarter, NOBLE will deliver:

	 	•	 	A report of actual spending relative to budget in a spreadsheet to accompany
quarterly invoices (in a format determined by the MANAGEMENT COMMITTEE).
	 
	 	•	 	A report of FTE allocations and time spent on the project based on attached
planning document.

	 	 	At each meeting of the MANAGEMENT COMMITTEE (whether it be quarterly or trimesterly), NOBLE
will deliver:

	 	•	 	A report on INTELLECTUAL PROPERTY generated during the period.
	 
	 	•	 	Copies of slide presentations summarizing research progress (in a
format determined by the MANAGEMENT COMMITTEE).
	 
	 	•	 	A report on progress against objectives including: phenotypic and [***]
information collected on different populations evaluated in this collaboration.

	 	 	Additional information, if not specifically included in the delivered information (above),
shall be delivered (or later provided, wherein the delivering party shall indicate the
delivery method and time) as supporting information at the related quarterly or trimesterly
meeting, if available:
	 
	 	 	NOBLE will deliver:

	 	•	 	Breeding records
	 
	 	•	 	Copies of field or greenhouse books and records

			
	 	 	 
	CERES-NOBLE
Schedule Breeding-Genomics
	 	Page 3 of 13

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

 

	 	•	 	Copies of raw field trial data
	 
	 	•	 	Raw [***] and plant data
	 
	 	•	 	[***], dry tissue, and [***] from different populations as required

	 	 	CERES will deliver:

	 	•	 	[***] information
	 
	 	•	 	[***] map locations as appropriate

	9.	 	COMMENCEMENT/TERMINATION:
	 
	 	 	Commencement: August 1, 2009
	 
	 	 	Termination: July 31, 2012
	 
	10.	 	REPORT PREPARATION:
	 
	 	 	Dr. Joe Bouton  (NOBLE)

Dr. Malay Saha (NOBLE)
	 
	 	 	Dr. Charlie Rodgers (CERES)

Dr. Xue Feng Ma (CERES)
	 
	11.	 	REPORT DATES:
	 
	 	 	Reports and information: Due at quarterly or trimesterly meetings of the MANAGEMENT
COMMITTEE.
	 
	12.	 	ASSETS:
	 
	 	 	Not applicable
	 
	13.	 	INSURANCE:
	 
	 	 	Not applicable
	 
	14.	 	CONTRIBUTION TO JOINT INTELLECTUAL PROPERTY:
	 
	 	 	Controlled by MRA
	 
	15.	 	SPECIAL CONDITIONS:

	 	15.1.	 	VARIETY RELEASE

     15.1.1 “RELEASE DATE” means the date that CERES determines that a variety
developed, tested and evaluated pursuant to the terms of this SCHEDULE is ready for
release, wherein upon such decision, such variety will be formally released by the
institutions of the variety’s breeder(s), whether NOBLE, CERES or CERES and NOBLE
jointly.

			
	 	 	 
	CERES-NOBLE Schedule Breeding-Genomics
	 	Page 4 of 13

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

 

     15.1.2 For the purposes of this SCHEDULE, CERES, on advice of the breeder(s) of
each variety via the MANAGEMENT COMMITTEE, shall establish, in its sole discretion,
an appropriate RELEASE DATE for such varieties.

     15.1.3 At or about the RELEASE DATE for a variety, CERES will determine a
COMMERCIAL NAME for such variety under which the seed of the same will be marketed
and sold. “COMMERCIAL NAME” means the complete, preferred name of a released variety
under which it will be marketed and sold.

     15.1.4 All parties agree that the development of new varieties will not always
result in varieties that are commercially acceptable or releasable. Provided all
parties execute their respective obligations under this SCHEDULE in an appropriate
and reasonable manner, no one party shall be liable to the other for any refund or
other recompense because no commercially acceptable new variety is produced.

	16.	 	INTELLECTUAL PROPERTY RIGHTS:

	 	16.1	 	NOBLE Background Intellectual Property:

	 	•	 	[***] (NOBLE), [***] (NOBLE),
[***] (NOBLE), NF/GA001 (in-licensed from UGARF), NF/GA002
(in-licensed from UGARF), NF/GA991 (in-licensed from UGARF), NF/GA992
(in-licensed from UGARF), and NF/GA993 (in-licensed from UGARF).

	 	16.2	 	CERES Background Intellectual Property:

	 	•	 	Sequences from switchgrass and other species
	 
	 	•	 	Gene trait association information
	 
	 	•	 	Patent applications covering any of the foregoing
	 
	 	•	 	[***] sequences

	17.	 	SUBCONTRACTORS AND LOCATIONS:
	 
	 	 	Not applicable
	 
	18.	 	PROVISIONS FOR EARLY TERMINATION:
	 
	 	 	This SCHEDULE does not terminate automatically upon termination of the MRA.
	 
	 	 	This SCHEDULE shall expire pursuant to the terms set forth in this SCHEDULE, unless extended
by the mutual agreement of the parties, or unless sooner terminated in accordance with the
following provisions of this Paragraph:

     (a) mutual, written agreement of the parties;

     (b) failure of one party to satisfy its material obligations under this
Agreement, and such party subsequently fails to cure such failure(s) within (i)
thirty (30) days for failures to remit payment for amounts due under this

			
	 	 	 
	CERES-NOBLE
Schedule Breeding-Genomics
	 	Page 5 of 13

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

 

Agreement and (ii) ninety (90) days for all other obligations in each case
after receipt of written notice from the non-breaching party specifying such
failure(s);

     (c) one (1) year’s written notice of termination by either CERES or NOBLE to
the other party in case either the terminating party or the other party ceases
substantially all activities in the COLLABORATION CROPS;

     (d) NOBLE will have the right to terminate this Agreement unilaterally with
thirty (30) days’ written notice to CERES, (i) if CERES seeks protection under any
bankruptcy, insolvency, receivership, trust, deed, creditors arrangement or
comparable proceeding or if any such proceeding is instituted against CERES (and not
dismissed within one hundred twenty (120) days); (ii) in case of dissolution or
winding up of CERES (excluding any situation where all or substantially all of
CERES’ assets, stock or business to which this Agreement relates are acquired by a
third party (whether by sale, acquisition, merger, operation of law or otherwise));
(iii) CERES fails in a substantial manner to implement and continue the activities
set forth in EXHIBIT F (or other similar activities in furtherance of commercial
exploitation of the COLLABORATION CROPS), and does not remedy such failure or offer
a remediation plan which is reasonably acceptable to NOBLE within ninety (90) days
after receipt of a written notice from NOBLE specifying such failure; or (iv) with
one hundred twenty (120) days’ written notice to CERES, if the institutional
mission, purpose or structure of NOBLE would change substantially and adversely
affect NOBLE’S ability to satisfy its obligations hereunder; or

     (e) CERES will have the right to terminate this Agreement unilaterally: (i)
with thirty (30) days’ written notice to NOBLE if Dr. Joe
Bouton ceases to be associated
with NOBLE and the research activities associated with this SCHEDULE, and NOBLE has
not replaced him within one hundred twenty (120) days by a person reasonably
acceptable to CERES; (ii) with ninety (90) days’ written notice to NOBLE, if the
institutional mission, purpose or structure of NOBLE would change substantially; or
(iii) with one (1) years’ written notice to NOBLE, if CERES has compelling business
reasons to cease the collaboration.

	19.	 	USE AND COMMERCIALIZATION RIGHTS:
	 
	 	 	Controlled by MRA
	 
	20.	 	CONFIDENTIALITY/PUBLICATION:
	 
	 	 	Controlled by MRA

			
	 	 	 
	CERES-NOBLE Schedule Breeding-Genomics
	 	Page 6 of 13

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

 

21. FUNDING APPROVED:

Projected Budget (per year from CERES):

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Personnel	 	Year 1	 	Year 2	 	Year 3	 	Sub-totals
	 
	Existing
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1. Res. Scientist-1 (50%) + Fringe Benefits
	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 
	2. Res. Associate + Fringe Benefits
	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 
	3. Res. Assistant -1 + Fringe Benefits
	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 
	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Addition of New Goals
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	4. Res. Assistant -3 + Fringe Benefits
	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 
	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Sub-total (Salary + Benefits)
	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 
	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Travel
	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 
	Supplies
	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	Total Direct Costs
	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 
	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Indirect ( 50% of Direct)
	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 
	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Total
	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 
	 

Budget justification:

Salaries:

Personnel listed in items #1-3 (Existing) were funded in two earlier schedules (Schedules 2 and 3,
which expired by their respective terms) with #1 being
Dr. Hem Bhandari, #2 being the technician in Dr. Saha’s [***]   project, and #3 being the tech assisting with the field data collection. Additional personnel
support (item #4) is requested for one full-time Research Assistant for 3 years. The Research
Assistant (#4) will work in breeding and mapping projects to provide additional hands for the field
evaluations. Fringe benefits are calculated at [***]% to include FICA, health insurance and thrift.
Five percent fixed salary increases are requested for each successive year.

Travel:

Travel funds are requested to allow the main scientific personnel to attend one scientific
conference within North America each year.

Supplies:

$[***] per year is requested for general chemicals. This amount is also exactly the sum of the
supply budgets for the existing schedules and represents no increase in this budget line. Supplies
for field, greenhouse and growth chamber studies will also be procured from this fund.

			
	 	 	 
	CERES-NOBLE Schedule Breeding-Genomics
	 	Page 7 of 13

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

 

Billing Schedule: Invoices will be sent by NOBLE to CERES for actual expenses from the previous
period on the 15th of the first month of each calendar quarter, not to exceed the
amounts specified above.

			
	 	 	 
	CERES-NOBLE Schedule Breeding-Genomics
	 	Page 8 of 13

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

 

IN WITNESS THEREOF this SCHEDULE has been executed on the date hereinbefore entered.

CERES, INC.

	 	 	 	 	 	 	 
	

	 	/s/ Anna Rath
	 	9/18/09	 	 
	 	 	 
	By:

	 	Anna Rath
	 	Date	 	 
	 

	 	Vice President of Commercial Development	 	 	 	 
	 
	 	 	 	 	 	 
	 

	 	/s/ Richard Flavell
	 	Sept. 17, 2009
	 	 	 
	By:

	 	Richard Flavell, CBE, FRS
	 	Date	 	 
	 

	 	Chief Scientific Officer	 	 	 	 
	 
	 	 	 	 	 	 
	THE SAMUEL ROBERTS NOBLE FOUNDATION, INC.	 	 	 	 
	 
	 	 	 	 	 	 
	 

	 	/s/ Michael A. Cawley
	 	10.02.09	 	 
	 	 	 
	By:

	 	Michael A. Cawley
	 	Date	 	 
	 

	 	President	 	 	 	 

			
	 	 	 
	CERES-NOBLE Schedule Breeding-Genomics
	 	Page 9 of 13

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

 

Attachment A

RESEARCH
AND DEVELOPMENT PLAN & PROJECT PLAN BREEDING-GENOMICS

CERES-NOBLE SCHEDULE 5 (BREEDING-GENOMICS; 20[***]-20[***])

OBJECTIVE: Develop commercial switchgrass cultivars for use in bioenergy and
forage cropping systems via conventional breeding and molecular [***] selection.

Goal
1: [***] Cultivar Development

	 	A.	 	Development and testing of new [***] based on
[***] selection from the current nurseries
(Timeline: June 20[***]-May 20[***])

	 	a.	 	Select parental [***] of superior [***]
	 
	 	b.	 	Select superior individuals from within the superior [***]
	 
	

	 	c.	 	[***] selected [***] to produce [***] seed of two [***]: one
based on [***] (from “a”) and one based
on within [***] (from “b”)
	

	 
	 	d.	 	Multi-location testing of these new [***]

	 	B.	 	Begin the Cycle [***] process based on association breeding with molecular [***] as outlined in the
“Noble Foundation Switchgrass [***] Selection” scheme shown in attached figure 1 (Timeline: June
20[***]-May 20[***]).

	 	a.	 	[***] the individuals within [***] from
current nurseries ([***] [***] from each [***] at each
location)
	 
	 	b.	 	[***] and use [***] to select among the progenies
	 
	 	c.	 	Plant selected progenies for field evaluation

	 	C.	 	In collaboration with UGA, several elite populations are being advanced by testing at
multiple locations as shown in attached figure 2 (June 20[***]-May 20[***])

	 	a.	 	For [***], Noble will conduct years [***], [***], and [***] of the outline.
	 
	 	b.	 	For [***], Noble will conduct years [***], [***], and [***] of the outline
	 
	 	c.	 	For [***] and [***], Ceres will plant them in 20[***] and conduct years [***], [***]
and [***] of the outline.

Goal
2: [***] Cultivar Development:

A. Development and testing
of [***] based on [***] selection from the current nurseries (Timeline: June
20[***]-May 20[***])

	 	a.	 	Select parental [***] of superior [***]
	 
	 	b.	 	Set up a field [***] of selected parental [***] (from “a”) to produce [***] seed
	 
	 	c.	 	Multi-location testing of new [***]

			
	 	 	 
	CERES-NOBLE
Schedule Breeding-Genomics
	 	Page 10 of 13

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

 

B.
Begin the Cycle [***] selection process based on
association breeding with molecular [***] as outlined in the “Noble
Foundation Switchgrass [***] Selection” scheme shown in attached figure 1 (Timeline: June 20[***]-May
20[***]).

	 	a.	 	[***] the individuals within [***] from current nurseries
	 
	 	b.	 	Construct model for [***] breeding [***]
	 
	 	c.	 	[***] and develop [***] A and B
	 
	 	d.	 	Use [***] to select among the progenies in [***]
	 
	 	e.	 	Produce [***] between [***] and [***]

Goal 3: [***]

	 	A.	 	Identify [***] associated with traits of interest
	 
	 	 	 	Phenotypic data collected on the Ceres proprietary population
will be analyzed with the map data to
[***] and associated [***]. Significant [***] with
positive and negative effect on the trait will be
determined and important [***] will be identified for [***]. (Timeline: June 20[***] —
April 20[***]).
	 
	 	B.	 	Application of selected [***] in a confirmation population
	 
	 	 	 	Selected [***] will be screened in a breeding
population. A [***] of plants with and without [***] for the
selected traits (expected traits: yield, seed [***], [***] date, [***], plant [***]) will be
identified. Selected [***] will be compared with the
original population. (Timeline: Sept. 20[***] —
April 20[***]).
	 
	 	C.	 	Field evaluation of the confirmation population
	 
	 	 	 	Selected plants with and without [***] and randomly
selected plants from original population will be
evaluated in field experiments. Phenotypic data will be collected on
the traits for which selection were made. (Timeline: April 20[***] — Feb. 20[***]).
	 
	 	D.	 	Assess [***] efficiency
	 
	 	 	 	Gain/loss from [***] will be evaluated.
[***] with significant gain will be selected for future
use in [***]. (Timeline: January 20[***] — May 20[***]).

Note: Division of Labor for [***] Analysis

	 	A.	 	Noble will phenotype all plants and provide leaf samples for plants to be [***] to Ceres.
	 
	 	B.	 	In the first phase, Ceres will [***] all samples supplied by Noble using our existing
set of [***] (approximately [***]). Ceres will deliver [***] information for
each [***]
and [***] map locations where appropriate to Noble. We expect this phase to be complete by
January 20[***]. Currently, the minimum number of [***] needed to accomplish our
objectives is not known. Ceres will continue to develop new [***] and to identify new and
more economical [***] technologies. In the next phases of this project (i.e. for

			
	 	 	 
	CERES-NOBLE
Schedule Breeding-Genomics
	 	Page 11 of 13

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

 

	 	 	 	samples collected in the 20[***] growing season and beyond), we expect additional [***] to
be available and applied as warranted.
	 
	 	C.	 	Both Noble and Ceres will have access to all phenotype and [***] information and will work
collaboratively to interpret the [***] associations and [***] breeding [***], [***] will proceed once a
validated set of phenotypes for the selected samples has been received by Ceres.

Figure 1.

[***]

			
	 	 	 
	CERES-NOBLE Schedule Breeding-Genomics
	 	Page 12 of 13

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

 

Figure
2. UGA Project

	Year1,2,3(or4if need more date),4,5,6,7,8,9grow[***] plants and [***] harvest [***]seed from [***] plants [***] plant [***], evaluate
select [***]% of [***] ([***]) [***] plants identify [***] plants per [***] and [***] plants [***] from [***] to make [***] seed
evaluations in [***] plant [***] for evaluation plant [***] for evaluation select [***]% of [***] ([***] select [***]% of [***] ([***]
identify [***] plants per [***]
and [***] plants [***] plants evaluations in [***] etc. etc. evaluations in [***] between [***] between [***] ceres-noble
schedule breeding [***] page 13 of 13 confidential treatment requested and the redacted material has been separately filed with the
Commission

			
	 	 	 
	CERES-NOBLE
Schedule Breeding-Genomics
	 	Page 13 of 13

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

 

Pages where confidential treatment has been requested are stamped ‘Confidential Treatment
Requested and the Redacted Material has been separately filed with the Commission,’ and the
confidential section has been marked as follows: [***].

SCHEDULE 6

THIS SCHEDULE is made this 1st day of November 2009;

			
	BETWEEN	 	CERES, INC., a Delaware corporation,
having its principal place of business at
1535 Rancho Conejo Blvd., Thousand Oaks,
CA 91320 (“CERES”) and

THE SAMUEL ROBERTS NOBLE FOUNDATION
INCORPORATED, an Oklahoma non-profit
corporation, having its principal place
of business at 2510 Sam Noble Parkway,
Ardmore, Oklahoma 73401 (“NOBLE”);

WHEREAS, CERES and NOBLE have entered into a Master Research Agreement (“MRA”), dated 19 May 2006,
which allows for the undertaking of RESEARCH PROJECTS pursuant to SCHEDULES, these terms being
defined in the MRA; and

THEREFORE, the parties have agreed to undertake the following RESEARCH PROJECT as defined herein on
the following terms and conditions:

GENERAL

	A.	 	Unless otherwise specified herein, the terms of the MRA shall apply to this SCHEDULE.
	 
	B.	 	In the event of any difference between the terms of this SCHEDULE and the MRA, then the terms
of this SCHEDULE shall prevail.

RESEARCH PROJECT TITLE: Best Management Practices for Switchgrass Stand Establishment in a Biomass
Cropping System

	1.	 	BACKGROUND:
	 
	 	 	Switchgrass (Panicum virgatum L.) is a target species for use as a biomass crop in bioenergy
production. The primary management problem in a switchgrass cropping system is achieving
good germination and controlling weeds as the seedlings become established in the first growing
season. In Schedule 1 of the MRA, studies were undertaken to
determine optimal seeding rate and placement
and to identify pre-plant and post-emergent herbicides that would be effective in
controlling common weeds without excessive damage on switchgrass. In addition, an
intercropping study was undertaken to determine whether nitrogen-fixing legumes could be
co-cultivated with switchgrass to reduce input requirements in an established stand. In
Schedule 6 of the MRA, we extend these studies taking what was learned and trialing more
focused methods across a broader range of environments.
	 
	2.	 	PROPOSAL OBJECTIVES:

	 	2.1	 	To identify legume species that can be intercropped with switchgrass to improve
sustainability of switchgrass biofuel production
	 
	 	2.2	 	To determine best management practices for establishing switchgrass into
perennial grass (CRP-like) pastures

CERES-NOBLE Schedule BMP for switchgrass

Page 1 of 10

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

	 	2.3	 	To determine minimum number of seedlings per [***]
needed to maximize yield and document
justification for replanting poor stands, using the BMP guidelines (learned in Schedule
1) to control weeds (FirstRate PRE fb Atrazine+Paramount+Prowl 2-leaf)
	 
	 	2.4	 	To validate herbicide recommendations developed in Schedule 1 across multiple
environments

	3.	 	WORK TO BE UNDERTAKEN:
	 
	 	 	See RESEARCH AND DEVELOPMENT PLAN (Attachment A to this SCHEDULE).
	 
	4.	 	DETAILED WORKPLAN:
	 
	 	 	The RESEARCH AND DEVELOPMENT PLAN contains:

	 	•	 	Research and evaluation activities to be performed by each party in
detail, including locations for such activities
	 
	 	•	 	Timelines of such activities
	 
	 	•	 	Goals, expected results and deliverables
	 
	 	•	 	Milestones and go/no-go decision points, if applicable
	 
	 	•	 	FTEs

	5.	 	LOCATION OF WORK:
	 
	 	 	NOBLE Work:
	 
	 	 	All NOBLE laboratory and greenhouse facilities and properties at its Ardmore, Dupy and Red
River locations are available for this project.
	 
	 	 	CERES Work:
	 
	 	 	The RESEARCH AND DEVELOPMENT PLAN does not call for any of the research activities to be
carried out in Ceres facilities.
	 
	6.	 	PHD LEVEL AND SENIOR SCIENTIFIC STAFF:
	 
	 	 	Dr. Twain Butler (NOBLE)

Dr. Joe Bouton (NOBLE)

Post Doc TBD (CNF, wherein “CNF” indicates a CERES-funded, NOBLE employee)
	 
	 	 	Dr. Jeff Gwyn (CERES)

Dr. Cory Christensen (CERES)

Bud Wylie (CERES)
	 
	7.	 	MAJOR CONSUMABLES/LIVESTOCK TO BE PURCHASED:
	 
	 	 	None
	 
	8.	 	REPORTS:
	 
	 	 	All reports shall be delivered to the MANAGEMENT COMMITTEE on or before the required
delivery dates for the same.

CERES-NOBLE Schedule BMP for switchgrass

Page 2 of 10

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

	 	 	

	 
	 	 	Each quarter regardless of whether there is a meeting of the MANAGEMENT COMMITTEE in that
quarter, NOBLE will deliver:

	 	•	 	A report of actual spending relative to budget in a spreadsheet to accompany
quarterly invoices (in a format determined by the MANAGEMENT COMMITTEE).
	 
	 	•	 	A report of FTE allocations and time spent on the project based on attached
planning document.

	 	 	At each meeting of the MANAGEMENT COMMITTEE (whether it be quarterly or trimesterly), NOBLE
will deliver:

	 	•	 	A report on INTELLECTUAL PROPERTY generated during the period.
	 
	 	•	 	Copies of slide presentations summarizing research progress (in a
format determined by the MANAGEMENT COMMITTEE).
	 
	 	•	 	A report on progress against objectives..

	 	 	Additional information, if not specifically included in the delivered information (above),
shall be delivered (or later provided, wherein the delivering party shall indicate the
delivery method and time) as supporting information at the related quarterly or trimesterly
meeting, if available:
	 
	 	 	NOBLE will deliver:

	 	•	 	Copies of raw field trial data upon request by Ceres.

	9.	 	COMMENCEMENT/TERMINATION:
	 
	 	 	Commencement: November 1, 2009
	 
	 	 	Termination: October 31, 2012
	 
	10.	 	REPORT PREPARATION:
	 
	 	 	Dr. Twain Butler (NOBLE)
	 
	 	 	Bud Wylie (CERES)
	 
	11.	 	REPORT DATES:
	 
	 	 	Reports and information: Due at quarterly or trimesterly meetings of the MANAGEMENT
COMMITTEE.
	 
	12.	 	ASSETS:
	 
	 	 	Not applicable
	 
	13.	 	INSURANCE:
	 
	 	 	Not applicable
	 
	14.	 	CONTRIBUTION TO JOINT INTELLECTUAL PROPERTY:
	 
	 	 	Controlled by MRA

CERES-NOBLE Schedule BMP for switchgrass

Page 3 of 10

 

	15.	 	SPECIAL CONDITIONS:
	 
	 	 	None
	 
	16.	 	INTELLECTUAL PROPERTY RIGHTS:

	 	16.1	 	NOBLE Background Intellectual Property:

	 	•	 	[***] (NOBLE), [***] (NOBLE), [***] (NOBLE), NF/GA001 (in-licensed from UGARF), NF/GA002
(in-licensed from UGARF), NF/GA991 (in-licensed from UGARF), NF/GA992 (in-licensed from
UGARF), and NF/GA993 (in-licensed from UGARF).
	 
	 	•	 	Management practices and protocols for forage cropping systems.

	 	16.2	 	CERES Background Intellectual Property:

	 	•	 	None

	17.	 	SUBCONTRACTORS AND LOCATIONS:
	 
	 	 	Not applicable
	 
	18.	 	PROVISIONS FOR EARLY TERMINATION:
	 
	 	 	This SCHEDULE does not terminate automatically upon termination of the MRA.
	 
	 	 	This SCHEDULE shall expire pursuant to the terms set forth in this SCHEDULE, unless extended
by the mutual agreement of the parties, or unless sooner terminated in accordance with the
following provisions of this Paragraph:
	 
		 	     (a) mutual, written agreement of the parties;
	 
	 	 	     (b) failure of one party to satisfy its material obligations under this Agreement, and
such party subsequently fails to cure such failure(s) within (i) thirty (30) days for
failures to remit payment for amounts due under this Agreement and (ii) ninety (90) days for
all other obligations in each case after receipt of written notice from the non-breaching
party specifying such failure(s);
	 
	 	 	     (c) one (1) year’s written notice of termination by either CERES or NOBLE to the other
party in case either the terminating party or the other party ceases substantially all
activities in the COLLABORATION CROPS;
	 
	 	 	     (d) NOBLE will have the right to terminate this Agreement unilaterally with thirty (30)
days’ written notice to CERES, (i) if CERES seeks protection under any bankruptcy,
insolvency, receivership, trust, deed, creditors arrangement or comparable proceeding or if
any such proceeding is instituted against CERES (and not dismissed within one hundred twenty
(120) days); (ii) in case of dissolution or winding up of CERES (excluding any situation
where all or substantially all of CERES’ assets, stock or business to which this Agreement
relates are acquired by a third party (whether by sale, acquisition, merger, operation of
law or otherwise)); (iii) CERES fails in a substantial manner to implement and continue the
activities set forth in EXHIBIT F (or other similar activities in furtherance of commercial
exploitation of the COLLABORATION CROPS),

CERES-NOBLE Schedule BMP for switchgrass

Page 4 of 10

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

	 	 	and does not remedy such failure or offer a
remediation plan which is reasonably acceptable to NOBLE within ninety (90) days after
receipt of a written notice from NOBLE specifying such failure; or (iv) with one hundred
twenty (120) days’ written notice to CERES, if the institutional mission, purpose or
structure of NOBLE would change substantially and adversely affect NOBLE’S ability to
satisfy its obligations hereunder; or
	 
		 	     (e) CERES will have the right to terminate this Agreement unilaterally: (i) with thirty
(30) days’ written notice to NOBLE if Dr. Joe Bouton ceases to be associated with NOBLE and the
research activities associated with this SCHEDULE, and NOBLE has not replaced him within one
hundred twenty (120) days by a person reasonably acceptable to CERES; (ii) with ninety (90)
days’ written notice to NOBLE, if the institutional mission, purpose or structure of NOBLE
would change substantially; or (iii) with one (1) years’ written notice to NOBLE, if CERES
has compelling business reasons to cease the collaboration.

	19.	 	USE AND COMMERCIALIZATION RIGHTS:
	 
	 	 	Controlled by MRA
	 
	20.	 	CONFIDENTIALITY/PUBLICATION:
	 
	 	 	Controlled by MRA
	 
	21.	 	FUNDING APPROVED:
	 
	 	 	Projected Budget (per year from CERES):

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Year 1	 	 	Year 2	 	 	Year 3	 	 	 	 
	 	 	Salaries	 	 	Salaries	 	 	Salaries	 	 	 	 
	 	 	incl.	 	 	incl.	 	 	incl.	 	 	 	 
	Personnel	 	fringe	 	 	fringe	 	 	fringe	 	 	Subtotals	 
	 
	Post doc + Fringe Benefits
	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 
	Travel/meals
	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 
	Supplies (herbicide/[***])
	 	$	[***]	 	 	$	[***]	 	 	 	 	 	 	$	[***]	 
	Total Direct Costs
	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 
	Indirect (50% of Direct)
	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	TOTAL
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Total
	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 	 	$	[***]	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

Budget justification:

Salaries:

[To be added]. Fringe benefits are calculated at [***]% to include FICA, health insurance and
thrift. Five percent fixed salary increases are requested for each successive year.

CERES-NOBLE Schedule BMP for switchgrass

Page 5 of 10

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

Travel:

Travel funds are requested to allow the main scientific personnel to attend one scientific
conference within North America each year.

Supplies:

[To be added]. per year is requested for [to be added].

Core Facilities:

[To be added].

Billing Schedule: Invoices will be sent by NOBLE to CERES for actual expenses from the previous
period on the 15th of the first month of each calendar quarter, not to exceed the
amounts specified above.

IN WITNESS THEREOF this SCHEDULE has been executed on the date hereinbefore entered.

CERES, INC.

	 	 	 	 	 

	 

	 	/s/ Anna Rath
	 	11/19/09
	 
	By:

	 	Anna Rath
	 	Date
	 

	 	Vice President of Commercial Development	 	 
	 
	 	 	 	 
	 

	 	/s/ Michael Stephenson
	 	11/20/09
	 
	By:

	 	Michael Stephenson
	 	Date
	 

	 	Vice President of Operations	 	 
	 
	 	 	 	 
	THE SAMUEL ROBERTS NOBLE FOUNDATION, INC.
	 
	 	 	 	 
	 

	 	/s/ Michael A. Cawley
	 	12/10/09
	 
	By:

	 	Michael A. Cawley
	 	Date
	 

	 	President	 	 

 CERES-NOBLE Schedule BMP for switchgrass

Page 6 of 10

 

ATTACHMENT A

RESEARCH AND DEVELOPMENT PLAN

	Objective 1: To identify legume species that can be intercropped with switchgrass to improve
sustainability of switchgrass biofuel production (Ardmore, OK)

Justification: In order for a switchgrass biofuel system to be sustainable, it must be
economical, high yielding, and have low inputs. One of the biggest components to maximizing
yield is N fertilizer. Incorporating legumes
that fix N into switchgrass systems can greatly
reduce N inputs and potentially improve economics.

Expected outcome: Identify appropriate legumes across multiple environments that are
compatible with switchgrass for biofuel production.

Experimental design: RCBD, [***] replications:

	 	1.	 	Locations: Burneyville; TBD.
	 
	 	2.	 	Treatments: crimson clover, arrowleaf clover, hairy vetch, annual medic, and
sweetclover (added for alkaline soils) in lowland switchgrass compared to [***], [***],
[***], [***] lb N/A.
	 
	 	3.	 	Timeline:

	 	a.	 	Year 1: 20[***] Spring: Monitor reseeding from legumes planted in
20[***] and 20[***] plantings at Dupy.
	 
	 	b.	 	20[***] (fall) establish new trial of winter legumes into
fully established SG stands at [***] new locations.
	 
	 	c.	 	Year 2: 20[***] fall Harvest 20[***] planting; re-establish
same winter legumes as well as monitor reseeding from previous planting: Harvest
legumes in spring; to estimate [***].
	 
	 	d.	 	Year 3: 20[***] (fall) Harvest SG to estimate contribution
from legumes.

Objective 2: To determine best management practices for establishing switchgrass into perennial
grass (CRP-like) pastures

Justification: Establishment into non-cropland has proven to be most difficult possibly due
to weed competition and potentially diseases where excessive residue occurs.

Expected Outcome: Document BMP for establishing switchgrass into permanent native grass
pasture (OK).

Experimental Design: split-plot RCBD:

Experiment I: ([***] preparation: no-tilled native range — OK): GA to duplicate in Tall [***]:

	 	1.	 	Location: Burneyville
	 
	 	2.	 	Treatments ([***]): 3 timing application of
glyphosate in: i) Sept-Oct,
Apr, and [***] prior to planting (fall + spring +
spring); ii) Oct and Apr,
[***] prior to planting (fall + spring); iii) Mar and Apr, [***] prior to
planting (w/ [***] application occurring [***]-[***] weeks after [***] application)
(spring + spring); iv) tillage (roto-tiller).
	 
	 	3.	 	Plots size [***] x [***]

CERES-NOBLE Schedule BMP for switchgrass

Page 7 of 10

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

	 	4.	 	Timeline:

	

	 	a.	 	Year 1: Fall 20[***] apply glyphosate trts.
	

	 
	 	b.	 	Year 2: 20[***] Spring glyphosate trts and plant
SG: Fall 20[***]
[***] fall glyphosate trts.
	 
	 	c.	 	Year 3: 20[***] spring glyphosate and spring
plant second year of
trial.

	 	 	Experiment II: Seeding [***] X sod destruction in no-tilled [***].

	 	1.	 	Location(s): [***]
	 
	 	2.	 	Treatments: Main plot: [***] ([***] or [***]). Subplot: sod destruction
(Mow, burn, tillage)
	 
	 	3.	 	Plot Size:[***] x [***]
	 
	 	4.	 	Timeline:

	 	a.	 	Year 1: 20[***] Spring plant seeding [***] x sod destruction
trial
	 
	 	b.	 	Year 2: 20[***] Spring plant seeding [***] x sod destruction
trial
	 
	 	c.	 	Year 3: 20[***] TBD, trials if needed.

	 	 	Experiment III: [***] X [***]
— no-tilled into mowed [***] (Spring Glyphosate and mowed):

	 	1.	 	Location(s): [***]; Burneyville
	 
	 	2.	 	Treatments: Main plot +/- [***] seed ([***]/[***]/[***]/or [***], TBD):
Subplot: POE applied at [***] stage (none, [***] and/or [***], TBD).
	 
	 	3.	 	Plots size: [***] x [***]; subplot [***] x [***]
	 
	 	4.	 	Timeline:

	 	a.	 	Year 1: 20[***] Spring plant [***] x [***] trial.
	 
	 	b.	 	Year 2: 20[***] Spring plant [***] x [***] trial.
	 
	 	c.	 	Year 3: 20[***] TBD, trials if needed.

Objective
3: To determine minimum number of seedlings per [***]
needed to maximize yield and document justification
for replanting poor stands, using the BMP guidelines (learned in Schedule 1) to control weeds (FirstRate PRE
fb Atrazine+Paramount+Prowl 2-leaf).

Justification:
Better tools are needed to determine if partial stands (very low
seeding rates) will result
in acceptable yields.

Expected
Outcome: Determine lowest seeding rate at which switchgrass can
be established while maintaining maximum DM yield.

Experimental Design: [***], [***] replications:

	 	1.	 	Location(s): Dupy Loam soil; [***] sand
	 
	 	2.	 	Treatments: Evaluate populations of approximately
[***] ([***] seeds/[***]), [***]
([***] seeds/[***]), [***]
([***] seeds/[***]), [***]
([***] seeds/[***]), [***]
([***] seeds/[***]) on
[***]-[***] inch row [***] , which is
similar to seeding rates of [***], [***],
[***], [***], and [***] lb/A;
Assuming [***]% emergence of seeds and [***]
seeds per lb of switchgrass seed.
	 
	 	3.	 	Timeline:

	 	a.	 	Year 1: 20[***] (spring) plant SG and evaluate plant
populations;
Harvest in fall.

CERES-NOBLE Schedule BMP for switchgrass

Page 8 of 10

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

	 	b.	 	Year 2: 20[***] (spring) plant SG and evaluate plant populations;
Harvest in fall.
	 
	 	c.	 	Year 3: 20[***] (fall) Harvest SG [***] from previous years
plantings.

Objective 4: To validate herbicide recommendations developed in Schedule 1 across multiple
environments

Justification: Weed control is still the [***] factor for successful establishment and
herbicide efficacy depends on soil [***], soil pH, and rainfall.

Expected Outcome: Document which herbicide should be used on a given soil type, environment,
and weed spectrum present.

Experimental Design: Lowland switchgrass, RCBD, split plot design; [***] replications;

	 	1.	 	Locations: [***]-sand; [***]-clay; Dupy-loam; GA-sand
	 
	 	2.	 	Herbicide Treatments (BMP atrazine applied [***]-leaf and [***], [***] amine
applied at [***]-leaf to control ALL broadleaf weeds).
	 
	 	3.	 	Target Weeds (to be [***]-planted with SG): crabgrass, broadleaf signalgrass,
and Johnsongrass
	 
	 	4.	 	Main Plot: FirstRate applied pre-emergence ([***] oz sandy soils or [***] oz
loam soils) or No pre-emergent herbicide

	 	a.	 	Subplots (No PRE herbicide):

	 	i.	 	[***]-leaf stage ([***] DAE): [***] oz
Paramount + MSO, [***] oz Option, [***] pt Prowl; [***] oz
Paramount+[***] oz Option; [***] oz Paramount+[***] oz Option+[***]
pt Prowl
	 
	 	ii.	 	[***]-leaf stage ([***] DAE): [***] oz
Paramount, [***] oz Option, [***] oz Paramount + [***] oz Option +
[***] pt Prowl [***] oz Accent; [***] oz Accent + [***] oz Paramount
+ [***] pt Prowl
	 
	 	iii.	 	[***]-leaf stage ([***] DAE): [***] oz
Accent; [***] Accent + [***] oz Paramount + [***] pt Prowl; [***] pt
MSMA; [***]. No herbicide

	 	b.	 	Subplots (FirstRate PRE):

	 	i.	 	[***]-leaf stage ([***] DAE): [***] oz
Paramount + MSO, [***] oz Option, [***] pt Prowl; [***] oz
Paramount+[***] oz Option; [***] oz Paramount+[***] oz Option+[***]
pt Prowl
	 
	 	ii.	 	[***]-leaf stage ([***]DAE): [***] oz
Paramount, [***] oz Option, [***] oz Paramount + [***] oz Option +
[***] pt Prowl [***] oz Accent; [***] [***] oz Accent + [***] oz
Paramount + [***] pt Prowl
	 
	 	iii.	 	[***]-leaf stage ([***] DAE): [***] oz
Accent; [***] Accent + [***] oz Paramount + [***] pt Prowl; [***] pt
MSMA; [***]. No herbicide

	 	5.	 	Plot size: [***] x [***]; spay [***] to planting ([***]’ [***]-SG, [***]’
[***]-SG, [***]’[***]-SG, [***]’SG-only).
	 
	 	6.	 	Timeline:

	 	a.	 	Year 1: 20[***] (spring) plant SG and evaluate herbicides.

CERES-NOBLE Schedule BMP for switchgrass

Page 9 of 10

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

 

	 	b.	 	Year 2: 20[***] (spring) plant SG and evaluate herbicides.
	 
	 	c.	 	Year 3: 20[***] TBD if needed.

CERES-NOBLE Schedule BMP for switchgrass

Page 10 of 10

Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00197-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00197-of-00352.parquet"}]]